Compounds > glimepiride
Page last updated: 2024-10-28

glimepiride and Diabetes Mellitus, Adult-Onset

glimepiride has been researched along with Diabetes Mellitus, Adult-Onset in 538 studies

glimepiride: structure given in first source

Research Excerpts

ExcerptRelevanceReference
"To investigate the effect of left ventricular ejection fraction (LVEF) on the behavior of N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in patients with heart failure and type 2 diabetes mellitus with the use of canagliflozin compared to glimepiride."9.69Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial. ( Eguchi, K; Kitada, S; Kodama, K; Node, K; Ohte, N; Seo, Y; Takeishi, Y; Tanaka, A; Teragawa, H; Yamada, T, 2023)
"Our findings suggest that 24 weeks of treatment with canagliflozin, relative to glimepiride, reduced WBC counts in patients with type 2 diabetes and heart failure."9.51Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial. ( Imai, T; Matsunaga, K; Minamino, T; Nakamura, I; Node, K; Ozaki, Y; Sata, M; Shimabukuro, M; Tanaka, A, 2022)
"In this prespecified secondary analysis of a phase IV, double-blind trial, 46 metformin-treated, overweight patients with T2D were included and randomly assigned (1:1) to once-daily linagliptin (5 mg) or glimepiride (1 mg) for 8 weeks."9.34Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial. ( Kraaijenhof, J; Kramer, MHH; Muskiet, MHA; Ouwens, DM; Smits, MM; Tonneijck, L; van Raalte, DH, 2020)
"In this double-blind randomized trial, 46 overweight T2DM patients without renal impairment received once-daily linagliptin (5 mg) or glimepiride (1 mg) for 8 weeks."9.34Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial. ( Danser, AHJ; Hartmann, B; Holst, JJ; Joles, JA; Kramer, MHH; Muskiet, MHA; Ouwens, DM; Smits, MM; Tonneijck, L; Touw, DJ; van Raalte, DH, 2020)
" This study aimed to evaluate the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin on the biomarkers of inflammation, thrombosis, and atherosclerosis in T2DM patients with symptomatic coronary artery disease (CAD)."9.34Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. ( Kabel, M; Mostafa, T; Omran, G; Shokry, A; Werida, R, 2020)
"This study provides evidence that, compared to glimepiride, saxagliptin more effectively achieves a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in T2D patients who are inadequately controlled with metformin monotherapy, especially in overweight patients with moderate hyperglycaemia and a relatively short duration of diabetes."9.30Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr ( Bi, Y; Cheng, J; Gu, T; Li, D; Ma, J; Shao, J; Shi, B; Sun, Z; Xu, L; Zhang, H; Zhang, Q; Zhong, S; Zhu, D; Zhu, L, 2019)
"Several studies have demonstrated the decreased insulin resistance (IR) in persons with type 2 diabetes mellitus (T2DM) treated with glimepiride."9.30The differential influence of glimepiride and glibenclamide on insulin resistance and adiponectin levels in patients with type 2 diabetes. ( Bahtiri, E; Begolli, L; Blaslov, K; Car, N; Emini-Sadiku, M; Haliti, E, 2019)
"The aim of this study was to analyze the efficacy, insulin sensitivity and safety in the event of administering sulfonylurea-based drugs and metformin in combination with basal insulin."9.30A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy. ( Chun, SW; Hong, JH; Kim, SJ; Lee, JM; Lim, DM; Park, KS; Park, KY; Yu, HM, 2019)
"Adding mitiglinide/voglibose to vildagliptin therapy results in more efficient postprandial glucose control and less hypoglycemia than adding glimepiride."9.27Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial. ( Fujimoto, K; Hamamoto, Y; Hamasaki, A; Honjo, S; Shibayama, Y; Yamaguchi, E, 2018)
"A total of 250 patients with type 2 diabetes who are drug-naïve or taking any anti-diabetic agents and suffering from chronic heart failure with a New York Heart Association classification I to III will be randomized centrally into either canagliflozin or glimepiride groups (1: 1) using the dynamic allocation method stratified by age (<65, ≥65 year), HbA1c level (<6."9.22Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. ( Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A, 2016)
"The percentage of patients experiencing any hypoglycemia event (ie, symptomatic event or event of plasma glucose concentration <54 mg/dL regardless of symptoms) was lower with saxagliptin compared with glimepiride (5."9.22Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin. ( Cook, W; Hirshberg, B; Ohman, P; Perl, S; Wei, C, 2016)
"To evaluate the effects of vildagliptin compared to glimepiride on glycemic control, insulin resistance and post-prandial lipemia."9.19Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D, 2014)
"Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is a biomarker and mediator of cardiovascular disease in patients with impaired glucose tolerance (IGT) or diabetes mellitus (DM)."9.17Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes. ( Imaizumi, T; Mizoguchi, M; Tahara, A; Tahara, N; Yamagishi, S, 2013)
"Our study indicated that pioglitazone decreased the visceral fat volume and its metabolic activity in patients with impaired glucose tolerance or type 2 diabetes mellitus."9.17Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus. ( Abe, T; Fukumoto, Y; Honda, A; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mizoguchi, M; Narula, J; Nitta, Y; Tahara, A; Tahara, N; Yamagishi, S, 2013)
" This study investigates the impact of a pioglitazone plus metformin therapy on biomarkers of inflammation and platelet activation in comparison to a treatment with glimepiride plus metformin."9.15The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study. ( Forst, T; Fuchs, W; Hohberg, C; Lehmann, U; Löbig, M; Müller, J; Musholt, PB; Pfützner, A; Schöndorf, T, 2011)
"The aim of this study was to evaluate the effect of exenatide compared to glimepiride on body weight, glycemic control and insulin resistance in type 2 diabetic patients taking metformin."9.15Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. ( Bonaventura, A; Bossi, AC; Derosa, G; Fogari, E; Franzetti, IG; Guazzini, B; Maffioli, P; Putignano, P; Querci, F; Testori, G, 2011)
"The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging."9.15Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011)
"Vildagliptin add-on has similar efficacy to glimepiride after 2 years' treatment, with markedly reduced hypoglycaemia risk and no weight gain."9.14Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. ( Ahren, B; Couturier, A; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, V; Matthews, DR; Zinman, B, 2010)
"To compare the effects of an insulin sensitizer, pioglitazone, with an insulin secretagogue, glimepiride, on the progression of coronary atherosclerosis in patients with type 2 diabetes."9.13Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. ( De Larochellière, R; Hu, B; Jure, H; Kupfer, S; Lincoff, AM; Mavromatis, K; Nesto, R; Nicholls, SJ; Nissen, SE; Perez, A; Saw, J; Staniloae, CS; Tuzcu, EM; Wolski, K, 2008)
"Glimepiride appears to improve insulin resistance and atherosclerotic disorders."9.12Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. ( Ito, S; Koshiba, K; Nakaya, Y; Nomura, M, 2006)
"This study compared the effects of pioglitazone or rosiglitazone added to glimepiride on a range of lipid parameters, focusing on Lp(a) and Hcy, in patients with type 2 diabetes mellitus and the metabolic syndrome."9.12Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gaddi, A; Gravina, A; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA, 2006)
"The goals of this study were to compare changes in measures of glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes who received pioglitazone or glimepiride for 1 year."9.11Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. ( Antúnez, O; Fabián, G; Flores-Lozano, F; Garza, E; González Gálvez, G; Herz, M; Johns, D; Konkoy, C; Morales, H; Tan, M; Zúñiga Guajardo, S, 2004)
"The aim of this study was to assess the differential effect on glucose and lipid variables and tolerability of the combination of glimepiride plus pioglitazone or rosiglitazone in patients with type 2 diabetes mellitus (DM) and metabolic syndrome."9.11Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. ( Bertone, G; Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Gaddi, A; Piccinni, MN; Ragonesi, PD, 2004)
"To evaluate the differential effect on coagulation and fibrinolysis parameters of combination therapy with glimepiride-metformin and with rosiglitazone-metformin beyond their effect on glucose metabolism in patients with type 2 diabetes and metabolic syndrome."9.11Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. ( Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Gaddi, AV; Ghelfi, M; Peros, E; Piccinni, MN; Salvadeo, S, 2005)
"To compare the effects of glimepiride plus pioglitazone or plus rosiglitazone in diabetic patients with the metabolic syndrome on coagulation and fibrinolysis parameters."9.11A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. ( Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Fogari, R; Gaddi, A; Piccinni, MN; Ragonesi, PD; Salvadeo, S, 2005)
"The primary aim of the present study was to compare the effect of long-term (12-month) combination treatment with glimepiride or rosiglitazone plus metformin on blood pressure in patients with type 2 diabetes mellitus (DM-2) and the metabolic syndrome."9.11Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. ( Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gaddi, AV; Ghelfi, M; Piccinni, MN; Pricolo, F; Salvadeo, S, 2005)
"We investigated the effect of glimepiride, a third-generation sulfonylurea hypoglycemic agent, on insulin resistance in elderly patients with type 2 diabetes, in connection with plasma adiponectin and 8-epi-prostagrandin F2alpha (8-epi-PGF2alpha), an oxidative stress marker."9.10Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. ( Fukatsu, A; Hayashi, T; Iguchi, A; Kano, H; Matsui-Hirai, H; Miyazaki, A; Nomura, N; Suzuki, Y; Tsunekawa, T, 2003)
"Our study compared the effects of glimepiride or glibenclamide treatment on body weight over 12 months of treatment in patients with Type 2 diabetes in routine outpatient practice."9.10Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. ( Beuth, J; Kolb, H; Martin, S; Scherbaum, WA; Schneider, B; van Leendert, R, 2003)
" Eight cases of acute pancreatitis (AP) with liraglutide and one with any comparator (glimepiride) were found."8.91Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. ( Jensen, TM; Saha, K; Steinberg, WM, 2015)
"This study was a post hoc analysis of the CANDLE trial (UMIN000017669), which compared the effect of 24 weeks of treatment with canagliflozin or glimepiride for changes in N-terminal pro-brain natriuretic peptide in patients with T2DM and chronic heart failure (CHF)."8.31Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial. ( Ajioka, M; Hiramitsu, S; Imai, T; Kadokami, T; Node, K; Shimabukuro, M; Suzuki, M; Takahashi, N; Tanaka, A; Yamaguchi, S, 2023)
"The objective of this study was to evaluate QoL in patients of type 2 diabetes mellitus (T2DM) with hypertension after add-on empagliflozin to triple drug therapy (metformin, teneligliptin, and glimepiride)."8.12Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study. ( Bhat, MH; Masoodi, SR; Mir, SA; Najar, IA; Patyar, RR; Patyar, S, 2022)
"Canagliflozin 100 and 300 mg provided sustained reductions in body weight, BMI, and waist circumference in a greater proportion of patients with T2DM versus glimepiride or placebo over 104 weeks."7.83Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. ( Blonde, L; Canovatchel, W; Fung, A; Meininger, G; Stenlöf, K; Xie, J, 2016)
"Nonalcoholic fatty liver disease (NAFLD) is a liver phenotype of type 2 diabetes and obesity."7.11Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial. ( Arai, K; Goto, H; Harada, K; Honda, M; Iida, N; Kaneko, S; Kita, Y; Mizukoshi, E; Nakamura, H; Nakano, Y; Takamura, T; Takata, N; Takeshita, Y; Tanaka, T; Tsujiguchi, H; Yamashita, T, 2022)
"Linagliptin treatment for 104 weeks was recently reported to achieve non-inferior glucose-lowering effects compared with glimepiride in patients with type 2 diabetes inadequately controlled with metformin."6.78Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 years. ( Emser, A; Gallwitz, B; Rosenstock, J; von Eynatten, M; Woerle, HJ, 2013)
"Dyslipidemia in patients with type 2 diabetes is characterized by elevated triglyceride levels, decreased high-density lipoprotein (HDL) cholesterol, and a predominance of small dense low-density lipoprotein (LDL) particles."6.76PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. ( Forst, T; Fuchs, W; Lehmann, U; Lobmann, R; Merke, J; Müller, J; Pfützner, A; Schöndorf, T; Tschöpe, D, 2011)
"Insulin resistance was defined by elevated intact proinsulin values or homeostasis model assessment for insulin resistance score of more than 2."6.72Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. ( Forst, T; Hamann, A; Matthaei, S; Pfützner, A; Schöndorf, T; Seidel, D; Winkler, K, 2006)
"Treatment with glimepiride also resulted in significant and stable weight loss relative to baseline, with the exception of patients with a body mass index of <25 kg/m(2)."6.71Effects of glimepiride on HbA(1c) and body weight in Type 2 diabetes: results of a 1.5-year follow-up study. ( Klingler, A; Lechleitner, M; Luger, A; Weitgasser, R, 2003)
"To investigate the effect of left ventricular ejection fraction (LVEF) on the behavior of N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in patients with heart failure and type 2 diabetes mellitus with the use of canagliflozin compared to glimepiride."5.69Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial. ( Eguchi, K; Kitada, S; Kodama, K; Node, K; Ohte, N; Seo, Y; Takeishi, Y; Tanaka, A; Teragawa, H; Yamada, T, 2023)
"Our findings suggest that 24 weeks of treatment with canagliflozin, relative to glimepiride, reduced WBC counts in patients with type 2 diabetes and heart failure."5.51Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial. ( Imai, T; Matsunaga, K; Minamino, T; Nakamura, I; Node, K; Ozaki, Y; Sata, M; Shimabukuro, M; Tanaka, A, 2022)
"Men with type 2 diabetes (T2D) and obesity are often characterised by low testosterone (T)."5.48Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity. ( Hao, M; Kuang, HY; Li, BW; Ma, XF; Pan, J; Shao, N; Wu, WH; Yu, XY; Yu, YM; Zhang, HJ, 2018)
"Men with type 2 diabetes are often characterized by abnormal plasma testosterone levels."5.43The effect of testosterone on cardiovascular risk factors in men with type 2 diabetes and late-onset hypogonadism treated with metformin or glimepiride. ( Gilowski, W; Krysiak, R; Okopień, B, 2016)
"Byetta was withdrawn, the patient was treated for acute pancreatitis and the symptoms subsided."5.35Exenatide and acute pancreatitis. ( Basha, S; Jain, R; Ramachandran, A; Shetty, S; Tripathy, NR, 2008)
"In this prespecified secondary analysis of a phase IV, double-blind trial, 46 metformin-treated, overweight patients with T2D were included and randomly assigned (1:1) to once-daily linagliptin (5 mg) or glimepiride (1 mg) for 8 weeks."5.34Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial. ( Kraaijenhof, J; Kramer, MHH; Muskiet, MHA; Ouwens, DM; Smits, MM; Tonneijck, L; van Raalte, DH, 2020)
"In this double-blind randomized trial, 46 overweight T2DM patients without renal impairment received once-daily linagliptin (5 mg) or glimepiride (1 mg) for 8 weeks."5.34Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial. ( Danser, AHJ; Hartmann, B; Holst, JJ; Joles, JA; Kramer, MHH; Muskiet, MHA; Ouwens, DM; Smits, MM; Tonneijck, L; Touw, DJ; van Raalte, DH, 2020)
" This study aimed to evaluate the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin on the biomarkers of inflammation, thrombosis, and atherosclerosis in T2DM patients with symptomatic coronary artery disease (CAD)."5.34Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. ( Kabel, M; Mostafa, T; Omran, G; Shokry, A; Werida, R, 2020)
"This study provides evidence that, compared to glimepiride, saxagliptin more effectively achieves a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in T2D patients who are inadequately controlled with metformin monotherapy, especially in overweight patients with moderate hyperglycaemia and a relatively short duration of diabetes."5.30Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr ( Bi, Y; Cheng, J; Gu, T; Li, D; Ma, J; Shao, J; Shi, B; Sun, Z; Xu, L; Zhang, H; Zhang, Q; Zhong, S; Zhu, D; Zhu, L, 2019)
"Several studies have demonstrated the decreased insulin resistance (IR) in persons with type 2 diabetes mellitus (T2DM) treated with glimepiride."5.30The differential influence of glimepiride and glibenclamide on insulin resistance and adiponectin levels in patients with type 2 diabetes. ( Bahtiri, E; Begolli, L; Blaslov, K; Car, N; Emini-Sadiku, M; Haliti, E, 2019)
"The aim of this study was to analyze the efficacy, insulin sensitivity and safety in the event of administering sulfonylurea-based drugs and metformin in combination with basal insulin."5.30A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy. ( Chun, SW; Hong, JH; Kim, SJ; Lee, JM; Lim, DM; Park, KS; Park, KY; Yu, HM, 2019)
" Linagliptin is a glucose-lowering agent of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class that is of particular interest for the prevention of accelerated cognitive decline, because it may potentially benefit the brain through pleiotropic effects, beyond glucose lowering."5.27Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus. ( Biessels, GJ; Espeland, MA; Janssen, J; Johansen, OE; Mattheus, M; van den Berg, E; Zinman, B, 2018)
"Adding mitiglinide/voglibose to vildagliptin therapy results in more efficient postprandial glucose control and less hypoglycemia than adding glimepiride."5.27Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial. ( Fujimoto, K; Hamamoto, Y; Hamasaki, A; Honjo, S; Shibayama, Y; Yamaguchi, E, 2018)
"Vildagliptin effectively improved glucose level with a significantly greater reduction in glycemic variability and hypoglycemia than glimepiride in patients with T2DM ongoing metformin therapy."5.24The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus. ( Hur, KY; Jin, SM; Kim, G; Kim, JH; Lee, MK; Oh, S, 2017)
"Compared with glimepiride, Sita/Met as an initial treatment led to significantly greater improvements in glycemic control and body weight changes, with a lower incidence of hypoglycemia, over 30 weeks."5.24Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study. ( Chung, SC; Kim, IJ; Kim, SS; Kim, YI; Lee, KJ; Lee, SJ; Lee, YS; Park, JH, 2017)
"Changes from baseline in HbA1c, body weight, and systolic blood pressure (BP) with canagliflozin 100 and 300 mg versus placebo or active comparator (i."5.22Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. ( Alba, M; Cerdas, S; Chacon, Mdel P; Eliaschewitz, FG; Lavalle-González, FJ; Tong, C, 2016)
"A total of 250 patients with type 2 diabetes who are drug-naïve or taking any anti-diabetic agents and suffering from chronic heart failure with a New York Heart Association classification I to III will be randomized centrally into either canagliflozin or glimepiride groups (1: 1) using the dynamic allocation method stratified by age (<65, ≥65 year), HbA1c level (<6."5.22Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. ( Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A, 2016)
"The percentage of patients experiencing any hypoglycemia event (ie, symptomatic event or event of plasma glucose concentration <54 mg/dL regardless of symptoms) was lower with saxagliptin compared with glimepiride (5."5.22Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin. ( Cook, W; Hirshberg, B; Ohman, P; Perl, S; Wei, C, 2016)
"5 mg, compared with daily insulin glargine without forced titration, demonstrated greater HbA1c reduction and weight loss, with a higher incidence of gastrointestinal adverse events and a lower risk of hypoglycemia."5.20Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). ( Benroubi, M; Giorgino, F; Pechtner, V; Sun, JH; Zimmermann, AG, 2015)
"High blood glucose level, lipid profile disturbances and plasma homocysteine (Hcy) are important risk factors for cardiovascular diseases in patients with type 2 diabetes."5.20Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus. ( Abd-Allah, GM; Hassan, MH, 2015)
"Pioglitazone suppresses RAGE expression and increases circulating sRAGE/esRAGE, and those activities are not necessarily dependent on plasma glucose or insulin resistance levels."5.19Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE). ( Emoto, M; Fujii, H; Fukui, M; Fukumoto, S; Inaba, M; Koyama, H; Monden, M; Mori, K; Morioka, T; Nishizawa, Y; Shoji, T; Tanaka, S, 2014)
" We evaluated the following variables: BMI; glycaemic control; fasting plasma insulin; homeostatic model assessment of insulin resistance index; fasting plasma proinsulin; glucagon; lipid profile; adiponectin; high-sensitivity C-reactive protein; interleukin-6; and tumour necrosis factor-α."5.19Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D, 2014)
"To evaluate the effects of vildagliptin compared to glimepiride on glycemic control, insulin resistance and post-prandial lipemia."5.19Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D, 2014)
" Here, we examined whether pioglitazone plus nateglinide (PIO) interferes with hepatocellular lipid (HCL) content and/or improves insulin sensitivity in well-controlled non-obese patients with type 2 diabetes mellitus (T2DM)."5.17Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes. ( Anderwald, CH; Bernroider, E; Brehm, A; Krebs, M; Krssak, M; Nowotny, P; Phielix, E; Roden, M; Schmid, AI, 2013)
"Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is a biomarker and mediator of cardiovascular disease in patients with impaired glucose tolerance (IGT) or diabetes mellitus (DM)."5.17Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes. ( Imaizumi, T; Mizoguchi, M; Tahara, A; Tahara, N; Yamagishi, S, 2013)
"Our study indicated that pioglitazone decreased the visceral fat volume and its metabolic activity in patients with impaired glucose tolerance or type 2 diabetes mellitus."5.17Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus. ( Abe, T; Fukumoto, Y; Honda, A; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mizoguchi, M; Narula, J; Nitta, Y; Tahara, A; Tahara, N; Yamagishi, S, 2013)
"Liraglutide monotherapy for 2 years provides significant and sustained improvements in glycaemic control and body weight compared with glimepiride monotherapy, at a lower risk of hypoglycaemia."5.15Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. ( Bode, B; Chang, CT; Garber, A; Hale, P; Henry, RR; Ratner, R, 2011)
" This study investigates the impact of a pioglitazone plus metformin therapy on biomarkers of inflammation and platelet activation in comparison to a treatment with glimepiride plus metformin."5.15The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study. ( Forst, T; Fuchs, W; Hohberg, C; Lehmann, U; Löbig, M; Müller, J; Musholt, PB; Pfützner, A; Schöndorf, T, 2011)
"The aim of this study was to evaluate the effect of exenatide compared to glimepiride on body weight, glycemic control and insulin resistance in type 2 diabetic patients taking metformin."5.15Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. ( Bonaventura, A; Bossi, AC; Derosa, G; Fogari, E; Franzetti, IG; Guazzini, B; Maffioli, P; Putignano, P; Querci, F; Testori, G, 2011)
"The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging."5.15Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011)
"In T2DM patients, pioglitazone was associated with improvement in some measures of left ventricular diastolic function, myocardial glucose uptake, and whole-body insulin sensitivity."5.14Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. ( Bax, JJ; de Jong, HW; de Roos, A; Diamant, M; Heine, RJ; Kamp, O; Lamb, HJ; Lammertsma, AA; Lubberink, M; Paulus, WJ; Rijzewijk, LJ; Romijn, JA; Smit, JW; van der Meer, RW, 2009)
"The aim of the study was to compare the effects of vildagliptin added to pioglitazone or glimepiride on metabolic and insulin resistance related-indices in poorly controlled type 2 diabetic patients (T2DM)."5.14Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. ( Ciccarelli, L; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Mereu, R; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA, 2010)
"As weight gain and hypoglycaemia associated with glimepiride therapy can negatively impact weight perceptions, psychological well-being and overall quality of life in type 2 diabetes, we investigated whether liraglutide treatment could improve these factors."5.14Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. ( Blonde, L; Bode, BW; Garber, A; Hale, PM; Hammer, M; Magwire, M; Testa, MA, 2010)
"Vildagliptin add-on has similar efficacy to glimepiride after 2 years' treatment, with markedly reduced hypoglycaemia risk and no weight gain."5.14Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. ( Ahren, B; Couturier, A; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, V; Matthews, DR; Zinman, B, 2010)
"To compare the effects of an insulin sensitizer, pioglitazone, with an insulin secretagogue, glimepiride, on the progression of coronary atherosclerosis in patients with type 2 diabetes."5.13Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. ( De Larochellière, R; Hu, B; Jure, H; Kupfer, S; Lincoff, AM; Mavromatis, K; Nesto, R; Nicholls, SJ; Nissen, SE; Perez, A; Saw, J; Staniloae, CS; Tuzcu, EM; Wolski, K, 2008)
"Glimepiride appears to improve insulin resistance and atherosclerotic disorders."5.12Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. ( Ito, S; Koshiba, K; Nakaya, Y; Nomura, M, 2006)
"To compare the incidence of nocturnal hypoglycemia and glycemic control following bedtime or morning insulin glargine (LANTUS; glargine) plus glimepiride."5.12Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. ( Maxeiner, S; Raptis, S; Standl, E, 2006)
"In patients with T2DM, inadequately controlled on OADs, once-daily insulin glargine plus glimepiride is effective in improving metabolic control with a reduced incidence of nocturnal hypoglycemia compared with NPH insulin."5.12Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. ( Aschner, P; Calvo, C; Eliaschewitz, FG; Jimenez, J; Ramirez, LA; Ruiz, M; Valbuena, H; Villena, J, 2006)
"This study compared the effects of pioglitazone or rosiglitazone added to glimepiride on a range of lipid parameters, focusing on Lp(a) and Hcy, in patients with type 2 diabetes mellitus and the metabolic syndrome."5.12Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gaddi, A; Gravina, A; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA, 2006)
"These results confirm earlier reports that insulin glargine provides superior glycemic control with less hypoglycemia and demonstrates that these benefits are consistent between different ethnicities."5.12Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. ( Chung, KD; Kim, KW; Pan, CY; Sinnassamy, P, 2007)
"Glimepiride reduced A1C similarly to metformin with greater weight gain, and there was comparable safety over 24 weeks in the treatment of pediatric subjects with type 2 diabetes."5.12Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. ( Cara, JF; Danne, T; Gottschalk, M; Vlajnic, A, 2007)
"To assess the pharmacokinetic characteristics of glimepiride and its metabolites in normal-weight and morbidly obese patients with type 2 diabetes to determine whether the pharmacokinetics of glimepiride are altered by obesity."5.11Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. ( Chi, EM; Lehr, KH; Shukla, UA, 2004)
"The goals of this study were to compare changes in measures of glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes who received pioglitazone or glimepiride for 1 year."5.11Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. ( Antúnez, O; Fabián, G; Flores-Lozano, F; Garza, E; González Gálvez, G; Herz, M; Johns, D; Konkoy, C; Morales, H; Tan, M; Zúñiga Guajardo, S, 2004)
"The aim of this study was to assess the differential effect on glucose and lipid variables and tolerability of the combination of glimepiride plus pioglitazone or rosiglitazone in patients with type 2 diabetes mellitus (DM) and metabolic syndrome."5.11Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. ( Bertone, G; Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Gaddi, A; Piccinni, MN; Ragonesi, PD, 2004)
" Metformin and pioglitazone had beneficial effects on lipid levels, improved insulin sensitivity and improved insulin secretion also."5.11Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians. ( Ramachandran, A; Salini, J; Snehalatha, C; Vijay, V, 2004)
"To evaluate the differential effect on coagulation and fibrinolysis parameters of combination therapy with glimepiride-metformin and with rosiglitazone-metformin beyond their effect on glucose metabolism in patients with type 2 diabetes and metabolic syndrome."5.11Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. ( Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Gaddi, AV; Ghelfi, M; Peros, E; Piccinni, MN; Salvadeo, S, 2005)
"To compare the effects of glimepiride plus pioglitazone or plus rosiglitazone in diabetic patients with the metabolic syndrome on coagulation and fibrinolysis parameters."5.11A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. ( Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Fogari, R; Gaddi, A; Piccinni, MN; Ragonesi, PD; Salvadeo, S, 2005)
"The primary aim of the present study was to compare the effect of long-term (12-month) combination treatment with glimepiride or rosiglitazone plus metformin on blood pressure in patients with type 2 diabetes mellitus (DM-2) and the metabolic syndrome."5.11Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. ( Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gaddi, AV; Ghelfi, M; Piccinni, MN; Pricolo, F; Salvadeo, S, 2005)
"The purpose of this study was to assess the effect of glimepiride on insulin sensitivity and secretion in subjects with type 2 diabetes."5.10Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. ( Gerich, J; Gooding, WE; Korytkowski, M; Reid, L; Tedesco, MB; Thomas, A, 2002)
"We investigated the effect of glimepiride, a third-generation sulfonylurea hypoglycemic agent, on insulin resistance in elderly patients with type 2 diabetes, in connection with plasma adiponectin and 8-epi-prostagrandin F2alpha (8-epi-PGF2alpha), an oxidative stress marker."5.10Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. ( Fukatsu, A; Hayashi, T; Iguchi, A; Kano, H; Matsui-Hirai, H; Miyazaki, A; Nomura, N; Suzuki, Y; Tsunekawa, T, 2003)
"The risk for nocturnal hypoglycemia was lower with glimepiride in combination with morning and bedtime insulin glargine than with glimepiride in combination with bedtime NPH insulin in patients with type 2 diabetes."5.10Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. ( Fritsche, A; Häring, HU; Schweitzer, MA, 2003)
"Our study compared the effects of glimepiride or glibenclamide treatment on body weight over 12 months of treatment in patients with Type 2 diabetes in routine outpatient practice."5.10Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. ( Beuth, J; Kolb, H; Martin, S; Scherbaum, WA; Schneider, B; van Leendert, R, 2003)
"In type 2 diabetic patients, the vasodilating response to forearm ischemia was the same whether patients were treated with diet treatment alone or with glibenclamide or glimepiride at blood glucose-lowering equipotent closes."5.09Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia. ( Brunelli, C; Cordera, R; Cordone, S; Olivotti, L; Rossettin, P; Schiavo, M; Spallarossa, P, 2001)
"To assess the effect of empagliflozin on bone fractures and bone mineral density in patients with type 2 diabetes in pooled placebo-controlled trial data and a head-to-head study versus glimepiride."4.98Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride. ( Kaspers, S; Kohler, S; Salsali, A; Woerle, HJ; Zeller, C, 2018)
" Eight cases of acute pancreatitis (AP) with liraglutide and one with any comparator (glimepiride) were found."4.91Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. ( Jensen, TM; Saha, K; Steinberg, WM, 2015)
"This study was a post hoc analysis of the CANDLE trial (UMIN000017669), which compared the effect of 24 weeks of treatment with canagliflozin or glimepiride for changes in N-terminal pro-brain natriuretic peptide in patients with T2DM and chronic heart failure (CHF)."4.31Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial. ( Ajioka, M; Hiramitsu, S; Imai, T; Kadokami, T; Node, K; Shimabukuro, M; Suzuki, M; Takahashi, N; Tanaka, A; Yamaguchi, S, 2023)
" Glimepiride is used to treat type II diabetes but is associated with side effects, like lower half-life, faster elimination, and hypoglycemia."4.12Self-assembled di- and tripeptide gels for the passive entrapment and pH-responsive, sustained release of an antidiabetic drug, glimepiride. ( Bhatia, Y; Halder, M; Singh, Y, 2022)
"The objective of this study was to evaluate QoL in patients of type 2 diabetes mellitus (T2DM) with hypertension after add-on empagliflozin to triple drug therapy (metformin, teneligliptin, and glimepiride)."4.12Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study. ( Bhat, MH; Masoodi, SR; Mir, SA; Najar, IA; Patyar, RR; Patyar, S, 2022)
" We report a case of a 71-year-old woman with type 2 diabetes on dapagliflozin, presenting with foul-smelling discharge and a large abscess in the perianal area."4.02Fournier's gangrene with dapagliflozin in a rural hospital: a case report. ( Aly, A; Davey, M; Elbeddini, A; Erickson, D; Gallinger, J; Hooda, N; Lee, S; Tayefehchamani, Y, 2021)
" His HbA1c-concentration is 71 mmol/mol, despite an initial 8% weight loss and treatment with metformin and glimepiride."3.96[Starting insulin or not? And if so, which basal insulin?] ( Tack, CJ; van de Laar, FA, 2020)
" This study sought to determine whether there is a differential risk of hospitalization for cardiovascular diseases (CVDs) between DPP-4 inhibitors and glimepiride."3.85Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes: A retrospective cohort study. ( Chin, HJ; Lee, EK; Nam, JH; Shin, JY, 2017)
"Canagliflozin 100 and 300 mg provided sustained reductions in body weight, BMI, and waist circumference in a greater proportion of patients with T2DM versus glimepiride or placebo over 104 weeks."3.83Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. ( Blonde, L; Canovatchel, W; Fung, A; Meininger, G; Stenlöf, K; Xie, J, 2016)
"Using nationwide administrative Danish registries, we followed all individuals without prior stroke or myocardial infarction who initiated metformin and an IS from 1997 through 2009."3.81Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study. ( Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015)
"In quarters with glipizide/glimepiride use, hospital admissions or emergency department visits for hypoglycemia were more common in person quarters with concurrent warfarin use compared with quarters without warfarin use (294/416,479 v 1903/3,938,939; adjusted odds ratio 1."3.81Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis. ( Goldman, DP; Gong, C; Jena, AB; Peters, A; Romley, JA; Williams, B, 2015)
" This was driven by the relative advantage of weight loss compared with rosiglitazone, glimepiride, and insulin glargine, and administration frequency compared with exenatide."3.78Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results. ( Bøgelund, M; Ericsson, Å; Jendle, J; Nilsen, B; Ridderstråle, M; Torffvit, O, 2012)
"Glimepiride can rapidly and stably improve glycemic control and lipoprotein metabolism, significantly alleviate insulin resistance and enhance fibrinolytic activity."3.76Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. ( Du, W; Huang, QX; Liu, L; Liu, YH; Xie, XM; Xu, DY; Zhao, SP, 2010)
" Myocardial ischemia after coronary angioplasty was evaluated in 20 nondiabetic and 23 diabetic patients chronically taking either glibenclamide or glimepiride."3.72Impairment of myocardial protection in type 2 diabetic patients. ( Chou, TF; Lee, TM, 2003)
"To investigate the effect of glimepiride and metformin on free fatty acid (FFA) in patients with Type 2 diabetes mellitus and to further study the relationship between free fatty acid and insulin resistance in patients with Type 2 diabetes mellitus."3.72[Effects of glimepiride and metformin on free fatty acid in patients with Type 2 diabetes mellitus]. ( Feng, Q; Mao, JP; Tang, JZ; Tang, WL; Yang, ZF; Zhou, ZG, 2004)
"Seventy drug-naïve patients with type 2 diabetes (mean age, 52."3.30Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study. ( Ahn, J; Florez, JC; Lim, S; Nauck, MA; Sohn, M, 2023)
"Dapagliflozin has a borderline significant effect on IRAPe but not IL-34, and Glimepiride has significant effect on IL-34 but not IRAPe."3.30Comparative study of Dapagliflozin versus Glimepiride effect on insulin regulated aminopeptidase (IRAP) and interleukin-34 (IL-34) in patient with type 2 diabetes mellitus. ( El-Gharbawy, NM; Omran, GA; Werida, RH; Zekry, R, 2023)
"Mean composite kidney disease progression occurred in 135 (10."3.30Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial. ( Bebu, I; de Boer, IH; Ghosh, A; Inzucchi, SE; Ismail-Beigi, F; McGill, JB; Mudaliar, S; Schade, D; Steffes, MW; Tamborlane, WV; Tan, MH; Wexler, DJ; Younes, N, 2023)
"Liraglutide treatment did not significantly influence levels of circulating miRNAs."3.30Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial. ( Jendle, J; Kruse, R; Nyström, T; Scherbak, NN, 2023)
"Intrarenal haemodynamics were estimated using the Gomez equations."3.11Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial. ( Danser, AHJ; Hartmann, B; Holst, JJ; Joles, JA; Kramer, MHH; Muskiet, MHA; Ouwens, DM; Smits, MM; Tonneijck, L; van Raalte, DH, 2022)
"Patients with type 2 diabetes who have cardiovascular disease and are receiving empagliflozin have a lower rate of primary composite cardiovascular outcomes."3.11Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study. ( Hasebe, M; Ito, K; Kondo, Y; Satoh, S; Tamura, H; Terauchi, Y, 2022)
"Nonalcoholic fatty liver disease (NAFLD) is a liver phenotype of type 2 diabetes and obesity."3.11Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial. ( Arai, K; Goto, H; Harada, K; Honda, M; Iida, N; Kaneko, S; Kita, Y; Mizukoshi, E; Nakamura, H; Nakano, Y; Takamura, T; Takata, N; Takeshita, Y; Tanaka, T; Tsujiguchi, H; Yamashita, T, 2022)
"In participants with type 2 diabetes, the incidences of microvascular complications and death were not materially different among the four treatment groups."3.11Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. ( Bebu, I; Burch, HB; Buse, JB; Cherrington, AL; Fortmann, SP; Green, JB; Kahn, SE; Kirkman, MS; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Phillips, LS; Pop-Busui, R; Steffes, M; Tiktin, M; Tripputi, M; Wexler, DJ; Younes, N, 2022)
"In people with type 2 diabetes, GLP-1 RAs reduce the risk of cardiovascular (CV) disease and may also potentially represent a treatment for fatty liver disease."3.01Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. ( Hyötyläinen, T; Jendle, J; Nyström, T; Orešič, M, 2021)
"Hydroxychloroquine was associated with significant reduction in HbA1c from baseline (7-8."3.01Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs. ( Chakravarti, HN; Nag, A, 2021)
" The primary endpoint was time to first occurrence of three-point major adverse CV events (MACE: CV death, non-fatal myocardial infarction, or non-fatal stroke)."3.01Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial. ( Andersen, KR; Espeland, MA; Johansen, OE; Kadowaki, T; Keller, A; Marx, N; Mattheus, M; McGuire, DK; Pratley, RE; Rosenstock, J; Seino, Y; Weber, M; Zinman, B, 2021)
"We aimed to investigate the effect of dosage reduction of four hypoglycemic multidrug regimens on the incidences of acute glycemic complications in people with type 2 diabetes who fast during Ramaḍān."3.01Effect of Dosage Reduction of Hypoglycemic Multidrug Regimens on the Incidences of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramaḍān: A Randomized Controlled Trial. ( Amarin, JZ; Beirat, AF; Hasan, YY; Hassoun Al Najar, AM; Qtaishat, A; Tierney, ME; Zaghlol, LY; Zaghlol, RY; Zayed, AA, 2021)
"Non-alcoholic fatty liver disease (NAFLD) is often observed in individuals with type 2 diabetes mellitus, and it is known that the presence of type 2 diabetes mellitus leads to the aggravation of NAFLD."2.94Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study. ( Fushimi, Y; Hirata, Y; Hirukawa, H; Irie, S; Kaku, K; Kaneto, H; Kimura, T; Kinoshita, T; Kohara, K; Mune, T; Nakamura, Y; Nakanishi, S; Nakashima, K; Nishioka, M; Obata, A; Sanada, J; Shimoda, M; Tanabe, A; Tatsumi, F, 2020)
" The study aimed to evaluate the bioequivalence and safety profiles of two different formulations of glimepiride 1 mg from two different manufactures in healthy Chinese subjects in the fasting and fed state in order to acquire adequate pharmacokinetic evidence for registration approval of the test formulation."2.94Evaluation of Bioequivalency and Pharmacokinetic Parameters for Two Formulations of Glimepiride 1-mg in Chinese Subjects. ( Chen, S; Ju, G; Qiu, W; Xu, Y; Yan, K; Zheng, Z, 2020)
" The most frequent gastrointestinal drug-related adverse events with dulaglutide were diarrhea, abdominal distension, nausea and vomiting."2.94Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post-hoc analyses of a randomized, double-blind, phase III study. ( Chen, LL; Du, LY; Li, QM; Li, YB; Liu, XM; Ma, JH; Shi, LX; Shi, YQ; Wang, F, 2020)
"Pioglitazone has proved effective in raising HDL cholesterol (HDL-C) and lowering small dense low-density lipoprotein (LDL), but no clinical studies have examined its effect on lipoprotein oxidation in patients with DM2."2.90Long-term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. ( Burlina, S; Chilelli, NC; Cosma, C; Lapolla, A; Marin, R; Ragazzi, E; Roverso, M; Sartore, G; Seraglia, R; Vaccaro, O, 2019)
"People with type 2 diabetes mellitus (T2D) have preclinical cardiac and vascular dysfunction associated with low cardiorespiratory fitness (CRF)."2.90Sitagliptin improves diastolic cardiac function but not cardiorespiratory fitness in adults with type 2 diabetes. ( Cree-Green, M; Huebschmann, AG; Rafferty, D; Regensteiner, JG; Reusch, JEB; Scalzo, RL; Schauer, I, 2019)
" A Liver Safety Evaluation Committee consisting of hepatologists blinded to treatment assignments evaluated hepatic adverse events (AEs) and serious AEs (SAEs) for causal relationship to study drug."2.87Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience. ( Marcinak, JF; Munsaka, MS; Ohira, T; Smith, N; Watkins, PB, 2018)
" The most common drug-related adverse events in both dulaglutide groups (≥5% of patients) included diarrhoea, nausea, increased lipase, decreased appetite, abdominal distension and vomiting."2.87Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial. ( Chen, YH; Cho, YM; Gu, L; Huang, CN; Li, P; Wang, F; Wang, WQ; Yang, J, 2018)
"A total of 168 patients with type 2 diabetes treated with >4 mg of glimepiride and 1000 mg of metformin by using free or fixed-dose combination therapy for at least 2 weeks were enrolled."2.87Comparison of Adherence to Glimepiride/Metformin Sustained Release Once-daily Versus Glimepiride/Metformin Immediate Release BID Fixed-combination Therapy Using the Medication Event Monitoring System in Patients With Type 2 Diabetes. ( Ahn, KJ; Cha, BY; Chung, MY; Kang, JG; Kim, IJ; Kim, JD; Kim, JT; Lee, HW; Min, KW; Park, CY; Park, KS; Park, SW; Won, JC, 2018)
"Patients with type 2 diabetes and HbA1c 53-86 mmol/mol (7% to 10%) were randomized to empagliflozin 25 mg or glimepiride 1 to 4 mg for 104 weeks as add-on to metformin."2.87Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial. ( Andersen, KR; Ridderstråle, M; Rosenstock, J; Salsali, A; Woerle, HJ, 2018)
"215 patients newly diagnosed with type 2 diabetes mellitus were randomized into Glimepiride-Metformin group (Group1) having 111 patients and Vildagliptin-Metformin group (Group 2) having 106 patients."2.87Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients. ( Kaundal, PK; Mokta, JK; Mokta, K; Sahai, AK, 2018)
" With the exception of hypoglycemia, the incidences of adverse events and discontinuations were similar between treatment groups."2.84A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. ( Engel, SS; Gantz, I; Handelsman, Y; Iredale, C; Kaufman, KD; Lai, E; Lauring, B; O'Neill, EA; Suryawanshi, S; Wei, Z, 2017)
" The overall incidences of adverse events (AEs), serious AEs, drug-related AEs and discontinuations were generally similar between treatment groups."2.84A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin. ( Ceesay, P; Engel, SS; Gantz, I; Kaufman, KD; Lai, E; Latham, M; Lee, SH; O'Neill, EA; Round, E; Suryawanshi, S, 2017)
"A total of 16 patients with type 2 diabetes whose glycated hemoglobin was >7% were randomized to add vildagliptin or glimepiride."2.84Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride. ( Cho, YM; Jang, HC; Jung, HS; Kim, SY; Kwak, S; Park, KS, 2017)
"Japanese patients with type 2 diabetes mellitus who were stably maintained on ≤2mg/day glimepiride alone were recruited and randomly assigned to receive additional sitagliptin (n=37) or αGI (n=37)."2.84Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163, a marker for activated macrophage, in individuals with type 2 diabetes mellitus. ( Hattori, A; Koshizaka, M; Takemoto, M; Tokuyama, H; Yokote, K, 2017)
" The incidences of adverse events (AEs) were 29."2.84Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial. ( Bi, Y; Engel, SS; Ji, L; Ji, Q; Jia, W; Lu, J; Mao, A; Mu, Y; Ran, X; Weng, J; Xu, W; Yang, W; Yao, B; Zeng, L; Zhao, B; Zhao, J; Zhou, Z; Zhu, D, 2017)
" Safety endpoints were adverse events including hypoglycaemia."2.84Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial). ( Ishida, H; Kitaoka, M; Ohsugi, M; Satoh, J; Seino, Y; Shihara, N; Terauchi, Y; Yabe, D; Yamada, Y, 2017)
"Patients with type 2 diabetes have an increased risk of fragility fractures; the cause is unclear but is likely multifactorial."2.82COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES. ( Baeres, FM; Garber, A; Gilbert, MP; Holst, JJ; Marre, M; Pratley, RE; Thomsen, H, 2016)
" The most common treatment-emergent adverse events for dulaglutide 1."2.82A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). ( Dungan, KM; Fahrbach, JL; Jiang, HH; Perez Manghi, F; Pintilei, E; Robertson, KE; Shell, J; Weitgasser, R, 2016)
" The insulin dosing algorithm was not sufficient to equalize nocturnal hypoglycaemia between the two insulins."2.80Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes. ( Bolli, GB; Candelas, C; Dain, MP; Deerochanawong, C; Home, PD; Landgraf, W; Mathieu, C; Pilorget, V; Riddle, MC, 2015)
"Patients with type 2 diabetes failing metformin were randomized to add-on exenatide twice daily (n = 515) or glimepiride (n = 514) until treatment failure defined by hemoglobin A1C."2.80Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. ( Dotta, F; Festa, A; Gallwitz, B; Guerci, B; Kiljański, J; Rosas-Guzmàn, J; Schernthaner, G; Simó, R; Zhou, M, 2015)
" Insulin dosage and weight-gain were similar."2.79Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. ( Gao, L; Riddle, MC; Rosenstock, J; Vlajnic, A, 2014)
" The incidence rates of adverse events and adverse drug reactions, including hypoglycaemia, during the double-blind randomized period were similar in both groups."2.79Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension. ( Kadowaki, T; Kondo, K, 2014)
"People with inadequately controlled type 2 diabetes (n = 99) were randomly assigned on a 1∶1∶1 basis to receive insulin glargin, with fixed doses of glimepiride, metformin, and glimepiride plus metformin."2.79Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes. ( Chon, S; Kang, JG; Lee, CB; Noh, J; Oh, SJ; Park, CY; Park, SW, 2014)
" Rates of serious adverse events in the albiglutide group were similar to comparison groups."2.79HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. ( Ahrén, B; Cirkel, DT; Feinglos, MN; Johnson, SL; Perry, C; Stewart, M; Yang, F, 2014)
"Glimepiride was up-titrated once weekly in a treat-to-target manner; liraglutide was up-titrated once weekly to 1."2.79Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial. ( Bagger, JI; Faber, J; Hansen, T; Holst, JJ; Knop, FK; Pedersen, O; Vilsbøll, T; Østoft, SH, 2014)
"Fifty-six type 2 diabetes mellitus patients who had been treated with 50 mg of sitagliptin, ≥ 1,000 mg of metformin, and ≤ 1 mg of glimepiride with an HbA1c level of <7."2.78Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus. ( Arai, K; Hirao, K; Hirao, S; Hirao, T; Maeda, H; Sirabe, S; Yamamoto, R; Yamauchi, M, 2013)
"Linagliptin treatment for 104 weeks was recently reported to achieve non-inferior glucose-lowering effects compared with glimepiride in patients with type 2 diabetes inadequately controlled with metformin."2.78Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 years. ( Emser, A; Gallwitz, B; Rosenstock, J; von Eynatten, M; Woerle, HJ, 2013)
"The following patients with type 2 diabetes mellitus were recruited for the study: those aged 18-79 years, on a stable dose of metformin monotherapy ≥1,500 mg/day for ≥12 weeks, with an HbA1c ≥7."2.78Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical tri ( Charbonnel, B; Davies, MJ; Engel, SS; Eymard, E; Prabhu, V; Steinberg, H; Thakkar, P; Xu, L, 2013)
"The epidemic of type 2 diabetes (T2DM) threatens to become the major public health problem of this century."2.78Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). ( Buse, JB; Kahn, SE; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Staten, M; Wexler, D, 2013)
"Vildagliptin treatment was associated with less fluctuation of glucose levels than glimepiride treatment as assessed by 24-h CGM device, suggesting vildagliptin may have the potential to offer long-term beneficial effects for patients with T2DM in preventing the development of complications of diabetes."2.78Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring. ( Forst, T; Foteinos, G; He, YL; Kulmatycki, K; Mattapalli, D; Neelakantham, S; Taylor, A, 2013)
" 39 (8%) patients had serious adverse events in the glimepiride group versus 24 (5%) in the canagliflozin 100 mg group and 26 (5%) in the 300 mg group."2.78Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. ( Arias, P; Balis, DA; Canovatchel, W; Cefalu, WT; Leiter, LA; Meininger, G; Niskanen, L; Xie, J; Yoon, KH, 2013)
"Empagliflozin is a sodium glucose cotransporter 2 (SGLT2) inhibitor in development for the treatment of T2DM."2.78Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. ( Broedl, UC; Kim, G; Ridderstråle, M; Svaerd, R; Woerle, HJ; Zeller, C, 2013)
"MTT was applied to previously untreated Type 2 Diabetes Mellitus (T2DM) subjects."2.78The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study. ( Fujioka, Y; Inoue, K; Izawa, S; Kato, M; Matsuzawa, K; Nakanishi, R; Ohkura, H; Ohkura, T; Shiochi, H; Sumi, K; Taniguchi, S; Yamamoto, K; Yamamoto, N, 2013)
" Even if limited by the small number of studied subjects, who were not matched in the two treatment groups, this research study represents the first FMD evidence suggesting that chronic administration of exenatide improves arterial dilation."2.78Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. ( Carallo, C; De Luca, S; Gnasso, A; Irace, C; Loprete, A; Scavelli, F; Shehaj, E, 2013)
"Pioglitazone is an insulin sensitizer used for the management of type 2 diabetes mellitus (T2DM)."2.78Effect of pioglitazone on testosterone in eugonadal men with type 2 diabetes mellitus: a randomized double-blind placebo-controlled study. ( Bhansali, A; Sachdeva, N; Sridhar, S; Walia, R, 2013)
"Glimepiride was the most commonly prescribed sulfonylurea (75."2.78Usage pattern, glycemic improvement, hypoglycemia, and body mass index changes with sulfonylureas in real-life clinical practice: results from OBSTACLE Hypoglycemia Study. ( Agrawal, N; Deepak, MC; Kalra, S; Narang, P; Singh, V; Uvaraj, MG, 2013)
"1%) had five treatment-related adverse events, and 10 patients in group B (32."2.78A multicenter, phase III evaluation of the efficacy and safety of a new fixed-dose pioglitazone/glimepiride combination tablet in Japanese patients with type 2 diabetes. ( Hirayama, M; Hiroi, S; Kaku, K; Kawakami, K; Kuriyama, K; Matsuno, K; Sugiura, K, 2013)
"Glimepiride treatment as initial mono-therapy could effectively improve blood glucose control in type 2 diabetic patients, with a favorable safety profile."2.78Efficacy and safety of glimepiride as initial treatment in Chinese patients with Type 2 diabetes mellitus. ( Duan, WR; Gao, Y; Guo, XH; Han, P; Lv, XF; Yang, HZ; Zhang, XZ, 2013)
"In newly diagnosed type 2 diabetes, therapy with oral drugs + insulin has had favourable outcomes on recovery and maintenance of β-cell function and protracted glycaemic remission compared with treatment with oral drugs alone."2.77Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes. ( Chen, YM; Lu, HY; Mu, PW; Shu, J; Wang, MM; Wen, XQ; Xie, RY; Zeng, LY; Zhang, YH, 2012)
"Glimepiride treatment more modestly decreased LDL particle number and increased LDL particle size."2.77Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes. ( D'Agostino, R; Davidson, MH; Haffner, S; Mazzone, T; Perez, A; Sam, S, 2012)
" Primary endpoints were the area under the curve from the time of dosing to infinity (AUC(inf)) and the maximum observed plasma concentration (C(max)) of each drug."2.77No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. ( Kadokura, T; Keirns, J; Krauwinkel, WJ; Smulders, RA; van Dijk, J; Veltkamp, SA; Zhang, W, 2012)
"Patients aged 18-85 years with type 2 diabetes inadequately treated by metformin were randomly assigned via a computer-generated randomisation sequence to receive exenatide twice daily or glimepiride once daily as add-on to metformin."2.77Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. ( Basson, BR; Dotta, F; Festa, A; Gallwitz, B; Guerci, B; Guzman, J; Kiljański, J; Sapin, H; Schernthaner, G; Simó, R; Trautmann, M, 2012)
"In total, 155 type 2 diabetes patients were randomly assigned to two groups, which only differed in the frequency of follow-up visits."2.77Effects of frequency of follow-up on quality of life of type 2 diabetes patients on oral hypoglycemics. ( Hu, M; Sun, Z; Zeng, F; Zhou, Z, 2012)
"Thirty-one type 2 diabetes patients treated with metformin (glycosylated hemoglobin [HbA1c] 6."2.77Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose? ( Colette, C; Comenducci, A; Dejager, S; Monnier, L; Vallée, D, 2012)
"Glimepiride and metformin were effective in improving glucose and lipid profiles and norepinephrine levels."2.77Metformin, but not glimepiride, improves carotid artery diameter and blood flow in patients with type 2 diabetes mellitus. ( Correia, MR; Cunha, MR; Fukui, RT; Lage, SG; Machado, HA; Rocha, DM; Santos, RF; Silva, ME; Vieira, M; Wajchenberg, BL, 2012)
"Treatment with liraglutide 1."2.76Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl ( Bech, OM; Bhattacharyya, A; Chen, L; Ji, Q; Kim, KW; Kumar, A; Liu, X; Ma, J; Tandon, N; Yang, W; Yoon, KH; Zychma, M, 2011)
"patients with type 2 diabetes and an HbA(1c) of 6."2.76Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. ( Arechavaleta, R; Chen, Y; Duran, L; Goldstein, BJ; Kaufman, KD; Krobot, KJ; O'Neill, EA; Seck, T; Williams-Herman, D, 2011)
"0%), even at maximal dosage levels of one or two oral agents, and are at increased risk for diabetes-related complications."2.76Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. ( Conner, C; Hammer, M; Lee, WC, 2011)
"Dyslipidemia in patients with type 2 diabetes is characterized by elevated triglyceride levels, decreased high-density lipoprotein (HDL) cholesterol, and a predominance of small dense low-density lipoprotein (LDL) particles."2.76PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. ( Forst, T; Fuchs, W; Lehmann, U; Lobmann, R; Merke, J; Müller, J; Pfützner, A; Schöndorf, T; Tschöpe, D, 2011)
"We included 78 men with type 2 diabetes (aged 56."2.75Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes. ( de Haan, W; de Roos, A; Diamant, M; Jonker, JT; Lamb, HJ; Rensen, PC; Rijzewijk, LJ; Romijn, JA; Smit, JW; Tamsma, JT; van der Meer, RW; Wang, Y, 2010)
"Ninety-eight patients with type 2 diabetes and a fasting blood glucose (FBG) levels between 7."2.75Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes. ( Chen, Y; Hu, YY; Wu, FZ; Ye, SD; Zhao, LL; Zheng, M, 2010)
"New treatments for type 2 diabetes mellitus are needed to retain insulin-glucose coupling and lower the risk of weight gain and hypoglycaemia."2.74Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. ( Bode, B; Garber, A; Garcia-Hernandez, PA; Hale, PM; Henry, R; Olvera-Alvarez, I; Ratner, R; Rodriguez-Pattzi, H; Zdravkovic, M, 2009)
"In subjects with type 2 diabetes, once-daily liraglutide induced similar glycemic control, reduced body weight, and lowered the occurrence of hypoglycemia compared with glimepiride, when both had background therapy of metformin."2.74Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. ( Düring, M; Frid, A; Hermansen, K; Matthews, DR; Mitha, IH; Nauck, M; Shah, NS; Tankova, T; Zdravkovic, M, 2009)
" The incidence of adverse events (AEs), serious AEs and adjudicated cardiovascular events was 74."2.74Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. ( Ahrén, B; Byiers, S; Dejager, S; Ferrannini, E; Fonseca, V; Matthews, D; Shao, Q; Zinman, B, 2009)
"Twenty-eight patients with type 2 diabetes already on metformin, without known cardiovascular disease, were randomized in 2 groups; glimepiride (4 mg od) was added in group A (n=14) and pioglitazone (30 mg od) in group B (n=14) for 6 months."2.74Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes. ( Kanioglou, C; Katsouras, CS; Kazakos, N; Kolettis, T; Liveris, K; Makriyiannis, D; Michalis, LK; Naka, KK; Papathanassiou, K; Pappas, K; Tsatsoulis, A, 2009)
"Forty patients with type 2 diabetes mellitus were included."2.74Glimepiride increases high-density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus. ( Araki, T; Emoto, M; Ikuno, Y; Konishi, T; Koyama, H; Lee, E; Mori, K; Motoyama, K; Nishizawa, Y; Shoji, T; Teramura, M; Yokoyama, H, 2009)
"Poor control of type 2 diabetes results in substantial long-term consequences."2.74Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. ( Alfonso-Cristancho, R; Blonde, L; Conner, C; Hammer, M; Sullivan, SD, 2009)
"Two hundred seventy-one type 2 diabetes mellitus patients with poor glycemic control and who were overweight were enrolled in this study."2.74Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Salvadeo, SA, 2009)
"Metformin/repaglinid is an efficient and safe therapeutic regime in the treatment of the type 2 DM that ensure a better control of PBG levels (Tab."2.74Evaluation of the repaglinide efficiency in comparison to the glimepiride in the type 2 diabetes patients poorly regulated by the metmorfine administration. ( Antic, S; Dimic, D; Radenkovic, S; Velojic Golubovic, M, 2009)
"Seven hundred forty-six patients with type 2 diabetes who participated in the LEAD-3 trial, and three hypothetical cohorts of 5000 patients each that were based on the baseline characteristics of the patients in the LEAD-3 trial."2.74A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus. ( Alfonso-Cristancho, R; Blonde, L; Conner, C; Hammer, M; Sullivan, SD, 2009)
"glimepiride were evaluated in normoalbuminuric patients with type 2 diabetes mellitus."2.74Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. ( Bob, F; Bozdog, G; Dragos Jianu, C; Dumitrascu, V; Gadalean, F; Giju, S; Gluhovschi, C; Gluhovschi, G; Ianculescu, C; Marian, R; Petrica, L; Petrica, M; Ursoniu, S; Velciov, S; Vlad, A, 2009)
"One hundred twenty (120) patients with type 2 diabetes mellitus were randomized and treated with glimepiride plus rosiglitazone or glimepiride plus metformin for 12 weeks."2.73Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. ( Ahn, CW; Cha, BS; Chung, CH; Kang, ES; Kim, DJ; Kim, HJ; Kim, SH; Lee, HC; Lee, KW; Nam, CM; Nam, M, 2007)
" Insulin dosage in each group was titrated to target fasting blood glucose (FBG) of 100 mg/dL or less (2.73Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. ( Busch, K; Janka, HU; Plewe, G, 2007)
" 47%) and drug-related adverse experiences (AEs) (15 vs."2.73Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. ( Fanurik, D; Hermansen, K; Khatami, H; Kipnes, M; Luo, E; Stein, P, 2007)
"To compare the pharmacokinetic and pharmacodynamic effects of glimepiride between once- and twice-daily dosing in type 2 diabetic patients."2.73Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once- versus twice-daily dosing. ( Kaku, K; Kanda, Y; Kawasaki, F; Kohara, K; Kotani, K; Matsuda, M; Matsuki, M; Shigetoh, M; Shimoda, M; Tawaramoto, K, 2007)
"In total, 192 type 2 diabetes patients were enrolled into the study."2.73Relaxin expression correlates significantly with serum fibrinogen variation in response to antidiabetic treatment in women with type 2 diabetes mellitus. ( Armbruster, FP; Borchert, M; Forst, T; Grabellus, M; Hohberg, C; Hoopmann, M; Löbig, M; Lübben, G; Pfützner, A; Roth, W; Schöndorf, T, 2007)
"This study assessed the efficacy and safety of two different dosing regimens of fixed-dose combination (FDC) rosiglitazone (RSG) plus glimepiride (GLIM) compared with RSG or GLIM monotherapy in drug-naive subjects with type 2 diabetes mellitus (T2DM)."2.73Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes. ( Chou, HS; Ferreira-Cornwell, C; Goldstein, BJ; Jones, AR; Krebs, J; Palmer, JP; Waterhouse, B, 2008)
"Strategies for the addition of RSG in combination with GLIM were evaluated with data from two randomized, double-blind, placebo (PBO)-controlled studies."2.73Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes. ( Chou, HS; Hamann, A; Matthaei, S; Rosenstock, J; Seidel, DK, 2008)
"placebo in patients with type 2 diabetes mellitus (T2DM) who are inadequately controlled [haemoglobin A(1c) (HbA(1c)) 7."2.73Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. ( Banerji, MA; Baron, MA; Camisasca, RP; Couturier, A; Ebeling, P; Foley, JE; Garber, AJ; Gudbjörnsdottir, S, 2008)
"Pioglitazone treatment led to improvement in levels of multiple cardiovascular risk markers, including high-sensitivity C-reactive protein, apolipoprotein B, apolipoprotein A1, high-density lipoprotein (HDL) cholesterol, triglyceride, insulin, and free fatty acid."2.73Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. ( Chen, Z; D'Agostino, R; Davidson, M; Feinstein, S; Haffner, S; Kondos, GT; Mazzone, T; Meyer, PM; Perez, A, 2008)
"Insulin resistance was defined by elevated intact proinsulin values or homeostasis model assessment for insulin resistance score of more than 2."2.72Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. ( Forst, T; Hamann, A; Matthaei, S; Pfützner, A; Schöndorf, T; Seidel, D; Winkler, K, 2006)
" The pharmacokinetic study showed that the area under the concentration-time curve for glimepiride in the CYP2C9*1/*3 subjects was approximately 2."2.72Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. ( Hasegawa, R; Kaniwa, N; Shibasaki, T; Suzuki, K; Tohkin, M; Yanagawa, T, 2006)
"Glimepiride treatment was associated with an increased risk of hypoglycemia and pioglitazone with higher rate of peripheral edema."2.72Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. ( Issa, M; Umpierrez, G; Vlajnic, A, 2006)
"Starting insulin in Type 2 diabetes patients with twice-daily BIAsp 30 plus met can reduce HbA (1c) and mean prandial plasma glucose increment to a greater extent than once-daily glarg plus glim."2.72Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. ( Kann, PH; Medding, J; Moeller, J; Mokan, M; Mrevlje, F; Regulski, M; Szocs, A; Wascher, T; Zackova, V, 2006)
"Glimepiride-treated patients also achieved a significantly greater improvement in FPG, with an adjusted mean (SE) treatment difference of -46."2.71Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. ( Atherton, T; Bugos, C; Dirnberger, G; Luis Bautista, J, 2003)
"To compare the metabolic and vascular effects of two sulphonylureas (SU), gliclazide (specific for the pancreatic [SUR1] receptor) and glimepiride (a nonspecific agent that also binds to vascular and cardiac [SUR2] receptors), during chronic administration in metformin-treated patients with Type 2 diabetes (T2DM)."2.71Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study. ( Davis, KR; Dhindsa, P; Donnelly, R, 2003)
"Treatment with glimepiride also resulted in significant and stable weight loss relative to baseline, with the exception of patients with a body mass index of <25 kg/m(2)."2.71Effects of glimepiride on HbA(1c) and body weight in Type 2 diabetes: results of a 1.5-year follow-up study. ( Klingler, A; Lechleitner, M; Luger, A; Weitgasser, R, 2003)
"Glimepiride was associated with a significantly greater responder rate than acarbose (61 vs 34%, p < 0."2.71Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone. ( Bielesz, GK; Egger, T; Feinböck, C; Frank, E; Grossschädl, F; Irsigler, K; Klingler, A; Luger, A; Siebenhofer, A; Winkler, F, 2003)
" In the diabetic patients, glimepiride tablets were administered orally, initially at 2 mg once daily in the morning, with the dosage increased by 1 mg every 2 weeks until fasting plasma glucose (FPG) decreased to 6."2.71Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus. ( Kabadi, MU; Kabadi, UM, 2004)
"Patients with Type 2 diabetes (T2DM) are at high risk of morbidity and mortality from cardiovascular complications, and hypoglycaemia increases this risk."2.71Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. ( Ciccarelli, L; Derosa, G; Fogari, R; Franzetti, I; Gadaleta, G, 2004)
" Insulin dosage was titrated to target FBG 2.71Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. ( Janka, HU; Kliebe-Frisch, C; Plewe, G; Riddle, MC; Schweitzer, MA; Yki-Järvinen, H, 2005)
"Type 2 diabetes is associated with increased cardiovascular risk."2.71Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. ( Forst, T; Konrad, T; Langenfeld, M; Lübben, G; Marx, N; Pfützner, A; Walcher, D, 2005)
"A total of 114 patients with Type 2 diabetes who had never used oral hypoglycaemic drugs were studied for 12 months."2.71Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. ( Ichiyanagi, K; Igarashi, K; Kawasaki, T; Sakai, T; Watanabe, H; Yamanouchi, T, 2005)
"Patients with a diagnosis of type 2 diabetes for a minimum of 1 year received glimepiride (titrated sequentially from 2 to 4 to 8 mg/d over 6 weeks, followed by 20 weeks of maintenance therapy) or placebo in combination with an established regimen of immediate- or extended release metformin and rosiglitazone or pioglitazone."2.71Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. ( Issa, M; Lake, B; Melis, R; Roberts, VL; Stewart, J, 2005)
" These significant levels were achieved within 8 weeks and all patients tolerated the drug well with no reported case of serious adverse events including hypoglycaemia."2.71Evaluation of efficacy and safety of fixed dose combination of glimepiride 2 mg pluspioglitazone 15 mg plus metformin SR 500 mg in the management of patients with type-2 diabetes mellitus. ( Chopra, D; Kinagi, SB; Langade, DG; Meshram, DM; Morye, V; Naikwadi, AA, 2005)
" The patients started at a baseline dosage of 1 mg which was then it was gradually adjusted according to the blood sugar level."2.70Amaryl (glimepiride) in patients with type 2 diabetes mellitus. ( Botushanov, NP; Husianitis, HK; Iliev, DA; Simeonov, SB, 2002)
"Patients aged 35-70 years with poorly controlled diabetes [fasting plasma glucose (FPG) > or =1,40 g/l and < 3 g/l at baseline] were treated with glimepiride for 6 months, with dosage titrated from 1-6 mg daily, depending on the monthly FPG measurement."2.70Predictors of response to glimepiride in patients with type 2 diabetes mellitus. ( Altman, JJ; Charpentier, G; Derobert, E; Etienne, S; Fleury, F; Grimaldi, A; Halimi, S; Oriol, V; Vaur, L, 2001)
"Glimepiride was indicated to be safe."2.70Glimepiride in type 2 diabetes mellitus Thai patients. ( Benjasuratawong, Y; Chandraprasert, S; Deerochanawong, C; Himathongkam, T; Nitiyanant, W; Sarinnapakorn, V; Suthijumroon, A; Suwanwalaikorn, S; Vichayanrat, A; Vongterapak, S, 2001)
"Therefore, glibenclamide treatment of Type 2 diabetes mellitus may have hazardous cardiovascular effects when used under conditions of ischaemia."2.70Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients. ( Abbink, EJ; Jansen van Rosendaal, A; Lutterman, JA; Pickkers, P; Russel, FG; Smits, P; Tack, CJ, 2002)
" A dosage of 70/30 insulin before supper was titrated, seeking fasting capillary blood glucose (FBG) 120 mg/dl (6."2.69Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. ( Riddle, MC; Schneider, J, 1998)
"Sulfonylureas are used to treat patients with type 2 diabetes mellitus when diet and exercise fail."2.69Appropriate timing of glimepiride administration in patients with type 2 diabetes millitus: a study in Mediterranean countries. ( Gomis, R; Raptis, SA; Ravella, R, 2000)
"Glimepiride is a new long-acting the third generation sulfonylurea given once daily."2.69[Evaluation of efficacy, safety and tolerance of glimepiride (Amaryl) in patients with type 2 diabetes]. ( Drzewoski, J; Jasik, M; Karnafel, W; Kasperska-Czyzykowa, T; Lopatyński, J, 2000)
"To assess the efficacy, safety, and dose-response relationship of glimepiride in patients with NIDDM."2.68A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. ( Goldberg, RB; Holvey, SM; Schneider, J, 1996)
"Glimepiride is an effective and well-tolerated oral glucose-lowering agent."2.68Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. ( Muchmore, DB; Rosenstock, J; Samols, E; Schneider, J, 1996)
" The long-term follow-up (457 patients) confirmed that glimepiride (1-8 mg) once daily provides equivalent metabolic control to a higher dosage (2."2.68Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. ( Draeger, KE; Lomp, HJ; Rosskamp, R; Schüler, E; Wernicke-Panten, K, 1996)
"To provide a more effective treatment of type 2 diabetes mellitus (T2DM), this study aims to compare different efficacies of six kinds of hypoglycemic drugs based on metformin, including glimepiride, pioglitazone, exenatide, glibenclamide, rosiglitazone, and vildagliptin, in T2DM by a network meta-analysis that were verified by randomized-controlled trials (RCTs)."2.61Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials. ( Chen, SH; Liu, XN; Peng, Y; Sun, QY, 2019)
"The projected rise in the incidence of type 2 diabetes mellitus (T2DM) could develop into a substantial health problem worldwide."2.53Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. ( Hemmingsen, B; Metzendorf, MI; Richter, B; Sonne, DP, 2016)
" The safety variables included were as follows: weight variation at the end of treatment; presentation of any type of adverse event; presentation of serious adverse events; patients who experienced any type of hypoglycaemia; patients who experienced severe hypoglycaemia; treatments suspended due to adverse effects; and deaths for any reason."2.52Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis. ( Almendro, N; Amate, JM; Bouza, C; Gonzalez-Canudas, J; Lopez-Cuadrado, T; Rivas-Ruiz, R; Saz-Parkinson, Z, 2015)
"Liraglutide is a once-daily human glucagon-like peptide-1 analogue used in the treatment of type 2 diabetes (T2D)."2.48The design of the liraglutide clinical trial programme. ( Nauck, MA, 2012)
"Glimepiride is a second-generation sulfonylurea that stimulates pancreatic β cells to release insulin."2.48Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]. ( Basit, A; Fawwad, A; Riaz, M, 2012)
"New drugs for type 2 diabetes that act on incretin metabolism have been shown to improve glycemic control, reduce body weight and have a low risk for hypoglycemia."2.48[Liraglutide: new results in the treatment of type 2 diabetes mellitus]. ( Mateos, JL; Wajchenberg, BL, 2012)
" Longer-acting GLP-1 agonists are dosed less frequently, appear to be associated with less nausea, and may be associated with better rates of adherence than shorter-acting agents."2.47Optimizing outcomes for GLP-1 agonists. ( Freeman, JS, 2011)
"When patients with type 2 diabetes fail to achieve strict HbA1c control with oral glucose-lowering drugs, insulin is the standard recourse."2.46Liraglutide. Type 2 diabetes: more prudent to continue using exenatide. ( , 2010)
"Vildagliptin is a potent and selective oral dipeptidyl peptidase-4 inhibitor that improves glycaemic control in patients with type 2 diabetes mellitus (T2DM) by increasing both alpha- and beta-cell responsiveness to glucose."2.45Translating science into clinical practice: focus on vildagliptin in combination with metformin. ( Barnett, AH, 2009)
"Treatment with pioglitazone produced improvement in several parameters, such as systolic blood pressure and lipid levels, including a 14% increase in HDL cholesterol, and reduced CIMT progression, compared with glimepiride."2.45The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus. ( Davidson, M; Mazzone, T; Polonsky, T, 2009)
"Type 2 diabetes has become a major burden to the health care systems worldwide."2.44Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination. ( Forst, T; Pfützner, A; Wilhelm, B, 2007)
"Pioglitazone is a potent and selective peroxisome proliferator-activated receptor-gamma agonist that improves whole-body insulin sensitivity and augments hepatic glucose uptake."2.44Pioglitazone plus glimepiride: a promising alternative in metabolic control. ( Derosa, G, 2007)
"Pioglitazone HCL is an insulin sensitizer in the TZD family and glimepiride is an insulin secretagogue in the SU family."2.44A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes. ( Dorkhan, M; Frid, A, 2007)
"In the treatment of elderly type 2 diabetes, it is important to detect hypoglycemia correctly, because the elderly patients often exhibit atypical symptoms from hypoglycemia."2.43[Knack of treatment with oral hypoglycemic drugs in the elderly]. ( Hashizume, K; Komatsu, M, 2006)
"Glimepiride is a once-daily SU that was introduced in 1995."2.42Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. ( Massi-Benedetti, M, 2003)
"Type 2 diabetes mellitus is a progressive disorder, and although oral monotherapy is often initially successful, it is associated with a high secondary failure rate, which contributes to the development of long-term diabetes complications resulting from persistent hyperglycemia."2.41Combining sulfonylureas and other oral agents. ( Riddle, M, 2000)
" Its convenient once daily dosing may enhance compliance for diabetic patients who often also require medications for other co-morbid conditions, such as hypertension, hyperlipidaemia and cardiac disease."2.41Clinical review of glimepiride. ( McCall, AL, 2001)
"Glimepiride is expected to be a new efficient agent for the treatment of Type 2 diabetes."2.41[Glimepiride (Amaryl): a review of its pharmacological and clinical profile]. ( Bando, K; Yamada, Y, 2001)
"Glimepiride is a sulphonylurea agent that stimulates insulin release from pancreatic beta-cells and may act via extrapancreatic mechanisms."2.40Glimepiride. A review of its use in the management of type 2 diabetes mellitus. ( Balfour, JA; Langtry, HD, 1998)
"Glimepiride is a sulfonylurea that is pharmacologically distinct from other sulfonylureas because of differences in receptor-binding properties and potentially selective effects on ATP-sensitive K+ channels."2.40Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. ( Campbell, RK, 1998)
"In older patients with type 2 diabetes, life expectancy and the presence of microvascular complications determine the appropriate intensity of glucose control."2.40Type 2 diabetes: glycemic targets and oral therapies for older patients. ( Lardinois, CK, 1998)
"Current agents for the treatment of Type 2 diabetes mellitus improve the metabolic profile but do not reinstate normality."2.40New agents for Type 2 diabetes. ( Bailey, CJ; Nattrass, M, 1999)
"Glimepiride is a new generation sulphonylurea being prudently characterized in more than 2000 NIDDM patients."2.39Clinical profile of the novel sulphonylurea glimepiride. ( Draeger, E; Rosskamp, R; Wernicke-Panten, K, 1996)
" All of the patients provided an extensive medial history which included information on concomitant medications, underlying diseases, and ongoing adverse events."2.39An overview of the safety and tolerance of glimepiride. ( Schneider, J, 1996)
" A recent multicenter trial of a new sulfonylurea, glimepiride, in combination with a single injection of 70/30 insulin before dinner has confirmed that this approach is safe and more consistently effective than insulin alone for obese patients beginning insulin in a setting resembling clinical practice."2.39Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine. ( Riddle, MC, 1996)
" Pharmacokinetic data on sulfonylureas are generally inconsistent in cirrhotic patients."2.39Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. ( Rosenkranz, B, 1996)
" This study aims to investigate the possible influence of orally administered low- and high-dose glimepiride (GLM) on pharmacokinetic characteristics (PK) of benzbromarone (BNR) in rats."1.91Effects of different doses glimepiride intake on the pharmacokinetics of benzbromarone in rats. ( Chen, Z; Gu, X; Lin, Y; Liu, J; Wang, Y; Weng, Q; Xiong, J; Xu, H; Yu, Y, 2023)
" Among NS and SNEDDS, NS was found more efficacious than that of the SNEDDS possibly due to higher enhancement of oral bioavailability in case of NS."1.72Expanding arsenal against diabetes mellitus through nanoformulations loaded with glimepiride and simvastatin: A comparative study. ( Chellappan, DK; Dua, K; Dureja, H; Gulati, M; Gupta, G; Gupta, PK; Gupta, S; Jha, NK; Jha, SK; Khursheed, R; Kumar, B; Pandey, NK; Prasher, P; Sharma, A; Singh, SK; Vishwas, S, 2022)
"Tauopathy is a group of neurodegenerative diseases in which the pathogenesis processes are related to tau protein."1.72Glimepiride mitigates tauopathy and neuroinflammation in P301S transgenic mice: role of AKT/GSK3β signaling. ( Azab, SS; El-Desouky, S; Elsherbiny, DA; Salama, M; Zaki, MO, 2022)
"Serious hypoglycemia is a major adverse event associated with insulin secretagogues."1.72Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. ( Bilker, WB; Brensinger, CM; Flory, JH; Hee Nam, Y; Hennessy, S; Leonard, CE, 2022)
" In conclusion, the potential cost of CYP2C9 genotype-guided dosing for glimepiride therapy is relatively high, and associated with modest improvements with respect to the number of hypoglycaemia avoided, as compared with standard dosing."1.62Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study. ( Bourguignon, L; Fokoun, C; Goutelle, S; Rabier, H; Serrier, H; Tod, M, 2021)
"Ginsenoside Rg3 may inhibit the activity of cytochrome P450 enzymes in vitro."1.62Metabolic study of ginsenoside Rg3 and glimepiride in type 2 diabetic rats by liquid chromatography coupled with quadrupole-Orbitrap mass spectrometry. ( Dai, Y; Fu, Y; Li, X; Tao, X; Yang, D; Yu, J; Yue, H; Zheng, F, 2021)
"Glimepiride was also associated with a lower incidence of all-cause mortality (HR 0."1.56Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population-based cohort study. ( Dell'Aniello, S; Douros, A; Suissa, S; Yu, OHY, 2020)
"To generate a mouse model of type 2 diabetes mellitus (DM), male C57BL/6J mice were fed with high-fat diet and injected with streptozotocin."1.51Specific PERK inhibitors enhanced glucose-stimulated insulin secretion in a mouse model of type 2 diabetes. ( Ham, DS; Jung, HS; Kim, JW; Kim, MJ; Kim, MN; Min, SH; Park, KS; Yoon, KH, 2019)
"A total of 95 T2DM and NAFLD patients were randomly divided into group A (saxagliptin group), group B (glimepiride group), and group C (glimepiride combined with polyene phosphatidylcholine group)."1.51The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data. ( Fan, B; Guo, XL; Li, JJ; Zhang, P; Zheng, ZS, 2019)
"15 obese patients with type 2 diabetes were studied, all using metformin (1-2 g/day) and sulfonylurea (glimiperide)."1.51Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes. ( Digtiar, NI; Kaidashev, IP; Kaidasheva, EI; Savchenko, LG; Selikhova, LG; Shlykova, OA; Vesnina, LE, 2019)
"Glimepiride was associated with the best clinical outcome, showing the lowest mortality and lowest cardiovascular event risk of the five insulin secretagogues."1.51Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis. ( Huang, HK; Yeh, JI, 2019)
"Men with type 2 diabetes (T2D) and obesity are often characterised by low testosterone (T)."1.48Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity. ( Hao, M; Kuang, HY; Li, BW; Ma, XF; Pan, J; Shao, N; Wu, WH; Yu, XY; Yu, YM; Zhang, HJ, 2018)
"Obesity is a major cause of type 2 diabetes mellitus (T2DM) in mammals."1.46Development of a Novel Zebrafish Model for Type 2 Diabetes Mellitus. ( Nishimura, N; Shimada, Y; Zang, L, 2017)
"The incidence of renal-related adverse events (AEs) with canagliflozin in patients with type 2 diabetes mellitus from a pooled population of patients in 7 active- and placebo-controlled trials (N = 5598) and in a 104-week study vs glimepiride (N = 1450) was low and similar in canagliflozin and non-canagliflozin groups."1.46Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. ( Balis, D; Canovatchel, W; Desai, M; Rosenthal, N; Sun, D; Xie, J; Yavin, Y, 2017)
" We aimed to systematically screen for drugs that interact with the five most commonly used secretagogues-glipizide, glyburide, glimepiride, repaglinide, and nateglinide-to cause serious hypoglycemia."1.46Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues. ( Bilker, WB; Brensinger, CM; Chiang, C; Han, X; Hennessy, S; Leonard, CE; Li, L, 2017)
"Men with type 2 diabetes are often characterized by abnormal plasma testosterone levels."1.43The effect of testosterone on cardiovascular risk factors in men with type 2 diabetes and late-onset hypogonadism treated with metformin or glimepiride. ( Gilowski, W; Krysiak, R; Okopień, B, 2016)
"Glimepiride was found to interact with AChE enzyme at the same locus as that of substrate acetylcholine iodide (AChI)."1.43Kinetics and Molecular Docking Study of an Anti-diabetic Drug Glimepiride as Acetylcholinesterase Inhibitor: Implication for Alzheimer's Disease-Diabetes Dual Therapy. ( Abuzenadah, AM; Ahmad, A; Haneef, M; Naaz, D; Rizvi, SM; Shaikh, S; Shakil, S, 2016)
"Glimepiride is a second-generation sulfonylurea excites pancreatic beta cells to discharge insulin."1.43Evaluation, efficacy and tolerability of GlucoNovax tablet in type 2 diabetic patients. ( Ali, Z; Daniyal, M; Naveed, S; S I, I; Usmanghani, K, 2016)
"Many patients with type 2 diabetes mellitus(T2DM) do not achieve satisfactory glycemic control by monotherapy alone, and often require multiple oral hypoglycemic agents (OHAs)."1.42[Fixed-dose combination]. ( Nagai, Y, 2015)
"Treatment with liraglutide resulted in mean decreases in hemoglobin A1c (HbA1c) of -1."1.42Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy. ( Brunetti, A; Capula, C; Chiefari, E; Foti, D; Greco, M; Liguori, R; Oliverio, R; Puccio, L; Pullano, V; Tirinato, D; Vero, A; Vero, R, 2015)
"The Cardiff Model was used to simulate disease progression and estimate the long-term effect of treatments on patients."1.42Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China. ( Deng, J; Dong, H; Gu, S; Mu, Y; Shi, L, 2015)
"Thirty-four patients with type 2 diabetes received glimepiride for 24 weeks."1.40Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report. ( Hiwatashi, A; Inoue, T; Komatsu, A; Komoda, H; Nakamura, I; Node, K; Oyama, J; Sakamoto, Y; Shiraki, A; Taguchi, I; Takeuchi, M; Yamagishi, S, 2014)
"Her treatment was metformin 850 mg every 12 hours and glimepiride 4 mg every 24 hours."1.40How to prevent and treat pharmacological hypoglycemias. ( Mezquita Raya, P; Reyes García, R, 2014)
"The IHE Cohort Model of Type 2 Diabetes was used to evaluate clinical and economic outcomes from a societal perspective."1.40Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin. ( Persson, U; Steen Carlsson, K, 2014)
"A total of 8,194 incident cancer cases and 32,776 diabetic controls were included."1.38Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. ( Chang, CH; Chuang, LM; Lai, MS; Lin, JW; Wu, LC, 2012)
"Glimepiride was withdrawn if possible."1.38Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy. ( Kaneto, H; Katakami, N; Matsuoka, TA; Shimomura, I; Shiraiwa, T; Takahara, M, 2012)
"Maturity-onset diabetes of the young (MODY) is a group of disorders accounting for 2-5% of diabetes; MODY2 is caused by inactivating GCK mutations."1.36A novel glucokinase gene mutation and its effect on glycemic/C-peptide fluctuations in a patient with maturity-onset diabetes of the young type 2. ( Bremer, AA; Jame, M; Loomba-Albrecht, LA, 2010)
"Severe hypoglycemia was defined as a symptomatic event requiring treatment with intravenous glucose and was confirmed by a blood glucose measurement of < 50 mg/dl."1.36Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. ( Hahn, M; Hammer, C; Holstein, A; Kovacs, P; Kulamadayil, NS, 2010)
" Based on laboratory findings, we determined the clinical significance of potential CYP2C9-mediated drug-drug interactions in hospitalized patients receiving glibenclamide, glimepiride or glipizide, all of which are metabolized by CYP2C9, together with a CYP2C9 inhibitor."1.36Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. ( Heikkilä, P; Huupponen, R; Laine, K; Tirkkonen, T, 2010)
"Nearly half of all US patients with type 2 diabetes mellitus (T2DM) are unable to maintain adequate glycosylated hemoglobin (HbA₁(c)) control (ie, <7."1.36Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. ( Conner, C; Hammer, M; Lee, WC, 2010)
"The animal models of type 2 diabetes are very complex and are as heterogeneous as the disease."1.35Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes. ( Arulmozhi, DK; Bodhankar, SL; Kurian, R; Veeranjaneyulu, A, 2008)
"Byetta was withdrawn, the patient was treated for acute pancreatitis and the symptoms subsided."1.35Exenatide and acute pancreatitis. ( Basha, S; Jain, R; Ramachandran, A; Shetty, S; Tripathy, NR, 2008)
"Metformin failure was defined as hemoglobin A1c (HbA1c) > or = 6."1.35The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics. ( Gallwitz, B; Guzmán, JR; Kazda, C; Kraus, P; Nicolay, C; Rose, L; Schernthaner, G; Simó, R, 2009)
"gliclazide treatment."1.35Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. ( Khalangot, M; Kovtun, V; Kravchenko, V; Tronko, M, 2009)
"A total of 400 patients with type 2 diabetes, who were > or = 35 years old and who had been treated with metformin and a sulphonylurea for at least 6 months, completed questionnaires during their usual primary care office visit."1.35Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. ( Krishnarajah, G; Lyu, R; Mavros, P; Vexiau, P; Yin, D, 2008)
"In this fasting sample of patients with type 2 diabetes, glimepiride, repaglinide, and insulin glargine did not produce significant changes in glucose and lipid parameters."1.34A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. ( Bayram, F; Cesur, M; Corapcioglu, D; Emral, R; Gonen, S; Gursoy, A; Kamel, N; Ozduman, M; Tonyukuk, V; Uysal, AR; Yilmaz, AE, 2007)
"Glimepiride has the lowest ratio of insulin release to glucose decrease compared with other sulphonylureas."1.32Glimepiride reduces mononuclear activation of the redox-sensitive transcription factor nuclear factor-kappa B. ( Andrassy, M; Balletshofer, B; Bierhaus, A; Chen, J; Elsenhans, S; Häring, HU; Heinle, H; Isermann, B; Kanitz, M; Nawroth, PP; Rudofsky, G; Schiekofer, S; Schleicher, E; Schneider, J, 2003)
"Patients with type 2 diabetes who are failing on oral agents will generally gain a large amount of body fat when switched to insulin treatment."1.32Prevention of weight gain in type 2 diabetes requiring insulin treatment. ( de Boer, H; Jansen, M; Koerts, J; Verschoor, L, 2004)
"Glimepiride is a novel sulfonylurea drug for treatment of non-insulin-dependent diabetes mellitus with higher blood sugar lowering efficacy in diabetic patients than glibenclamide raising the question whether this characteristics is in line with different binding of glimepiride and glibenclamide to the beta-cell sulfonylurea receptor."1.29Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics. ( Hartz, D; Kramer, W; Müller, G; Okonomopulos, R; Pünter, J, 1994)
"Glimepiride was well-tolerated and there were no drug-related adverse events."1.29Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. ( Lange, C; Malerczyk, V; Metelko, Z; Mrzljak, V; Profozic, V; Rosenkranz, B, 1996)

Research

Studies (538)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's35 (6.51)18.2507
2000's185 (34.39)29.6817
2010's248 (46.10)24.3611
2020's70 (13.01)2.80

Authors

AuthorsStudies
Washburn, WN1
Frías, JP3
Maaske, J2
Suchower, L1
Johansson, L1
Hockings, PD1
Iqbal, N1
Wilding, JPH1
Muskiet, MHA3
Tonneijck, L3
Smits, MM3
Kramer, MHH3
Ouwens, DM3
Hartmann, B2
Holst, JJ4
Danser, AHJ2
Joles, JA2
van Raalte, DH3
Jendle, J5
Hyötyläinen, T1
Orešič, M1
Nyström, T7
Miura, M1
Tanaka, S2
Ikeda, M2
Kawakami, J1
Watanabe, H2
Namiki, N1
Uchida, S1
Tamura, H1
Kondo, Y1
Ito, K1
Hasebe, M1
Satoh, S1
Terauchi, Y4
Pandey, NK1
Singh, SK2
Kumar, B1
Gulati, M1
Vishwas, S1
Khursheed, R1
Dureja, H1
Chellappan, DK1
Jha, NK1
Sharma, A1
Jha, SK1
Gupta, PK1
Gupta, S1
Gupta, G2
Prasher, P1
Dua, K1
Kim, HJ2
Jeong, IK1
Hur, KY2
Kim, SK1
Noh, JH1
Chun, SW3
Kang, ES5
Rhee, EJ1
Choi, SH1
Halder, M1
Bhatia, Y1
Singh, Y1
Succurro, E1
Vizza, P1
Papa, A1
Miceli, S1
Cicone, F1
Fiorentino, TV1
Sciacqua, A1
Andreozzi, F1
Veltri, P1
Cascini, GL1
Sesti, G1
Takeshita, Y1
Honda, M2
Harada, K1
Kita, Y1
Takata, N2
Tsujiguchi, H1
Tanaka, T2
Goto, H1
Nakano, Y1
Iida, N1
Arai, K4
Yamashita, T1
Mizukoshi, E1
Nakamura, H1
Kaneko, S1
Takamura, T1
Zaki, MO1
El-Desouky, S1
Elsherbiny, DA1
Salama, M1
Azab, SS1
Mégarbane, B1
Abe, E1
Chevillard, L1
Tanaka, A7
Imai, T2
Shimabukuro, M2
Nakamura, I2
Matsunaga, K1
Ozaki, Y1
Minamino, T1
Sata, M2
Node, K8
Nathan, DM3
Lachin, JM4
Bebu, I2
Burch, HB2
Buse, JB3
Cherrington, AL1
Fortmann, SP1
Green, JB2
Kahn, SE4
Kirkman, MS1
Krause-Steinrauf, H3
Larkin, ME3
Phillips, LS1
Pop-Busui, R1
Steffes, M1
Tiktin, M2
Tripputi, M1
Wexler, DJ3
Younes, N3
Balasubramanyam, A1
Butera, NM1
Cohen, RM1
Crandall, JP1
Rasouli, N1
Deng, Y1
Polley, EC1
Wallach, JD1
Dhruva, SS1
Herrin, J1
Quinto, K1
Gandotra, C1
Crown, W1
Noseworthy, P1
Yao, X1
Lyon, TD1
Shah, ND1
Ross, JS1
McCoy, RG1
Yamaguchi, S1
Hiramitsu, S1
Takahashi, N1
Kadokami, T1
Ajioka, M1
Suzuki, M3
Najar, IA3
Masoodi, SR3
Mir, SA3
Bhat, MH3
Patyar, RR3
Patyar, S3
Lanthier, L3
Mutchmore, A3
Plourde, MÉ3
Cauchon, M3
Elabi, OF3
Karampatsi, D3
Vercalsteren, E3
Lietzau, G4
Klein, T4
Darsalia, V4
Patrone, C4
Paul, G3
Ohte, N2
Kitada, S2
Yamada, T2
Eguchi, K3
Teragawa, H2
Takeishi, Y2
Kodama, K2
Seo, Y2
Brown, K2
Donato, AA2
Lim, S2
Sohn, M1
Florez, JC1
Nauck, MA4
Ahn, J1
Shrivastava, A1
Kesavadev, J1
Mohan, V1
Saboo, B2
Shrestha, D1
Maheshwari, A1
Makkar, BM1
Modi, KD2
Kumar Das, A1
Rosenstock, J11
Kolkailah, AA1
McGuire, DK2
Espeland, MA5
Mattheus, M4
Pfarr, E2
Lund, SS1
Marx, N5
Oduola-Akande, MD1
Ishola, IO1
Olubodun-Obadun, TG1
Akande, AJ1
Adeyemi, OO1
Solanki, R1
Wadhwana, P1
Patel, R1
Gayakvad, B1
Kothari, C1
Patel, C1
Jawed, B1
Ahmed, S2
Abbas, SQ1
Ahmed, Z1
Andleeb, S1
Ahmad, SA1
Asif, M1
Akhter, E1
Hussain, MW1
Iqbal, A1
Ishaqui, AA1
Sawami, K1
Lin, Y1
Gu, X1
Liu, J1
Weng, Q1
Xiong, J1
Chen, Z2
Yu, Y1
Xu, H1
Wang, Y2
Alsadoon, L1
Abdullah, K1
Chung, SM1
Moon, JS2
Hong, JH2
Hwang, IC1
Nakatani, D1
Dohi, T1
Hikoso, S1
Nanasato, M1
Shimizu, W2
Sakata, Y2
Zekry, R1
Omran, GA1
El-Gharbawy, NM1
Werida, RH2
de Boer, IH1
Ghosh, A1
Inzucchi, SE1
McGill, JB1
Mudaliar, S1
Schade, D1
Steffes, MW1
Tamborlane, WV1
Tan, MH1
Ismail-Beigi, F1
Paz-Pacheco, E1
Nevado, J1
Paz, EMC1
Jasul, G1
Aman, AYC1
Alejandro-Ribaya, EL1
Francisco, MD1
Guanzon, MLV1
Uyking-Naranjo, M1
Añonuevo-Cruz, C1
Maningat, MPD1
Jaring, C1
Nacpil-Dominguez, P1
Pala-Mohamad, A1
Uy-Canto, A1
Quisumbing, JP1
Lat, AM1
Bernardo, DC1
Mansibang, NM1
Ribaya, VS1
Calpito, KJA1
Ferrer, JP1
Biwang, J1
Melegrito, J1
Deguit, CD1
Panerio, CE1
Scherbak, NN2
Kruse, R2
Stojanovic, J1
Andjelic-Jelic, M1
Vuksanovic, M1
Marjanovic-Petkovic, M1
Jojic, B1
Stojanovic, M1
Beljic-Zivkovic, T1
Ramzy, A1
Ebrahim, YN1
Helmy, MW1
Lee, DY1
Douros, A1
Dell'Aniello, S1
Yu, OHY1
Suissa, S1
Riddle, MC7
Farishta, F1
Phatak, S1
Godbole, SG1
Banzal, S1
Kashiv, P1
Kumar, J1
Gonzalez-Galvez, G1
Johnsson, E2
Testa, MA2
Simonson, DC1
Dronamraju, N2
Garcia-Sanchez, R2
Peters, AL1
Magni, G1
Kehr, J1
Yoshitake, T1
Candeias, E1
Duarte, AI1
Pettersson, H1
Skogsberg, J1
Abbracchio, MP1
Ceruti, S1
Nasreen, W1
Sarker, S1
Sufian, MA1
Md Opo, FAD1
Shahriar, M1
Akhter, R1
Halim, MA1
Park, H1
Jin Seo, H1
Hong, SH1
Ha, ES1
Lee, S2
Kim, JS1
Baek, IH1
Kim, MS1
Hwang, SJ1
Kitazawa, T1
Seino, H1
Ohashi, H2
Inazawa, T1
Inoue, M1
Ai, M1
Fujishiro, M1
Kuroda, H1
Yamada, M2
Anai, M1
Ishihara, H1
Kinoshita, T1
Shimoda, M2
Nakashima, K1
Fushimi, Y1
Hirata, Y1
Tanabe, A1
Tatsumi, F1
Hirukawa, H1
Sanada, J1
Kohara, K2
Irie, S1
Kimura, T1
Nakamura, Y2
Nishioka, M1
Obata, A1
Nakanishi, S1
Mune, T1
Kaku, K3
Kaneto, H4
Kraaijenhof, J1
Dhopeshwarkar, N1
Brensinger, CM3
Bilker, WB3
Soprano, SE1
Flory, JH2
Dawwas, GK1
Gagne, JJ1
Hennessy, S3
Leonard, CE3
Chakravarti, HN1
Nag, A1
Ag, U1
K, P1
J, G1
S, V1
Mv, A1
Cho, EH1
Han, K1
Kim, B1
Lee, DH2
Ju, G1
Yan, K1
Xu, Y1
Chen, S1
Zheng, Z1
Qiu, W1
Touw, DJ1
Werida, R1
Kabel, M1
Omran, G1
Shokry, A1
Mostafa, T1
Jasmine, MR1
Nanda, N1
Sahoo, J1
Velkumary, S1
Pal, GK1
Pratley, RE2
Kadowaki, T2
Seino, Y3
Zinman, B7
Andersen, KR3
Keller, A1
Weber, M1
Johansen, OE5
Tack, CJ3
van de Laar, FA1
Elbeddini, A1
Tayefehchamani, Y1
Davey, M1
Gallinger, J1
Hooda, N1
Aly, A1
Erickson, D1
Biessels, GJ2
Verhagen, C1
Janssen, J2
van den Berg, E2
Wallenstein, G1
Salem, A1
Men, P1
Ramos, M1
Zhang, YJ1
Ustyugova, A1
Lamotte, M1
Yen, FS1
Hsu, CC1
Su, YC1
Wei, JC1
Hwu, CM1
Fokoun, C1
Serrier, H1
Rabier, H1
Goutelle, S1
Tod, M1
Bourguignon, L1
Yang, D1
Li, X1
Fu, Y1
Tao, X1
Zheng, F1
Yu, J1
Yue, H1
Dai, Y1
Zaghlol, LY1
Beirat, AF1
Amarin, JZ1
Hassoun Al Najar, AM1
Hasan, YY1
Qtaishat, A1
Tierney, ME1
Zaghlol, RY1
Zayed, AA1
Hee Nam, Y1
Zang, L1
Shimada, Y1
Nishimura, N1
Handelsman, Y1
Lauring, B2
Gantz, I3
Iredale, C1
O'Neill, EA3
Wei, Z1
Suryawanshi, S2
Kaufman, KD3
Engel, SS5
Lai, E2
Chin, HJ1
Nam, JH1
Lee, EK1
Shin, JY1
Home, PD3
Ahrén, B5
Reusch, JEB2
Rendell, M1
Weissman, PN1
Cirkel, DT2
Miller, D1
Ambery, P2
Carr, MC2
Kim, G3
Oh, S1
Jin, SM1
Kim, JH2
Lee, MK3
Takahara, M2
Shiraiwa, T3
Katakami, N3
Matsuoka, TA3
Shimomura, I3
Lee, SH2
Round, E1
Latham, M1
Ceesay, P1
Chon, S2
Rhee, SY1
Ahn, KJ2
Baik, SH2
Park, Y1
Nam, MS1
Lee, KW2
Yoo, SJ1
Koh, G1
Kim, YS1
Woo, JT2
Garvey, WT1
Van Gaal, L1
Leiter, LA3
Vijapurkar, U2
List, J1
Cuddihy, R1
Ren, J1
Davies, MJ2
Marcinak, JF1
Munsaka, MS1
Watkins, PB1
Ohira, T1
Smith, N1
Fujimoto, K1
Shibayama, Y1
Yamaguchi, E1
Honjo, S1
Hamasaki, A1
Hamamoto, Y1
Heald, AH1
Livingston, M1
Bien, Z1
Moreno, GYC1
Laing, I1
Stedman, M1
Chen, YH1
Huang, CN1
Cho, YM2
Li, P1
Gu, L1
Wang, F2
Yang, J1
Wang, WQ1
Kim, JD1
Park, CY3
Cha, BY1
Kim, IJ2
Park, KS6
Lee, HW2
Min, KW3
Won, JC1
Chung, MY1
Kim, JT1
Kang, JG2
Park, SW2
Liu, X3
Zeng, L2
Xu, W2
Shao, N1
Yu, XY1
Yu, YM1
Li, BW1
Pan, J1
Wu, WH1
Zhang, HJ1
Ma, XF1
Hao, M1
Kuang, HY1
Dawra, VK1
Cutler, DL1
Zhou, S1
Krishna, R1
Shi, H2
Liang, Y1
Alvey, C1
Hickman, A1
Saur, D1
Terra, SG2
Sahasrabudhe, V1
Kohler, S1
Kaspers, S1
Salsali, A2
Zeller, C3
Woerle, HJ11
Müller-Wieland, D1
Kellerer, M1
Cypryk, K1
Skripova, D1
Rohwedder, K1
Kurlyandskaya, R1
Sjöström, CD1
Jacob, S2
Seufert, J2
Csomós, K1
Ridderstråle, M4
Peng, Y1
Chen, SH1
Liu, XN1
Sun, QY1
Sidelmann Christensen, A1
Storgaard, H1
Hædersdal, S1
Hansen, T2
Knop, FK3
Vilsbøll, T2
Kim, Y1
Jang, HC3
Kim, DJ2
Oh, T1
Kim, ES1
Kim, NH1
Choi, KM1
Kim, SR1
You, J1
Kim, SJ2
Gu, T1
Ma, J3
Zhang, Q1
Zhu, L1
Zhang, H1
Xu, L3
Cheng, J1
Shi, B1
Li, D1
Shao, J1
Sun, Z2
Zhong, S1
Bi, Y2
Zhu, D2
Gallo, S1
Charbonnel, B2
Goldman, A1
Huyck, S1
Darekar, A1
Kim, MJ1
Kim, MN1
Min, SH1
Ham, DS1
Kim, JW1
Yoon, KH6
Jung, HS2
Sartore, G1
Chilelli, NC1
Seraglia, R1
Ragazzi, E1
Marin, R1
Roverso, M1
Cosma, C1
Vaccaro, O1
Burlina, S1
Lapolla, A1
Li, JJ1
Zhang, P1
Fan, B1
Guo, XL1
Zheng, ZS1
Savchenko, LG1
Digtiar, NI1
Selikhova, LG1
Kaidasheva, EI1
Shlykova, OA1
Vesnina, LE1
Kaidashev, IP1
Shi, LX1
Liu, XM1
Shi, YQ1
Li, QM1
Ma, JH1
Li, YB1
Du, LY1
Chen, LL1
Huang, HK1
Yeh, JI1
Scalzo, RL1
Rafferty, D1
Schauer, I1
Huebschmann, AG1
Cree-Green, M1
Regensteiner, JG1
Lee, JY1
Jang, SY1
Nam, CM2
Patorno, E1
Schneeweiss, S1
Gopalakrishnan, C1
Martin, D1
Franklin, JM1
Emini-Sadiku, M1
Car, N1
Begolli, L1
Blaslov, K1
Haliti, E1
Bahtiri, E1
Mokta, JK1
Sahai, AK1
Kaundal, PK1
Mokta, K1
Yu, HM1
Park, KY1
Lim, DM1
Lee, JM1
Wang, B1
Zhong, J1
Lin, H1
Zhao, Z1
Yan, Z1
He, H1
Ni, Y1
Liu, D1
Zhu, Z1
Maeda, H2
Sirabe, S1
Yamamoto, R2
Yamauchi, M3
Hirao, T2
Hirao, S2
Hirao, K3
Gallwitz, B9
Emser, A1
von Eynatten, M6
Strojek, K2
Hruba, V2
Elze, M2
Langkilde, AM2
Parikh, S2
Nauck, M3
Del Prato, S1
Berndt-Zipfel, C2
Michelson, G1
Dworak, M3
Mitry, M2
Löffler, A3
Pfützner, A15
Forst, T16
Phielix, E1
Brehm, A1
Bernroider, E1
Krssak, M1
Anderwald, CH1
Krebs, M1
Schmid, AI1
Nowotny, P1
Roden, M1
Boglou, P1
Steiropoulos, P1
Papanas, N1
Bouros, D1
Steinberg, H1
Eymard, E1
Thakkar, P1
Prabhu, V1
Staten, M1
Wexler, D1
Heyer, EJ1
Mergeche, JL1
Bruce, SS1
Connolly, ES1
Tahara, N5
Yamagishi, S5
Mizoguchi, M4
Tahara, A5
Imaizumi, T4
He, YL1
Foteinos, G1
Neelakantham, S1
Mattapalli, D1
Kulmatycki, K1
Taylor, A1
Arayne, MS1
Sultana, N1
Tabassum, A1
Cefalu, WT1
Arias, P2
Niskanen, L2
Xie, J4
Balis, DA2
Canovatchel, W4
Meininger, G4
Diamant, M4
Morsink, LM1
Hung, YC1
Lin, CC1
Wang, TY1
Chang, MP1
Sung, FC1
Chen, CC1
Svaerd, R1
Broedl, UC2
Kodama, N4
Honda, A3
Nitta, Y3
Kaida, H3
Ishibashi, M3
Abe, T1
Ikeda, H3
Narula, J2
Fukumoto, Y2
Vlajnic, A3
Gao, L2
Kondo, K1
Ohkura, T1
Inoue, K1
Fujioka, Y1
Nakanishi, R1
Shiochi, H1
Sumi, K1
Yamamoto, N1
Matsuzawa, K1
Izawa, S1
Ohkura, H1
Kato, M1
Yamamoto, K2
Taniguchi, S1
Hayabuchi, N2
Boehm, BO1
Grill, V1
Torjesen, PA1
Bhattacharya, S2
Patel, S6
Wetzel, K1
Oyama, J3
Komoda, H1
Shiraki, A1
Sakamoto, Y1
Taguchi, I2
Hiwatashi, A1
Komatsu, A1
Takeuchi, M1
Inoue, T3
Ha, KS1
Yoon, JS1
Lee, HC4
Won, KC1
Kobayashi, K1
Yokoh, H1
Sato, Y2
Takemoto, M2
Uchida, D1
Kanatsuka, A1
Kuribayashi, N1
Terano, T1
Hashimoto, N2
Sakurai, K1
Hanaoka, H1
Ishikawa, K1
Onishi, S1
Yokote, K2
Anastassiadis, E1
Diessel, S1
Reyes García, R1
Mezquita Raya, P1
Nybäck-Nakell, Å1
Adamson, U1
Lins, PE1
Landstedt-Hallin, L1
Shirabe, S1
Kumakura, A1
Noh, J1
Oh, SJ1
Lee, CB1
Pareek, A2
Chandurkar, N1
Thomas, N1
Viswanathan, V1
Deshpande, A1
Gupta, OP1
Shah, A1
Kakrani, A1
Bhandari, S1
Thulasidharan, NK1
Devaramani, S1
Vijaykumar, NB1
Sharma, S1
Agrawal, N2
Mahesh, M1
Kothari, K1
Koyama, H2
Monden, M1
Shoji, T3
Morioka, T1
Fukumoto, S1
Mori, K2
Emoto, M2
Fukui, M2
Fujii, H1
Nishizawa, Y2
Inaba, M1
Yang, W3
Xing, X1
Lv, X1
Li, Y3
Yuan, G1
Sun, F1
Wang, W1
Woloschak, M1
Lukashevich, V1
Kozlovski, P1
Kothny, W1
Derosa, G15
Bonaventura, A3
Bianchi, L2
Romano, D2
Fogari, E7
D'Angelo, A5
Maffioli, P5
Johnson, SL1
Stewart, M2
Yang, F2
Perry, C2
Feinglos, MN3
Østoft, SH1
Bagger, JI1
Pedersen, O1
Faber, J1
Steen Carlsson, K1
Persson, U1
Bolli, GB1
Mathieu, C1
Deerochanawong, C2
Landgraf, W1
Candelas, C1
Pilorget, V1
Dain, MP1
Gudipaty, L1
Rosenfeld, NK1
Fuller, CS1
Gallop, R1
Schutta, MH1
Rickels, MR1
Umayahara, R1
Yonemoto, T1
Kyou, C1
Morishita, K1
Ogawa, T1
Taguchi, Y1
Langslet, G2
Millington, D1
Vercruysse, F1
Shamanna, P1
Miller, M1
Hehnke, U2
Mehlburger, L1
Dugi, KA2
Mogensen, UM1
Andersson, C1
Fosbøl, EL1
Schramm, TK1
Vaag, A1
Scheller, NM1
Torp-Pedersen, C1
Gislason, G1
Køber, L1
Simpson, SH2
Lee, J1
Choi, S1
Vandermeer, B1
Abdelmoneim, AS2
Featherstone, TR1
Jensen, TM1
Saha, K1
Steinberg, WM1
Adachi, H1
Yanai, H1
Laakso, M1
Groop, PH1
Barnett, AH3
Tamminen, I1
Amate, JM1
Lopez-Cuadrado, T1
Almendro, N1
Bouza, C1
Saz-Parkinson, Z1
Rivas-Ruiz, R1
Gonzalez-Canudas, J1
Lee, YH2
Lee, CJ1
Lee, HS1
Choe, EY1
Lee, BW3
Ahn, CW3
Cha, BS3
Balkau, B1
El-Haggar, SM1
Farrag, WF1
Kotkata, FA1
Schernthaner, G7
Durán-Garcia, S1
Hanefeld, M1
Östgren, CJ1
Malvolti, E1
Hardy, E1
Kastelein, JJ1
Bluhmki, E1
Ryckaert, B1
Winkler, G1
Nagai, Y2
Chiefari, E1
Capula, C1
Vero, A1
Oliverio, R1
Puccio, L1
Liguori, R1
Pullano, V1
Greco, M1
Foti, D1
Tirinato, D1
Vero, R1
Brunetti, A1
Rosas-Guzmán, J2
Dotta, F4
Guerci, B3
Simó, R4
Festa, A3
Kiljański, J3
Zhou, M2
Amin, NB1
Aggarwal, N1
Pall, D1
Paragh, G1
Denney, WS1
Le, V1
Riggs, M1
Calle, RA1
Kato, H1
Ohta, A1
Tenjin, A1
Tsukiyama, H1
Sasaki, Y1
Fukuda, H1
Ohshige, T1
Terashima, Y1
Sada, Y1
Kondo, A1
Sasaoka, T1
Tanaka, Y1
Gu, S1
Deng, J1
Shi, L2
Mu, Y2
Dong, H1
Tani, S1
Nagao, K1
Hirayama, A1
Hartley, P1
Shentu, Y1
Betz-Schiff, P1
Golm, GT1
Sisk, CM1
Shankar, RR1
Hansen, JS1
Zhao, X1
Irmler, M1
Hoene, M1
Scheler, M1
Beckers, J1
Hrabĕ de Angelis, M1
Häring, HU5
Pedersen, BK1
Lehmann, R1
Xu, G1
Plomgaard, P1
Weigert, C1
Giorgino, F1
Benroubi, M1
Sun, JH1
Zimmermann, AG1
Pechtner, V1
Harishankar, MK1
Logeshwaran, S1
Sujeevan, S1
Aruljothi, KN1
Dannie, MA1
Devi, A1
Kasahara, N1
Fukase, H1
Ohba, Y1
Saito, T1
Miyata, K1
Iida, S1
Takano, Y1
Ikeda, S1
Harigai, M1
Terao, K1
Hammami, S1
Ksouda, K1
Affes, H1
Sahnoun, Z1
Zeghal, K1
Hassan, MH1
Abd-Allah, GM1
Chirila, C1
Zheng, Q1
Davenport, E1
Kaschinski, D1
Hach, T1
Palencia, R1
Stylianou, A1
Atkinson, G1
Dott, C1
Baylor Curtis, L1
Haque, N1
LaCroix, K1
Aso, Y1
Fukushima, M2
Sagara, M1
Jojima, T2
Iijima, T1
Suzuki, K3
Momobayashi, A1
Kasai, K1
Inukai, T1
Gilbert, MP1
Marre, M2
Garber, A4
Baeres, FM1
Thomsen, H1
Lavalle-González, FJ1
Eliaschewitz, FG3
Cerdas, S1
Chacon, Mdel P1
Tong, C1
Alba, M1
Romley, JA1
Gong, C1
Jena, AB1
Goldman, DP1
Williams, B1
Peters, A1
Krysiak, R1
Gilowski, W1
Okopień, B1
Nagakura, J1
Yamakawa, T1
Taguri, M1
Tsuchiya, H1
Shigematsu, E1
Suzuki, J1
Morita, S1
Kadonosono, K1
Pettus, J1
McNabb, B1
Eckel, RH1
Skyler, JS1
Dhalla, A1
Guan, S1
Jochelson, P1
Belardinelli, L1
Henry, RH1
Dungan, KM1
Weitgasser, R2
Perez Manghi, F1
Pintilei, E1
Fahrbach, JL1
Jiang, HH1
Shell, J1
Robertson, KE1
Rizvi, SM1
Shaikh, S1
Naaz, D1
Shakil, S1
Ahmad, A1
Haneef, M1
Abuzenadah, AM1
Geissel, W1
Blonde, L5
Stenlöf, K1
Fung, A1
Kitakaze, M1
Watada, H2
Tomiyama, H1
Ako, J1
Anzai, T1
Uematsu, M1
Yamashina, A1
Saito, Y1
Ueda, S1
Murohara, T1
Kuwata, H1
Yabe, D2
Kim, SS1
Lee, KJ1
Park, JH1
Kim, YI1
Lee, YS1
Chung, SC1
Lee, SJ1
Yamagishi, SI1
Bekki, M1
Nakamura, T2
Sugiyama, Y1
Oshige, T1
Kumashiro, Y1
Igata, S1
Patel, CA1
Bailey, RA1
Alam, F1
Islam, MA1
Kamal, MA1
Gan, SH1
Kwak, S1
Kim, SY1
Ali, Z1
Daniyal, M1
S I, I1
Usmanghani, K1
Naveed, S1
van Dijk, P1
Bouma, A1
Landman, GW1
Groenier, KH1
Bilo, H1
Kleefstra, N1
van Hateren, KJ1
Farooq, R1
Amin, S1
Hayat Bhat, M1
Malik, R1
Wani, HA1
Majid, S1
Nomoto, H1
Miyoshi, H1
Furumoto, T1
Oba, K1
Tsutsui, H1
Inoue, A1
Atsumi, T1
Manda, N1
Kurihara, Y1
Aoki, S1
Hemmingsen, B1
Sonne, DP1
Metzendorf, MI1
Richter, B1
Dong, Y1
Chen, YT1
Yang, YX1
Shou, D1
Li, CY1
Shao, H1
Zhai, S1
Zou, D1
Mir, MU1
Zawadzki, NK1
Shi, Q1
Liu, S1
Perl, S1
Cook, W1
Wei, C1
Ohman, P1
Hirshberg, B1
Sakura, H1
Sasamoto, K1
Hasumi, S1
Ujihara, N1
Kasahara, T1
Tomonaga, O1
Nunome, H1
Iwamoto, Y1
Park, SE1
Lee, WJ1
Cho, JH1
Jung, CH1
Suh, S1
Hur, GC1
Kim, SH2
Jang, YH1
Desai, M1
Yavin, Y1
Balis, D1
Sun, D1
Rosenthal, N1
Jax, T2
Stirban, A1
Terjung, A1
Esmaeili, H1
Berk, A1
Thiemann, S2
Chilton, R1
Han, X1
Chiang, C1
Li, L1
Hattori, A1
Tokuyama, H1
Koshizaka, M1
Zhao, J1
Ji, Q2
Zhou, Z2
Yao, B1
Mao, A1
Zhao, B1
Ran, X2
Lu, J1
Ji, L1
Jia, W1
Weng, J1
Yamada, Y2
Ishida, H1
Ohsugi, M1
Kitaoka, M1
Satoh, J1
Shihara, N1
Hirama, N1
Uchida, K1
Hattori, Y1
Arnolds, S1
Rave, K1
Shah, R1
Fresco, C1
Arulmozhi, DK1
Kurian, R1
Bodhankar, SL1
Veeranjaneyulu, A1
Rubin, CJ1
Ledeine, JM1
Fiedorek, FT1
Henry, R1
Ratner, R2
Garcia-Hernandez, PA1
Rodriguez-Pattzi, H1
Olvera-Alvarez, I1
Hale, PM2
Zdravkovic, M5
Bode, B2
Frid, A4
Hermansen, K5
Shah, NS1
Tankova, T2
Mitha, IH1
Düring, M3
Matthews, DR6
Wu, JJ1
Tsai, TF1
von Bibra, H1
Scheffer, PG1
Siegmund, T1
Schumm-Draeger, PM1
Duckworth, W1
Abraira, C1
Moritz, T1
Reda, D1
Emanuele, N1
Reaven, PD1
Zieve, FJ1
Marks, J1
Davis, SN2
Hayward, R1
Warren, SR1
Goldman, S1
McCarren, M1
Vitek, ME1
Henderson, WG1
Huang, GD1
Ferrannini, E3
Fonseca, V2
Matthews, D2
Byiers, S1
Shao, Q1
Dejager, S4
Papathanassiou, K2
Naka, KK2
Kazakos, N2
Kanioglou, C2
Makriyiannis, D2
Pappas, K2
Katsouras, CS1
Liveris, K1
Kolettis, T1
Tsatsoulis, A2
Michalis, LK2
Okamoto, T1
Okamoto, L1
Lisanti, MP1
Akishita, M1
Araki, T1
Konishi, T1
Ikuno, Y1
Lee, E1
Teramura, M1
Motoyama, K1
Yokoyama, H2
Sullivan, SD2
Alfonso-Cristancho, R2
Conner, C4
Hammer, M6
Nakano, T1
Inoue, I1
Satoh, K1
Yamazaki, M1
Awata, T2
Kurihara, S2
Goto, S1
Shinoda, Y1
Komoda, T1
Katayama, S2
Tripathy, NR1
Basha, S1
Jain, R1
Shetty, S1
Ramachandran, A2
van der Meer, RW2
Rijzewijk, LJ2
de Jong, HW1
Lamb, HJ2
Lubberink, M1
Romijn, JA2
Bax, JJ1
de Roos, A2
Kamp, O1
Paulus, WJ1
Heine, RJ2
Lammertsma, AA1
Smit, JW2
Gropler, RJ1
Salvadeo, SA3
Ferrari, I7
Gravina, A2
Mereu, R2
Palumbo, I1
Cicero, AF8
Chogtu, B1
Singh, NP1
Chawla, S1
Gupta, U1
Hohberg, C7
Lübben, G5
Karagiannis, E1
Borchert, M3
Schöndorf, T6
Gottschalk, M2
Danne, T2
Fuerst-Recktenwald, S1
Dimic, D1
Velojic Golubovic, M1
Antic, S1
Radenkovic, S1
Polonsky, T1
Mazzone, T5
Davidson, M2
Ebato, C1
Shimizu, T1
Arakawa, M1
Mita, T1
Fujitani, Y1
Kawamori, R4
Hirose, T2
Kazda, C1
Guzmán, JR1
Kraus, P2
Nicolay, C1
Rose, L2
Sharma, AK1
Srinivasan, BP1
Khalangot, M1
Tronko, M1
Kravchenko, V1
Kovtun, V1
Strauss, BJ1
Garber, AJ2
Salti, I1
Loomba-Albrecht, LA1
Jame, M1
Bremer, AA1
Xu, DY1
Zhao, SP1
Huang, QX1
Du, W1
Liu, YH1
Liu, L1
Xie, XM1
Petrica, L1
Petrica, M1
Vlad, A1
Dragos Jianu, C1
Gluhovschi, G1
Ianculescu, C1
Dumitrascu, V1
Giju, S1
Gluhovschi, C1
Bob, F1
Ursoniu, S1
Gadalean, F1
Velciov, S1
Bozdog, G1
Marian, R1
Briscoe, VJ1
Griffith, ML1
Shen, J1
Ran, J1
Zhang, Y1
Wang, M2
Yan, L1
Cheng, H1
Fu, Z1
Foley, JE3
Fonseca, VA1
Jonker, JT1
de Haan, W1
Tamsma, JT1
Rensen, PC1
Müller, G2
Schulz, A1
Hartz, D2
Dearey, EA1
Wetekam, EM1
Okonomopulos, R2
Crecelius, A1
Wied, S1
Frick, W1
Matoba, K1
Matsuba, I1
Takai, M1
Takeda, H1
Kanamori, A1
Mori, H1
Pantalone, KM3
Kattan, MW3
Yu, C3
Wells, BJ3
Arrigain, S3
Jain, A3
Atreja, A3
Zimmerman, RS3
Thayer, S1
Arondekar, B1
Harley, C1
Darkow, TE1
Kolotkin, RL1
Weber, MM2
Löbig, M5
Lehmann, U4
Müller, J3
Friedrich, C1
Fuchs, W4
Kikuchi, M1
Haneda, M2
Koya, D1
Tobe, K1
Onishi, Y1
Couturier, A3
Mimori, N1
Inaba, Y1
Goodman, M1
Holstein, A5
Hammer, C3
Hahn, M1
Kulamadayil, NS1
Kovacs, P1
Ragonesi, PD5
Querci, F2
Franzetti, IG2
Gadaleta, G2
Ciccarelli, L10
Piccinni, MN8
Davidson, MH3
Beam, CA1
Haffner, S3
Perez, A5
D'Agostino, R3
Tunis, SL1
Sauriol, L1
Minshall, ME1
Bode, BW1
Magwire, M1
Derwahl, M1
Blümner, E1
Maeda, T1
Higuchi, Y1
Koyanagi, M1
Sasaki, M1
Arima, T1
Mimori, K1
Makino, N1
Tirkkonen, T1
Heikkilä, P1
Huupponen, R1
Laine, K1
Shaik, NA1
Shaik, JP1
Ali, S1
Imran, A1
Rao, DK1
Hu, YY1
Ye, SD1
Zhao, LL1
Zheng, M1
Wu, FZ1
Chen, Y2
Nagayama, D1
Saiki, A1
Endo, K1
Yamaguchi, T1
Ban, N1
Kawana, H1
Ohira, M1
Oyama, T1
Miyashita, Y1
Shirai, K1
Haupt, A2
Peters, N1
Petto, H2
Poll, L1
Al-Jebawi, AF1
Sone, H1
Yamada, D1
Honjo, J1
Chen, L1
Tandon, N1
Bhattacharyya, A1
Kumar, A1
Kim, KW2
Bech, OM1
Zychma, M1
Lee, WC2
Arechavaleta, R1
Seck, T1
Krobot, KJ1
Duran, L1
Williams-Herman, D1
Goldstein, BJ2
Henry, RR1
Hale, P1
Chang, CT1
Matsuhisa, M3
Yamasaki, Y2
Chandurkar, NB1
Salkar, HR1
Borkar, MS1
Tiwari, D1
Freeman, JS1
GAO, F1
XUE, YM1
HAN, YJ1
FU, XJ1
HE, FY1
Tschöpe, D1
Lobmann, R1
Merke, J1
Bell, DS1
Dharmalingam, M1
Kumar, S1
Sawakhande, RB1
Musholt, PB1
Putignano, P1
Bossi, AC1
Guazzini, B1
Testori, G1
Ahmed, D1
Sharma, M1
Pillai, KK1
Irace, C2
Fiorentino, R1
Carallo, C2
Scavelli, F2
Gnasso, A2
Mori, Y3
Taniguchi, Y1
Sezaki, K1
Yokoyama, J1
Utsunomiya, K1
Mu, PW1
Chen, YM1
Lu, HY1
Wen, XQ1
Zhang, YH1
Xie, RY1
Shu, J1
Wang, MM1
Zeng, LY1
Hasenbank, SE1
Seubert, JM1
Brocks, DR1
Light, PE2
Tawakol, A1
Finn, AV1
Oba, T1
Mawatari, K1
Yasukawa, H1
Harada, H1
Marwick, TH1
Bechlioulis, A1
Kostoula, A1
Vezyraki, P1
Jermendy, G1
Sam, S1
Lang, VY1
Fatehi, M1
Nutter, B1
Bailey, CJ2
Burant, CF1
Viswanathan, P1
Marcinak, J1
Cao, C1
Vakilynejad, M1
Xie, B1
Leifke, E1
Horowitz, M1
Flint, A1
Jones, KL1
Hindsberger, C1
Rasmussen, MF1
Kapitza, C1
Doran, S1
Chapman, IM1
Chang, CH1
Lin, JW1
Wu, LC1
Lai, MS1
Chuang, LM1
Wu, CS1
Sung, SF1
Tong, SH1
Ong, CT1
Smulders, RA1
Zhang, W1
Veltkamp, SA1
van Dijk, J1
Krauwinkel, WJ1
Keirns, J1
Kadokura, T1
Ragia, G1
Tavridou, A1
Petridis, I1
Manolopoulos, VG1
Magnusson, NE1
Dyrskjøt, L1
Grimm, D1
Wehland, M1
Pietsch, J1
Rungby, J1
Madsbad, S1
Guzman, J1
Basson, BR1
Sapin, H1
Trautmann, M1
Komiyama, N1
Hu, M1
Zeng, F1
De Luca, S1
Shehaj, E1
Loprete, A1
Scheen, AJ2
Paquot, N1
Rauch, T1
Monnier, L1
Colette, C1
Comenducci, A1
Vallée, D1
Srivastava, S1
Saxena, GN1
Keshwani, P1
Gupta, R1
Sridhar, S1
Walia, R1
Sachdeva, N1
Bhansali, A1
Torffvit, O1
Ericsson, Å1
Nilsen, B1
Bøgelund, M1
Rathmann, W1
Kostev, K1
Gruenberger, JB1
Bader, G1
Giani, G1
Machado, HA1
Vieira, M1
Cunha, MR1
Correia, MR1
Fukui, RT1
Santos, RF1
Rocha, DM1
Wajchenberg, BL2
Lage, SG1
Silva, ME1
Yadav, SK1
Mishra, S1
Mishra, B1
Christensen, M1
Flaherty, AM1
Harper, R1
Toorawa, R1
Thomsen, AB1
Shah, N1
Mitha, I1
Goncharenko, ON1
Ametov, AS1
Isakova, MR1
Zhao, FL1
Li, SC1
Basit, A2
Riaz, M1
Fawwad, A1
Mateos, JL1
Oueslati, I1
Ben Said, R1
Kammoun, I1
Haouat, E1
Ben Salem, L1
Turki, Z1
Ben Slama, C1
Hausenloy, DJ1
Wynne, AM1
Mocanu, MM1
Yellon, DM1
Kalra, S1
Deepak, MC1
Narang, P1
Singh, V1
Uvaraj, MG1
Hiroi, S1
Sugiura, K1
Matsuno, K1
Hirayama, M1
Kuriyama, K1
Kawakami, K1
Guo, XH1
Lv, XF1
Han, P1
Zhang, XZ1
Yang, HZ1
Duan, WR1
Gao, Y1
Hwang, YC1
Kang, M1
Park, JS1
Chung, DJ1
Kim, KA1
Lee, IK1
Nam, M2
Park, TS1
Son, SM1
Sung, YA1
Klamp, I1
Korytkowski, M1
Thomas, A1
Reid, L1
Tedesco, MB1
Gooding, WE1
Gerich, J1
Nakamura, N2
Takamatsu, J1
Overkamp, D1
Volk, A1
Maerker, E1
Heide, PE1
Wahl, HG1
Rett, K1
Kausch, C1
Dahl, D1
Bachmann, O1
Stumvoll, M1
Matthaei, S3
Kasayama, S1
Hashimoto, K1
Koga, M1
Kawase, I1
Tsunekawa, T1
Hayashi, T1
Suzuki, Y1
Matsui-Hirai, H1
Kano, H1
Fukatsu, A1
Nomura, N1
Miyazaki, A1
Iguchi, A1
Singh, J1
Unnikrishnan, AG1
Agrawal, NK1
Agrawal, JK1
Lee, TM1
Chou, TF1
Tang, L1
Yang, YS1
Ji, RY1
Simeonov, SB1
Botushanov, NP1
Iliev, DA1
Husianitis, HK1
Luis Bautista, J1
Bugos, C1
Dirnberger, G1
Atherton, T1
Plaschke, A4
Egberts, EH4
Mugellini, A1
Crescenzi, G1
Fogari, R5
Zueva, NA1
Sologub, NV1
Efimov, AS1
Schiekofer, S1
Rudofsky, G1
Andrassy, M1
Schneider, J7
Chen, J1
Isermann, B1
Kanitz, M1
Elsenhans, S1
Heinle, H1
Balletshofer, B1
Schleicher, E1
Nawroth, PP1
Bierhaus, A1
Fritsche, A1
Schweitzer, MA2
Dhindsa, P1
Davis, KR1
Donnelly, R1
Becić, F1
Kapić, E1
Becić, E1
Earle, KE1
Rushakoff, RJ1
Goldfine, ID1
Nagasaka, S1
Taniguchi, A1
Aiso, Y1
Yatagai, T1
Nakai, Y1
Kuroe, A1
Ishibashi, S1
Lechleitner, M1
Luger, A2
Klingler, A2
Massi-Benedetti, M2
Kokić, S1
Buković, D1
Radman, M1
Capkun, V1
Gabrić, N1
Lesko, V1
Karelović, D1
Stancerić, T1
Martin, S2
Kolb, H1
Beuth, J1
van Leendert, R1
Schneider, B1
Scherbaum, WA1
Noakes, R1
Skugor, M1
Siraj, ES1
Yoshioka, K1
Yoshida, T1
Yoshikawa, T2
Ptak, M3
Kuhn, J1
Kratzsch, C1
Diekmann, J1
Kleesiek, K1
Maurer, HH2
Komiya, H1
Kurokawa, N1
Tajima, N2
Veitch, PC1
Clifton-Bligh, RJ1
Shukla, UA1
Chi, EM1
Lehr, KH1
de Boer, H2
Jansen, M2
Koerts, J1
Verschoor, L2
Feinböck, C1
Egger, T1
Bielesz, GK1
Winkler, F1
Siebenhofer, A1
Grossschädl, F1
Frank, E1
Irsigler, K1
Jasik, M2
Kabadi, MU1
Kabadi, UM2
Rizzo, MR2
Barbieri, M2
Grella, R2
Passariello, N2
Barone, M1
Paolisso, G2
Hassan, Y1
Hassan, S1
Mikhail, N1
Wali, S1
Matsumoto, K1
Sera, Y1
Abe, Y1
Tominaga, T1
Yeki, Y1
Miyake, S1
Duboeuf, T1
De Widerspach-Thor, A1
Scotto, B1
Bacq, Y1
Korytkowski, MT1
Tan, M1
Johns, D1
González Gálvez, G1
Antúnez, O1
Fabián, G1
Flores-Lozano, F1
Zúñiga Guajardo, S1
Garza, E1
Morales, H1
Konkoy, C1
Herz, M2
Gaddi, A4
Bertone, G1
Heurgué, A1
Bernard-Chabert, B1
Higuero, T1
Lukas-Croisier, C1
Caron, J1
Cadiot, G1
Thiéfin, G1
Tenberken, O1
Grimaldi, A2
Di Mario, U1
Drzewoski, J3
Kempler, P1
Kvapil, M1
Novials, A1
Rottiers, R1
Rutten, GE1
Shaw, KM1
Franzetti, I1
Hamaguchi, T1
Asakawa, H1
Itoh, Y2
Kamado, K1
Tokunaga, K1
Tomita, K1
Masuda, H1
Watanabe, N1
Namba, M1
McCluskey, D2
Touger, MS1
Melis, R2
Schleusener, DS1
Orbay, E1
Sargin, M1
Sargin, H1
Gözü, H1
Bayramiçli, OU1
Yayla, A1
Snehalatha, C1
Salini, J1
Vijay, V1
Shimizu, H1
Monden, T1
Nagai, T1
Shoda, Y1
Sato, T2
Mori, M1
Janka, HU4
Plewe, G2
Kliebe-Frisch, C1
Yki-Järvinen, H1
Chounta, A1
Zouridakis, S1
Ellinas, C1
Tsiodras, S1
Zoumpouli, C1
Kopanakis, S1
Giamarellou, H1
Gaddi, AV3
Salvadeo, S5
Peros, E1
Ghelfi, M4
Inukai, K1
Watanabe, M1
Nakashima, Y1
Sawa, T1
Tanaka, M1
Kashiwabara, H1
Yokota, K1
Charpentier, G3
Fleury, F3
Dubroca, I1
Vaur, L3
Clerson, P1
El-Din, J1
Brockmöller, J1
Kirchheiner, J1
Langenfeld, M1
Walcher, D1
Konrad, T2
Yang, B1
Tian, H1
Ren, Y1
Tong, N1
Yu, H1
Han, L1
Yamanouchi, T1
Sakai, T1
Igarashi, K1
Ichiyanagi, K1
Kawasaki, T1
Tang, JZ1
Mao, JP1
Yang, ZF1
Zhou, ZG1
Tang, WL1
Feng, Q1
Fuellert, SD1
Sachara, C1
Gottschall, V1
Dailey, G1
Fassbender, WJ1
Ose, H1
Kitagawa, Y1
Hirata, C1
Ichio, N1
Kadono, M1
Mogami, S1
Onishi, M1
Ichida, Y1
Nakajima, T1
Hasegawa, G1
Pricolo, F3
Seidel, D1
Winkler, K1
Hamann, A2
Yanagawa, T1
Shibasaki, T1
Kaniwa, N1
Hasegawa, R1
Tohkin, M1
Roberts, VL1
Stewart, J1
Issa, M2
Lake, B1
Zargar, A1
Mahtab, H1
Meshram, DM1
Langade, DG1
Kinagi, SB1
Naikwadi, AA1
Morye, V1
Chopra, D1
Kabadi, M1
Komatsu, M1
Hashizume, K1
Koshiba, K1
Nomura, M1
Nakaya, Y1
Ito, S1
Dangelo, A1
Montagna, L1
Standl, E1
Maxeiner, S1
Raptis, S1
Umpierrez, G1
Anwar, A1
Azmi, KN1
Hamidon, BB1
Khalid, BA1
Calvo, C1
Valbuena, H1
Ruiz, M1
Aschner, P1
Villena, J1
Ramirez, LA1
Jimenez, J1
Ojima, K1
Fuujimori, Y1
Fujimori, Y1
Aoyagi, I1
Kusama, H1
Yamazaki, Y1
Kojima, M1
Kojima, S1
Shibata, N1
Lorra, B1
Abdollahnia, MR1
Kann, PH2
Mathieu, D1
Pehnert, C1
Oligschleger, C1
Kaiser, M1
Cesur, M1
Corapcioglu, D1
Gursoy, A1
Gonen, S1
Ozduman, M1
Emral, R1
Uysal, AR1
Tonyukuk, V1
Yilmaz, AE1
Bayram, F1
Kamel, N1
Keizers, R1
Ruineman-Koerts, J1
Pan, CY1
Sinnassamy, P1
Chung, KD1
Meyer, PM2
Feinstein, SB1
Kondos, GT2
D'Agostino, RB1
Provost, JC1
Haffner, SM1
Wascher, T1
Zackova, V1
Moeller, J1
Medding, J1
Szocs, A1
Mokan, M1
Mrevlje, F1
Regulski, M1
Chung, CH1
Busch, K1
Ben Salem, C1
Hmouda, H1
Bouraoui, K1
Giugliano, D1
Esposito, K1
Kida, Y1
Cara, JF1
Armbruster, FP2
Roth, W2
Köder, C1
Grabellus, M2
Högy, B1
Wilhelm, B1
Kipnes, M1
Luo, E1
Fanurik, D1
Khatami, H1
Stein, P1
Matsuki, M1
Matsuda, M1
Kanda, Y1
Tawaramoto, K1
Shigetoh, M1
Kawasaki, F1
Kotani, K1
Hoopmann, M1
Chou, HS2
Palmer, JP1
Jones, AR1
Waterhouse, B1
Ferreira-Cornwell, C1
Krebs, J1
Blake, EW1
Bhattacharya, SK1
Shastri, S1
Mahajan, P1
Madhu, SV1
Tripathi, AK1
Rauniar, GP1
Das, BP1
Paudel, KR1
Takayama, H1
Hayashida, CY1
Vendramini, MF1
Schiel, R2
Müller, UA2
Fehér, J1
Lengyel, G1
Dorkhan, M1
Hessel, F1
Walzer, S1
Mã Ller, E1
Seidel, DK1
Banerji, MA1
Ebeling, P1
Gudbjörnsdottir, S1
Camisasca, RP1
Baron, MA1
Steg, PG1
Nissen, SE1
Nicholls, SJ1
Wolski, K1
Nesto, R1
Kupfer, S1
Jure, H1
De Larochellière, R1
Staniloae, CS1
Mavromatis, K1
Saw, J1
Hu, B1
Lincoff, AM1
Tuzcu, EM1
Feinstein, S1
Vexiau, P1
Mavros, P1
Krishnarajah, G1
Lyu, R1
Yin, D1
Kawashima, S1
Sakamoto, K1
Yasuda, T1
Kuroda, A1
Kasami, R1
Pünter, J1
Kramer, W1
Leclercq-Meyer, V1
Malaisse, WJ3
Lebrun, P1
Sener, A1
Morishima, T1
Kubota, M1
Kamada, T1
Draeger, E2
Tsumura, K1
Goldberg, RB1
Holvey, SM1
Rosskamp, R2
Wernicke-Panten, K2
Samols, E1
Muchmore, DB1
Draeger, KE2
Lomp, HJ1
Schüler, E1
Dills, DG1
Rosenkranz, B2
Clark, HE1
Pfeiffer, C1
Profozic, V1
Metelko, Z1
Mrzljak, V1
Lange, C1
Malerczyk, V1
Sonnenberg, GE1
Garg, DC1
Weidler, DJ1
Dixon, RM1
Jaber, LA1
Bowen, AJ1
DeChemey, GS1
Mullican, WS1
Stonesifer, LD1
van der Wal, PS1
van Iperen, AM1
Martini, C1
Aarsen, M1
Smits, P2
Ladrière, L1
Malaisse-Lagae, F1
Fuhlendorff, J1
Kaneko, T1
Sakamoto, N1
Langtry, HD1
Balfour, JA1
Veneman, TF1
van Haeften, TW1
Schade, DS1
Jovanovic, L1
Campbell, RK1
Lardinois, CK1
Brogard, JM2
Toyota, T1
Blicklé, JF1
Andres, E1
Neyrolles, N1
Rao, SV1
Bethel, MA1
Dusoleil, A1
Condat, B1
Sobesky, R1
Pelletier, G1
Buffet, C1
Reeker, W1
Schneider, G1
Felgenhauer, N1
Tempel, G1
Kochs, E1
Nattrass, M1
Riddle, M1
Gomis, R1
Raptis, SA1
Ravella, R1
Sitruk, V1
Mohib, S1
Grando-Lemaire, V1
Ziol, M1
Trinchet, JC1
Filipiak, KJ1
Kasperska-Czyzykowa, T2
Karnafel, W2
Lopatyński, J1
Spallarossa, P1
Schiavo, M1
Rossettin, P1
Cordone, S1
Olivotti, L1
Cordera, R1
Brunelli, C1
McCall, AL1
Bando, K1
Kabir, M1
Halimi, S2
Derobert, E1
Oriol, V1
Etienne, S1
Altman, JJ1
Chandraprasert, S1
Suthijumroon, A1
Vichayanrat, A1
Himathongkam, T1
Nitiyanant, W1
Benjasuratawong, Y1
Suwanwalaikorn, S1
Sarinnapakorn, V1
Vongterapak, S1
Abbink, EJ1
Pickkers, P1
Jansen van Rosendaal, A1
Lutterman, JA1
Russel, FG1
Kiayias, JA1
Vlachou, ED1
Theodosopoulou, E1
Lakka-Papadodima, E1

Clinical Trials (131)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Biometabolic Impact of Continuation of GLP-1 Agonists Following Bariatric[NCT06132477]150 participants (Anticipated)Observational [Patient Registry]2023-11-30Not yet recruiting
Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment Versus Glimepiride Both in Combination With Metformin[NCT01425580]Phase 262 participants (Actual)Interventional2012-01-31Completed
Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver[NCT02649465]Phase 440 participants (Actual)Interventional2015-11-11Completed
Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study[NCT01794143]Phase 35,047 participants (Actual)Interventional2013-05-31Completed
A 52-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3bTrial With a Blinded 104-week Long -Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in C[NCT02419612]Phase 3444 participants (Actual)Interventional2015-08-14Completed
A Phase 4, Monocenter, Randomized, Double-blind, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Linagliptin Versus the Sulfonylurea (SU) Der[NCT02106104]Phase 448 participants (Actual)Interventional2014-03-31Completed
The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases[NCT03693560]Phase 480 participants (Actual)Interventional2018-10-08Completed
A Multicentre, International, Randomised, Parallel Group, Double Blind Study to Evaluate Cardiovascular Safety of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.[NCT01243424]Phase 36,103 participants (Actual)Interventional2010-11-11Completed
A Phase III Randomised, Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 10773 Compared to Glimepiride Administered Orally During 104 Weeks With a 104 Week Extension Period in Patients With Type 2 Diabetes Mellitus and Insuff[NCT01167881]Phase 31,549 participants (Actual)Interventional2010-08-31Completed
Effect of Dosage Reduction of Glucose-Lowering Multidrug Regimens on the Incidence of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan: An Open-Label, Parallel-Group, Randomized, Controlled Trial[NCT04237493]Phase 4687 participants (Actual)Interventional2017-02-14Completed
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin[NCT01682759]Phase 3751 participants (Actual)Interventional2012-09-10Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects With Type 2 Diabetes Mellitus[NCT00849056]Phase 3310 participants (Actual)Interventional2009-01-31Completed
A Randomized, Open-label, Parallel-group, Multicenter Study to Determine the Efficacy and Long-term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus.[NCT00838916]Phase 3779 participants (Actual)Interventional2009-02-28Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared With Placebo in Subjects With Type 2 Diabetes Mellitus[NCT00849017]Phase 3309 participants (Actual)Interventional2009-01-31Completed
A Randomized, Double-blind, Placebo and Active-Controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepiride Compared With Metformin Plus Glimepiride and Placeb[NCT00839527]Phase 3685 participants (Actual)Interventional2009-02-28Completed
A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, [NCT00838903]Phase 31,049 participants (Actual)Interventional2009-02-28Completed
The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes[NCT01404676]Phase 434 participants (Actual)Interventional2010-06-30Completed
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Gl[NCT01704261]Phase 3307 participants (Actual)Interventional2012-10-18Completed
A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Co[NCT00968812]Phase 31,452 participants (Actual)Interventional2009-09-30Completed
Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment. A 26-week Double-blind Placebo-controlled, Randomised, Multicentre, Multi-national, Parallel-group [NCT01620489]Phase 3279 participants (Actual)Interventional2012-06-14Completed
A 52-Week, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Active Controlled, Phase IV Study to Evaluate the Safety and Efficacy of Dapagliflozin or Dapagliflozin Plus Saxagliptin Compared With Sulphonylurea All Given as Add-on Therapy to Metformi[NCT02471404]Phase 4939 participants (Actual)Interventional2015-09-21Completed
Efficacy and Safety of Saxagliptin and Glimepiride in Chinese Patients With Type 2 Diabetes Controlled Inadequately With Metformin Monotherapy (SPECIFY Study) : a 48-week, Multi-center, Randomized, Open-label Trial[NCT02280486]Phase 4388 participants (Actual)Interventional2015-01-31Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monothe[NCT02033889]Phase 3621 participants (Actual)Interventional2013-12-13Completed
Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin.[NCT00700856]Phase 43,371 participants (Anticipated)Interventional2008-09-30Active, not recruiting
Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes[NCT01951339]36 participants (Actual)Interventional2013-10-31Completed
Prediction of Findings From the Ongoing CAROLINA Trial Using Healthcare Database Analyses[NCT03648424]48,262 participants (Actual)Observational2011-05-01Completed
A Randomised Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 1356 ( 5.0 mg, Administered Orally Once Daily) Compared to Glimepiride Over Two Years in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metfo[NCT00622284]Phase 31,560 participants (Actual)Interventional2008-02-29Completed
A 24-Week,Int.,Rand.,Double-blind,Parallel-group,Multi-centre, Plac.-Controlled Phase III Study With a 24-Wk Ext.Per.to Eval.the Efficacy and Safety of Dapagliflozin in Comb.With Glimepiride (a Sulphonylurea) in Subjects With Type2 Diab.Who Have Inadeq. G[NCT00680745]Phase 3597 participants (Actual)Interventional2008-04-30Completed
Effects of Glimepiride Monotherapy Versus Combined Neteglinide-Pioglitazone Therapy on Insulin Sensitivity in Type 2 Diabetic Patients[NCT01570660]24 participants (Actual)Interventional2002-02-28Completed
Physicians Committee for Responsible Medicine, A Randomized, Crossover Trial of the Effect of a Dietary Intervention on Intracellular Lipid, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes[NCT04088981]60 participants (Anticipated)Interventional2024-07-31Suspended (stopped due to The study was not initiated due to COVID-19 restrictions.)
A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Co[NCT01296412]Phase 3653 participants (Actual)Interventional2011-03-11Completed
Effect of Augmentation of Cerebral Blood Flow on Neuropsychometric Performance After Carotid Endarterectomy in Type II Diabetic Patients[NCT00597545]10 participants (Actual)Interventional2007-03-31Terminated (stopped due to Half of DM patients had EEG changes and therefore were excluded.)
Neurologic and Neuropsychometric Outcome in Patients Undergoing Carotid Endarterectomy[NCT00597883]585 participants (Actual)Observational2003-03-31Completed
Pilot Study to Assess the Difference in Glycemic Profiles Between Vildagliptin and Glimepiride Using Continuous Glucose Monitoring Device[NCT01262586]Phase 324 participants (Actual)Interventional2010-11-30Completed
A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen: The 'Can Do Ramadan' Study[NCT02694263]Phase 425 participants (Actual)Interventional2016-07-31Completed
Prospective, Parallel Goups Study, Aimed to Evaluating Possible Benefits of the Treatment of New Generation Hypoglycaemic Drugs Compared to Sulphonylureas for the Tratment of Type 2 Diabetes Mellitus[NCT04272359]138 participants (Anticipated)Observational [Patient Registry]2019-05-06Recruiting
Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study[NCT02999841]Phase 4100 participants (Anticipated)Interventional2016-03-31Recruiting
Detection of Plaque Inflammation and Visualization of Anti-Inflammatory Effects of Pioglitazone on Plaque Inflammation in Subjects With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus by FDG-PET/CT[NCT00722631]70 participants (Actual)Interventional2007-05-31Completed
A Phase III Study of MP-513 in Combination With Thiazolidinedione in Japanese Patients With Type 2 Diabetes Mellitus[NCT01026194]Phase 3204 participants (Actual)Interventional2009-12-31Completed
A Phase III Study of MP-513 in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus[NCT00974090]Phase 3194 participants (Actual)Interventional2009-09-30Completed
A Phase IIb, Double-blind, Parallel Group, Multi-center, Dose-finding Study to Investigate the Efficacy and Safety of 4 Doses of MP-513 When Added to Ongoing Metformin Monotherapy in Subjects With Type 2 Diabetes Mellitus, With an Open Label Extension[NCT00971243]Phase 2448 participants (Actual)Interventional2009-08-31Completed
International Multicenter Trial on the Prognostic Value of Arterial 18F-FDG PET Imaging in Patients With History of Myocardial Infarction[NCT05138718]2,041 participants (Anticipated)Observational [Patient Registry]2021-12-01Recruiting
Lantus vs Sulfonylurea as add-on Therapy in Type 2 Diabetic Patients Failing Metformin Monotherapy: Comparison of Effects on Beta Cell Function and Metabolic Profile.[NCT00562172]Phase 475 participants (Actual)Interventional2007-09-30Completed
Effect of Saxagliptin in Addition to Dapagliflozin and Metformin on Insulin Resistance, Islet Cell Dysfunction, and Metabolic Control in Subjects With Type 2 Diabetes Mellitus on Previous Metformin Treatment[NCT02304081]Phase 464 participants (Actual)Interventional2015-01-31Completed
Insulin Glargine Combined With Sulfonylurea Versus Metformin in Patients With Type 2 Diabetes: A Randomized, Controlled Trial.[NCT00708578]Phase 499 participants (Actual)Interventional2008-05-31Completed
A Multicenter, Double-blind, Randomized, Parallel-group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 50mg qd to Placebo as add-on Therapy to Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Mono[NCT01357252]Phase 3279 participants (Actual)Interventional2011-04-30Completed
Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes[NCT03199638]14 participants (Actual)Interventional2016-04-01Completed
Phase 2 Study: A Double-blind, Randomised, Clinical Cross-over Trial to Investigate the Treatment Potential of Liraglutide Compared to Glimepiride in MODY Patients[NCT01610934]Phase 2/Phase 315 participants (Actual)Interventional2012-08-31Completed
Effects of SGLT-2 Inhibitor on Myocardial Perfusion, Function and Metabolism in Type 2 DM Patients at High Cardiovascular Risk: The SIMPle Randomized Clinical Trial[NCT03151343]Phase 392 participants (Actual)Interventional2017-03-29Completed
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation: A Randomised Double-blind Placebo-controlled Trial (The SEESAW Study)[NCT02798744]Phase 468 participants (Actual)Interventional2016-12-31Completed
Superiority of Insulin Glargine Lantus vs. NPH: Treat to Normoglycemia Concept.Effect of Insulin Glargine in Comparison to Insulin NPH in Insulin-nave People With Type 2 Diabetes Mellitus Treated With at Least One OAD and Not Adequately Controlled[NCT00949442]Phase 4708 participants (Actual)Interventional2009-07-31Completed
Effect of Liraglutide on Glycaemic Control in Japanese Subjects With Type 2 Diabetes.[NCT00154414]Phase 2226 participants (Actual)Interventional2005-01-31Completed
Effect on Glycemic Control of Liraglutide in Combination With Rosiglitazone Plus Metformin Versus Rosiglitazone Plus Metformin in Subjects With Type 2 Diabetes[NCT00333151]Phase 3576 participants (Actual)Interventional2006-05-31Completed
Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes.[NCT00154401]Phase 2177 participants (Actual)Interventional2005-01-31Completed
Liraglutide Effect and Action in Diabetes (LEAD-1): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride Versus Glimepiride Monotherapy Versus Glimepiride and Rosiglitazone Combination Therapy in Subje[NCT00318422]Phase 31,041 participants (Actual)Interventional2006-05-31Completed
Liraglutide Effect and Action in Diabetes (LEAD-5): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride and Metformin Versus Glimepiride and Metformin Combination Therapy, and Versus Insulin Glargine [NCT00331851]Phase 3584 participants (Actual)Interventional2006-05-31Completed
The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes. A 26 Week, Randomised, Open-label, Parallel-group, Multicentre, Multinational Trial With a 26 Week Extensio[NCT00856986]Phase 3987 participants (Actual)Interventional2009-03-31Completed
The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus: A 12-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial With an Open-label Glimepiride Arm[NCT00620282]Phase 349 participants (Actual)Interventional2008-02-29Completed
Effect of Liraglutide or Glimepiride Added to Metformin on Glycaemic Control in Subjects With Type 2 Diabetes[NCT00614120]Phase 3929 participants (Actual)Interventional2008-01-31Completed
Effect of Liraglutide in Combination With Sulfonylurea (SU) on Glycaemic Control in Subjects With Type 2 Diabetes[NCT00395746]Phase 3264 participants (Actual)Interventional2006-10-31Completed
Effect of Liraglutide or Exenatide Added to a Background Treatment of Metformin, Sulphonylurea or a Combination of Both on Glycaemic Control in Subjects With Type 2 Diabetes[NCT00518882]Phase 3467 participants (Actual)Interventional2007-08-31Completed
Liraglutide Effect and Action in Diabetes (LEAD-3): Effect on Glycemic Control of Liraglutide Versus Glimepiride in Type 2 Diabetes[NCT00294723]Phase 3746 participants (Actual)Interventional2006-02-28Terminated (stopped due to The trial was terminated at week 195 due to an insufficient number of subjects remaining to obtain reasonable statistical power)
The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Subjects With Type 2 Diabetes. A 26-week, Randomised, Open-label, Active Comparator, Three-armed, Parallel-group, Multi-centre, Multinational Trial With a 52-week Ext[NCT00700817]Phase 3665 participants (Actual)Interventional2008-06-30Completed
Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With[NCT00318461]Phase 31,091 participants (Actual)Interventional2006-05-31Completed
A Double-blind, Two Period Cross-over, Single Centre Trial in Healthy Subjects Investigating the Influence on the Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Drug After Multiple Dose Administration of Liraglutide[NCT01508858]Phase 121 participants (Actual)Interventional2006-11-30Completed
Dose-response Relationship of Five Dose Levels of NNC90-1170 and Placebo on Glycaemic Control in Type 2 Diabetic Patients Compared to OHA Treatment. A 12-week Multi-centre, Double-blind, Randomised, Parallel Group Trial With an Open Labelled OHA Arm[NCT01509755]Phase 2196 participants (Anticipated)Interventional2000-10-31Completed
Effect on Glycemic Control of Individual Maximum Effective Dose of NNC 90-1170 as Add on Therapy to Metformin Compared to Monotherapy of NNC 90-1170 or Metformin or a Metformin-SU Combination Therapy in Patients With Type 2 Diabetes. A Double-blind, Doubl[NCT01511172]Phase 2145 participants (Actual)Interventional2002-08-31Completed
NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes[NCT01511198]Phase 2223 participants (Actual)Interventional2001-02-28Completed
A 52-Week, Randomised, Double Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Compared to Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Contr[NCT01006603]Phase 4957 participants (Actual)Interventional2009-10-31Completed
Long Term Treatment With Exenatide Versus Glimepiride in Patients With Type 2 Diabetes Pretreated With Metformin (EUREXA: European Exenatide Study)[NCT00359762]Phase 31,029 participants (Actual)Interventional2006-09-30Completed
A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety And Efficacy Of Pf-04937319 And Glimepiride In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin[NCT01517373]Phase 2304 participants (Actual)Interventional2012-02-29Completed
A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety And Efficacy Of Pf-04937319 And Sitagliptin On Glycemic Control In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Met[NCT01475461]Phase 2345 participants (Actual)Interventional2011-11-30Completed
A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control[NCT01189890]Phase 3480 participants (Actual)Interventional2010-08-16Completed
Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial[NCT03590626]60 participants (Actual)Interventional2019-01-01Completed
A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Glimepiride[NCT01075282]Phase 3810 participants (Actual)Interventional2010-02-28Completed
Effect of Phytoecdysterone Administration on Cytotoxicity, Genotoxicity and Metabolic Control in Subjects With Prediabetes[NCT03906201]34 participants (Anticipated)Interventional2019-02-06Recruiting
A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Versus Sitagliptin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformi[NCT01137812]Phase 3756 participants (Actual)Interventional2010-07-31Completed
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Con[NCT01106677]Phase 31,284 participants (Actual)Interventional2010-05-31Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin as Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Di[NCT01081834]Phase 3678 participants (Actual)Interventional2010-03-31Completed
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Met[NCT01106625]Phase 3469 participants (Actual)Interventional2010-05-31Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Contr[NCT01106651]Phase 3716 participants (Actual)Interventional2010-06-30Completed
A Multicenter, Randomized, Double Blind Study to Compare the Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (Janumet®) Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus[NCT00993187]Phase 4292 participants (Actual)Interventional2010-05-04Completed
Randomized, Three Period Cross Over, Double Blind, Double Dummy Study in Type 2 Diabetic Patients to Assess the Endothelial Effects of Linagliptin, Glimepiride and Placebo Therapy for 28 Days ('ENDOTHELINA')[NCT01703286]Phase 142 participants (Actual)Interventional2012-10-31Completed
A Multicenter, Randomized, Active-Controlled, Open-label Clinical Trial to Evaluate the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose as a Third OAHA on Top of Sitagliptin+Metformin Combination Therapy in Chinese Patients With Ty[NCT01709305]Phase 45,570 participants (Actual)Interventional2012-11-08Completed
Efficacy and Safety Comparison of Sitagliptin and Glimepiride in Elderly Japanese Patients With Type 2 Diabetes[NCT01183104]305 participants (Actual)Interventional2010-08-31Completed
A Phase 3, Randomized, Three-Arm, Double-blind, Active Controlled, Parallel Group, Multicenter Trial to Evaluate the Safety and Efficacy of Muraglitazar in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Subjects Wtih T[NCT00095030]Phase 31,752 participants Interventional2004-02-29Completed
Protective Effect of Glucagonlike Peptide-1 on Reperfusion Injury in Patients With Acute Myocardial Infarction[NCT02001363]90 participants (Anticipated)Interventional2013-11-30Recruiting
Chinese People's Liberation Army General Hospital[NCT02930265]400 participants (Anticipated)Interventional2016-09-30Enrolling by invitation
Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus[NCT01761318]Phase 450 participants (Actual)Interventional2013-11-30Completed
Interest of GLP1 Analogues (aGLP1) in Overweight Type 2 Diabetic Patients With Chronic Inflammatory Bowel Disease (IBD)[NCT05196958]20 participants (Anticipated)Interventional2022-01-25Recruiting
Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients[NCT04529278]Phase 218 participants (Actual)Interventional2021-01-18Active, not recruiting
A Phase III, Randomized, Parallel, Double-blind, and Non-inferiority Clinical Trial to Compare Efficacy and Safety of CinnaGen-liraglutide to Innovator Liraglutide Product (Victoza®) in Patients With Type II Diabetes (T2D)[NCT03421119]Phase 3300 participants (Anticipated)Interventional2019-06-20Not yet recruiting
CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)[NCT00032487]Phase 31,791 participants (Actual)Interventional2000-12-01Completed
Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409]150 participants (Anticipated)Interventional2016-11-30Active, not recruiting
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705]Phase 4102 participants (Actual)Interventional2012-08-31Completed
Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645]Phase 4100 participants (Anticipated)Interventional2018-12-01Not yet recruiting
A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 12 Weeks Treatment With Vildagliptin to Placebo as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy[NCT00325117]Phase 3200 participants Interventional2006-04-30Completed
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease[NCT01604213]Phase 460 participants (Actual)Interventional2012-09-30Completed
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin[NCT00701090]Phase 31,035 participants (Actual)Interventional2008-05-31Completed
Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic Dyslipidemia[NCT00770653]Phase 3305 participants (Actual)Interventional2007-04-30Completed
Healthy China - The Improvement Projects for the Screening Ability of Diabetes and Its Complications And for the Standardized Ability of Diagnosis and Treatment for Patients With Early Diabetic Nephropathy[NCT05047471]10,000 participants (Anticipated)Observational2021-12-25Enrolling by invitation
Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes[NCT02526810]Phase 470 participants (Anticipated)Interventional2015-07-31Recruiting
A Phase 2, Randomized, Double-Blind, Double-Dummy Placebo-and Active-Controlled, Multicenter Study to Determine the Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus[NCT01007097]Phase 2426 participants (Actual)Interventional2009-12-31Completed
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.[NCT05419726]20 participants (Anticipated)Observational2023-02-01Recruiting
A 4 Week Single Center, Double-dummy, Randomised Double-blind, Balanced Incomplete Latin Square Design Study to Evaluate the Effects of Liraglutide on Appetite in Subjects With Type 2 Diabetes Compared to Glimepiride and Placebo[NCT01511692]Phase 143 participants (Actual)Interventional2005-11-30Completed
Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin[NCT03076112]Phase 3170 participants (Actual)Interventional2017-04-25Completed
Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes[NCT05478707]Phase 264 participants (Anticipated)Interventional2023-10-05Recruiting
Prospective, Randomized, Open-label Study With Blinded Endpoint (PROBE Design) to Compare the 72 hr Glycemic Profiles Obtained by Continuous Subcutaneous Glucose Monitoring (CSGM) in Type 2 Diabetic Patients at Baseline With Metformin Monotherapy and Afte[NCT01193296]Phase 436 participants (Actual)Interventional2010-06-30Completed
Comparison of the Effects of Rosiglitazone and Glimepiride, Both Given in Combination With Metformin, on 24-Hour Glycemia in Type 2 Diabetes Patients Not Controlled With Metformin Alone. A 3-Month Multicentre, Randomized, Parallel-Group, Open-Label Study.[NCT00318656]Phase 423 participants (Actual)Interventional2005-11-30Completed
A Randomised, db, Placebo-controlled, Parallel Group Efficacy and Safety Study of BI 1356 (5mg), Administered Orally Once Daily for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic [NCT00740051]Phase 3227 participants (Actual)Interventional2008-08-31Completed
Prospective Observational Study to Assess Correlation Between Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes Treated With Sulfonylurea[NCT00907881]1,069 participants (Actual)Observational2009-08-31Completed
Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono- Therapy in Chinese Type 2 Diabetes Mellitus (T2DM)[NCT00908921]Phase 4391 participants (Actual)Interventional2009-04-30Completed
Efficacy/Safety Study of Adding Glimepiride to Type 2 Diabetes Patients With Inadequate Glycemic Control Based on Combination With Metformin And Basal Insulin[NCT02026310]40 participants (Actual)Interventional2014-01-31Completed
Basal Insulin Therapy in Patients With Insulin Resistance: A 6 Month Comparison of Insulin Glargine and NPH Insulin[NCT01854723]Phase 40 participants (Actual)Interventional2013-04-30Withdrawn
Bedtime Insulin Glargine or Bedtime Neutral Protamine Lispro Combined With Sulfonylurea and Metformin in Type 2 Diabetes. A Randomized, Controlled Trial[NCT00641407]Phase 4100 participants (Actual)Interventional2007-01-31Completed
New Approach to Treat Type II Diabetes Failing on Maximal Oral Treatment[NCT00151697]Phase 3150 participants (Anticipated)Interventional2005-05-31Completed
Phase 4 Study of Comparison of Combination Therapy of Gliclazide MR and Basal Insulin With Pre-mix Insulin Monotherapy for the Patients With Type 2 Diabetes Mellitus[NCT00736515]Phase 4160 participants (Actual)Interventional2008-10-31Completed
Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes[NCT04943692]Phase 3500 participants (Anticipated)Interventional2021-08-31Suspended (stopped due to Administrative decision of the investigation direction)
Open Label Randomized Multicenter Clinical Trial to Compare Immunogenicity of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients[NCT03352674]Phase 2133 participants (Actual)Interventional2016-09-30Completed
A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus Glimepiride on the Rate of Progression of Atherosclerotic Disease as Measured by Carotid Intima-Media Thickn[NCT00225264]Phase 3458 participants (Actual)Interventional2003-10-31Completed
Effect of Pioglitazone Compared With Metformin on Endothelial Microparticles in Type 2 Diabetes. A Randomized Trial[NCT00815399]Phase 4150 participants (Actual)Interventional2007-10-31Completed
Comparison of Efficacy and Safety of Biphasic Insulin Aspart 30 Plus Metformin With Insulin Glargine Plus Glimepiride in Type 2 Diabetes[NCT00619697]Phase 4260 participants (Actual)Interventional2003-12-31Completed
Glimepiride Versus Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus: A Single Blind Comparison Study[NCT00353691]Phase 3100 participants Interventional2002-10-31Completed
A Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Glimepiride Alone or in Combination With Metf[NCT00106704]Phase 3441 participants (Actual)Interventional2005-03-31Completed
A 24 Week, Open-Label, Single Arm, Multi-Center Clinical Study to Document the Benefits of the Combination of Lantus and Amaryl in Ethnic Japanese Type 2 Diabetic Patients Living Outside of Japan (in US or Brazil), Who Failed Good Metabolic Control With O[NCT00642915]Phase 4100 participants (Actual)Interventional2003-06-30Completed
Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes[NCT00099944]Phase 3515 participants (Actual)Interventional2004-05-31Completed
A Double-Blind, Randomized, Comparator-Controlled Study In Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease as Measured by Intravascular Ultr[NCT00225277]Phase 3547 participants (Actual)Interventional2003-07-31Completed
Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445]Phase 477 participants (Actual)Interventional2008-11-30Completed
Effect of Oral Combination Therapy of Metformin Extended Release Over Glimepiride in a Single Dosage Form in Patients With Type 2 Diabetes Mellitus With Failure of Monotherapy[NCT00941161]Phase 428 participants (Anticipated)Interventional2009-02-28Completed
Bioavailability of Glimepiride/Extended Release Metformin (4/850 mg) in Healthy Mexican Volunteers[NCT01437800]Phase 124 participants (Actual)Interventional2011-01-31Completed
Bioavailability of Glimepiride/Extended Release Metformin (4/850 mg) After a High Fat Diet, in Healthy Mexican Volunteers[NCT01437813]Phase 124 participants (Actual)Interventional2011-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Hemoglobin A1c (HbA1c) at Week 52

To examine whether the mean change from baseline in HbA1c with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin is superior to titrated glimepiride plus metformin after 52 weeks of double-blind treatment. (NCT02419612)
Timeframe: Baseline and Week 52

Intervention% HbA1c (Least Squares Mean)
Dapagliflozin 10mg and Saxagliptin 5mg-1.35
Titrated Glimepiride-0.98

Change From Baseline in Systolic Blood Pressure (SBP) at Week 52

To examine whether the change from baseline in SBP with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin is superior to titrated glimepiride plus metformin after 52 weeks of double-blind treatment. (NCT02419612)
Timeframe: Baseline and Week 52

InterventionmmHg (Least Squares Mean)
Dapagliflozin 10mg and Saxagliptin 5mg-2.6
Titrated Glimepiride1.0

Change From Baseline in Total Body Weight at Week 52

To examine whether the mean change from baseline in total body weight with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin is superior to titrated glimepiride plus metformin after 52 weeks of double-blind treatment. (NCT02419612)
Timeframe: Baseline and Week 52

Interventionkilogram (kg) (Least Squares Mean)
Dapagliflozin 10mg and Saxagliptin 5mg-3.11
Titrated Glimepiride0.95

Percentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 156

Therapeutic glycemic response was defined as HbA1c <7.0%. Subjects rescued or discontinued prior to, and subjects with missing measurements at Week 156 were treated as non-responders. The percentage of subjects with a therapeutic glycemic response is based on the logistic regression method with adjustment for baseline HbA1c. (NCT02419612)
Timeframe: At Week 156

InterventionPercentage of Subjects (Number)
Dapagliflozin 10mg and Saxagliptin 5mg21.4
Titrated Glimepiride11.7

Percentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 52

Therapeutic glycemic response was defined as HbA1c <7.0%. Subjects rescued or discontinued prior to, and subjects with missing measurements at Week 52 were treated as non-responders. The percentage of subjects with a therapeutic glycemic response is based on the logistic regression method with adjustment for baseline HbA1c. (NCT02419612)
Timeframe: At Week 52

InterventionPercentage of subjects (Number)
Dapagliflozin 10mg and Saxagliptin 5mg44.3
Titrated Glimepiride34.3

Percentage of Subjects With Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.

Treatment intensification was defined as the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control. Time to treatment intensification was censored after 156-week treatment period if treatment intensification had not occurred by then. Subjects rescued at Week 156 were counted as having an event for the analysis. The values presented are the percentage of subjects requiring the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control during the 156-week treatment period. (NCT02419612)
Timeframe: Up to Week 156

InterventionPercentage of Subjects (Number)
Dapagliflozin 10mg and Saxagliptin 5mg37.0
Titrated Glimepiride55.6

Percentage of Subjects With Treatment Intensification During the 52-week Short-term Treatment Period

Treatment intensification was defined as the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control. Time to treatment intensification was censored after the 52-week treatment period if treatment intensification had not occurred by then. Subjects rescued at Week 52 were counted as having an event for the analysis. The values presented are the percentage of subjects requiring the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control during the 52-week short -term treatment period. (NCT02419612)
Timeframe: Up to Week 52

InterventionPercentage of Subjects (Number)
Dapagliflozin 10mg and Saxagliptin 5mg1.3
Titrated Glimepiride8.8

Time to Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.

Treatment intensification was defined as the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control. Time to treatment intensification was censored after 156-week treatment period if treatment intensification had not occurred by then. Subjects rescued at Week 156 were counted as having an event for the analysis. Time to treatment intensification curves were generated using Kaplan-Meier estimates and compared using a Cox proportional hazards model. (NCT02419612)
Timeframe: Up to Week 156

InterventionWeeks (Median)
Dapagliflozin 10mg and Saxagliptin 5mgNA
Titrated Glimepiride92.3

CGM Sub-study : Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Millimoles/ Litre) to End of Study

Baseline data for the continuous glucose monitoring sub-study was collected and analyzed. However, the participant number was far less than original planned. The study was stopped early around week 64 (V9) due to recruitment issues and data were not pre-specified to be analyzed and reported at week 64 time point as target was with an estimated time point of 432 weeks for primary or secondary end points. Thus this endpoint was not analysed and only the baseline data collected were analysed and the results are reported in this CGM substudy endpoint. (NCT01243424)
Timeframe: Baseline

InterventionMillimoles/ Litre (mmol/L) (Mean)
All Participants2.45

Change From Baseline of Insulin Secretion Rate (ISR) at Fixed Glucose Concentration at 208 Weeks

The endpoint change from baseline of ISR at fixed glucose concentration at 208 weeks as derived from a 3-hour meal tolerance test is Beta-cell function sub-study endpoint. (NCT01243424)
Timeframe: Baseline and week 208

InterventionPicomol/ minute/meter^2 (pmol/min/m²) (Mean)
Linagliptin11.07
Glimepiride6.95

Change From Baseline to Final Visit in Creatinine

Change from baseline to final visit in creatinine is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment. (NCT01243424)
Timeframe: Baseline and week 432

Interventionmg/dL (Least Squares Mean)
Linagliptin0.08
Glimepiride0.09

Change From Baseline to Final Visit in Estimated Glomerular Filtration Rate (eGFR)

Change from baseline to final visit in eGFR is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment. (NCT01243424)
Timeframe: Baseline and week 432

InterventionmL/minute/1.73 meter^2 (Least Squares Mean)
Linagliptin-4.0
Glimepiride-5.0

Change From Baseline to Final Visit in Fasting Plasma Glucose (FPG)

Change from baseline to final visit in fasting plasma glucose (FPG) is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment. (NCT01243424)
Timeframe: Baseline and week 432

InterventionMilligram/ deciliter (mg/dL) (Least Squares Mean)
Linagliptin12.4
Glimepiride19.7

Change From Baseline to Final Visit in Hemoglobin A1c (HbA1c)

Change from baseline to final visit in HbA1c is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment. (NCT01243424)
Timeframe: Baseline and week 432

InterventionPercentage glycosylated hemoglobin (%) (Least Squares Mean)
Linagliptin0.06
Glimepiride0.15

Change From Baseline to Final Visit in Triglycerides

Change from baseline to final visit in triglycerides is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment. (NCT01243424)
Timeframe: Baseline and week 432

Interventionmg/dL (Least Squares Mean)
Linagliptin1.7
Glimepiride5.2

Change From Baseline to Final Visit in Urine Albumin Creatinine Ratio (UACR)

Change from baseline to final visit in UACR is presented as secondary diabetes-related endpoint. Least square mean is adjusted geometric mean (gMean) ratio. The Final Visit value referred to the last value obtained on-treatment. (NCT01243424)
Timeframe: Baseline and week 432

Interventionmg/ gcrea (Geometric Mean)
Linagliptin1.52
Glimepiride1.57

Continuous Glucose Monitoring (CGM) Sub-study: Change From Baseline in the Inter-quartile Range of Diurnal Glucose Variability (Milligrams/ Deciliter) to End of Study

Baseline data for the continuous glucose monitoring sub-study was collected and analyzed. However, the participant number was far less than original planned. The study was stopped early around week 64 (V9) due to recruitment issues and data were not pre-specified to be analyzed and reported at week 64 time point as target was with an estimated time point of 432 weeks for primary or secondary end points. Thus this endpoint was not analysed and only the baseline data collected were analysed and the results are reported in this CGM substudy endpoint. (NCT01243424)
Timeframe: Baseline

InterventionMilligrams/ deciliter (mg/ dL) (Mean)
All Participants44.2

Percentage of Participants Taking Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, Without >2% Weight Gain, and Without Moderate/Severe Hypoglycaemic Episodes During Maintenance Phase

The second key secondary endpoint was a composite endpoint of treatment sustainability, defined as the percentage of patients taking trial medication at trial end, maintained glycaemic control (HbA1c ≤7.0%) without need for rescue medication, without >2% weight gain, and without moderate/severe hypoglycaemic episodes during maintenance phase. (NCT01243424)
Timeframe: From Visit 6 (Week 16) to Final visit (Week 432) (Maintenance Phase)

InterventionPercentage of participants (%) (Number)
Linagliptin16.0
Glimepiride10.2

Percentage of Participants Who Were on Trial Medication at Trial End, Maintained Glycaemic Control (HbA1c ≤7.0%) Without Need for Rescue Medication, and Without >2% Weight Gain During Maintenance Phase

The third key secondary endpoint was a composite endpoint of treatment sustainability, defined as percentage of patients who were on trial medication at trial end, maintained glycaemic control (HbA1c ≤7.0%) without need for rescue medication, and without >2% weight gain during maintenance phase. (NCT01243424)
Timeframe: From Visit 6 (Week 16) to Final visit (Week 432) (Maintenance Phase)

InterventionPercentage of participants (%) (Number)
Linagliptin17.4
Glimepiride14.1

Percentage of Participants With Occurrence of Accelerated Cognitive Decline at End of Follow-up

Occurrence of accelerated cognitive decline based on regression based index (RBI) score at end of follow-up (a dichotomous outcome measure; presence or absence of accelerated cognitive decline) is Cognition sub-study endpoint. (NCT01243424)
Timeframe: 433 weeks

InterventionPercentage of participants (%) (Number)
Linagliptin27.8
Glimepiride27.6

Percentage of Participants With Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events

"Percentage of participants with occurrence of any of the following components of the composite endpoint of all adjudication-confirmed events of:~CV death (including fatal stroke and fatal MI)~non-fatal MI~non-fatal stroke~hospitalisation for unstable angina pectoris~TIA~hospitalisation for heart failure~hospitalisation for coronary revascularisation procedures (CABG, PCI)" (NCT01243424)
Timeframe: From start of the treatment until 7 days after the end of treatment, up to 433 weeks

InterventionPercentage of participants (%) (Number)
Linagliptin17.1
Glimepiride17.8

Percentage of Participants With the Occurrence of at Least One Event of 3P-MACE

Percentage of participants occurrence of at least one of the following adjudicated components of CV death (including fatal stroke and fatal MI), non-fatal MI (excluding silent MI) and non-fatal stroke is presented as secondary CV endpoint. (NCT01243424)
Timeframe: From randomization until individual day of trial completion, up to 432 weeks

InterventionPercentage of participants (%) (Number)
Linagliptin11.8
Glimepiride12.0

Percentage of Participants With the Occurrence of at Least One Event of 4P -MACE

Percentage of participants occurrence of at least one of the following adjudicated components of CV death (including fatal stroke and fatal MI), non-fatal MI (excluding silent MI), non-fatal stroke, and hospitalisation for unstable angina pectoris is presented as secondary CV endpoint. (NCT01243424)
Timeframe: From randomization until individual day of trial completion, up to 432 weeks

InterventionPercentage of participants (%) (Number)
Linagliptin13.2
Glimepiride13.3

The First 3-point Major Adverse Cardiovascular Events (3P-MACE)

The first occurrence of any of the following Clinical Event Committee (CEC) confirmed adjudicated components of the primary composite endpoint: CV death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI (excluding silent MI), or nonfatal stroke is presented. (NCT01243424)
Timeframe: From randomization until individual day of trial completion, up to 432 weeks

InterventionEvents/ 1000 patients-years (Number)
Linagliptin20.7
Glimepiride21.2

The First 4-point (4P)- MACE

The first key secondary endpoint was time to first occurrence of any of the following adjudicated components of the composite endpoint: CV death (including fatal stroke and fatal MI), non-fatal stroke, non-fatal MI (excluding silent MI), or hospitalisation for unstable angina pectoris. (NCT01243424)
Timeframe: From randomization until individual day of trial completion, up to 432 weeks

InterventionEvents/ 1000 patients-years (Number)
Linagliptin23.4
Glimepiride23.7

Time to First Occurrence of Any of the Components of the Composite Endpoint of All Adjudication-confirmed Events

"Time to first occurrence of any of the following components of the composite endpoint of all adjudication-confirmed events of:~CV death (including fatal stroke and fatal MI)~non-fatal MI~non-fatal stroke~hospitalisation for unstable angina pectoris~Transient ischaemic attack (TIA)~hospitalisation for heart failure~hospitalisation for coronary revascularisation procedures (CABG, PCI)" (NCT01243424)
Timeframe: From start of the treatment until 7 days after the end of treatment, up to 433 weeks

InterventionEvents/ 1000 patients-years (Number)
Linagliptin31.1
Glimepiride32.4

Change From Baseline to Final Visit Fasting Total Cholesterol, Low-density Lipoprotein (LDL) Cholesterol and High-density Lipoprotein (HDL) Cholesterol

Change from baseline to final visit in total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol is presented as secondary diabetes-related endpoint. Least square mean is adjusted mean. The Final Visit value referred to the last value obtained on-treatment. (NCT01243424)
Timeframe: Baseline and week 432

,
Interventionmg/dL (Least Squares Mean)
LDL cholesterolHDL cholesterolTotal cholesterol
Glimepiride-6.50.3-0.5
Linagliptin-6.10.7-5.4

Percentage of Participants With Transition in Albuminuria Classes

Percentage of patients with transition in albuminuria classes is presented as secondary endpoint. Data for last value on treatment (LVOT) to baseline (base) is presented. (NCT01243424)
Timeframe: Baseline and week 432

,
InterventionPercentage of participants (%) (Number)
Base (<30mg/gcrea) LVOT (<30mg/gcrea)Base(<30mg/gcrea)LVOT(>=30 to<=300mg/gcrea)Base (<30 mg/gcrea) LVOT (>300 mg/gcrea)Base (>=30 to <=300 mg/gcrea) LVOT(<30mg/gcrea)Base(>=30to<=300mg/gcrea)LVOT(>=30to<=300mg/gcrea)Base (>=30 to <=300 mg/gcrea) LVOT(>300 mg/gcrea)Base (>300 mg/gcrea) LVOT (<30 mg/gcrea)Base (>300 mg/gcrea) LVOT(>=30 to<=300mg/gcrea)Base (>300 mg/gcrea) LVOT(>300 mg/gcrea)
Glimepiride57.716.01.45.112.13.70.30.92.7
Linagliptin58.414.11.45.412.73.50.10.83.4

The Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment.

(NCT01167881)
Timeframe: Baseline and 104 weeks

Interventionpercentage of HbA1c (Mean)
Empaglifozin 25 mg-0.66
Glimepiride-0.55

The Change From Baseline in HbA1c After 52 Weeks of Treatment.

(NCT01167881)
Timeframe: baseline and 52 weeks

Interventionpercentage of HbA1c (Mean)
Empaglifozin 25 mg-0.73
Glimepiride-0.66

The Change in Body Weight From Baseline After 104 Weeks of Treatment.

(NCT01167881)
Timeframe: baseline and 104 weeks

Interventionkilograms (Mean)
Empaglifozin 25 mg-3.11
Glimepiride1.33

The Change in Body Weight From Baseline After 52 Weeks of Treatment.

(NCT01167881)
Timeframe: baseline and 52 weeks

Interventionkilograms (Mean)
Empaglifozin 25 mg-3.21
Glimepiride1.59

The Change in Diastolic Blood Pressure (DBP) From Baseline After 104 Weeks of Treatment.

(NCT01167881)
Timeframe: baseline and 104 weeks

InterventionmmHg (Mean)
Empaglifozin 25 mg-1.8
Glimepiride0.9

The Change in Diastolic Blood Pressure (DBP) From Baseline After 52 Weeks of Treatment.

(NCT01167881)
Timeframe: baseline and 52 weeks

InterventionmmHg (Mean)
Empaglifozin 25 mg-1.9
Glimepiride1.0

The Change in Systolic Blood Pressure (SBP) From Baseline After 104 Weeks of Treatment.

(NCT01167881)
Timeframe: baseline and 104 weeks

InterventionmmHg (Mean)
Empaglifozin 25 mg-3.1
Glimepiride2.5

The Change in Systolic Blood Pressure (SBP) From Baseline After 52 Weeks of Treatment.

(NCT01167881)
Timeframe: baseline and 52 weeks

InterventionmmHg (Mean)
Empaglifozin 25 mg-3.6
Glimepiride2.2

The Occurrence of Confirmed Hypoglycaemic Events During 104 Weeks of Treatment.

(NCT01167881)
Timeframe: baseline and 104 weeks

Interventionparticipants (Number)
Empaglifozin 25 mg19
Glimepiride189

The Occurrence of Confirmed Hypoglycaemic Events During 52 Weeks of Treatment.

(NCT01167881)
Timeframe: baseline and 52 weeks

Interventionparticipants (Number)
Empaglifozin 25 mg12
Glimepiride159

Change From Baseline in Body Weight at Week 54 Excluding Data After Gylcemic Rescue

(NCT01682759)
Timeframe: Baseline and Week 54

Interventionkg (Least Squares Mean)
Omarigliptin-0.4
Glimepiride1.5

Change From Baseline in Fasting Plasma Glucose at Week 54

Blood glucose was measured on a fasting basis. FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 54 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 54 minus FPG at baseline). (NCT01682759)
Timeframe: Baseline and Week 54

Interventionmg/dL (Least Squares Mean)
Omarigliptin-2.7
Glimepiride-8.3

Change From Baseline in Hemoglobin A1C at Week 54

Hemoglobin A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Thus, this change from baseline reflects the Week 54 A1C minus the Week 0 A1C. (NCT01682759)
Timeframe: Baseline and Week 54

InterventionA1C (%) (Least Squares Mean)
Omarigliptin-0.30
Glimepiride-0.48

Percentage of Participants Achieving a Hemoglobin A1C of <6.5% at Week 54

The percentage of participants who achieved A1C values <6.5% (48 mmol/mol) in the FAS Population at Week 54. (NCT01682759)
Timeframe: Week 54

InterventionPercentage of participants (Number)
Omarigliptin25.1
Glimepiride28.8

Percentage of Participants Achieving a Hemoglobin A1C of <7.0% at Week 54

The percentage of participants who achieved A1C values <7.0% (53 mmol/mol) in the FAS Population at Week 54. (NCT01682759)
Timeframe: Week 54

InterventionPercentage of participants (Number)
Omarigliptin47.7
Glimepiride58.0

Percentage of Participants Who Discontinued From the Study Due to an Adverse Event Excluding Data After Glycemic Rescue

(NCT01682759)
Timeframe: Up to Week 54

InterventionPercentage of participants (Number)
Omarigliptin3.7
Glimepiride2.7

Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure. (NCT01682759)
Timeframe: Up to Week 57

InterventionPercentage of participants (Number)
Omarigliptin54.7
Glimepiride61.6

Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Excluding Data After Glycemic Rescue

Symptomatic episode of hypoglycemia was an episode with clinical symptoms reported by the investigator as hypoglycemia (concurrent fingerstick glucose not required). (NCT01682759)
Timeframe: Up to Week 54

InterventionPercentage of participants (Number)
Omarigliptin5.3
Glimepiride26.7

Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The BL HbA1c value is defined as the last non-missing value before the start of treatment. Change from BL was calculated as the value at Week 52 minus the value at BL. Based on analysis of covariance (ANCOVA): change = treatment + BL HbA1c + prior myocardial infarction history + age category + region + current antidiabetic therapy. The last observation carried forward (LOCF) method was used to impute missing post-BL HbA1c values; the last non-missing post-BL on-treatment measurement was used to impute the missing measurement. HbA1c values obtained after hyperglycemic rescue were treated as missing and were replaced with pre-rescue values. One Intent-to-Treat (ITT) participant (par.) had all post-BL HbA1c measurements occur after hyperglycemic rescue. This par. is included in the ITT Population counts but did not contribute to this analysis. (NCT00849056)
Timeframe: Baseline and Week 52

InterventionPercentage of HbA1c in the blood (Least Squares Mean)
Placebo + Pioglitazone With or Without Metformin-0.05
Albiglutide 30 mg + Pioglitazone With or Without Metformin-0.81

Change From Baseline in Body Weight at Week 156

The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. (NCT00849056)
Timeframe: Baseline and Week 156

InterventionKilograms (Mean)
Placebo + Pioglitazone With or Without Metformin1.50
Albiglutide 30 mg + Pioglitazone With or Without Metformin-0.16

Change From Baseline in Body Weight at Week 52

The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. The LOCF method was used to impute missing post-Baseline weight values. Weight values obtained after hyperglycemia rescue were treated as missing and replaced with prerescue values. Based on ANCOVA: change = treatment + Baseline weight + prior myocardial infarction history + age category + region + current antidiabetic therapy. (NCT00849056)
Timeframe: Baseline and Week 52

InterventionKilograms (Least Squares Mean)
Placebo + Pioglitazone With or Without Metformin0.45
Albiglutide 30 mg + Pioglitazone With or Without Metformin0.28

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 156

The Baseline FPG value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline FPG minus the Baseline FPG. (NCT00849056)
Timeframe: Baseline and Week 156

InterventionMillimoles per liter (mmol/L) (Mean)
Placebo + Pioglitazone With or Without Metformin0.03
Albiglutide 30 mg + Pioglitazone With or Without Metformin-1.26

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52

The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is the last non-missing value before the start of treatment. The LOCF method was used to impute missing post-Baseline FPG values. FPG values obtained after hyperglycemia rescue were treated as missing and replaced with pre-rescue values. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Based on ANCOVA: change = treatment + Baseline weight + prior myocardial infarction history + age category + region + current antidiabetic therapy. (NCT00849056)
Timeframe: Baseline and Week 52

InterventionMillimoles per liter (mmol/L) (Least Squares Mean)
Placebo + Pioglitazone With or Without Metformin0.35
Albiglutide 30 mg + Pioglitazone With or Without Metformin-1.28

Time to Hyperglycemia Rescue

Participants who experienced persistent hyperglycemia (high blood glucose) could have qualified for hyperglycemia rescue. The conditions for hyperglycemia rescue were as follows: FPG >=280 milligrams/deciliter (mg/dL) between >=Week 2 and =250 mg/dL between >=Week 4 and =8.5% and a <=0.5% reduction from Baseline between >=Week 12 and =8.5% between >=Week 24 and =8.0% between >= Week 48 and NCT00849056)
Timeframe: From the start of study medication until the end of the treatment (up to Week 156)

InterventionWeeks (Median)
Placebo + Pioglitazone With or Without Metformin52.86
Albiglutide 30 mg + Pioglitazone With or Without MetforminNA

Change From Baseline in HbA1c at Weeks 104 and 156

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. This analysis used observed HbA1c values, excluding those obtained after hyperglycemia rescue; no missing data imputation was performed. (NCT00849056)
Timeframe: Baseline and Weeks 104 and 156

,
InterventionPercentage of HbA1c in the blood (Mean)
Week 104, n= 29, 72Week 156, n=26, 54
Albiglutide 30 mg + Pioglitazone With or Without Metformin-0.92-0.87
Placebo + Pioglitazone With or Without Metformin-0.72-0.50

Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 156

The number of participants who achieved the HbA1c treatment goal (i.e., HbA1c response levels of <6.5%, <6.5%, and <7.0% at Week 156) were assessed. (NCT00849056)
Timeframe: Week 156

,
InterventionParticipants (Number)
HbA1c <6.5%HbA1c <7%HbA1c <7.5%
Albiglutide 30 mg + Pioglitazone With or Without Metformin203244
Placebo + Pioglitazone With or Without Metformin71217

Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 52

The number of participants who achieved the HbA1c treatment goal (i.e., HbA1c response levels of <6.5%, <6.5%, and <7.0% at Week 52) were assessed. (NCT00849056)
Timeframe: Week 52

,
InterventionParticipants (Number)
HbA1c <6.5%HbA1c <7%HbA1c <7.5%
Albiglutide 30 mg + Pioglitazone With or Without Metformin376696
Placebo + Pioglitazone With or Without Metformin82244

Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The BL HbA1c value is defined as the last non-missing value before the start of treatment. Change from BL was calculated as the value at Week 52 minus the value at BL. Based on analysis of covariance (ANCOVA): change = treatment + BL HbA1c + prior myocardial infarction history + age category + region + current antidiabetic therapy. Difference of least squares means (albiglutide - insulin glargine) is from the ANCOVA model. The last observation carried forward (LOCF) method was used to impute missing post-Baseline HbA1c values; the last non-missing post-BL on-treatment measurement was used to impute the missing measurement. HbA1c values obtained after hyperglycemic rescue were treated as missing and were replaced with pre-rescue values. (NCT00838916)
Timeframe: Baseline and Week 52

InterventionPercentage of HbA1c in the blood (Least Squares Mean)
Albiglutide 30 mg + Metformin +/- Sulfonylurea-0.67
Insulin Glargine 10 Units + Metformin +/- Sulfonylurea-0.79

Change From Baseline in Body Weight at Week 156

The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. (NCT00838916)
Timeframe: Baseline and Week 156

InterventionKilograms (Mean)
Albiglutide 30 mg + Metformin +/- Sulfonylurea-3.47
Insulin Glargine 10 Units + Metformin +/- Sulfonylurea0.90

Change From Baseline in Body Weight at Week 52

The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. The LOCF method was used to impute missing post-Baseline weight values. Weight values obtained after hyperglycemia rescue were treated as missing and replaced with prerescue values. Based on ANCOVA: change = treatment + Baseline weight + Baseline HbA1c category + prior myocardial infarction history + age category + region + current antidiabetic therapy. (NCT00838916)
Timeframe: Baseline and Week 52

InterventionKilograms (Least Squares Mean)
Albiglutide 30 mg + Metformin +/- Sulfonylurea-1.05
Insulin Glargine 10 Units + Metformin +/- Sulfonylurea1.56

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 156

The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. (NCT00838916)
Timeframe: Baseline and Week 156

InterventionMillimoles per liter (mmol/L) (Mean)
Albiglutide 30 mg + Metformin +/- Sulfonylurea-0.83
Insulin Glargine 10 Units + Metformin +/- Sulfonylurea-2.19

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52

The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is the last non-missing value before the start of treatment. The LOCF method was used to impute missing post-Baseline FPG values. FPG values obtained after hyperglycemia rescue were treated as missing and replaced with pre-rescue values. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Based on ANCOVA: change = treatment + Baseline FPG + Baseline HbA1c category + prior myocardial infarction history + age category + region + current antidiabetic therapy. (NCT00838916)
Timeframe: Baseline and Week 52

InterventionMillimoles per liter (mmol/L) (Least Squares Mean)
Albiglutide 30 mg + Metformin +/- Sulfonylurea-0.87
Insulin Glargine 10 Units + Metformin +/- Sulfonylurea-2.06

Change From Baseline in Glucose Profile Measured by 24-hour Area Under Curve (AUC) at Week 52

A 24-hour glucose profile was collected at Baseline and Week 52 at a subset of sites in a subset of participants per treatment group using the continuous glucose monitoring device. Glucose measurements were obtained at 5 minute increments in the 24-hour period. The area under the curve (AUC) was determined using the trapezoidal method on the measurements obtained during the first 24 hours of continuous monitoring. This analysis used observed values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed. The Baseline value is the last non-missing value before the start of treatment. (NCT00838916)
Timeframe: Baseline and Week 52

InterventionMillimoles per hour per liter (mmol.h/L) (Mean)
Albiglutide 30 mg + Metformin +/- Sulfonylurea0.457
Insulin Glargine 10 Units + Metformin +/- Sulfonylurea-1.657

Change From Baseline in HbA1c at Week 156

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. This analysis used observed HbA1c values, excluding those obtained after hyperglycemia rescue; no missing data imputation was performed. (NCT00838916)
Timeframe: Baseline and Week 156

InterventionPercentage of HbA1c in the blood (Mean)
Albiglutide 30 mg + Metformin +/- Sulfonylurea-0.83
Insulin Glargine 10 Units + Metformin +/- Sulfonylurea-1.00

Time to Hyperglycemia Rescue

Participants who experienced persistent hyperglycemia (high blood glucose) could have qualified for hyperglycemia rescue. The conditions for hyperglycemia rescue were as follows: FPG >=280 milligrams/deciliter (mg/dL) between >=Week 2 and =250 mg/dL between >=Week 4 and =8.5% and a <=0.5% reduction from Baseline between >=Week 12 and =8.5% between >=Week 24 and =8.0% between >= Week 48 and NCT00838916)
Timeframe: From the start of study medication until the end of the treatment (up to Week 156)

InterventionWeeks (Median)
Albiglutide 30 mg + Metformin +/- Sulfonylurea107.57
Insulin Glargine 10 Units + Metformin +/- SulfonylureaNA

Albiglutide Plasma Concentrations at Week 8 and Week 24

Albiglutide plasma concentration data was analyzed at Week 8 pre-dose, Week 8 post-dose, Week 24 pre-dose and Week 24 post-dose. All participants receiving albiglutide were initiated on a 30 mg weekly dosing regimen; however, beginning at Week 4, uptitration of albiglutide was allowed based on glycemic response. As such, albiglutide plasma concentrations achieved at each sampling time represent a mixed population of participants receiving either 30 mg or 50 mg weekly for various durations. (NCT00838916)
Timeframe: Weeks 8 and 24

Interventionnanograms/milliliter (ng/mL) (Mean)
Week 8, Pre-dose, n=408Week 8, Post-dose, n=398Week 24, Pre-dose, n=416Week 24, Post-dose, n=401
Albiglutide 30 mg + Metformin +/- Sulfonylurea1642.831911.352159.302748.15

Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 156

The number of participants who achieved the HbA1c treatment goal (i.e., HbA1c response levels of <6.5%, <7%, and <7.5% at Week 156) were assessed. (NCT00838916)
Timeframe: Week 156

,
InterventionParticipants (Number)
HbA1c <6.5%HbA1c <7%HbA1c <7.5%
Albiglutide 30 mg + Metformin +/- Sulfonylurea335985
Insulin Glargine 10 Units + Metformin +/- Sulfonylurea184671

Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 52

The number of participants who achieved the HbA1c treatment goal (i.e., HbA1c response levels of <6.5%, <7%, and <7.5% at Week 52) were assessed. (NCT00838916)
Timeframe: Week 52

,
InterventionParticipants (Number)
HbA1c <6.5%HbA1c <7%HbA1c <7.5%
Albiglutide 30 mg + Metformin +/- Sulfonylurea54156268
Insulin Glargine 10 Units + Metformin +/- Sulfonylurea2578135

Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52

Glycated hemoglobin (HbA1c) is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The BL HbA1c is defined as the last non-missing value before the start of treatment. Change from BL was calculated as the value at Week 52 minus the value at BL. The analysis was performed using an Analysis of Covariance (ANCOVA) model with treatment group, region, history of prior myocardial infarction (yes versus no), and age category (<65 years versus ≥65 years) as factors and Baseline HbA1c as a continuous covariate. The last observation carried forward (LOCF) method was used to impute missing post-BL HbA1c values; the last non-missing post-BL on-treatment measurement was used to impute the missing measurement. HbA1c values obtained after hyperglycemic rescue were treated as missing and were replaced with pre-rescue values. (NCT00849017)
Timeframe: Baseline and Week 52

InterventionPercentage of HbA1c in the blood (Least Squares Mean)
Placebo0.15
Albiglutide 30 mg-0.70
Albiglutide 50 mg-0.89

Change From Baseline in Body Weight at Week 156

The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. (NCT00849017)
Timeframe: Baseline and Week 156

InterventionKilograms (Mean)
Placebo-2.91
Albiglutide 30 mg-1.32
Albiglutide 50 mg-2.24

Change From Baseline in Body Weight at Week 52

The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. The LOCF method was used to impute missing post-Baseline weight values. Weight values obtained after hyperglycemia rescue were treated as missing and replaced with prerescue values. Based on ANCOVA: change = treatment + Baseline weight + prior myocardial infarction history + age category + region + current antidiabetic therapy. (NCT00849017)
Timeframe: Baseline and Week 52

InterventionKilograms (Least Squares Mean)
Placebo-0.66
Albiglutide 30 mg-0.39
Albiglutide 50 mg-0.86

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 156

The Baseline FPG value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline FPG minus the Baseline FPG. (NCT00849017)
Timeframe: Baseline and Week 156

InterventionMillimoles per liter (mmol/L) (Mean)
Placebo-0.23
Albiglutide 30 mg-1.31
Albiglutide 50 mg-1.83

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52

The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is the last non-missing value before the start of treatment. The LOCF method was used to impute missing post-Baseline FPG values. FPG values obtained after hyperglycemia rescue were treated as missing and replaced with pre-rescue values. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Based on ANCOVA: change = treatment + Baseline weight + prior myocardial infarction history + age category + region + current antidiabetic therapy. (NCT00849017)
Timeframe: Baseline and Week 52

InterventionMillimoles per liter (mmol/L) (Least Squares Mean)
Placebo1.00
Albiglutide 30 mg-0.88
Albiglutide 50 mg-1.38

Change From Baseline in Postprandial Blood Glucose Profile Parameter- 4 Hour Blood Glucose AUC

Changes from Baseline at Week 52 in postprandial parameters after a mixed-meal (MM) tolerance test were analyzed. Post prandial blood glucose parameter analyzed was: 4 hour blood glucose area under urve AUC The AUC was determined using the trapezoidal method using measurements until 4 hours following the meal. The standardized AUC is the total AUC divided by elapsed time. Those parameters were analyzed analogous to the primary endpoint using an ANCOVA model with treatment group as a factor, and corresponding Baseline postprandial profile as a continuous covariate. This analysis used observed values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed. (NCT00849017)
Timeframe: Baseline and Week 52

InterventionNanomoles/Liter (nmol/L) (Least Squares Mean)
Placebo-0.51
Albiglutide 30 mg-1.74
Albiglutide 50 mg-2.05

Change From Baseline in Postprandial Blood Glucose Profile Parameter-4 Hour C-peptide AUC

Changes from Baseline at Week 52 in postprandial parameters after a mixed-meal (MM) tolerance test were analyzed. Post prandial blood glucose parameter analyzed was 4 hour c-peptide AUC. The AUC was determined using the trapezoidal method using measurements until 4 hours following the meal. The standardized AUC is the total AUC divided by elapsed time. Those parameters were analyzed analogous to the primary endpoint using an ANCOVA model with treatment group as a factor, and corresponding Baseline postprandial profile as a continuous covariate. This analysis used observed values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed. (NCT00849017)
Timeframe: Baseline and Week 52

InterventionNanomoles/Liter (nmol/L) (Least Squares Mean)
Placebo0.05
Albiglutide 30 mg Weekly0.03
Albiglutide 50 mg Weekly0.08

Time to Hyperglycemia Rescue

Participants who experienced persistent hyperglycemia (high blood glucose) could have qualified for hyperglycemia rescue. The conditions for hyperglycemia rescue were as follows: FPG >=280 milligrams/deciliter (mg/dL) between >=Week 2 and =250 mg/dL between >=Week 4 and =8.5% and a <=0.5% reduction from Baseline between >=Week 12 and =8.5% between >=Week 24 and =8.0% between >= Week 48 and NCT00849017)
Timeframe: From the start of study medication until the end of the treatment (up to Week 156)

InterventionWeeks (Median)
Placebo49.71
Albiglutide 30 mg118.43
Albiglutide 50 mgNA

Albiglutide Plasma Concentration at Weeks 8 and 24

Albiglutide plasma concentration data was analyzed at Week 8 pre-dose, Week 8 post dose, Week 24 pre-dose and Week 24 post-dose. All participants who received albiglutide were initiated on a 30mg weekly dosing regimen; however, beginning at Week 12, participants in the albiglutide 50 mg treatment group were uptitrated to receive albiglutide 50 mg for the remainder of the study. (NCT00849017)
Timeframe: Weeks 8 and 24

,
Interventionnanograms/milliliter (ng/mL) (Mean)
Week 8 Pre-dose, n=85, 85Week 8 Post-dose, n=87, 80Week 24 Pre-dose, n=79, 74Week 24 Post-dose, n=81, 72
Albiglutide 30 mg1582190019122289
Albiglutide 50 mg1433175930603484

Change From Baseline in HbA1c at Weeks 104 and 156

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. This analysis used observed HbA1c values, excluding those obtained after hyperglycemia rescue; no missing data imputation was performed. (NCT00849017)
Timeframe: Baseline and Weeks 104 and 156

,,
InterventionPercentage of HbA1c in the blood (Mean)
Week 104, n=21, 39, 42Week 156, n=14, 30, 32
Albiglutide 30 mg-0.93-0.96
Albiglutide 50 mg-1.18-1.07
Placebo-0.40-0.61

Change From Baseline in Postprandial Blood Glucose Profile Parameters-4 Hour Insulin AUC and 4 Hour Proinsulin AUC

Changes from Baseline at Week 52 in postprandial parameters after a mixed-meal (MM) tolerance test were analyzed. Post prandial blood glucose parameters analyzed were: 4-hour insulin AUC (4 hr Ins AUC), and 4-hour proinsulin AUC (4 hr pro-Ins AUC). The AUC was determined using the trapezoidal method using measurements until 4 hours following the meal. The standardized AUC is the total AUC divided by elapsed time. Those parameters were analyzed analogous to the primary endpoint using an ANCOVA model with treatment group as a factor, and corresponding Baseline postprandial profile as a continuous covariate. This analysis used observed values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed. (NCT00849017)
Timeframe: Baseline and Week 52

,,
Interventionpicomoles/Liter (pmol/L) (Least Squares Mean)
4hr Ins AUC4hr Pro-Ins AUC
Albiglutide 30 mg2.91.9
Albiglutide 50 mg39.9-10.7
Placebo49.21.0

Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 156

The number of participants who acheieved the HbA1c treatment goal (i.e., HbA1c response levels of <6.5%, <7%, and <7.5% at Week 156) were assessed. (NCT00849017)
Timeframe: Week 156

,,
InterventionParticipants (Number)
Week 156, HbA1c <6.5%Week 156, HbA1c <7.0%Week 156, HbA1c <7.5%
Albiglutide 30 mg101824
Albiglutide 50 mg111929
Placebo6813

Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 52

The number of participants who acheieved the HbA1c treatment goal (i.e., HbA1c response levels of <6.5%, <7%, and <7.5% at Week 52) were assessed. (NCT00849017)
Timeframe: Week 52

,,
InterventionParticipants (Number)
Week 52, HbA1c <6.5%Week 52, HbA1c <7.0%Week 52, HbA1c <7.5%
Albiglutide 30 mg254959
Albiglutide 50 mg243962
Placebo102134

Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The BL HbA1c value is defined as the last non-missing value before the start of treatment. Change from BL was calculated as the value at Week 52 minus the value at BL. Based on analysis of covariance (ANCOVA): change = treatment + BL HbA1c + prior myocardial infarction history + age category + region. The last observation carried forward (LOCF) method was used to impute missing post-BL HbA1c values; the last non-missing post-BL on-treatment measurement was used to impute the missing measurement. HbA1c values obtained after hyperglycemic rescue were treated as missing and were replaced with pre-rescue values. Nine par. with post-BL values obtained >14 days after the last dose or after hyperglycemic rescue were included in the analysis population but were not analyzed for this endpoint. (NCT00839527)
Timeframe: Baseline and Week 52

InterventionPercentage of HbA1c in the blood (Least Squares Mean)
Placebo + Metformin + Glimepiride0.33
Pioglitazone + Metformin + Glimepiride-0.80
Albiglutide + Metformin + Glimepiride-0.55

Change From Baseline in Body Weight at Week 52

The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. The LOCF method was used to impute missing post-Baseline weight values. Weight values obtained after hyperglycemia rescue were treated as missing and replaced with pre-rescue values. Based on ANCOVA: change = treatment + Baseline weight + Baseline HbA1c category + prior myocardial infarction history + age category + region. (NCT00839527)
Timeframe: Baseline and Week 52

InterventionKilograms (Least Squares Mean)
Placebo + Metformin + Glimepiride-0.40
Pioglitazone + Metformin + Glimepiride4.43
Albiglutide + Metformin + Glimepiride-0.42

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52

The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is the last non-missing value before the start of treatment. The LOCF method was used to impute missing post-Baseline FPG values. FPG values obtained after hyperglycemia rescue were treated as missing and replaced with pre-rescue values. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Based on ANCOVA: change = treatment + Baseline FPG + Baseline HbA1c category + prior myocardial infarction history + age category + region. (NCT00839527)
Timeframe: Baseline and Week 52

InterventionMillimoles per liter (mmol/L) (Least Squares Mean)
Placebo + Metformin + Glimepiride0.64
Pioglitazone + Metformin + Glimepiride-1.74
Albiglutide + Metformin + Glimepiride-0.69

Time to Hyperglycemia Rescue

Participants who experienced persistent hyperglycemia (high blood glucose) could have qualified for hyperglycemia rescue. The conditions for hyperglycemia rescue were as follows: FPG >=280 milligrams/deciliter (mg/dL) between >=Week 2 and =250 mg/dL between >=Week 4 and =8.5% and a <=0.5% reduction from Baseline between >=Week 12 and =8.5% between >=Week 24 and =8.0% between >= Week 48 and NCT00839527)
Timeframe: From the start of study medication until the end of the treatment (up to Week 156)

InterventionWeeks (Median)
Placebo + Metformin + Glimepiride49.57
Pioglitazone + Metformin + GlimepirideNA
Albiglutide + Metformin + Glimepiride137.71

Change From Baseline in Body Weight at Week 104 and Week 156

The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. This analysis used observed body weight values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed. (NCT00839527)
Timeframe: Baseline, Week 104, and Week 156

,,
InterventionKilograms (Mean)
Week 104, n=12, 130, 104Week 156, n=9, 90, 71
Albiglutide + Metformin + Glimepiride-0.90-1.53
Pioglitazone + Metformin + Glimepiride6.286.52
Placebo + Metformin + Glimepiride-2.16-4.47

Change From Baseline in FPG at Week 104 and Week 156

The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. This analysis used observed FPG values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed. (NCT00839527)
Timeframe: Baseline, Week 104, and Week 156

,,
InterventionMillimoles per liter (mmol/L) (Mean)
Week 104, n=12, 128, 103Week 156, n=9, 88, 71
Albiglutide + Metformin + Glimepiride-0.99-0.88
Pioglitazone + Metformin + Glimepiride-1.98-1.94
Placebo + Metformin + Glimepiride0.43-0.50

Change From Baseline in HbA1c at Week 104 and Week 156

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. This analysis used observed HbA1c values, excluding those obtained after hyperglycemia rescue; no missing data imputation was performed. (NCT00839527)
Timeframe: Baseline, Week 104, and Week 156

,,
InterventionPercentage of HbA1c in the blood (Mean)
Week 104, n=12, 130, 104Week 156, n=9, 89, 71
Albiglutide + Metformin + Glimepiride-0.76-0.46
Pioglitazone + Metformin + Glimepiride-1.09-0.97
Placebo + Metformin + Glimepiride-0.32-0.10

Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 156

The number of participants who acheieved the HbA1c treatment goal (i.e., HbA1c response levels of <6.5%, <7%, and <7.5% at Week 156) was assessed. (NCT00839527)
Timeframe: Week 156

,,
InterventionParticipants (Number)
HbA1c <6.5%HbA1c <7.0%HbA1c <7.5%
Albiglutide + Metformin + Glimepiride162645
Pioglitazone + Metformin + Glimepiride234468
Placebo + Metformin + Glimepiride135

Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 52

The number of participants who acheieved the HbA1c treatment goal (i.e., HbA1c response levels of <6.5%, <7%, and <7.5% at Week 52) was assessed. Values were carried forward for participants who were rescued or discontinued from active treatment before Week 52. (NCT00839527)
Timeframe: Week 52

,,
InterventionParticipants (Number)
HbA1c <6.5%HbA1c <7.0%HbA1c <7.5%
Albiglutide + Metformin + Glimepiride2779126
Pioglitazone + Metformin + Glimepiride3794150
Placebo + Metformin + Glimepiride41019

Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 104

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The BL HbA1c value is defined as the last non-missing value before the start of treatment. Change from BL was calculated as the value at Week 104 minus the value at BL. Based on analysis of covariance (ANCOVA): change = treatment + BL HbA1c + prior myocardial infarction history + age category + region. Difference of least squares means (albiglutide - placebo, albiglutide - sitagliptin, albiglutide - glimepiride) is from the ANCOVA model. The last observation carried forward (LOCF) method was used to impute missing post-Baseline HbA1c values; the last non-missing post-BL on-treatment measurement was used to impute the missing measurement. HbA1c values obtained after hyperglycemic rescue were treated as missing and were replaced with pre-rescue values. (NCT00838903)
Timeframe: Baseline and Week 104

InterventionPercentage of HbA1c in the blood (Least Squares Mean)
Placebo Plus Metformin0.27
Sitagliptin 100 mg Plus Metformin-0.28
Glimepiride 2 mg Plus Metformin-0.36
Albiglutide 30 mg Plus Metformin-0.63

Change From Baseline in Body Weight at Week 104

The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. The LOCF method was used to impute missing post-Baseline weight values. Weight values obtained after hyperglycemia rescue were treated as missing and replaced with prerescue values. Based on ANCOVA: change = treatment + Baseline weight + Baseline HbA1c category + prior myocardial infarction history + age category + region. (NCT00838903)
Timeframe: Baseline and Week 104

InterventionKilograms (Least Squares Mean)
Placebo Plus Metformin-1.00
Sitagliptin 100 mg Plus Metformin-0.86
Glimepiride 2 mg Plus Metformin1.17
Albiglutide 30 mg Plus Metformin-1.21

Change From Baseline in Body Weight at Week 156

The Baseline value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline weight minus the Baseline weight. This analysis used observed body weight values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed. (NCT00838903)
Timeframe: Baseline and Week 156

InterventionKilograms (Mean)
Placebo Plus Metformin-3.61
Sitagliptin 100 mg Plus Metformin-2.05
Glimepiride 2 mg Plus Metformin0.98
Albiglutide 30 mg Plus Metformin-2.31

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 104

The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is the last non-missing value before the start of treatment. The LOCF method was used to impute missing post-Baseline FPG values. FPG values obtained after hyperglycemia rescue were treated as missing and replaced with pre-rescue values. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Based on ANCOVA: change = treatment + Baseline FPG + Baseline HbA1c category + prior myocardial infarction history + age category + region. (NCT00838903)
Timeframe: Baseline and Week 104

InterventionMillimoles per liter (mmol/L) (Least Squares Mean)
Placebo Plus Metformin0.55
Sitagliptin 100 mg Plus Metformin-0.12
Glimepiride 2 mg Plus Metformin-0.41
Albiglutide 30 mg Plus Metformin-0.98

Change From Baseline in FPG at Week 156

The FPG test measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. The Baseline FPG value is the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. This analysis used observed FPG values excluding those obtained after hyperglycemia rescue; no missing data imputation was performed. (NCT00838903)
Timeframe: Baseline and Week 156

InterventionMillimoles per liter (mmol/L) (Mean)
Placebo Plus Metformin-0.11
Sitagliptin 100 mg Plus Metformin-0.50
Glimepiride 2 mg Plus Metformin-0.71
Albiglutide 30 mg Plus Metformin-1.30

Change From Baseline in HbA1c at Week 156

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. Baseline HbA1c value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. This analysis used observed HbA1c values, excluding those obtained after hyperglycemia rescue; no missing data imputation was performed . (NCT00838903)
Timeframe: Baseline and Week 156

InterventionPercentage of HbA1c in the blood (Mean)
Placebo Plus Metformin-0.46
Sitagliptin 100 mg Plus Metformin-0.56
Glimepiride 2 mg Plus Metformin-0.59
Albiglutide 30 mg Plus Metformin-0.88

Time to Hyperglycemia Rescue

Participants who experienced persistent hyperglycemia (high blood glucose) could have qualified for hyperglycemia rescue.The conditions for hyperglycemic rescue were as follows: FPG >=280 milligrams/deciliter (mg/dL) between >=Week 2 and =250 mg/dL between >=Week 4 and =8.5% and a <=0.5% reduction from Baseline between >=Week 12 and =8.5% between >=Week 24 and =8.0% between >= Week 48 and NCT00838903)
Timeframe: From the start of study medication until the end of the treatment (up to Week 156)

InterventionWeeks (Median)
Placebo Plus Metformin67.71
Sitagliptin 100 mg Plus MetforminNA
Glimepiride 2 mg Plus MetforminNA
Albiglutide 30 mg Plus MetforminNA

Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 104

The number of participants who achieved the HbA1c treatment goal (i.e., HbA1c response levels of <6.5%, <7%, and <7.5% at Week 52) were assessed. (NCT00838903)
Timeframe: Week 104

,,,
InterventionParticipants (Number)
HbA1c <6.5%HbA1c <7.0%HbA1c <7.5%
Albiglutide 30 mg Plus Metformin50113172
Glimepiride 2 mg Plus Metformin4094147
Placebo Plus Metformin71527
Sitagliptin 100 mg Plus Metformin4594132

Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of <6.5%, <7%, and <7.5% at Week 156

The number of participants who achieved the HbA1c treatment goal (i.e., HbA1c response levels of <6.5%, <7%, and <7.5% at Week 156) were assessed. (NCT00838903)
Timeframe: Week 156

,,,
InterventionParticipants (Number)
HbA1c <6.5%HbA1c <7.0%HbA1c <7.5%
Albiglutide 30 mg Plus Metformin316990
Glimepiride 2 mg Plus Metformin154469
Placebo Plus Metformin4713
Sitagliptin 100 mg Plus Metformin234469

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

Blood glucose was measured on a fasting basis. FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 24 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 24 minus FPG at baseline). (NCT01704261)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Omarigliptin-19.6
Placebo-3.0

Change From Baseline in Hemoglobin A1c (A1C) at Week 24

A1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Thus, this change from baseline reflects the Week 24 A1C minus the Week 0 A1C. (NCT01704261)
Timeframe: Baseline and Week 24

Intervention%A1C (Least Squares Mean)
Omarigliptin-0.67
Placebo-0.06

Percentage of Participants Who Discontinued From the Study Due to an AE

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure. (NCT01704261)
Timeframe: Up to Week 24

InterventionPercentage of participants (Number)
Omarigliptin2.6
Placebo2.6

Percentage of Participants Who Experienced at Least One Adverse Event (AE)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure. (NCT01704261)
Timeframe: Up to Week 27

InterventionPercentage of participants (Number)
Omarigliptin57.5
Placebo47.7

Percentage of Participants Attaining A1C Glycemic Goals of <7% and <6.5% at Week 24

The percentage of participants who achieved A1C values <6.5% (48 mmol/mol) or <7.0% (53 mmol/mol) in the FAS population at Week 24. (NCT01704261)
Timeframe: 24 weeks

,
InterventionPercentage of participants (Number)
<7.0%<6.5%
Omarigliptin23.810.1
Placebo4.42.1

Change in HbA1c From Baseline to Week 104

The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 104 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change. (NCT00968812)
Timeframe: Baseline, Week 104

InterventionPercent (Least Squares Mean)
Canagliflozin 100 mg-0.65
Canagliflozin 300 mg-0.74
Glimepiride-0.55

Change in HbA1c From Baseline to Week 52

The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change. (NCT00968812)
Timeframe: Day 1 (Baseline) and Week 52

InterventionPercent (Least Squares Mean)
Canagliflozin 100 mg-0.82
Canagliflozin 300 mg-0.93
Glimepiride-0.81

Percent Change in Body Weight From Baseline to Week 52

The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean percent change. (NCT00968812)
Timeframe: Day 1 (Baseline) and Week 52

InterventionPercent change (Least Squares Mean)
Canagliflozin 100 mg-4.2
Canagliflozin 300 mg-4.7
Glimepiride1.0

Percentage of Patients Experiencing at Least 1 Hypoglycemic Event From Baseline to Week 52

The table below shows the percentage of patients who experienced at least 1 documented hypoglycemic event from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in percentages. (NCT00968812)
Timeframe: Day 1 (Baseline) and Week 52

InterventionPercentage of patients (Number)
Canagliflozin 100 mg5.6
Canagliflozin 300 mg4.9
Glimepiride34.2

Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in Body Mass Index (BMI)

Calculated as estimated mean change in BMI (kg/m˄2) from baseline to Week 26 based on the statistical model. (NCT01620489)
Timeframe: Week 0, week 26

Interventionkg/m^2 (Mean)
Lira 1.8 mg-0.88
Placebo-0.38

Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin)

Calculated as the estimated mean change from baseline in HbA1c (%) after 26 Weeks of treatment based on the statistical model. (NCT01620489)
Timeframe: Week 0, Week 26

Interventionpercentage (%) (Mean)
Lira 1.8 mg-1.05
Placebo-0.38

Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in Self-measured Plasma Glucose (SMPG) 7-point Profiles

SMPG was measured before and 90 minutes after breakfast, lunch and dinner and at bedtime at Week 0, 12 and 26. A summary measure of the 7 values was derived for each applicable visit as the area under the curve divided by the period of time elapsed between the first and last measurement. The change from baseline to week 26 was estimated using the statistical model. (NCT01620489)
Timeframe: Week 0, week 26

Interventionmmol/L (Mean)
Lira 1.8 mg-1.59
Placebo-0.51

Estimated Mean Ratio to Baseline and Observed Coefficient of Variation in Renal Function-estimated Glomerular Filtration Rate (eGFR) (to Check How Well the Kidneys Are Functioning Using Modification of Diet in Renal Disease (MDRD) Formula)

Calculated as the estimated ratio to baseline in eGFR (mL/min/1.73m˄2) after 26 Weeks of treatment based on the statistical model. (NCT01620489)
Timeframe: Week 0, week 26

InterventionmL/min/1.73m˄2 (Geometric Mean)
Lira 1.8 mg0.99
Placebo1.01

Estimated Proportion of Responders Achieving HbA1c <7.0% and no Minor or Severe Hypoglycaemic Episodes After 26 Weeks of Treatment

Calculated as estimated percentage of subjects achieving HbA1c <7.0% and no minor or severe hypoglycaemic episodes observed within 26 weeks of treatment based on the statistical model. (NCT01620489)
Timeframe: At week 26

Interventionpercentage of patients (Number)
Lira 1.8 mg33.23
Placebo11.23

Estimated Proportion of Responders Achieving HbA1c <7.0% and no Weight Gain After 26 Weeks of Treatment

Calculated as estimated percentage of subjects achieving HbA1c <7.0% and no weight gain after 26 weeks of treatment based on the statistical model. (NCT01620489)
Timeframe: At week 26

Interventionpercentage of patients (Number)
Lira 1.8 mg46.03
Placebo15.99

Change in Fasting Plasma Glucose (FPG) From Baseline to Week 52

Change in FPG from baseline (week 0) to week 52 (NCT02471404)
Timeframe: Baseline, week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis

InterventionFPG (mmol/L) (Least Squares Mean)
Dapaglifozin 10mg-1.62
Saxagliptin 5mg and Dapagliflozin 10mg-2.08
Glimepiride 1mg/2mg/4mg-1.49

Change in Haemoglobin A1c (HbA1c) From Baseline to Week 52

Change in HbA1c from baseline (week 0) to week 52. (NCT02471404)
Timeframe: Baseline, week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis

InterventionHbA1c % (Least Squares Mean)
Dapaglifozin 10mg-0.82
Saxagliptin 5mg and Dapagliflozin 10mg-1.2
Glimepiride 1mg/2mg/4mg-0.99

Change in Total Body Weight From Baseline at Week 52

Change in body weight from baseline (week 0) to week 52 (NCT02471404)
Timeframe: Baseline, week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis

InterventionWeight (kg) (Least Squares Mean)
Dapaglifozin 10mg-3.54
Saxagliptin 5mg and Dapagliflozin 10mg-3.15
Glimepiride 1mg/2mg/4mg1.76

Number of Patients Rescued

Number (%) of patients rescued. (NCT02471404)
Timeframe: Over the 52 week treatment period

InterventionPercentage of participants (Number)
Dapaglifozin 10mg18.6
Saxagliptin 5mg and Dapagliflozin 10mg8.3
Glimepiride 1mg/2mg/4mg21.4

Patients With at Least One Episode of Confirmed Hypoglycaemia

Percentage of patients reporting at least 1 episode of hypoglycaemia (symptomatic + blood glucose <=50 mg/dL) during the double-blind treatment period (NCT02471404)
Timeframe: Up to Week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis

InterventionPercentage of participants (Number)
Dapaglifozin 10mg0
Saxagliptin 5mg and Dapagliflozin 10mg0.32
Glimepiride 1mg/2mg/4mg4.21

Time to Rescue

The time to rescue (from first dose date after randomisation to start of rescue medication or discontinuation due to lack of glycaemic control) during the 52 week double blind treatment period (NCT02471404)
Timeframe: Over the 52 week treatment period

InterventionWeeks (Median)
Dapaglifozin 10mgNA
Saxagliptin 5mg and Dapagliflozin 10mgNA
Glimepiride 1mg/2mg/4mgNA

Change From Baseline in A1C at Week 104 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 104 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionPercent A1C (Mean)
Placebo/Glimepiride-0.58
Ertugliflozin 5 mg-0.60
Ertugliflozin 15 mg-0.89

Change From Baseline in A1C at Week 26 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionPercent A1C (Least Squares Mean)
Placebo/Glimepiride-0.03
Ertugliflozin 5 mg-0.73
Ertugliflozin 15 mg-0.91

Change From Baseline in A1C at Week 52 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 52 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionPercent A1C (Mean)
Placebo/Glimepiride-0.68
Ertugliflozin 5 mg-0.72
Ertugliflozin 15 mg-0.96

Change From Baseline in Body Weight at Week 104 (Excluding Rescue Approach)

The change in body weight from baseline reflects the Week 104 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionKilograms (Mean)
Placebo/Glimepiride-0.18
Ertugliflozin 5 mg-3.77
Ertugliflozin 15 mg-3.63

Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)

The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionKilograms (Least Squares Mean)
Placebo/Glimepiride-1.33
Ertugliflozin 5 mg-3.01
Ertugliflozin 15 mg-2.93

Change From Baseline in Body Weight at Week 52 (Excluding Rescue Approach)

The change in body weight from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionKilograms (Mean)
Placebo/Glimepiride0.07
Ertugliflozin 5 mg-3.23
Ertugliflozin 15 mg-3.35

Change From Baseline in Fasting Plasma Glucose at Week 104 (Excluding Rescue Approach)

Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 104 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 104 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104

Interventionmg/dL (Mean)
Placebo/Glimepiride-10.9
Ertugliflozin 5 mg-18.2
Ertugliflozin 15 mg-28.2

Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)

Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26

Interventionmg/dL (Least Squares Mean)
Placebo/Glimepiride-0.85
Ertugliflozin 5 mg-27.54
Ertugliflozin 15 mg-39.10

Change From Baseline in Fasting Plasma Glucose at Week 52 (Excluding Rescue Therapy)

Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 52 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 52 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52

Interventionmg/dL (Mean)
Placebo/Glimepiride-12.0
Ertugliflozin 5 mg-22.4
Ertugliflozin 15 mg-35.2

Change From Baseline in Sitting Diastolic Blood Pressure at Week 104 (Excluding Rescue Approach)

This change from baseline reflects the Week 104 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionmmHg (Mean)
Placebo/Glimepiride-0.46
Ertugliflozin 5 mg-2.36
Ertugliflozin 15 mg-1.52

Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)

This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionmmHg (Least Squares Mean)
Placebo/Glimepiride0.23
Ertugliflozin 5 mg-1.59
Ertugliflozin 15 mg-2.19

Change From Baseline in Sitting Diastolic Blood Pressure at Week 52 (Excluding Rescue Approach)

This change from baseline reflects the Week 52 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionmmHg (Mean)
Placebo/Glimepiride0.38
Ertugliflozin 5 mg-1.40
Ertugliflozin 15 mg-1.19

Change From Baseline in Sitting Systolic Blood Pressure at Week 104 (Excluding Rescue Approach)

This change from baseline reflects the Week 104 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionmmHg (Mean)
Placebo/Glimepiride0.05
Ertugliflozin 5 mg-3.61
Ertugliflozin 15 mg-3.13

Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)

This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionmmHg (Least Squares Mean)
Placebo/Glimepiride-0.70
Ertugliflozin 5 mg-4.38
Ertugliflozin 15 mg-5.20

Change From Baseline in Sitting Systolic Blood Pressure at Week 52 (Excluding Rescue Approach)

This change from baseline reflects the Week 52 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionmmHg (Mean)
Placebo/Glimepiride0.65
Ertugliflozin 5 mg-2.63
Ertugliflozin 15 mg-4.28

Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride-1.23
Ertugliflozin 5 mg-1.11
Ertugliflozin 15 mg-0.96

Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride0.09
Ertugliflozin 5 mg-0.19
Ertugliflozin 15 mg-0.13

Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)

BMD at the total hip was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride-1.18
Ertugliflozin 5 mg-1.72
Ertugliflozin 15 mg-2.02

Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)

BMD at the distal forearm was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride0.06
Ertugliflozin 5 mg-0.15
Ertugliflozin 15 mg-0.13

Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride-0.40
Ertugliflozin 5 mg-0.10
Ertugliflozin 15 mg0.30

Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionPercentage change (Least Squares Mean)
Placebo/Glimepiride0.22
Ertugliflozin 5 mg-0.01
Ertugliflozin 15 mg0.12

Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)

BMD at the total hip was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride-0.63
Ertugliflozin 5 mg-0.55
Ertugliflozin 15 mg-0.36

Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)

BMD at the distal forearm was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride-0.44
Ertugliflozin 5 mg-0.59
Ertugliflozin 15 mg-0.39

Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride-0.69
Ertugliflozin 5 mg-0.49
Ertugliflozin 15 mg-0.44

Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride-0.10
Ertugliflozin 5 mg-0.28
Ertugliflozin 15 mg0.07

Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)

BMD at the total hip was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride-0.82
Ertugliflozin 5 mg-1.04
Ertugliflozin 15 mg-1.32

Percent Change From Baseline in Bone Biomarker Carboxy-Terminal Cross-Linking Telopeptides of Type I Collagen (CTX) at Week 26 (Excluding Bone Rescue Approach)

CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionPercent change (Mean)
Placebo/Glimepiride10.8
Ertugliflozin 5 mg51.9
Ertugliflozin 15 mg80.2

Percent Change From Baseline in Bone Biomarker CTX at Week 104 (Excluding Bone Rescue Approach)

CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionPercent change (Mean)
Placebo/Glimepiride19.29
Ertugliflozin 5 mg26.94
Ertugliflozin 15 mg32.53

Percent Change From Baseline in Bone Biomarker CTX at Week 52 (Excluding Bone Rescue Approach)

CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionPercent change (Mean)
Placebo/Glimepiride15.54
Ertugliflozin 5 mg34.36
Ertugliflozin 15 mg41.57

Percent Change From Baseline in Bone Biomarker P1NP at Week 104 (Excluding Bone Rescue Approach)

P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionPercent change (Mean)
Placebo/Glimepiride19.38
Ertugliflozin 5 mg10.11
Ertugliflozin 15 mg24.21

Percent Change From Baseline in Bone Biomarker P1NP at Week 52 (Excluding Bone Rescue Approach)

P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionPercent Change (Mean)
Placebo/Glimepiride24.50
Ertugliflozin 5 mg8.41
Ertugliflozin 15 mg19.79

Percent Change From Baseline in Bone Biomarker Parathyroid Hormone (PTH) at Week 26 (Excluding Bone Rescue Approach)

PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionPercent change (Mean)
Placebo/Glimepiride-0.98
Ertugliflozin 5 mg0.28
Ertugliflozin 15 mg0.14

Percent Change From Baseline in Bone Biomarker Procollagen Type I N-terminal Propeptide (P1NP) at Week 26 (Excluding Bone Rescue Approach)

P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26

InterventionPercent change (Mean)
Placebo/Glimepiride0.5
Ertugliflozin 5 mg0.8
Ertugliflozin 15 mg0.5

Percent Change From Baseline in Bone Biomarker PTH at Week 104 (Excluding Bone Rescue Approach)

PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionPercent change (Mean)
Placebo/Glimepiride10.12
Ertugliflozin 5 mg8.16
Ertugliflozin 15 mg5.46

Percent Change From Baseline in Bone Biomarker PTH at Week 52 (Excluding Bone Rescue Approach)

PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52

InterventionPercent Change (Mean)
Placebo/Glimepiride8.11
Ertugliflozin 5 mg11.09
Ertugliflozin 15 mg2.48

Percent Change From BMD at Week 104 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)

BMD at the distal forearm was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104

InterventionPercent change (Least Squares Mean)
Placebo/Glimepiride-0.58
Ertugliflozin 5 mg-0.40
Ertugliflozin 15 mg-0.64

Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment. (NCT02033889)
Timeframe: Up to Week 104

InterventionPercentage of Participants (Number)
Placebo/Glimepiride2.4
Ertugliflozin 5 mg3.4
Ertugliflozin 15 mg3.9

Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment. (NCT02033889)
Timeframe: Up to Week 106

InterventionPercentage of Participants (Number)
Placebo/Glimepiride77.5
Ertugliflozin 5 mg70.5
Ertugliflozin 15 mg75.6

Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 104

Per protocol participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. (NCT02033889)
Timeframe: Up to Week 104

InterventionPercentage of participants (Number)
Placebo/Glimepiride24.4
Ertugliflozin 5 mg11.1
Ertugliflozin 15 mg10.7

Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 26

Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. (NCT02033889)
Timeframe: Up to Week 26

InterventionPercentage of Participants (Number)
Placebo/Glimepiride17.7
Ertugliflozin 5 mg2.9
Ertugliflozin 15 mg1.5

Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 52

Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. (NCT02033889)
Timeframe: Up to Week 52

InterventionPercentage of Participants (Number)
Placebo/Glimepiride17.2
Ertugliflozin 5 mg4.3
Ertugliflozin 15 mg1.5

Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 104 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 104

InterventionPercentage of Participants (Number)
Placebo/Glimepiride7.2
Ertugliflozin 5 mg10.6
Ertugliflozin 15 mg12.2

Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 26

InterventionPercentage of Participants (Number)
Placebo/Glimepiride2.9
Ertugliflozin 5 mg8.7
Ertugliflozin 15 mg12.2

Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 52 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 52

InterventionPercentage of Participants (Number)
Placebo/Glimepiride11.0
Ertugliflozin 5 mg10.6
Ertugliflozin 15 mg14.6

Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 104 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 104

InterventionPercentage of Participants (Number)
Placebo/Glimepiride19.1
Ertugliflozin 5 mg24.6
Ertugliflozin 15 mg33.7

Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 26

InterventionPercentage of Participants (Number)
Placebo/Glimepiride15.8
Ertugliflozin 5 mg35.3
Ertugliflozin 15 mg40.0

Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 52 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 52

InterventionPercentage of Participants (Number)
Placebo/Glimepiride30.6
Ertugliflozin 5 mg34.8
Ertugliflozin 15 mg36.6

Time to Glycemic Rescue Therapy at Week 26

Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. (NCT02033889)
Timeframe: Week 26

InterventionDays (Median)
Placebo/Glimepiride105
Ertugliflozin 5 mg112
Ertugliflozin 15 mg139

Ertugliflozin Plasma Concentrations (ng/mL): Summary Statistics Over Time (Excluding Rescue Approach)

Pharmacokinetic samples were collected at approximately 24 hours following the prior day's dose and before administration of the current day's dose. The lower limit of quantitation (LLOQ) was 0.500 mg/mL. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Pre-dose and/or 60 minutes post-dose on Weeks 6, 12, 18, and 30

,,
Interventionng/mL (Mean)
Week 6:Pre-doseWeek 12:Pre-doseWeek 12:60 mins post-doseWeek 18:Pre-doseWeek 18:60 mins post-doseWeek 30:Pre-dose
Ertugliflozin 15 mg38.3829.23228.1324.46214.9630.55
Ertugliflozin 5 mg14.8912.3474.849.9174.3912.66
Placebo/GlimepirideNANANA0.010.010.15

Change in Oxygen Uptake Kinetics (VO2 Kinetics)

Oxygen uptake kinetics will be tested on a stationary bike before and after 3 months of study medication. VO2 kinetics is reported as the time constant associated with the change in oxygen update from rest to steady state. (NCT01951339)
Timeframe: Pre-intervention (Baseline) and post-intervention (3 months)

,
Interventionseconds (Mean)
Pre-interventionPost-intervention
Glimepiride Plus Placebo54.254.6
Sitagliptin Plus Placebo56.267.5

Changes From Baseline in 31P Measurement: Adenosine Diphosphate (ADP) Time Constant

Potential change in muscle mitochondrial function will be assessed after three months of study medication treatment (NCT01951339)
Timeframe: Pre-intervention (Baseline) and post-intervention (3 months)

,
Interventionseconds (Mean)
Pre-interventionPost-intervention
Glimepiride Plus Placebo24.521.2
Sitagliptin Plus Placebo28.019.4

Changes From Baseline in 31P Measurement: Adenosine Triphosphate (ATP) Peaks

Potential change in muscle mitochondrial function will be assessed after three months of study medication treatment (NCT01951339)
Timeframe: Pre-intervention (Baseline) and post-intervention (3 months)

,
InterventionmM (Mean)
Pre-interventionPost-intervention
Glimepiride Plus Placebo7.938.02
Sitagliptin Plus Placebo8.1912.66

Changes From Baseline in 31P Measurement: Free Pi Time Constant

Potential change in muscle mitochondrial function will be assessed after three months of study medication treatment. Data are represented as the change in Pi through the scan. (NCT01951339)
Timeframe: Pre-intervention (Baseline) and post-intervention (3 months)

,
Interventionseconds (Mean)
Pre-interventionPost-intervention
Glimepiride Plus Placebo28.5426.15
Sitagliptin Plus Placebo29.7327.94

Changes From Baseline in 31P Measurement: pH

Potential change in muscle mitochondrial function will be assessed after three months of study medication treatment (NCT01951339)
Timeframe: Pre-intervention (Baseline) and post-intervention (3 months)

,
InterventionpH (Mean)
Pre-interventionPost-intervention
Glimepiride Plus Placebo6.886.89
Sitagliptin Plus Placebo6.886.85

Changes From Baseline in 31P Measurement: Phosphocreatine Time Constant

Potential change in muscle mitochondrial function will be assessed after three months of study medication treatment (NCT01951339)
Timeframe: Pre-intervention (Baseline) and post-intervention (3 months)

,
Interventionseconds (Mean)
Pre-interventionPost-intervention
Glimepiride Plus Placebo30.929.6
Sitagliptin Plus Placebo34.126.6

Changes From Baseline in Echocardiographic Measures (Stroke Volume)

Potential change in cardiac function will be assessed by echocardiography before and after 3 months of study medication (NCT01951339)
Timeframe: Pre-intervention (Baseline) and post-intervention (3 months)

,
InterventionmL/beat (Mean)
Pre-interventionPost-intervention
Glimepiride Plus Placebo72.777.8
Sitagliptin Plus Placebo58.264.6

Peak Oxygen Consumption (VO2peak).

Subjects' peak oxygen consumption will be tested on a stationary bike before and after 3 months of study medication. (NCT01951339)
Timeframe: Pre-intervention (Baseline) and post-intervention (3 months)

,
Interventionml/min (Mean)
Pre-interventionPost-intervention
Glimepiride Plus Placebo19531881
Sitagliptin Plus Placebo18931849

2 hr Postprandial Glucose (PPG) Change From Baseline at Week 104

This change from baseline reflects the Week 104 2 hr PPG minus the Baseline 2hr PPG. Means are treatment adjusted for baseline HbA1c, baseline 2hr PPG and number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Baseline and week 104

Interventionmg/dL (Mean)
Linagliptin-28.47
Glimepiride-18.72

Body Weight Change From Baseline at Week 104

This key secondary endpoint, change from baseline, reflects the Week 104 body weight minus the baseline body weight. Means are treatment adjusted for baseline HbA1c, baseline weight and the number of previous antidiabetic-medications. (NCT00622284)
Timeframe: Baseline and week 104

Interventionkg (Mean)
Linagliptin-1.39
Glimepiride1.29

Body Weight Change From Baseline at Week 52

This key secondary endpoint, change from baseline, reflects the Week 52 body weight minus the baseline body weight. Means are treatment adjusted for baseline HbA1c, baseline weight and the number of previous antidiabetic-medications. (NCT00622284)
Timeframe: Baseline and week 52

Interventionkg (Mean)
Linagliptin-1.12
Glimepiride1.38

Change in Baseline Lipid Parameter Cholesterol at Week 104

(NCT00622284)
Timeframe: Baseline and week 104

Interventionmg/dL (Mean)
Linagliptin0
Glimepiride1

Change in Baseline Lipid Parameter HDL at Week 104

(NCT00622284)
Timeframe: Baseline and week 104

Interventionmg/dl (Mean)
Linagliptin1
Glimepiride0

Change in Baseline Lipid Parameter Low Density Lipoprotein (LDL) at Week 104

(NCT00622284)
Timeframe: Baseline and week 104

Interventionmg/dL (Mean)
Linagliptin1
Glimepiride3

Change in Baseline Lipid Parameter Triglyceride at Week 104

(NCT00622284)
Timeframe: Baseline and week 104

Interventionmg/dL (Mean)
Linagliptin-11
Glimepiride-7

Fasting Plasma Glucose (FPG) Change From Baseline at Week 104

This change from baseline reflects the Week 104 FPG minus the Baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Baseline and week 104

Interventionmg/dL (Mean)
Linagliptin-2.34
Glimepiride-8.72

Fasting Plasma Glucose (FPG) Change From Baseline at Week 52

This change from baseline reflects the Week 52 FPG minus the Baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and the number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Baseline and week 52

Interventionmg/dL (Mean)
Linagliptin-8.40
Glimepiride-15.24

HbA1c Change at Week 104

The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement available during the first phase of the study. Last observation carried forward (LOCF) was used as imputation rule. (NCT00622284)
Timeframe: Baseline and week 104

InterventionPercent (Mean)
Linagliptin-0.21
Glimepiride-0.41

HbA1c Change at Week 12

(NCT00622284)
Timeframe: Baseline and week 12

InterventionPercent (Mean)
Linagliptin-0.43
Glimepiride-0.75

HbA1c Change at Week 16

(NCT00622284)
Timeframe: Baseline and week 16

InterventionPercent (Mean)
Linagliptin-0.45
Glimepiride-0.78

HbA1c Change at Week 28

(NCT00622284)
Timeframe: Baseline and week 28

InterventionPercent (Mean)
Linagliptin-0.43
Glimepiride-0.74

HbA1c Change at Week 4

Difference of base percent value [Week x(%) - baseline (%)] (NCT00622284)
Timeframe: Baseline and week 4

InterventionPercent (Mean)
Linagliptin-0.26
Glimepiride-0.33

HbA1c Change at Week 40

(NCT00622284)
Timeframe: Baseline and week 40

InterventionPercent (Mean)
Linagliptin-0.42
Glimepiride-0.69

HbA1c Change at Week 52

(NCT00622284)
Timeframe: Baseline and week 52

InterventionPercent (Mean)
Linagliptin-0.41
Glimepiride-0.63

HbA1c Change at Week 65

(NCT00622284)
Timeframe: Baseline and week 65

InterventionPercent (Mean)
Linagliptin-0.32
Glimepiride-0.53

HbA1c Change at Week 78

(NCT00622284)
Timeframe: Baseline and week 78

InterventionPercent (Mean)
Linagliptin-0.22
Glimepiride-0.43

HbA1c Change at Week 8

(NCT00622284)
Timeframe: Baseline and week 8

InterventionPercent (Mean)
Linagliptin-0.37
Glimepiride-0.58

HbA1c Change at Week 91

(NCT00622284)
Timeframe: Baseline and week 91

InterventionPercent (Mean)
Linagliptin-0.21
Glimepiride-0.43

HbA1c Change From Baseline at Week 104

This co-primary endpoint, change from baseline, reflects the Week 104 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Baseline and week 104

InterventionPercent (Mean)
Linagliptin-0.16
Glimepiride-0.36

HbA1c Change From Baseline at Week 52

This co-primary endpoint, change from baseline, reflects the Week 52 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Baseline and week 52

InterventionPercent (Mean)
Linagliptin-0.36
Glimepiride-0.57

Incidence of Hypoglycaemic Events up to 104 Weeks

A hypoglycaemic event is defined as patient showing clinical signs suggestive of low blood glucose confirmed by a HBGM of below 55 mg/dl (3.1 mmol/L) (NCT00622284)
Timeframe: Week 104

InterventionPatients (Number)
Linagliptin58
Glimepiride280

Incidence of Hypoglycaemic Events up to 52 Weeks

A hypoglycaemic event is defined as patient showing clinical signs suggestive of low blood glucose confirmed by a home blood glucose monitoring (HBGM) of below 55 mg/dl (3.1 mmol/L) (NCT00622284)
Timeframe: Week 52

InterventionPatients (Number)
Linagliptin41
Glimepiride249

Percentage of Patients With HbA1c <6.5% at Week 104

The percentage of patients with an HbA1c value below 6.5% at week 104, based upon patients with baseline HbA1c >= 6.5%. If a patient did not have an HbA1c value at week 104 they were considered a failure, so HbA1c >= 6.5%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Week 104

InterventionPercentage of patients (Number)
Linagliptin10.9
Glimepiride14.7

Percentage of Patients With HbA1c <6.5% at Week 52

The percentage of patients with an HbA1c value below 6.5% at week 52, based upon patients with baseline HbA1c >= 6.5%. If a patient did not have an HbA1c value at week 52 they were considered a failure, so HbA1c >= 6.5%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Week 52

InterventionPercentage of patients (Number)
Linagliptin16.9
Glimepiride22.7

Percentage of Patients With HbA1c <7.0% at Week 104

The percentage of patients with an HbA1c value below 7.0% at week 104, based upon patients with baseline HbA1c >= 7%. If a patient did not have an HbA1c value at week 104 they were considered a failure, so HbA1c >= 7.0%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Week 104

InterventionPercentage of patients (Number)
Linagliptin21.0
Glimepiride28.3

Percentage of Patients With HbA1c <7.0% at Week 52

The percentage of patients with an HbA1c value below 7.0% at week 52, based upon patients with baseline HbA1c >= 7%. If a patient did not have an HbA1c value at week 52 they were considered a failure, so HbA1c >= 7.0%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications. (NCT00622284)
Timeframe: Week 52

InterventionPercentage of patients (Number)
Linagliptin29.6
Glimepiride38.9

Percentage of Patients With HbA1c Lowering by 0.5% at Week 104

Occurrence of relative efficacy response, defined as a lowering of 0.5% HbA1c at week 104 (NCT00622284)
Timeframe: Week 104

InterventionPercentage of patients (Number)
Linagliptin26.2
Glimepiride33.5

Adjusted Mean Change in 2-h Post-challenge Plasma Glucose Rise

To show that dapagliflozin plus glimepiride results in greater reductions in the 2-h post-challenge plasma glucose rise as a response to an oral glucose tolerance test (OGTT) from baseline to Week 24. (NCT00680745)
Timeframe: Baseline to Week 24

Interventionmg/dL (Least Squares Mean)
Dapagliflozin 2.5mg + Glimepiride-37.5
Dapagliflozin 5mg + Glimepiride-32.0
Dapagliflozin 10mg + Glimepiride-34.9
Placebo + Glimepiride-6.0

Adjusted Mean Change in Body Weight

To show that dapagliflozin plus glimepiride results in greater reduction in body weight or less weight gain after 24 weeks of treatment when compared to placebo plus glimepiride. (NCT00680745)
Timeframe: Baseline to Week 24

Interventionkg (Least Squares Mean)
Dapagliflozin 2.5mg + Glimepiride-1.18
Dapagliflozin 5mg + Glimepiride-1.56
Dapagliflozin 10mg + Glimepiride-2.26
Placebo + Glimepiride-0.72

Adjusted Mean Change in Body Weight for Participants With Baseline Body Mass Index (BMI)≥27 kg/m2

To show that dapagliflozin plus glimepiride results in greater reductions in body weight or less weight gain in participants with baseline BMI ≥27 kg/m2 after 24 weeks of treatment when compared to placebo plus glimepiride. (NCT00680745)
Timeframe: Baseline to Week 24

Interventionkg (Least Squares Mean)
Dapagliflozin 2.5mg + Glimepiride-1.17
Dapagliflozin 5mg + Glimepiride-1.74
Dapagliflozin 10mg + Glimepiride-2.47
Placebo + Glimepiride-0.80

Adjusted Mean Change in Fasting Plasma Glucose (FPG)

To show that dapagliflozin plus glimepiride leads to greater reductions in FPG after 24 weeks of treatment compared to placebo plus glimepiride. (NCT00680745)
Timeframe: Baseline to Week 24

Interventionmg/dL (Least Squares Mean)
Dapagliflozin 2.5mg + Glimepiride-16.8
Dapagliflozin 5mg + Glimepiride-21.2
Dapagliflozin 10mg + Glimepiride-28.5
Placebo + Glimepiride-2.0

Adjusted Mean Change in HbA1c Levels

To assess the efficacy of dapagliflozin compared to placebo as add-on therapy to glimepiride in improving glycemic control in participants with type 2 diabetes, as determined by the change in HbA1C levels from baseline to the end of the 24-week double-blind treatment period. (NCT00680745)
Timeframe: Baseline to Week 24

InterventionPercent (Least Squares Mean)
Dapagliflozin 2.5mg + Glimepiride-0.58
Dapagliflozin 5mg + Glimepiride-0.63
Dapagliflozin 10mg + Glimepiride-0.82
Placebo + Glimepiride-0.13

Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%

To show that dapagliflozin plus glimepiride results in a larger proportion of participants achieving a therapeutic glycemic response, defined as HbA1c < 7% after 24 weeks of treatment, compared to placebo plus glimepiride. (NCT00680745)
Timeframe: At Week 24

InterventionPercentage of participants (Least Squares Mean)
Dapagliflozin 2.5mg + Glimepiride26.8
Dapagliflozin 5mg + Glimepiride30.3
Dapagliflozin 10mg + Glimepiride31.7
Placebo + Glimepiride13.0

Change From Baseline in Fasting Plasma Glucose (FPG)

Change from baseline at Week 26 is defined as Week 26 minus Week 0. (NCT01296412)
Timeframe: Baseline and Week 26

Interventionmg/dL (Least Squares Mean)
Sitagliptin +/- Glimepiride-33.7
Liraglutide-39.6

Change From Baseline in Hemoglobin A1c (A1C)

A1C is measured as percent. Thus, this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent. (NCT01296412)
Timeframe: Baseline and Week 26

Interventionpercent (Least Squares Mean)
Sitagliptin +/- Glimepiride-1.32
Liraglutide-1.42

Percentage of Participants Reaching A1C Goal of <6.5%

(NCT01296412)
Timeframe: Week 26

Interventionpercentage of participants (Number)
Sitagliptin +/- Glimepiride33.8
Liraglutide38.3

Percentage of Participants Reaching A1C Goal of <7.0%

(NCT01296412)
Timeframe: Week 26

Interventionpercentage of participants (Number)
Sitagliptin +/- Glimepiride62.8
Liraglutide72.3

Number of Participants With Improved Neuropsychometric Changes

Battery of neuropsychometric tests to evaluate a variety of cognitive functions. (NCT00597545)
Timeframe: Post-operatively at 1 day

Interventionparticipants (Number)
Conventional Shunt1
Prophylactic Shunt2

Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12

The change from Baseline in 2-hour Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline 2-hour Postprandial Plasma Glucose as a covariate. (NCT01026194)
Timeframe: at Week 0 and Week 12

Interventionmg / dL (Least Squares Mean)
Placebo/Teneli + Pio-5.6
Teneli/Teneli + Pio-56.9

Change From Baseline in Fasting Plasma Glucose at Week 12

The change from Baseline in Fasting Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline Fasting Plasma Glucose as a covariate. (NCT01026194)
Timeframe: at Week 0 and Week 12

Interventionmg / dL (Least Squares Mean)
Placebo/Teneli + Pio-4.5
Teneli/Teneli + Pio-21.0

Change From Baseline in HbA1c at Week 12

The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline HbA1c as a covariate. (NCT01026194)
Timeframe: at Week 0 and Week 12

InterventionPercent of HbA1c (Least Squares Mean)
Placebo/Teneli + Pio-0.20
Teneli/Teneli + Pio-0.94

Change From Baseline in the Areas Under the Curve From 0 to 2 h (AUC0-2h) for Postprandial Plasma Glucose at Week 12

The change from Baseline in AUC0-2h for Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline AUC0-2h for Postprandial Plasma Glucose as a covariate. (NCT01026194)
Timeframe: 0, 0.5, 1, 2 hours post-dose at Week 0 and Week 12

Interventionmg*h / dL (Least Squares Mean)
Placebo/Teneli + Pio-13.722
Teneli/Teneli + Pio-85.031

Change From Baseline in 2-hour Postprandial Plasma Glucose at Week 12

The change from Baseline in 2-hour Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline 2-hour Postprandial Plasma Glucose as a covariate. (NCT00974090)
Timeframe: at Week 0 and Week 12

Interventionmg / dL (Least Squares Mean)
Placebo / Teneli + SU6.0
Teneli / Teneli + SU-43.1

Change From Baseline in Fasting Plasma Glucose at Week 12

The change from Baseline in Fasting Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline Fasting Plasma Glucose as a covariate. (NCT00974090)
Timeframe: at Week 0 and Week 12

Interventionmg / dL (Least Squares Mean)
Placebo / Teneli + SU9.8
Teneli / Teneli + SU-17.3

Change From Baseline in HbA1c at Week 12

The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline HbA1c as a covariate. (NCT00974090)
Timeframe: at Week 0 and Week 12

Interventionpercentage of HbA1c (Least Squares Mean)
Placebo / Teneli + SU0.29
Teneli / Teneli + SU-0.71

Change From Baseline in the Areas Under the Curve From 0 to 2 h (AUC0-2h) for Postprandial Plasma Glucose at Week 12

The change from Baseline in AUC0-2h for Postprandial Plasma Glucose collected at Week 12. Least squares means were derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline AUC0-2h for Postprandial Plasma Glucose as a covariate. (NCT00974090)
Timeframe: 0, 0.5, 1, 2 hours post-dose at Week 0 and Week 12

Interventionmg・hr/dL (Least Squares Mean)
Placebo / Teneli + SU15.514
Teneli / Teneli + SU-65.544

Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24

Change in FPG from baseline to Week 24 or LOCF was assessed with an ANCOVA approach similar to that of the primary efficacy endpoint. (NCT00971243)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Teneli 5mg+Met-15.54
Teneli 10mg+Met-13.65
Teneli 20mg+Met-17.84
Teneli 40mg+Met-21.85
Placebo+Met-3.51

Change in HbA1c From Baseline to Week 24

The change of HbA1c from baseline to Week 24 or a last observation carried forward (LOCF), was assessed with an analysis of covariance (ANCOVA) model, with the centre and treatment effect as factors and the baseline HbA1c as a covariate. (NCT00971243)
Timeframe: Baseline and Week 24

Interventionpercentage of HbA1c (Least Squares Mean)
Teneli 5mg+Met-0.58
Teneli 10mg+Met-0.68
Teneli 20mg+Met-0.76
Teneli 40mg+Met-0.91
Placebo+Met-0.28

Change in Percent of Blood Glucose (BG) Within Target

Percent of BG between 70 and 180 mg/dL, as measured using Continuous Glucose Monitor (CGM) (NCT03199638)
Timeframe: baseline vs. at 3 months

,
InterventionPercentage of Blood Glucose (Mean)
baselineat 3 months
an Exercise + Glutamine Group57.669.2
an Exercise Group63.746.4

Change in the Mean Amplitude of Glycemic Excursions (MAGE)

MAGE describes the average amplitude of glycemic variations measured using continuous glucose monitoring (CGM) (NCT03199638)
Timeframe: before vs. at 3 months

,
Interventionmg/dL (Mean)
baselineat 3 months
an Exercise + Glutamine Group108123
an Exercise Group129139

HbA1c, Glycated Hemoglobin

change in glycated hemoglobin (NCT03199638)
Timeframe: baseline vs. at 3 months

,
Interventionpercentage of total hemoglobin (Mean)
baselineat 3 months
an Exercise + Glutamine Group8.38.4
an Exercise Group7.98.0

Insulin Dose

Change in insulin dose (Units/kg/day) used at home (NCT03199638)
Timeframe: baseline vs. at 3 months

,
InterventionUnits/kg/day (Mean)
baselineat 3 months
an Exercise + Glutamine Group0.981.0
an Exercise Group1.00.8

Insulin Sensitivity Score (ISS)

Change in insulin sensitivity score, determined using SEARCH ISS model published equation: logeIS = 4.64725 - 0.02032 × (waist, cm) - 0.09779 × (HbA1c, %) - 0.00235 × (Triglycerides, mg/dL). The range of ISS scores is between 1-15. Higher scores imply a better insulin sensistivity. (NCT03199638)
Timeframe: baseline vs. at 3 months

,
Interventionscore on a scale (Mean)
baselineat 3 months
an Exercise + Glutamine Group2.102.16
an Exercise Group2.172.20

Percent Blood Glucose (BG) >180

Change in Percent of BG above 180 mg, as determined using Continuous Glucose Monitor (CGM) (NCT03199638)
Timeframe: baseline vs. at 3 months

,
InterventionPercentage of Blood Glucose (Mean)
baslineat 3 months
an Exercise + Glutamine Group39.426.6
an Exercise Group29.146.4

Percent of BG <70 mg/dL

Change in Percent of BG below 70 mg/dL, as determined by Continuous Glucose Monitor (CGM) (NCT03199638)
Timeframe: baseline vs. at 3 months

,
InterventionPercentage of Blood Glucose (Mean)
baselineat 3 months
an Exercise + Glutamine Group3.14.4
an Exercise Group7.27.2

Adverse Events From Run-in (Week -12) to Week 52

(NCT00856986)
Timeframe: Run-in (week -12) to Week 52

Interventionevents (Number)
Lira 1.8716
Insulin Detemir + Lira 1.8845
Non-Randomised Lira 1.82389
Early Withdrawals Lira 1.8383
Intensified Group30

Mean Change From Randomisation in Body Weight at Week 26

(NCT00856986)
Timeframe: Week 0 (Randomisation), Week 26

Interventionkg (Least Squares Mean)
Lira 1.8-0.95
Insulin Detemir + Lira 1.8-0.16

Mean Change From Randomisation in Body Weight at Week 52

(NCT00856986)
Timeframe: Week 0, Week 52

Interventionkg (Least Squares Mean)
Lira 1.8-1.02
Insulin Detemir + Lira 1.8-0.05

Mean Change From Randomisation in Fasting C-peptide at Week 26.

(NCT00856986)
Timeframe: Week 0 (Randomisation), Week 26

Interventionmmol/L (Least Squares Mean)
Lira 1.8-0.08
Insulin Detemir + Lira 1.8-0.32

Mean Change From Randomisation in Fasting C-peptide at Week 52.

(NCT00856986)
Timeframe: Week 0, Week 52

Interventionmmol/L (Least Squares Mean)
Lira 1.80.02
Insulin Detemir + Lira 1.8-0.34

Mean Change From Randomisation in Fasting Plasma Glucose at Week 26

(NCT00856986)
Timeframe: Week 0 (Randomisation), Week 26

Interventionmmol/L (Least Squares Mean)
Lira 1.8-0.39
Insulin Detemir + Lira 1.8-2.12

Mean Change From Randomisation in Fasting Plasma Glucose at Week 52

(NCT00856986)
Timeframe: Week 0, Week 52

Interventionmmol/L (Least Squares Mean)
Lira 1.8-0.14
Insulin Detemir + Lira 1.8-1.91

Mean Change From Randomisation in Fasting Pro-insulin at Week 26.

(NCT00856986)
Timeframe: Week 0 (Randomisation), Week 26

Interventionpmol/L (Least Squares Mean)
Lira 1.8-1.12
Insulin Detemir + Lira 1.8-9.78

Mean Change From Randomisation in Fasting Pro-insulin at Week 52

(NCT00856986)
Timeframe: Week 0, Week 52

Interventionpmol/L (Least Squares Mean)
Lira 1.81.47
Insulin Detemir + Lira 1.8-4

Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26.

(NCT00856986)
Timeframe: Week 0 (Randomisation), week 26

InterventionPercentage point of total HbA1c (Least Squares Mean)
Lira 1.80.02
Insulin Detemir + Lira 1.8-0.51

Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 52 (for Intensified Subjects in Original Treatment Group)

(NCT00856986)
Timeframe: Week 0, Week 52

InterventionPercentage point of total HbA1c (Least Squares Mean)
Lira 1.8-0.1
Insulin Detemir + Lira 1.8-0.51

Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 52 (Values Before Intensification as LOCF)

(NCT00856986)
Timeframe: Week 0, Week 52

InterventionPercentage point of total HbA1c (Least Squares Mean)
Lira 1.80.01
Insulin Detemir + Lira 1.8-0.5

Mean Change From Randomisation in Hip Circumference at Week 26

(NCT00856986)
Timeframe: Week 0 (Randomisation), Week 26

Interventioncm (Least Squares Mean)
Lira 1.8-0.36
Insulin Detemir + Lira 1.8-0.38

Mean Change From Randomisation in Hip Circumference at Week 52

(NCT00856986)
Timeframe: Week 0, week 52

Interventioncm (Least Squares Mean)
Lira 1.8-0.79
Insulin Detemir + Lira 1.8-0.28

Mean Change From Randomisation in Lipids: Free Fatty Acids (FFA) at Week 26

(NCT00856986)
Timeframe: Week 0 (Randomisation), Week 26

Interventionmmol/L (Least Squares Mean)
Lira 1.8-0.03
Insulin Detemir + Lira 1.8-0.11

Mean Change From Randomisation in Lipids: Free Fatty Acids (FFA) at Week 52

(NCT00856986)
Timeframe: Week 0, Week 52

Interventionmmol/L (Least Squares Mean)
Lira 1.8-0.03
Insulin Detemir + Lira 1.8-0.07

Mean Change From Randomisation in Lipids: Triglycerides at Week 26

(NCT00856986)
Timeframe: Week 0 (Randomisation), Week 26

Interventionmmol/L (Least Squares Mean)
Lira 1.8-0.24
Insulin Detemir + Lira 1.8-0.33

Mean Change From Randomisation in Lipids: Triglycerides at Week 52

(NCT00856986)
Timeframe: Week 0, Week 52

Interventionmmol/L (Least Squares Mean)
Lira 1.8-0.22
Insulin Detemir + Lira 1.8-0.37

Mean Change From Randomisation in Waist Circumference at Week 26.

(NCT00856986)
Timeframe: Week 0 (Randomisation), Week 26

Interventioncm (Least Squares Mean)
Lira 1.8-0.66
Insulin Detemir + Lira 1.8-0.78

Mean Change From Randomisation in Waist Circumference at Week 52.

(NCT00856986)
Timeframe: Week 0, Week 52

Interventionparticipants (Least Squares Mean)
Lira 1.8-0.83
Insulin Detemir + Lira 1.8-0.83

Mean Change From Randomisation in Waist to Hip Ratio at Week 26

Waist to Hip Ratio is calculated by dividing Waist circumference with Hip circumference (NCT00856986)
Timeframe: Week 0 (Randomisation), Week 26

Interventioncm/cm (Least Squares Mean)
Lira 1.8-0.00356
Insulin Detemir + Lira 1.8-0.00332

Mean Change From Randomisation in Waist to Hip Ratio at Week 52

Waist to Hip Ratio is calculated by dividing Waist circumference with Hip circumference (NCT00856986)
Timeframe: Week 0, Week 52

Interventioncm/cm (Least Squares Mean)
Lira 1.8-0.00146
Insulin Detemir + Lira 1.8-0.00438

Hypoglycaemic Episodes (Excluding Outlier Subject), Weeks 0-26

Number of hypoglycaemic episodes from Week 0 to Week 26, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00856986)
Timeframe: weeks 0-26

,,
Interventionepisodes (Number)
MajorMinorSymptoms only
Insulin Detemir + Lira 1.802219
Lira 1.8029
Non-Randomised Lira 1.803126

Hypoglycaemic Episodes Weeks 0-52

Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00856986)
Timeframe: Week 0-52

,,,
Interventionepisodes (Number)
MajorMinorSymptoms onlyUnknown
Insulin Detemir + Lira 1.8033571
Intensified Group0120
Lira 1.804140
Non-Randomised Lira 1.8053422

Mean Change From Randomisation in 7-point Plasma Glucose Profile (Self-measured) at Week 26

Calculated as an estimate of the change in mean prandial increment of plasma glucose after breakfast, lunch and dinner (from baseline/randomisation (week 0) to 26 weeks), respectively. Prandial increments of plasma glucose were calculated as the difference between glucose values measured before and after each of these three meals, respectively. (NCT00856986)
Timeframe: Week 0 (Randomisation), Week 26

,
Interventionmmol/L (Least Squares Mean)
Change at Breakfast, N=133, 144Change at Lunch, N= 134, 143Change at Dinner, N= 133, 139
Insulin Detemir + Lira 1.8-2.09-1.43-1.18
Lira 1.8-0.97-0.83-0.48

Mean Change From Randomisation in 7-point Plasma Glucose Profile (Self-measured) at Week 52

Calculated as an estimate of the change in mean prandial increment of plasma glucose after breakfast, lunch and dinner (from baseline (week 0) to 52 weeks), respectively. Prandial increments of plasma glucose were calculated as the difference between glucose values measured before and after each of these three meals, respectively. (NCT00856986)
Timeframe: Week 0, Week 52

,
Interventionmmol/L (Least Squares Mean)
Change at Breakfast, N=148, 135Change at Lunch, N= 145, 136Change at Dinner, N= 144, 135
Insulin Detemir + Lira 1.8-2.43-1.14-1.4
Lira 1.8-0.68-0.51-0.96

Mean Change From Randomisation in Blood Pressure (Systolic and Diastolic) at Week 26.

(NCT00856986)
Timeframe: Week 0 (Randomisation), Week 26

,
InterventionmmHg (Least Squares Mean)
Systolic Blood PressureDiastolic Blood Pressure
Insulin Detemir + Lira 1.80.41-0.4
Lira 1.81.11-1.1

Mean Change From Randomisation in Blood Pressure (Systolic and Diastolic) at Week 52.

(NCT00856986)
Timeframe: Week 0, Week 52

,
InterventionmmHg (Least Squares Mean)
Systolic Blood PressureDiastolic Blood Pressure
Insulin Detemir + Lira 1.80.160.11
Lira 1.8-0.74-0.66

Mean Changes From Randomisation in Cholesterol Lipids at Week 26.

Cholesterol Lipids cover: Total Cholesterol, Low-density Lipoprotein Cholesterol (LDL-C), Very Low Density Lipoprotein Cholesterol (VLDL-C), High Density Lipoprotein Cholesterol (HDL-C) (NCT00856986)
Timeframe: Week 0 (Randomisation), Week 26

,
Interventionmmol/L (Least Squares Mean)
Change in Total CholesterolChange in LDL-CChange in VLDL-CChange in HDL-C
Insulin Detemir + Lira 1.80.05-0.030.010.05
Lira 1.80.04-0.040.050.02

Mean Changes From Randomisation in Cholesterol Lipids at Week 52.

Cholesterol Lipids cover: Total Cholesterol, Low-density Lipoprotein Cholesterol (LDL-C), Very Low Density Lipoprotein Cholesterol (VLDL-C), High Density Lipoprotein Cholesterol (HDL-C) (NCT00856986)
Timeframe: Week 0, Week 52

,
Interventionmmol/L (Least Squares Mean)
Change in Total CholesterolChange in LDL-CChange in VLDL-CChange in HDL-C
Insulin Detemir + Lira 1.8-0.03-0.1-0.030.07
Lira 1.8-0.02-0.080.030.02

Biomarkers of Cardiovascular Risk - Change in TNF-alpha

Change in TNF-alpha (NCT00620282)
Timeframe: week 0, week 12

Interventionpg/mL (Least Squares Mean)
Lira 1.8-0.024
Placebo0.397
Glimepiride-0.0050

Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF)

Assessed endothelial function by measuring the change in ACh-mediated FBF at euglycemia (90 mg/dL) using forearm venous occlusion plethysmography (VOP) technique. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute. (NCT00620282)
Timeframe: week 0, week 12

InterventionmL/100 mL/min (Least Squares Mean)
Lira 1.84.244
Placebo-3.187
Glimepiride2.164

Change in Body Weight

(NCT00620282)
Timeframe: week 0, week 12

Interventionkg (Least Squares Mean)
Lira 1.8-1.821
Placebo-0.293
Glimepiride1.038

Change in Fasting Plasma Glucose (FPG)

Change in FPG (NCT00620282)
Timeframe: week 0, week 12

Interventionmg/dL (Least Squares Mean)
Lira 1.8-41.672
Placebo-6.067
Glimepiride-32.019

Change in HbA1c (Glycosylated Haemoglobin A1c)

Percentage point change in HbA1c (NCT00620282)
Timeframe: week 0, week 12

Interventionpercentage of total haemoglobin (Least Squares Mean)
Lira 1.8-0.629
Placebo-0.094
Glimepiride-0.552

Change in Mean Postprandial Glucose (PPG) Based on Self-measured 7-point Plasma Glucose Profiles

The 7-point profile included plasma glucose measurements at the following time points: before each main meal (breakfast, lunch and dinner), 90 minutes after the start of each main meal (breakfast, lunch and dinner) and at bedtime. (NCT00620282)
Timeframe: week 0, week 12

Interventionmg/dL (Least Squares Mean)
Lira 1.8-32.175
Placebo-20.304
Glimepiride-35.99

Change in Sodium Nitroprusside (SNP)-Mediated Forearm Blood Flow (FBF)

Assessed endothelial function by measuring the change in SNP-mediated FBF at euglycemia (90 mg/dL) using forearm venous occlusion plethysmography (VOP) technique. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute. (NCT00620282)
Timeframe: week 0, week 12

InterventionmL/100 mL/min (Least Squares Mean)
Lira 1.83.455
Placebo-1.044
Glimepiride2.746

Fasting Lipid Profile - Change in HDL-C

Change in HDL-C (NCT00620282)
Timeframe: week 0, week 12

Interventionmg/dL (Least Squares Mean)
Lira 1.80.393
Placebo0.562
Glimepiride1.116

Fasting Lipid Profile - Change in LDL-C

Change in LDL-C (NCT00620282)
Timeframe: week 0, week 12

Interventionmg/dL (Least Squares Mean)
Lira 1.81.243
Placebo-2.459
Glimepiride-1.529

Fasting Lipid Profile - Change in Total Cholesterol (TC)

Change in TC (NCT00620282)
Timeframe: week 0, week 12

Interventionmg/dL (Least Squares Mean)
Lira 1.82.006
Placebo4.243
Glimepiride0.094

Fasting Lipid Profile - Change in Triglycerides (TG)

Change in TG (NCT00620282)
Timeframe: week 0, week 12

Interventionmg/dL (Least Squares Mean)
Lira 1.8-8.163
Placebo28.546
Glimepiride-4.377

Haematology and Biochemistry Tests - Number of Subjects With Blood Urea Nitrogen (BUN) Values Outside Reference Range

Number of subjects with serum BUN values outside reference range at Week 0 and Week 12, respectively. Reference range: Female (lower value 6.000 mg/dL, upper value 21.000 mg/dL) Male (lower value 8.000 mg/dL, upper value 25.000 mg/dL). (NCT00620282)
Timeframe: week 0, week 12

,,
Interventionparticipants (Number)
Week 0Week 12
Glimepiride10
Lira 1.811
Placebo02

Haematology and Biochemistry Tests - Number of Subjects With Creatinine Values Outside Reference Range

Number of subjects with serum creatinine values outside reference range at Week 0 and Week 12, respectively. Reference range: Female (lower value 0.600 mg/dL, upper value 1.100 mg/dL) Male (lower value 0.800 mg/dL, upper value 1.300 mg/dL). (NCT00620282)
Timeframe: week 0, week 12

,,
Interventionparticipants (Number)
Week 0Week 12
Glimepiride52
Lira 1.811
Placebo32

Number of Hypoglycaemic Episodes

Total number of hypoglycaemic episodes occurring from week 0 to week 12. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself and either plasma glucose was below 56 mg/dL or symptoms were reversed after food intake or glucagon/intravenous glucose administration. Minor if subject was able to treat her/himself and plasma glucose was below 56 mg/dL. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 56 mg/dL. (NCT00620282)
Timeframe: weeks 0-12

,,
Interventionepisodes (Number)
MajorMinorSymptoms Only
Glimepiride0104
Lira 1.8013
Placebo000

Change in Beta-cell Function

"Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).~Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5)." (NCT00614120)
Timeframe: week 0, week 16

Interventionpercentage point (%point) (Mean)
Lira 0.6 + Met15.3
Lira 1.2 + Met17.8
Lira 1.8 + Met21.7
Glim + Met21.8

Change in Body Weight

Change in body weight from baseline (week 0) to 16 weeks (end of treatment) (NCT00614120)
Timeframe: week 0, week 16

Interventionkg (Mean)
Lira 0.6 + Met-1.8
Lira 1.2 + Met-2.3
Lira 1.8 + Met-2.4
Glim + Met0.1

Change in Fasting Lipid Profile, APO-B

Change in fasting lipid profiles based on apolipoprotein B (Apo-B) from baseline (week 0) to 16 weeks (end of treatment). (NCT00614120)
Timeframe: week 0, week 16

Interventiong/L (Median)
Lira 0.6 + Met0.02
Lira 1.2 + Met0.00
Lira 1.8 + Met-0.00
Glim + Met0.01

Change in Glycosylated Haemoglobin A1c (HbA1c)

Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 16 weeks (end of treatment). (NCT00614120)
Timeframe: week 0, week 16

Interventionpercentage point of total HbA1c (Mean)
Lira 0.6 + Met-1.0
Lira 1.2 + Met-1.3
Lira 1.8 + Met-1.4
Glim + Met-1.3

Change in Self-measured Fasting Plasma Glucose

Change in self-measured fasting plasma glucose from baseline (week 0) to 16 weeks (end of treatment). Self-measurement of plasma glucose was performed using a glucose meter and subjects were instructed to record self-measured plasma glucose values into a diary. (NCT00614120)
Timeframe: week 0, week 16

Interventionmg/dL (Mean)
Lira 0.6 + Met-1.83
Lira 1.2 + Met-1.96
Lira 1.8 + Met-2.28
Glim + Met-2.13

7-point Self-measured Plasma Glucose Profiles

Summary of 7-Point Profiles of Self-Measured Plasma Glucose by Treatment, Week and Time. The 7 time points for self-measurements for all treatment groups were: Before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime, measured over 16 weeks of treatment (at week 0, 8, 12 and 16). (NCT00614120)
Timeframe: week 0, 8, 12 and 16

,,,
Interventionmg/dl (Mean)
Week 0 - Before breakfastWeek 0 - 90 minutes after breakfastWeek 0 - Before lunchWeek 0 - 90 minutes after lunchWeek 0 - Before dinnerWeek 0 - 90 minutes after dinnerWeek 0 - BedtimeWeek 8 - Before breakfastWeek 8 - 90 minutes after breakfastWeek 8 - Before lunchWeek 8 - 90 minutes after lunchWeek 8 - Before dinnerWeek 8 - 90 minutes after dinnerWeek 8 - BedtimeWeek 12 - Before breakfastWeek 12 - 90 minutes after breakfastWeek 12 - Before lunchWeek 12 - 90 minutes after lunchWeek 12 - Before dinnerWeek 12 - 90 minutes after dinnerWeek 12 - BedtimeWeek 16 - Before breakfastWeek 16 - 90 minutes after breakfastWeek 16 - Before lunchWeek 16 - 90 minutes after lunchWeek 16 - Before dinnerWeek 16 - 90 minutes after dinnerWeek 16 - Bedtime
Glim + Met163.8238.5175.8227.6180.2231.6202.7130.1201.2132.6184.3143.3190.2163.6128.5200.8129.3185.3144.2188.5159.9131.0195.1128.8182.2144.9192.6157.7
Lira 0.6 + Met168.2245.9178.5234.2194.8239.6205.7137.0198.5144.8187.2159.1193.7169.1137.8197.5141.8183.7156.4197.2168.2137.3195.6140.5185.8151.5195.0166.4
Lira 1.2 + Met167.5248.0180.5232.3184.8239.6208.1130.4190.1136.5176.9147.8187.1161.6130.2185.7135.6174.7143.4185.7158.9132.9188.7137.0181.4148.4183.3159.8
Lira 1.8 + Met168.8245.4176.9234.4190.9244.0219.3133.7178.5138.0177.9144.2183.3155.8130.2178.6134.1173.7144.5183.5158.9128.6177.6137.8173.2140.9173.2151.6

Change in Fasting Lipid Profile

"Change in fasting lipid profiles from baseline (week 0) to 16 weeks (end of treatment). Fasting lipid profiles is based on:~Total Cholesterol (TC)~Low-density Lipoprotein-cholesterol (LDL-C)~Very Low-density Lipoprotein-cholesterol (VLDL-C)~High-density Lipoprotein-cholesterol (HDL-C)~Triglyceride (TG)~Free Fatty Acid (FFA)" (NCT00614120)
Timeframe: week 0, week 16

,,,
Interventionmmol/L (Mean)
Change in TC (Absolute), N=221, 216, 216, 228Change in LDL-C (Absolute), N=221, 216, 216, 228Change in VLDL-C (Absolute), N=213, 210, 207, 220Change in HDL-C (Absolute), N=217, 212, 212, 220Change in TG (Absolute), N=220, 212, 213, 226Change in FFA (Absolute), N=218, 214, 216, 227
Glim + Met0.020.040.05-0.01-0.07-0.02
Lira 0.6 + Met0.060.060.03-0.02-0.08-0.03
Lira 1.2 + Met-0.01-0.030.05-0.05-0.06-0.04
Lira 1.8 + Met-0.030.000.01-0.05-0.22-0.10

Hypoglycaemic Episodes

Total number of hypoglycaemic episodes over 16 weeks of treatment occurring from baseline (week 0) to end of treatment (week 16). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00614120)
Timeframe: weeks 0-16

,,,
Interventionepisodes (Number)
MajorMinorSymptoms only
Glim + Met28086
Lira 0.6 + Met0612
Lira 1.2 + Met0011
Lira 1.8 + Met059

Body Weight After 24 Weeks of Treatment

(NCT00395746)
Timeframe: after 24 weeks of treatment

Interventionkg (Least Squares Mean)
0.6 mg + SU65.77
0.9 mg + SU65.34
SU Mono64.59

Body Weight After 52 Weeks of Treatment

(NCT00395746)
Timeframe: after 52 weeks of treatment

Interventionkg (Least Squares Mean)
0.6 mg + SU65.96
0.9 mg + SU65.87
SU Mono64.83

Fasting Plasma Glucose After 24 Weeks of Treatment

(NCT00395746)
Timeframe: after 24 weeks of treatment

Interventionmg/dL (Least Squares Mean)
0.6 mg + SU132.2
0.9 mg + SU126.2
SU Mono158.8

Fasting Plasma Glucose After 52 Weeks of Treatment

(NCT00395746)
Timeframe: after 52 weeks of treatment

Interventionmg/dL (Least Squares Mean)
0.6 mg + SU140.3
0.9 mg + SU134.5
SU Mono164.6

Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment

(NCT00395746)
Timeframe: after 24 weeks of treatment

Interventionpercentage of total haemoglobin (Least Squares Mean)
0.6 mg + SU7.02
0.9 mg + SU6.75
SU Mono8.02

Glycosylated Haemoglobin A1c (HbA1c) After 52 Weeks of Treatment

(NCT00395746)
Timeframe: after 52 weeks of treatment

Interventionpercentage of total haemoglobin (Least Squares Mean)
0.6 mg + SU7.42
0.9 mg + SU7.06
SU Mono8.39

Mean PG in 7-point Plasma Glucose Profile After 24 Weeks of Treatment

Plasma glucose (PG) profile measured after 24 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime. (NCT00395746)
Timeframe: after 24 weeks of treatment

Interventionmg/dL (Least Squares Mean)
0.6 mg + SU160.20
0.9 mg + SU150.05
SU Mono194.50

Mean PG in 7-point Plasma Glucose Profile After 52 Weeks of Treatment

7-point plasma glucose (PG) profile measured after 52 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime. (NCT00395746)
Timeframe: after 52 weeks of treatment

Interventionmg/dL (Least Squares Mean)
0.6 mg + SU171.42
0.9 mg + SU159.58
SU Mono205.92

Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 24 Weeks of Treatment

Mean postprandial plasma glucose (PG) increment in 7-point plasma glucose profile, ie the mean of the difference of plasma glucose measured before and after a meal, after 24 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime. (NCT00395746)
Timeframe: after 24 weeks of treatment

Interventionmg/dL (Least Squares Mean)
0.6 mg + SU86.38
0.9 mg + SU68.34
SU Mono79.71

Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 52 Weeks of Treatment

Mean postprandial plasma glucose (PG) increment in 7-point plasma glucose profile, ie the mean of the difference of plasma glucose measured before and after a meal, after 52 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime. (NCT00395746)
Timeframe: after 52 weeks of treatment

Interventionmg/dL (Least Squares Mean)
0.6 mg + SU82.28
0.9 mg + SU76.09
SU Mono89.39

Postprandial Glucose AUC After 24 Weeks of Treatment

Postprandial glucose AUC measured 0-3 hours after a meal after 24 weeks of treatment (NCT00395746)
Timeframe: after 24 weeks of treatment

Interventionmg/dL *h (Least Squares Mean)
0.6 mg + SU614.58
0.9 mg + SU575.50
SU Mono725.72

Postprandial Glucose AUC After 52 Weeks of Treatment

Postprandial Glucose AUC measured 0-3 hours after a meal after 52 weeks of treatment (NCT00395746)
Timeframe: after 52 weeks of treatment

Interventionmg/dL *h (Least Squares Mean)
0.6 mg + SU648.87
0.9 mg + SU589.98
SU Mono717.55

Hypoglycaemic Episodes

Hypoglycaemic episodes measured over 52 weeks of treatment. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00395746)
Timeframe: over 52 weeks of treatment

,,
Interventionnumber of events per year of exposure (Number)
All hypoglycaemic episodesMajorMinorSymptoms only
0.6 mg + SU3.1310.00001.4381.693
0.9 mg + SU3.7150.00001.3652.350
SU Mono2.9900.00001.2851.705

Change in Apolipoprotein B at Week 26

Change in apolipoprotein B (ApoB) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00518882)
Timeframe: week 0, week 26

Interventiong/L (Least Squares Mean)
Liraglutide -> Liraglutide -> Liraglutide-0.06
Exenatide -> Liraglutide -> Liraglutide-0.03

Change in Apolipoprotein B at Week 78

Change in apolipoprotein B (ApoB) from baseline (week 0) to 78 weeks (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group). (NCT00518882)
Timeframe: week 0, week 78

Interventiong/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide-0.08
Exenatide -> Liraglutide -> Liraglutide-0.07

Change in Apolipoprotein B, Weeks 26-78

Change in apolipoprotein B (ApoB) from Week 26 (end of randomisation) to Week 78 (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group). (NCT00518882)
Timeframe: week 26, week 78

Interventiong/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide-0.02
Exenatide -> Liraglutide -> Liraglutide-0.03

Change in Beta-cell Function at Week 26

"Change in Beta-cell function from baseline (week 0) to 26 weeks (end of randomisation). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).~Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5)." (NCT00518882)
Timeframe: week 0, week 26

Interventionpercentage point (%point) (Least Squares Mean)
Liraglutide -> Liraglutide -> Liraglutide32.12
Exenatide -> Liraglutide -> Liraglutide2.74

Change in Beta-cell Function at Week 78

"Change in Beta-cell function from baseline (week 0) to 78 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).~Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5)." (NCT00518882)
Timeframe: week 0, week 78

Interventionpercentage point (%point) (Mean)
Liraglutide -> Liraglutide -> Liraglutide24.86
Exenatide -> Liraglutide -> Liraglutide11.13

Change in Beta-cell Function, Weeks 26-78

"Change in Beta-cell function from Week 26 (end of randomisation) to Week 78 (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).~Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5)." (NCT00518882)
Timeframe: week 26, week 78

Interventionpercentage point (%point) (Mean)
Liraglutide -> Liraglutide -> Liraglutide-18.18
Exenatide -> Liraglutide -> Liraglutide2.29

Change in Body Weight at Week 26

Change in body weight from baseline (week 0) to 26 weeks (end of randomisation) (NCT00518882)
Timeframe: week 0, week 26

Interventionkg (Least Squares Mean)
Liraglutide -> Liraglutide -> Liraglutide-3.24
Exenatide -> Liraglutide -> Liraglutide-2.87

Change in Body Weight at Week 78

Change in body weight from baseline (Week 0) to 78 weeks (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group) (NCT00518882)
Timeframe: week 0, week 78

Interventionkg (Mean)
Liraglutide -> Liraglutide -> Liraglutide-3.3
Exenatide -> Liraglutide -> Liraglutide-3.2

Change in Body Weight, Weeks 26-78

Change in body weight from Week 26 (end of randomisation) to Week 78 (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group) (NCT00518882)
Timeframe: week 26, week 78

Interventionkg (Mean)
Liraglutide -> Liraglutide -> Liraglutide-0.4
Exenatide -> Liraglutide -> Liraglutide-0.7

Change in Fasting Plasma Glucose at Week 26

Change in fasting plasma glucose (FPG) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00518882)
Timeframe: week 0, week 26

Interventionmmol/L (Least Squares Mean)
Liraglutide -> Liraglutide -> Liraglutide-1.61
Exenatide -> Liraglutide -> Liraglutide-0.60

Change in Fasting Plasma Glucose at Week 78

Change in fasting plasma glucose from baseline (week 0) to 78 weeks (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group) (NCT00518882)
Timeframe: week 0, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide-1.3
Exenatide -> Liraglutide -> Liraglutide-0.8

Change in Fasting Plasma Glucose, Weeks 26-78

Change in fasting plasma glucose from Week 26 (end of randomisation) to Week 78 (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group) (NCT00518882)
Timeframe: week 26, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide0.7
Exenatide -> Liraglutide -> Liraglutide-0.1

Change in Free Fatty Acid at Week 26

Change in Free Fatty Acid (FFA) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00518882)
Timeframe: week 0, week 26

Interventionmmol/L (Least Squares Mean)
Liraglutide -> Liraglutide -> Liraglutide-0.17
Exenatide -> Liraglutide -> Liraglutide-0.10

Change in Free Fatty Acid at Week 78

Change in Free Fatty Acid (FFA) from baseline (week 0) to 78 weeks (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group). (NCT00518882)
Timeframe: week 0, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide-0.10
Exenatide -> Liraglutide -> Liraglutide-0.07

Change in Free Fatty Acid, Weeks 26-78

Change in Free Fatty Acid (FFA) from Week 26 (end of randomisation) to Week 78 (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group). (NCT00518882)
Timeframe: week 26, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide0.06
Exenatide -> Liraglutide -> Liraglutide0.01

Change in Glycosylated A1c (HbA1c) at Week 26

Percentage point change in glycosylated A1c (HbA1c) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00518882)
Timeframe: week 0, week 26

Interventionpercentage point of total HbA1c (Least Squares Mean)
Liraglutide -> Liraglutide -> Liraglutide-1.12
Exenatide -> Liraglutide -> Liraglutide-0.79

Change in Glycosylated A1c (HbA1c) at Week 78

Percentage point change in glycosylated A1c (HbA1c) from baseline (week 0) to 78 weeks (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group) (NCT00518882)
Timeframe: week 0, week 78

Interventionpercentage point of total HbA1c (Mean)
Liraglutide -> Liraglutide -> Liraglutide-0.98
Exenatide -> Liraglutide -> Liraglutide-0.85

Change in Glycosylated A1c (HbA1c), Weeks 26-78

Percentage point change in glycosylated A1c (HbA1c) from Week 26 (end of randomisation) to Week 78 (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group) (NCT00518882)
Timeframe: week 26, week 78

Interventionpercentage point of total HbA1c (Mean)
Liraglutide -> Liraglutide -> Liraglutide0.25
Exenatide -> Liraglutide -> Liraglutide-0.00

Change in High-density Lipoprotein-cholesterol at Week 26

Change in High-density Lipoprotein-cholesterol (HDL-C) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00518882)
Timeframe: week 0, week 26

Interventionmmol/L (Least Squares Mean)
Liraglutide -> Liraglutide -> Liraglutide-0.04
Exenatide -> Liraglutide -> Liraglutide-0.05

Change in High-density Lipoprotein-cholesterol at Week 78

Change in High-density Lipoprotein-cholesterol (HDL-C) from baseline (week 0) to 78 weeks (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group). (NCT00518882)
Timeframe: week 0, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide-0.03
Exenatide -> Liraglutide -> Liraglutide-0.02

Change in High-density Lipoprotein-cholesterol, Weeks 26-78

Change in High-density Lipoprotein-cholesterol (HDL-C) from Week 26 (end of randomisation) to Week 78 (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group). (NCT00518882)
Timeframe: week 26, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide-0.01
Exenatide -> Liraglutide -> Liraglutide0.00

Change in Low-density Lipoprotein-cholesterol at Week 26

Change in Low-density Lipoprotein-cholesterol (LDL-C) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00518882)
Timeframe: week 0, week 26

Interventionmmol/L (Least Squares Mean)
Liraglutide -> Liraglutide -> Liraglutide-0.44
Exenatide -> Liraglutide -> Liraglutide-0.40

Change in Low-density Lipoprotein-cholesterol at Week 78

Change in Low-density Lipoprotein-cholesterol (LDL-C) from baseline (week 0) to 78 weeks (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group). (NCT00518882)
Timeframe: week 0, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide-0.30
Exenatide -> Liraglutide -> Liraglutide-0.21

Change in Low-density Lipoprotein-cholesterol, Weeks 26-78

Change in low-density lipoprotein-cholesterol (LDL-C) from Week 26 (end of randomisation) to Week 78 (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group). (NCT00518882)
Timeframe: week 26, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide0.03
Exenatide -> Liraglutide -> Liraglutide0.08

Change in Mean Postprandial Increment of Plasma Glucose After Breakfast at Week 26

Change in mean postprandial increment of plasma glucose after breakfast from baseline (week 0) to 26 weeks (end of randomisation). Prandial increments of plasma glucose were calculated as the difference between plasma glucose values measured before and after breakfast. (NCT00518882)
Timeframe: week 0, week 26

Interventionmmol/L (Least Squares Mean)
Liraglutide -> Liraglutide -> Liraglutide-3.20
Exenatide -> Liraglutide -> Liraglutide-3.93

Change in Mean Postprandial Increment of Plasma Glucose After Breakfast at Week 78

Change in mean postprandial increment of plasma glucose after breakfast from baseline (week 0) to 78 weeks (end of treatment). Prandial increments of plasma glucose were calculated as the difference between plasma glucose values measured before and after breakfast. (NCT00518882)
Timeframe: week 0, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide-3.31
Exenatide -> Liraglutide -> Liraglutide-3.13

Change in Mean Postprandial Increment of Plasma Glucose After Breakfast, Weeks 26-78

Change in mean postprandial increment of plasma glucose after breakfast from Week 26 (end of randomisation) to Week 78 (end of treatment). Prandial increments of plasma glucose were calculated as the difference between plasma glucose values measured before and after breakfast. (NCT00518882)
Timeframe: week 26, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide0.06
Exenatide -> Liraglutide -> Liraglutide0.72

Change in Mean Postprandial Increment of Plasma Glucose After Dinner at Week 26

Change in mean postprandial increment of plasma glucose after dinner from baseline (week 0) to 26 weeks (end of randomisation). Prandial increments of plasma glucose were calculated as the difference between plasma glucose values measured before and after dinner. (NCT00518882)
Timeframe: week 0, week 26

Interventionmmol/L (Least Squares Mean)
Liraglutide -> Liraglutide -> Liraglutide-3.05
Exenatide -> Liraglutide -> Liraglutide-3.59

Change in Mean Postprandial Increment of Plasma Glucose After Dinner at Week 78

Change in mean postprandial increment of plasma glucose after dinner from baseline (week 0) to 78 weeks (end of treatment). Prandial increments of plasma glucose were calculated as the difference between plasma glucose values measured before and after dinner. (NCT00518882)
Timeframe: week 0, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide-2.21
Exenatide -> Liraglutide -> Liraglutide-2.55

Change in Mean Postprandial Increment of Plasma Glucose After Dinner, Weeks 26-78

Change in mean postprandial increment of plasma glucose after dinner from Week 26 (end of randomisation) to Week 78 (end of treatment). Prandial increments of plasma glucose were calculated as the difference between plasma glucose values measured before and after dinner. (NCT00518882)
Timeframe: week 26, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide0.32
Exenatide -> Liraglutide -> Liraglutide0.58

Change in Mean Postprandial Increment of Plasma Glucose After Lunch at Week 26

Change in mean postprandial increment of plasma glucose after lunch from baseline (week 0) to 26 weeks (end of randomisation). Prandial increments of plasma glucose were calculated as the difference between plasma glucose values measured before and after lunch. (NCT00518882)
Timeframe: week 0. week 26

Interventionmmol/L (Least Squares Mean)
Liraglutide -> Liraglutide -> Liraglutide-2.74
Exenatide -> Liraglutide -> Liraglutide-2.35

Change in Mean Postprandial Increment of Plasma Glucose After Lunch at Week 78

Change in mean postprandial increment of plasma glucose after lunch from baseline (week 0) to 78 weeks (end of treatment). Prandial increments of plasma glucose were calculated as the difference between plasma glucose values measured before and after lunch. (NCT00518882)
Timeframe: week 0, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide-1.93
Exenatide -> Liraglutide -> Liraglutide-2.17

Change in Mean Postprandial Increment of Plasma Glucose After Lunch, Weeks 26-78

Change in mean postprandial increment of plasma glucose after lunch from Week 26 (end of randomisation) to Week 78 (end of treatment). Prandial increments of plasma glucose were calculated as the difference between plasma glucose values measured before and after lunch. (NCT00518882)
Timeframe: week 26, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide0.67
Exenatide -> Liraglutide -> Liraglutide-0.09

Change in Mean Prandial Increment of Plasma Glucose After Breakfast at Week 26

Change in mean prandial increment of plasma glucose after breakfast from baseline (week 0) to 26 weeks (end of randomisation). Prandial increments of plasma glucose were calculated as the difference between glucose values measured before and after breakfast. (NCT00518882)
Timeframe: week 0, week 26

Interventionmmol/L (Least Squares Mean)
Liraglutide -> Liraglutide -> Liraglutide-0.83
Exenatide -> Liraglutide -> Liraglutide-2.16

Change in Mean Prandial Increment of Plasma Glucose After Breakfast at Week 78

Change in mean prandial increment of plasma glucose after breakfast from baseline (week 0) to 78 weeks (end of treatment). Prandial increments of plasma glucose were calculated as the difference between plasma glucose values measured before and after breakfast. (NCT00518882)
Timeframe: week 0, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide-1.08
Exenatide -> Liraglutide -> Liraglutide-0.99

Change in Mean Prandial Increment of Plasma Glucose After Breakfast, Weeks 26-78

Change in mean prandial increment of plasma glucose after breakfast from Week 26 (end of randomisation) to Week 78 (end of treatment). Prandial increments of plasma glucose were calculated as the difference between plasma glucose values measured before and after breakfast. (NCT00518882)
Timeframe: week 26, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide-0.22
Exenatide -> Liraglutide -> Liraglutide1.15

Change in Mean Prandial Increment of Plasma Glucose After Dinner at Week 26

Change in mean prandial increment of plasma glucose after dinner from baseline (week 0) to 26 weeks (end of randomisation). Prandial increments of plasma glucose were calculated as the difference between plasma glucose values measured before and after dinner. (NCT00518882)
Timeframe: week 0, week 26

Interventionmmol/L (Least Squares Mean)
Liraglutide -> Liraglutide -> Liraglutide-1.10
Exenatide -> Liraglutide -> Liraglutide-2.11

Change in Mean Prandial Increment of Plasma Glucose After Dinner at Week 78

Change in mean prandial increment of plasma glucose after dinner from baseline (week 0) to 78 weeks (end of treatment). Prandial increments of plasma glucose were calculated as the difference between plasma glucose values measured before and after dinner. (NCT00518882)
Timeframe: week 0, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide-0.35
Exenatide -> Liraglutide -> Liraglutide-0.95

Change in Mean Prandial Increment of Plasma Glucose After Dinner, Weeks 26-78

Change in mean prandial increment of plasma glucose after dinner from Week 26 (end of randomisation) to Week 78 (end of treatment). Prandial increments of plasma glucose were calculated as the difference between plasma glucose values measured before and after dinner. (NCT00518882)
Timeframe: week 26, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide0.22
Exenatide -> Liraglutide -> Liraglutide1.07

Change in Mean Prandial Increment of Plasma Glucose After Lunch at Week 26

Change in mean prandial increment of plasma glucose after lunch from baseline (week 0) to 26 weeks (end of randomisation). Prandial increments of plasma glucose were calculated as the difference between plasma glucose values measured before and after lunch. (NCT00518882)
Timeframe: week 0, week 26

Interventionmmol/L (Least Squares Mean)
Liraglutide -> Liraglutide -> Liraglutide0.06
Exenatide -> Liraglutide -> Liraglutide0.06

Change in Mean Prandial Increment of Plasma Glucose After Lunch at Week 78

Change in mean prandial increment of plasma glucose after lunch from baseline (week 0) to 78 weeks (end of treatment). Prandial increments of plasma glucose were calculated as the difference between plasma glucose values measured before and after lunch. (NCT00518882)
Timeframe: week 0, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide0.26
Exenatide -> Liraglutide -> Liraglutide-0.37

Change in Mean Prandial Increment of Plasma Glucose After Lunch, Weeks 26-78

Change in mean prandial increment of plasma glucose after lunch from Week 26 (end of randomisation) to Week 78 (end of treatment). Prandial increments of plasma glucose were calculated as the difference between plasma glucose values measured before and after a lunch. (NCT00518882)
Timeframe: week 26, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide0.05
Exenatide -> Liraglutide -> Liraglutide-0.09

Change in Total Cholesterol at Week 26

Change in total cholesterol (TC) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00518882)
Timeframe: week 0, week 26

Interventionmmol/L (Least Squares Mean)
Liraglutide -> Liraglutide -> Liraglutide-0.20
Exenatide -> Liraglutide -> Liraglutide-0.09

Change in Total Cholesterol at Week 78

Change in total cholesterol (TC) from baseline (week 0) to 78 weeks (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group). (NCT00518882)
Timeframe: week 0, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide-0.07
Exenatide -> Liraglutide -> Liraglutide0.09

Change in Total Cholesterol, Weeks 26-78

Change in total cholesterol (TC) from Week 26 (end of randomisation) to Week 78 (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group). (NCT00518882)
Timeframe: week 26, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide0.11
Exenatide -> Liraglutide -> Liraglutide0.12

Change in Triglyceride at Week 26

Change in triglyceride (TG) from from baseline (week 0) to 26 weeks (end of randomisation) (NCT00518882)
Timeframe: week 0, week 26

Interventionmmol/L (Least Squares Mean)
Liraglutide -> Liraglutide -> Liraglutide-0.41
Exenatide -> Liraglutide -> Liraglutide-0.23

Change in Triglyceride at Week 78

Change in triglyceride (TG) from baseline (week 0) to 78 weeks (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group). (NCT00518882)
Timeframe: week 0, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide-0.3
Exenatide -> Liraglutide -> Liraglutide-0.1

Change in Triglyceride, Weeks 26-78

Change in Triglyceride (TG) from Week 26 (end of randomisation) to Week 78 (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group). (NCT00518882)
Timeframe: week 26, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide0.1
Exenatide -> Liraglutide -> Liraglutide-0.0

Change in Very Low-density Lipoprotein-cholesterol at Week 26

Change in very low-density lipoprotein-cholesterol (VLDL-C) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00518882)
Timeframe: week 0, week 26

Interventionmmol/L (Least Squares Mean)
Liraglutide -> Liraglutide -> Liraglutide0.20
Exenatide -> Liraglutide -> Liraglutide0.27

Change in Very Low-density Lipoprotein-cholesterol at Week 78

Change in Very Low-density Lipoprotein-cholesterol (VLDL-C) from baseline (week 0) to 78 weeks (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group). (NCT00518882)
Timeframe: week 0, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide0.27
Exenatide -> Liraglutide -> Liraglutide0.31

Change in Very Low-density Lipoprotein-cholesterol, Weeks 26-78

Change in Very Low-density Lipoprotein-cholesterol (VLDL-C) from Week 26 (end of randomisation) to Week 78 (end of treatment) within each treatment group (the liraglutide -> liraglutide group and the exenatide -> liraglutide group). (NCT00518882)
Timeframe: week 26, week 78

Interventionmmol/L (Mean)
Liraglutide -> Liraglutide -> Liraglutide0.06
Exenatide -> Liraglutide -> Liraglutide0.03

Hypoglycaemic Episodes at Week 26

Total number of hypoglycaemic episodes occurring after baseline (week 0) and until week 26 (end of randomisation). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00518882)
Timeframe: weeks 0-26

,
Interventionepisodes (Number)
MajorMinorSymptoms only
Exenatide -> Liraglutide -> Liraglutide226493
Liraglutide -> Liraglutide -> Liraglutide020879

Hypoglyceamic Episodes, Weeks 26-78

Total number of hypoglycaemic episodes occurring after end of randomisation (week 26) and until week 78 (end of treatment). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00518882)
Timeframe: weeks 26-78

,
Interventionepisodes (Number)
MajorMinorSymptoms only
Exenatide -> Liraglutide -> Liraglutide017232
Liraglutide -> Liraglutide -> Liraglutide114037

Percentage of Subjects Achieving Treatment Target of Either HbA1c < 7.0% or =< 6.5% at Week 26

Percentage of subjects achieving treatment target of HbA1c less than 7.0% or less than or equal to 6.5% at Week 26 (end of randomisation) (NCT00518882)
Timeframe: week 0, week 26

,
Interventionpercentage (%) of subjects (Number)
Treatment target HbA1c < 7%Treatment target HbA1c =< 6.5%
Exenatide -> Liraglutide -> Liraglutide4220
Liraglutide -> Liraglutide -> Liraglutide5334

Percentage of Subjects Achieving Treatment Target of Either HbA1c < 7.0% or =< 6.5% at Week 78

Percentage of subjects achieving treatment target of HbA1c less than 7.0% or less than or equal to 6.5% at Week 78 (end of treatment) (NCT00518882)
Timeframe: week 0, week 78

,
Interventionpercentage (%) of subjects (Number)
Treatment target HbA1c < 7%Treatment target HbA1c =< 6.5%
Exenatide -> Liraglutide -> Liraglutide4835
Liraglutide -> Liraglutide -> Liraglutide4731

Change in Body Weight at Week 104

Change in body weight from baseline (week 0) to 104 weeks (end of 52-week extension) (NCT00294723)
Timeframe: week 0, week 104

Interventionkg (Least Squares Mean)
Lira 1.8-2.70
Lira 1.2-1.89
Glimepiride0.95

Change in Body Weight at Week 156

Change in body weight from baseline (week 0) to 156 weeks (NCT00294723)
Timeframe: week 0, week 156

Interventionkg (Least Squares Mean)
Lira 1.8-2.43
Lira 1.2-1.68
Glimepiride1.05

Change in Body Weight at Week 52

Change in body weight from baseline (week 0) to 52 weeks (end of double-blind period) (NCT00294723)
Timeframe: week 0, week 52

Interventionkg (Least Squares Mean)
Lira 1.8-2.45
Lira 1.2-2.05
Glimepiride1.12

Change in Fasting Plasma Glucose at Week 104

Change in fasting plasma glucose (FPG) from baseline (week 0) to 104 weeks (end of 52-week extension) (NCT00294723)
Timeframe: week 0, week 104

Interventionmg/dL (Least Squares Mean)
Lira 1.8-15.82
Lira 1.2-9.36
Glimepiride1.97

Change in Fasting Plasma Glucose at Week 156

Change in fasting plasma glucose (FPG) from baseline (week 0) to 156 weeks (NCT00294723)
Timeframe: week 0, week 156

Interventionmg/dL (Least Squares Mean)
Lira 1.8-12.06
Lira 1.2-5.45
Glimepiride4.57

Change in Fasting Plasma Glucose at Week 52

Change in fasting plasma glucose (FPG) from baseline (week 0) to 52 weeks (end of double-blind period) (NCT00294723)
Timeframe: week 0, week 52

Interventionmg/dL (Least Squares Mean)
Lira 1.8-25.57
Lira 1.2-15.21
Glimepiride-5.29

Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 104

Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 104 weeks (end of 52-week extension) (NCT00294723)
Timeframe: week 0, week 104

Interventionpercentage point of total HbA1c (Least Squares Mean)
Lira 1.8-0.88
Lira 1.2-0.59
Glimepiride-0.28

Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 156

Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 156 weeks (NCT00294723)
Timeframe: week 0, week 156

Interventionpercentage point of total HbA1c (Least Squares Mean)
Lira 1.8-0.71
Lira 1.2-0.44
Glimepiride-0.16

Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 52

Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 52 weeks (end of double-blind period) (NCT00294723)
Timeframe: week 0, week 52

Interventionpercentage point of total HbA1c (Least Squares Mean)
Lira 1.8-1.14
Lira 1.2-0.84
Glimepiride-0.51

Change in Mean Postprandial Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 104

Change in mean postprandial glucose (PPG) based on self-measured 8-point plasma glucose profiles from baseline (week 0) to 104 weeks (end of 52-week extension). The 8 time points for self-measurements of plasma glucose were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. (NCT00294723)
Timeframe: week 0, week 104

Interventionmg/dL (Least Squares Mean)
Lira 1.8-37.15
Lira 1.2-27.34
Glimepiride-24.85

Change in Mean Postprandial Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 156

Change in mean postprandial glucose (PPG) based on self-measured 8-point plasma glucose profiles from baseline (week 0) to 156 weeks. The 8 time points for self-measurements of plasma glucose were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. (NCT00294723)
Timeframe: week 0, week 156

Interventionmg/dL (Least Squares Mean)
Lira 1.8-34.83
Lira 1.2-25.68
Glimepiride-23.84

Change in Mean Postprandial Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 52

Change in mean postprandial glucose (PPG) based on self-measured 8-point plasma glucose profiles from baseline (week 0) to 52 weeks (end of double-blind period). The 8 time points for self-measurements of plasma glucose were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. (NCT00294723)
Timeframe: week 0, week 52

Interventionmg/dL (Least Squares Mean)
Lira 1.8-37.4
Lira 1.2-30.8
Glimepiride-24.5

Change in Prandial Increments of Plasma Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 104

Change in mean prandial increments of plasma glucose from baseline (week 0) to 104 weeks (end of 52-week extension). The 8 time points for self-measured 8-point plasma glucose profiles were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between post- and pre-meal values (for breakfast, lunch and dinner) divided by three. (NCT00294723)
Timeframe: week 0, week 104

Interventionmg/dL (Least Squares Mean)
Lira 1.8-11.76
Lira 1.2-8.28
Glimepiride-7.95

Change in Prandial Increments of Plasma Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 156

Change in mean prandial increments (incr.) of plasma glucose from baseline (week 0) to 156 weeks. The 8 time points for self-measured 8-point plasma glucose profiles were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between post- and pre-meal values (for breakfast, lunch and dinner) divided by three. (NCT00294723)
Timeframe: week 0, week 156

Interventionmg/dL (Least Squares Mean)
Lira 1.8-11.01
Lira 1.2-7.53
Glimepiride-7.97

Change in Prandial Increments of Plasma Glucose Based on Self-measured 8-point Plasma Glucose Profiles at Week 52

Change in mean prandial increments of plasma glucose from baseline (week 0) to 52 weeks (end of double-blind period). The 8 time points for self-measured 8-point plasma glucose profiles were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between post- and pre-meal values (for breakfast, lunch and dinner) divided by three. (NCT00294723)
Timeframe: week 0, week 52

Interventionmg/dL (Least Squares Mean)
Lira 1.8-9.6
Lira 1.2-8.4
Glimepiride-5.6

Hypoglycaemic Episodes

Total number of hypoglycaemic episodes occuring from baseline (week 0) to 104 weeks (end of the 52-week extension). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 56 mg/dL. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 56 mg/dL. (NCT00294723)
Timeframe: weeks 0-104

,,
Interventionepisodes (Number)
MajorMinorSymptoms only
Glimepiride0533405
Lira 1.2068133
Lira 1.817187

Hypoglycaemic Episodes

Total number of hypoglycaemic episodes occuring from week 104 to end of trial (week 195). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 56 mg/dL. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 56 mg/dL. (NCT00294723)
Timeframe: weeks 104-195

,,
Interventionepisodes (Number)
MajorMinorSymptoms only
Glimepiride1344
Lira 1.2031
Lira 1.80133

Mean Change From Baseline in Adiponectin at Week 26.

Calculated as an estimate of the mean change from baseline in Adiponectin at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26

Interventionmcg/mL (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg1.69
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg1.51
Sita -> Sita1.35

Mean Change From Baseline in Apolipoprotein B at Week 26

Calculated as an estimate of the change from baseline in apolipoprotein B (ApoB) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26

Interventiong/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-0.06
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-0.07
Sita -> Sita-0.05

Mean Change From Baseline in Apolipoprotein B at Week 52

Calculated as an estimate of the change from baseline in apolipoprotein B (ApoB) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52

Interventiong/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-0.03
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-0.03
Sita -> Sita-0.03

Mean Change From Baseline in Beta-cell Function at Week 26

"Calculated as an estimate of the mean change from baseline in beta-cell function at Week 26.~Derived from fasting plasma glucose (FPG) and fasting insulin using the homeostatic model assessment (HOMA) method with the assumption that normal-weight subjects aged under 35 years have a 100% beta-cell function (HOMA-B)." (NCT00700817)
Timeframe: Week 0, Week 26

Interventionpercentage point (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg27.23
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg28.70
Sita -> Sita4.18

Mean Change From Baseline in Beta-cell Function at Week 52

"Calculated as an estimate of the mean change from baseline in beta-cell function at Week 52.~Derived from fasting plasma glucose (FPG) and fasting insulin using the homeostatic model assessment (HOMA) method with the assumption that normal-weight subjects aged under 35 years have a 100% beta-cell function (HOMA-B)." (NCT00700817)
Timeframe: Week 0, Week 52

Interventionpercentage point (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg22.58
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg25.76
Sita -> Sita3.98

Mean Change From Baseline in Body Weight at Week 26

Calculated as an estimate of the mean change from baseline in body weight at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26

Interventionkg (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-2.86
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-3.38
Sita -> Sita-0.96

Mean Change From Baseline in Body Weight at Week 52

Calculated as an estimate of the mean change from baseline in body weight at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52

Interventionkg (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-2.78
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-3.68
Sita -> Sita-1.16

Mean Change From Baseline in Diastolic Blood Pressure (DBP) at Week 26

Calculated as an estimate of the mean change from baseline in diastolic blood pressure (DBP) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26

InterventionmmHg (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-0.71
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg0.07
Sita -> Sita-1.78

Mean Change From Baseline in Diastolic Blood Pressure (DBP) at Week 52

Calculated as an estimate of the mean change from baseline in diastolic blood pressure (DBP) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52

InterventionmmHg (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-0.53
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-0.87
Sita -> Sita-1.47

Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26

Calculated as an estimate of the mean change from baseline in fasting plasma glucose (FPG) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26

Interventionmmol/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-1.87
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-2.14
Sita -> Sita-0.83

Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52

Calculated as an estimate of the mean change from baseline in fasting plasma glucose (FPG) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52

Interventionmmol/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-1.71
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-2.04
Sita -> Sita-0.59

Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 78

Calculated as an estimate of the mean change in fasting plasma glucose (FPG) from baseline to Week 78. (NCT00700817)
Timeframe: Week 0, Week 78

Interventionmmol/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-1.30
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-1.65

Mean Change From Baseline in Free Fatty Acids (FFA) at Week 26

Calculated as an estimate of the change from baseline in free fatty acids (FFA) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26

Interventionmmol/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-0.03
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-0.07
Sita -> Sita-0.05

Mean Change From Baseline in Free Fatty Acids (FFA) at Week 52

Calculated as an estimate of the change from baseline in free fatty acids (FFA) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52

Interventionmmol/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-0.07
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-0.10
Sita -> Sita-0.06

Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26

Calculated as an estimate of the mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26

InterventionPercentage point of total HbA1c (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-1.24
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-1.5
Sita -> Sita-0.9

Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 52

Calculated as an estimate of the mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52

InterventionPercentage point of total HbA1c (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-1.29
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-1.51
Sita -> Sita-0.88

Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 78

Calculated as an estimate of the mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 78. (NCT00700817)
Timeframe: Week 0, Week 78

InterventionPercentage point of total HbA1c (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-0.94
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-1.28

Mean Change From Baseline in High-density Lipoprotein-cholesterol (HDL-C) at Week 26

Calculated as an estimate of the mean change from baseline in high-density lipoprotein-cholesterol (HDL-C) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26

Interventionmmol/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg0.00
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg0.00
Sita -> Sita0.00

Mean Change From Baseline in High-density Lipoprotein-cholesterol (HDL-C) at Week 52

Calculated as an estimate of the mean change from baseline in high-density lipoprotein-cholesterol (HDL-C) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52

Interventionmmol/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg0.01
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg0.02
Sita -> Sita0.01

Mean Change From Baseline in Highly Sensitive C-reactive Protein (hsCRP) at Week 26

Calculated as an estimate of the mean change from baseline in highly sensitive C-reactive protein (hsCRP) at week 26. (NCT00700817)
Timeframe: Week 0, Week 26

Interventionmg/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-1.02
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-0.99
Sita -> Sita-0.66

Mean Change From Baseline in Interleukin-6 (IL-6) at Week 26.

Calculated as an estimate of the mean change from baseline in interleukin-6 (IL-6) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26

Interventionpg/mL (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-1.70
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg1.71
Sita -> Sita0.91

Mean Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C) at Week 26

Calculated as an estimate of the mean change in low-density lipoprotein-cholesterol (LDL-C) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26

Interventionmmol/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg0.08
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg0.05
Sita -> Sita0.13

Mean Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C) at Week 52

Calculated as an estimate of the mean change in low-density lipoprotein-cholesterol (LDL-C) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52

Interventionmmol/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg0.09
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg0.09
Sita -> Sita0.17

Mean Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 26.

Calculated as an estimate of the mean change from baseline in N-terminal pro B-type Natriuretic Peptide (NT-proBNP) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26

Interventionpmol/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg5.19
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg3.74
Sita -> Sita3.71

Mean Change From Baseline in Overall Treatment Satisfaction (OTS) at Week 26

The Overall Treatment Satisfaction is a sum of 6 items from the Diabetes Treatment Satisfaction Questionnaire, which is a self-assessment of treatment satisfaction. The scale of each sub-item goes from 0 (lowest satisfaction) to 6 (highest satisfaction) and the overall scale of OTS therefore goes from 0 to 36. (NCT00700817)
Timeframe: Week 0, Week 26

Interventionscores on a scale (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg3.51
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg4.35
Sita -> Sita2.96

Mean Change From Baseline in Overall Treatment Satisfaction (OTS) at Week 52

The Overall Treatment Satisfaction is a sum of 6 items from the Diabetes Treatment Satisfaction Questionnaire, which is a self-assessment of treatment satisfaction. The scale of each sub-item goes from 0 (lowest satisfaction) to 6 (highest satisfaction) and the overall scale of OTS therefore goes from 0 to 36. (NCT00700817)
Timeframe: Week 0, Week 52

Interventionscores on a scale (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg3.32
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg4.31
Sita -> Sita2.96

Mean Change From Baseline in Plasminogen Activator Inhibitor-1 (PAI-1) at Week 26.

Calculated as an estimate of the mean change from baseline in plasminogen activator inhibitor-1 (PAI-1) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26

InterventionU/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-833
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-561
Sita -> Sita586

Mean Change From Baseline in Pulse at Week 26

Calculated as an estimate of the mean change from baseline in pulse at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26

Interventionbeats/minute (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg2.32
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg3.94
Sita -> Sita-0.64

Mean Change From Baseline in Pulse at Week 52

Calculated as an estimate of the mean change from baseline in pulse at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52

InterventionmmHg (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg1.72
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg3.09
Sita -> Sita0.09

Mean Change From Baseline in Systolic Blood Pressure (SBP) at Week 26

Calculated as an estimate of the mean change from baseline in Systolic Blood Pressure (SBP) at Week 26 (NCT00700817)
Timeframe: Week 0, Week 26

InterventionmmHg (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-0.55
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-0.72
Sita -> Sita-0.94

Mean Change From Baseline in Systolic Blood Pressure (SBP) at Week 52

Calculated as an estimate of the mean change from baseline in systolic blood pressure (SBP) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52

InterventionmmHg (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-0.37
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-2.55
Sita -> Sita-1.03

Mean Change From Baseline in Total Cholesterol at Week 26

Calculated as an estimate of the mean change from baseline in total cholesterol at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26

Interventionmmol/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-0.03
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-0.17
Sita -> Sita-0.02

Mean Change From Baseline in Total Cholesterol at Week 52

Calculated as an estimate of the mean change from baseline in total cholesterol at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52

Interventionmmol/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-0.01
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-0.09
Sita -> Sita0.03

Mean Change From Baseline in Triglycerides (TG) at Week 26

Calculated as an estimate of the change from baseline in triglycerides (TG) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26

Interventionmmol/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-0.19
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-0.43
Sita -> Sita-0.40

Mean Change From Baseline in Triglycerides (TG) at Week 52

Calculated as an estimate of the change from baseline in triglycerides (TG) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52

Interventionmmol/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-0.10
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-0.32
Sita -> Sita-0.23

Mean Change From Baseline in Tumour Necrosis Factor Alpha (TNF-alpha) at Week 26.

Calculated as an estimate of the mean change from baseline in Tumour Necrosis Factor Alpha (TNF-alpha) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26

Interventionpg/mL (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-0.55
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-0.74
Sita -> Sita-0.53

Mean Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C) at Week 26

Calculated as an estimate of the change from baseline in very low-density lipoprotein-cholesterol (VLDL-C) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26

Interventionmmol/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-0.11
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-0.20
Sita -> Sita-0.15

Mean Change From Baseline in Very Low-density Lipoprotein-cholesterol (VLDL-C) at Week 52

Calculated as an estimate of the change from baseline in very low-density lipoprotein-cholesterol (VLDL-C) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52

Interventionmmol/L (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-0.11
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-0.19
Sita -> Sita-0.15

Mean Change From Baseline in Von Willebrand Factor (vWf) at Week 26.

Calculated as an estimate of the mean change from baseline in von Willebrand Factor (vWf) at Week 26. vWf is a blood glycoprotein involved in haemostasis. (NCT00700817)
Timeframe: Week 0, Week 26

Interventionpercentage point (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-1.73
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-4.34
Sita -> Sita-1.8

Mean Change From Baseline in Waist Circumference at Week 26.

Calculated as an estimate of the mean change from baseline in Waist Circumference at Week 26 (NCT00700817)
Timeframe: Week 0, Week 26

Interventioncm (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-2.69
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-2.63
Sita -> Sita-1.12

Mean Change From Baseline in Waist Circumference at Week 52

Calculated as an estimate of the mean change from baseline in Waist Circumference at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52

Interventionparticipants (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-2.36
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-3.02
Sita -> Sita-1.23

Mean Change From Baseline in Waist to Hip Ratio at Week 26.

Calculated as an estimate of the mean change from baseline in Waist to Hip Ratio at Week 26. The measure is assessed as the circumference of the waist divided by the circumference of the hip. (NCT00700817)
Timeframe: Week 0, Week 26

Interventioncm/cm (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-0.01
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-0.01
Sita -> Sita-0.00

Mean Change From Baseline in Waist to Hip Ratio at Week 52

Calculated as an estimate of the mean change from baseline in Waist to Hip Ratio at Week 52. The measure is assessed as the circumference of the waist divided by the circumference of the hip. (NCT00700817)
Timeframe: Week 0, Week 52

Interventioncm/cm (Least Squares Mean)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg-0.00
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg-0.01
Sita -> Sita-0.00

Mean Change in Apolipoprotein B From Week 52 to Week 78

Mean change in apolipoprotein B (ApoB) from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78

Interventionmmol/L (Mean)
Sita -> Sita -> Lira 1.2 mg0.23
Sita -> Sita -> Lira 1.8 mg0.17

Mean Change in Beta-cell Function From Week 52 to Week 78

Mean change in beta-cell function from Week 52 to Week 78. Derived from fasting plasma glucose (FPG) and fasting insulin using the homeostatic model assessment (HOMA) method with the assumption that normal-weight subjects aged under 35 years have a 100% beta-cell function (HOMA-B). (NCT00700817)
Timeframe: Week 52, Week 78

Interventionpercentage point (Mean)
Sita -> Sita -> Lira 1.2 mg13.31
Sita -> Sita -> Lira 1.8 mg23.09

Mean Change in Body Weight From Week 52 to Week 78

Mean change in body weight from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78

Interventionkg (Mean)
Sita -> Sita -> Lira 1.2 mg-1.64
Sita -> Sita -> Lira 1.8 mg-2.48

Mean Change in Diastolic Blood Pressure (DBP) From Week 52 to Week 78

Mean change in diastolic blood pressure (DBP) from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78

InterventionmmHg (Mean)
Sita -> Sita -> Lira 1.2 mg-0.60
Sita -> Sita -> Lira 1.8 mg0.03

Mean Change in Fasting Plasma Glucose (FPG) From Week 52 to Week 78

Mean change in fasting plasma glucose (FPG) Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78

Interventionmmol/L (Mean)
Sita -> Sita -> Lira 1.2 mg-0.84
Sita -> Sita -> Lira 1.8 mg-1.42

Mean Change in Free Fatty Acids (FFA) From Week 52 to Week 78

Mean change in free fatty acids (FFA) from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78

Interventionmmol/L (Mean)
Sita -> Sita -> Lira 1.2 mg0.02
Sita -> Sita -> Lira 1.8 mg-0.01

Mean Change in Glycosylated Haemoglobin A1c (HbA1c) From Week 52 to Week 78

Mean Change in Glycosylated Haemoglobin A1c (HbA1c) from Week 52 to Week 78 (NCT00700817)
Timeframe: Week 52, Week 78

InterventionPercentage point of total HbA1c (Mean)
Sita -> Sita -> Lira 1.2 mg-0.24
Sita -> Sita -> Lira 1.8 mg-0.45

Mean Change in High-density Lipoprotein-cholesterol (HDL-C) From Week 52 to Week 78

Mean change in high-density lipoprotein-cholesterol (HDL-C) from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78

Interventionmmol/L (Mean)
Sita -> Sita -> Lira 1.2 mg0.02
Sita -> Sita -> Lira 1.8 mg-0.01

Mean Change in Low-density Lipoprotein-cholesterol (LDL-C) From Week 52 to Week 78

Mean change in low-density lipoprotein-cholesterol (LDL-C) from week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78

Interventionmmol/L (Mean)
Sita -> Sita -> Lira 1.2 mg-0.22
Sita -> Sita -> Lira 1.8 mg-0.25

Mean Change in Overall Treatment Satisfaction (OTS) From Week 52 to Week 78

The Overall Treatment Satisfaction is a sum of 6 items from the Diabetes Treatment Satisfaction Questionnaire, which is a self-assessment of treatment satisfaction. The scale of each sub-item goes from 0 (lowest satisfaction) to 6 (highest satisfaction) and the overall scale of OTS therefore goes from 0 to 36. (NCT00700817)
Timeframe: Week 52, Week 78

Interventionscores on a scale (Mean)
Sita -> Sita -> Lira 1.2 mg1.48
Sita -> Sita -> Lira 1.8 mg0.98

Mean Change in Pulse From Week 52 to Week 78

Mean change in pulse from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78

Interventionbeats/minute (Mean)
Sita -> Sita -> Lira 1.2 mg0.90
Sita -> Sita -> Lira 1.8 mg2.19

Mean Change in Systolic Blood Pressure (SBP) From Week 52 to Week 78

Mean change in systolic blood pressure (SBP) from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78

InterventionmmHg (Mean)
Sita -> Sita -> Lira 1.2 mg-2.12
Sita -> Sita -> Lira 1.8 mg0.35

Mean Change in Total Cholesterol From Week 52 to Week 78

Mean change in total cholesterol from Week 52 to Week 78 (NCT00700817)
Timeframe: Week 52, Week 78

Interventionmmol/L (Mean)
Sita -> Sita -> Lira 1.2 mg-0.16
Sita -> Sita -> Lira 1.8 mg-0.24

Mean Change in Triglycerides (TG) From Week 52 to Week 78

Mean change in triglycerides (TG) from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78

Interventionmmol/L (Mean)
Sita -> Sita -> Lira 1.2 mg-0.20
Sita -> Sita -> Lira 1.8 mg-0.26

Mean Change in Very Low-density Lipoprotein-cholesterol (VLDL-C) at Week 52 to Week 78

Mean change in very low-density lipoprotein-cholesterol (VLDL-C) from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78

Interventionmmol/L (Mean)
Sita -> Sita -> Lira 1.2 mg0.03
Sita -> Sita -> Lira 1.8 mg0.02

Mean Change in Waist Circumference From Week 52 to Week 78

Mean change in Waist Circumference from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78

Interventionkg (Mean)
Sita -> Sita -> Lira 1.2 mg-1.33
Sita -> Sita -> Lira 1.8 mg-2.05

Mean Change in Waist to Hip Ratio From Week 52 to Week 78

Mean change in Waist to Hip Ratio from Week 52 to Week 78. The measure is assessed as the circumference of the waist divided by the circumference of the hip. (NCT00700817)
Timeframe: Week 52, Week 78

Interventioncm/cm (Mean)
Sita -> Sita -> Lira 1.2 mg-0.01
Sita -> Sita -> Lira 1.8 mg-0.00

Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 26

Calculated as the percentage of subjects achieving treatment target of HbA1c < 7.0% at Week 26 (NCT00700817)
Timeframe: Week 0, Week 26

Interventionpercentage of subjects (Number)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg43
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg55
Sita -> Sita22

Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 52

Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c < 7.0% at Week 52 (NCT00700817)
Timeframe: Week 0, Week 52

Interventionpercentage of subjects (Number)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg50
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg63
Sita -> Sita27

Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 78

Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c < 7.0% at Week 78. Based on the extension 2 FAS. (NCT00700817)
Timeframe: Week 0, Week 78

Interventionpercentage of subjects (Number)
Sita -> Sita -> Lira 1.2 mg49
Sita -> Sita -> Lira 1.8 mg50

Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 78

Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c < 7.0% at Week 78. Based on the FAS. (NCT00700817)
Timeframe: Week 0, Week 78

Interventionpercentage of subjects (Number)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg35
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg51

Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 26

Calculated as the percentage of subjects achieving treatment target of HbA1c =< 6.5% at Week 26 (NCT00700817)
Timeframe: Week 0, Week 26

Interventionpercentage of subjects (Number)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg23
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg36
Sita -> Sita12

Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 52

Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c =< 6.5% at Week 52 (NCT00700817)
Timeframe: Week 0, Week 52

Interventionpercentage of subjects (Number)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg24
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg40
Sita -> Sita17

Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 78

Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c =< 6.5% at Week 78. Based on the extension 2 FAS. (NCT00700817)
Timeframe: Week 0, Week 78

Interventionpercentage of subjects (Number)
Sita -> Sita -> Lira 1.2 mg29
Sita -> Sita -> Lira 1.8 mg25

Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 78

Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c =< 6.5% at Week 78. Based on the FAS. (NCT00700817)
Timeframe: Week 0, Week 78

Interventionpercentage of subjects (Number)
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg12
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg27

Hypoglycaamic Episodes, Weeks 52-78

Number of hypoglycaemic episodes from Week 52 to Week 78, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00700817)
Timeframe: Week 52-78

,,,
Interventionepisodes (Number)
MajorMinorSymptoms onlyUnclassified
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg11230
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg05110
Sita -> Sita -> Lira 1.2 mg0310
Sita -> Sita -> Lira 1.8 mg0600

Hypoglycaemic Episodes (Excluding Outlier Subject), Weeks 0-26

Number of hypoglycaemic episodes from Week 0 to Week 26, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00700817)
Timeframe: Weeks 0-26

,,
Interventionepisodes (Number)
MajorMinorSymptoms onlyUnclassified
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg117120
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg016151
Sita -> Sita011100

Hypoglycaemic Episodes (Excluding Outlier Subject), Weeks 0-52

Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00700817)
Timeframe: Weeks 0-52

,,
Interventionepisodes (Number)
MajorMinorSymptoms onlyUnclassified
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg124140
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg028291
Sita -> Sita025120

Hypoglycaemic Episodes (Excluding Outlier Subject), Weeks 0-78

Number of hypoglycaemic episodes from Week 0 to Week 78, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00700817)
Timeframe: Weeks 0-78

,,
Interventionepisodes (Number)
MajorMinorSymptoms onlyUnclassified
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg236180
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg033401
Sita -> Sita034130

Hypoglyceamic Episodes, Weeks 0-26

Number of hypoglycaemic episodes from Week 0 to Week 26, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00700817)
Timeframe: Weeks 0-26

,,
Interventionepisodes (Number)
MajorMinorSymptoms onlyUnclassified
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg117120
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg037151
Sita -> Sita011100

Hypoglyceamic Episodes, Weeks 0-52

Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00700817)
Timeframe: Weeks 0-52

,,
Interventionepisodes (Number)
MajorMinorSymptoms onlyUnclassified
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg124140
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg051291
Sita -> Sita025120

Hypoglyceamic Episodes, Weeks 0-78

Number of hypoglycaemic episodes from Week 0 to Week 78, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00700817)
Timeframe: Weeks 0-78

,,
Interventionepisodes (Number)
MajorMinorSymptoms onlyUnclassified
Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg236180
Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg056401
Sita -> Sita034130

Change in Beta-cell Function at Week 104

"Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).~Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5)." (NCT00318461)
Timeframe: week 0, week 104

Interventionpercentage point (%point) (Least Squares Mean)
Lira 0.6 + Met64.48
Lira 1.2 + Met27.30
Lira 1.8 + Met17.81
Met Mono-7.89
Met + Glim11.25

Change in Beta-cell Function at Week 26

"Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).~Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5)." (NCT00318461)
Timeframe: week 0, week 26

Interventionpercentage point (%point) (Least Squares Mean)
Lira 0.6 + Met20.45
Lira 1.2 + Met20.33
Lira 1.8 + Met26.12
Met Mono-1.63
Met + Glim24.68

Change in Body Weight at Week 104

Change in body weight from baseline (week 0) to 104 weeks (end of treatment) (NCT00318461)
Timeframe: week 0, week 104

Interventionkg (Least Squares Mean)
Lira 0.6 + Met-2.07
Lira 1.2 + Met-3.03
Lira 1.8 + Met-2.91
Met Mono-1.80
Met + Glim0.70

Change in Body Weight at Week 26

Change in body weight from baseline (week 0) to 26 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 26

Interventionkg (Least Squares Mean)
Lira 0.6 + Met-1.78
Lira 1.2 + Met-2.58
Lira 1.8 + Met-2.79
Met Mono-1.51
Met + Glim0.95

Change in Fasting Plasma Glucose (FPG) at Week 104

Change in Fasting plasma glucose (FPG) from baseline (week 0) to 104 weeks (end of treatment) (NCT00318461)
Timeframe: week 0, week 104

Interventionmmol/L (Least Squares Mean)
Lira 0.6 + Met-0.80
Lira 1.2 + Met-1.20
Lira 1.8 + Met-1.18
Met Mono0.75
Met + Glim-0.64

Change in Fasting Plasma Glucose (FPG) at Week 26

Change in fasting plasma glucose (FPG) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 26

Interventionmmol/L (Least Squares Mean)
Lira 0.6 + Met-1.13
Lira 1.2 + Met-1.63
Lira 1.8 + Met-1.68
Met Mono0.40
Met + Glim-1.31

Change in Glycosylated A1c (HbA1c) at Week 104

Change in glycosylated A1c (HbA1c) baseline (week 0) to 104 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 104

Interventionpercentage of total haemoglobin (Least Squares Mean)
Lira 0.6 + Met-0.36
Lira 1.2 + Met-0.56
Lira 1.8 + Met-0.58
Met Mono0.25
Met + Glim-0.50

Change in Glycosylated A1c (HbA1c) at Week 26

Percentage point change in Glycosylated A1c (HbA1c) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 26

InterventionPercentage point of total HbA1c (Least Squares Mean)
Lira 0.6 + Met-0.69
Lira 1.2 + Met-0.97
Lira 1.8 + Met-1.00
Met Mono0.09
Met + Glim-0.98

Change in Mean Post Prandial Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 104

Change in mean post prandial plasma glucose from baseline (Week 0) to 104 weeks (end of treatment) The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime. Mean post prandial plasma glucose were calculated as the sum of the post pradial plasma glucose values divided by three. (NCT00318461)
Timeframe: week 0, week 104

Interventionmmol/L (Least Squares Mean)
Lira 0.6 + Met-1.59
Lira 1.2 + Met-2.22
Lira 1.8 + Met-2.10
Met Mono-0.43
Met + Glim-1.80

Change in Mean Post Prandial Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 26

Change in mean post prandial plasma glucose from baseline (Week 0) to 26 weeks (end of randomisation). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime. Mean post prandial plasma glucose were calculated as the sum of the post pradial plasma glucose values divided by three. (NCT00318461)
Timeframe: week 0, week 26

Interventionmmol/L (Least Squares Mean)
Lira 0.6 + Met-1.68
Lira 1.2 + Met-2.33
Lira 1.8 + Met-2.57
Met Mono-0.62
Met + Glim-2.46

Change in Mean Prandial Increments of Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 104

"Change in mean prandial increments of plasma glucose based on self-measured 7-point plasma glucose profiles from baseline (week 0) to 104 weeks (end of treatment). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime.~Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between values measured before and after a meal (breakfast, lunch and dinner) divided by three." (NCT00318461)
Timeframe: week 0, week 104

Interventionmmol/L (Least Squares Mean)
Lira 0.6 + Met-0.27
Lira 1.2 + Met-0.56
Lira 1.8 + Met-0.44
Met Mono-0.20
Met + Glim-0.29

Change in Mean Prandial Increments of Plasma Glucose Based on Self-measured 7-point Plasma Glucose Profiles at Week 26

"Change in mean prandial increments of plasma glucose based on self-measured 7-point plasma glucose profiles from baseline (week 0) to 26 weeks (end of randomisation). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime.~Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between values measured before and after a meal (breakfast, lunch and dinner) divided by three." (NCT00318461)
Timeframe: week 0, week 26

Interventionmmol/l (Least Squares Mean)
Lira 0.6 + Met-0.23
Lira 1.2 + Met-0.40
Lira 1.8 + Met-0.56
Met Mono-0.44
Met + Glim-0.44

Hypoglycaemic Episodes at Week 104

Total number of hypoglycaemic episodes occuring after baseline (week 0) until 104 weeks (end of treatment). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00318461)
Timeframe: weeks 0-104

,,,,
Interventionepisodes (Number)
AllMajorMinorSymptoms only
Lira 0.6 + Met5202329
Lira 1.2 + Met5112624
Lira 1.8 + Met4902227
Met + Glim5240284240
Met Mono180612

Hypoglycaemic Episodes at Week 26

Total number of hypoglycaemic episodes occuring after baseline (week 0) until week 26 (end of randomisation). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00318461)
Timeframe: weeks 0-26

,,,,
Interventionepisodes (Number)
MajorMinorSymptoms only
Lira 0.6 + Met01517
Lira 1.2 + Met037
Lira 1.8 + Met0922
Met + Glim0136175
Met Mono0610

Change From Baseline to Week 52 in Fasting Plasma Glucose (FPG)

Measured as the difference between the last on-treatment value (defined as obtained before or on the first day after the last dosing date)and the last pre-randomisation fasting plasma glucose value, as determined by central laboratory. Full analysis set. (NCT01006603)
Timeframe: From week 0 to week 52

Interventionmmol/L (Mean)
Saxagliptin 5 mg-0.73
Glimepiride 1 - 6 mg-1.29

Change From Baseline to Week 52 in HbA1c.

Measured as the difference between the last on-treatment value (defined as obtained before or on the 8th day after the last dosing date), and the last pre-randomisation HbA1c value, as determined by central laboratory. Full analysis set. (NCT01006603)
Timeframe: From week 0 to week 52.

Intervention% of glycosylated hemoglobin (Mean)
Saxagliptin 5 mg-0.44
Glimepiride 1 - 6 mg-0.64

Change From Baseline to Week 52 in Insulin

Measured as the difference between the last on-treatment value (defined as obtained before or on the first day after the last dosing date) and the last pre-randomisation fasting plasma insulin value, as determined by central laboratory. Full analysis set. (NCT01006603)
Timeframe: From week 0 to week 52

InterventionµU/mL (Mean)
Saxagliptin 5 mg-2.0
Glimepiride 1 - 6 mg-0.6

Change From Baseline to Week 52 in β-cell Function (as Measured by Homeostasis Model Assessment-β [HOMA-β]

β-cell function as estimated by the homeostasis model assessment (HOMA) model. Value is derived from FPG and fasting insulin; fasting insulin values below 2.074 μU/mL or above 57.595 μU/mL and FPG values below 3 mmol/L or above 25 mmol/L are excluded (as restricted by the calculation method used). Full analysis set. (NCT01006603)
Timeframe: From week 0 to week 52

Interventionpercentage of change from baseline (Mean)
Saxagliptin 5 mg3.83
Glimepiride 1 - 6 mg16.22

Proportion of Patients Achieving a Therapeutic Glycaemic Response at Week 52 Defined as HbA1c <7.0%

Proportion of patients with their last on-treatment value (defined as obtained before or on the 8th day after the last dosing date), as determined by central laboratory, below the specified limits. Full analysis set. (NCT01006603)
Timeframe: From week 0 to week 52

Interventionpercentage of responders (Number)
Saxagliptin 5 mg44.7
Glimepiride 1 - 6 mg54.7

Proportion of Patients Having Experienced at Least One Hypoglycaemic Event (Confirmed or Severe) Over the 52-week Double-blind Treatment Period.

"Hypoglyceamic event defined as, Confirmed hypoglycaemia: any event defined as either a symptomatic event with blood glucose level <3 mmol/L (<54 mg/dL) and no need for external assistance, or an asymptomatic blood glucose measurement <3 mmol/L (<54 mg/dL).~Major (or severe) hypoglycaemia: symptomatic events requiring external assistance due to severe impairment in consciousness or behaviour, with or without blood glucose level <3 mmol/L (<54 mg/dL), but with prompt recovery after glucose or glucagon administration. These events may be associated with sufficient neuroglycopenia to induce seizure or coma. Plasma glucose measurements may not be available during such an event, but neurological recovery, attributable to the restoration of plasma glucose to normal, was considered sufficient evidence that the event was induced by a low plasma glucose concentration. Safety analysis set." (NCT01006603)
Timeframe: From week 0 to week 52.

Interventionpercentage of patients (Number)
Saxagliptin 5 mg1.1
Glimepiride 1 - 6 mg15.3

Proportion of Patients Reaching HbA1c <7% After 52 Weeks of Treatment Without Confirmed or Severe Hypoglycaemia.

"Defined as obtained on or before the 8th day after the last dosing day, as determined by central laboratory. Safety analysis set.~Confirmed hypoglycaemia defined as: any event defined as either a symptomatic event with blood glucose level <3 mmol/L (<54 mg/dL) and no need for external assistance, or an asymptomatic blood glucose measurement <3 mmol/L (<54 mg/dL).~Major (or severe) hypoglycaemia defined as: symptomatic events requiring external assistance due to severe impairment in consciousness or behaviour, with or without blood glucose level <3 mmol/L (<54 mg/dL), but with prompt recovery after glucose or glucagon administration. These events may be associated with sufficient neuroglycopenia to induce seizure or coma. Plasma glucose measurements may not be available during such an event, but neurological recovery, attributable to the restoration of plasma glucose to normal, was considered sufficient evidence that the event was induced by a low plasma glucose concentration." (NCT01006603)
Timeframe: From week 0 to week 52.

,
Interventionpercentage of participants (Number)
All patientspatients aged <75 years (n=217, n=216)patients aged ≥75 years (n=142, n=143)
Glimepiride 1 - 6 mg38.233.345.5
Saxagliptin 5 mg37.939.235.9

Change in Body Weight From Baseline to Year 3

Change in Body weight from baseline to Year 3. (NCT00359762)
Timeframe: Baseline, Year 3 in Period II

Interventionkg (Least Squares Mean)
Exen + Met-3.92
Glim + Met1.47

Change in DI30/DG30 Ratio From Baseline to Endpoint

Change in DI30/DG30 ratio from baseline to endpoint. (NCT00359762)
Timeframe: Baseline, end of Period II (up to 4.5 years)

Interventionratio (Least Squares Mean)
Exen + Met12.10
Glim + Met0.91

Change in Disposition Index From Baseline to Endpoint

Change in disposition index from baseline to endpoint. (NCT00359762)
Timeframe: Baseline, end of Period II (up to 4.5 years)

Interventionratio (Least Squares Mean)
Exen + Met9.15
Glim + Met1.82

Change in Fasting Plasma Glucose From Baseline to Endpoint

Change in fasting plasma glucose from baseline to endpoint. (NCT00359762)
Timeframe: Baseline, end of Period II (up to 4.5 years)

Interventionmmol/L (Least Squares Mean)
Exen + Met-0.87
Glim + Met-0.41

Change in Fasting Proinsulin/Insulin Ratio From Baseline to Endpoint.

Change in fasting proinsulin (measured in pmol/L)/insulin (measured in pmol/L) ratio from baseline to endpoint. (NCT00359762)
Timeframe: Baseline, end of Period II (up to 4.5 years)

Interventionratio (Least Squares Mean)
Exen + Met0.03
Glim + Met0.05

Change in HbA1c From Baseline to Endpoint

Change in HbA1c from baseline to endpoint. Endpoint for HbA1c was defined as the HbA1c measured at the treatment failure for patients reaching primary endpoint and was the last observation in study period II for other patients (either followed until the end of the study period II or discontinuing the study). (NCT00359762)
Timeframe: Baseline, end of Period II (up to 4.5 years)

Interventionpercentage of total hemoglobin (Least Squares Mean)
Exen + Met-0.36
Glim + Met-0.21

Change in HbA1c From Baseline to Year 2 for Patients Not Randomized at Entry in Period III

Change in HbA1c from baseline to Year 2. (NCT00359762)
Timeframe: Baseline in Period III, Year 2 in Period III

Interventionpercentage of total hemoglobin (Mean)
Glim + Met + Exen - Not Randomized-0.47

Change in HbA1c From Baseline to Year 2 for Patients Randomized at Entry in Period III

Change in HbA1c from baseline to Year 2. (NCT00359762)
Timeframe: Baseline in Period III, Year 2 in Period III

Interventionpercentage of total hemoglobin (Least Squares Mean)
Exen + Met + Glim - Randomized-0.19
Exen + Met + Pio or Rosi - Randomized-0.47

Change in HbA1c From Baseline to Year 3

Change in HbA1c from baseline to Year 3. (NCT00359762)
Timeframe: Baseline, Year 3 in Period II

Interventionpercentage of total hemoglobin (Least Squares Mean)
Exen + Met-0.30
Glim + Met-0.12

Change in HOMA-B From Baseline to Endpoint

Change in HOMA-B from baseline to endpoint. (NCT00359762)
Timeframe: Baseline, end of Period II (up to 4.5 years)

Interventionratio (Least Squares Mean)
Exen + Met5.56
Glim + Met19.92

Change in Postprandial (2 Hours) Plasma Glucose From Baseline to Endpoint

Change from baseline in postprandial (2 hours) plasma glucose to endpoint. (NCT00359762)
Timeframe: Baseline, end of Period II (up to 4.5 years)

Interventionmmol/L (Least Squares Mean)
Exen + Met-2.72
Glim + Met-0.53

Diastolic Blood Pressure at Year 3

Diastolic Blood pressure at Year 3. (NCT00359762)
Timeframe: Year 3 in Period II

InterventionmmHg (Least Squares Mean)
Exen + Met77.45
Glim + Met79.16

Disposition Index at Year 3

Disposition Index at Year 3. Disposition index was calculated as (DI30/DG30 ratio)/(HOMA index for insulin resistance (HOMA-IR)); where HOMA-IR=(fasting insulin (measured in pmol/L) x fasting glucose (measured in mmol/L))/(22.5 x 7.175). (NCT00359762)
Timeframe: Year 3 in Period II

Interventionratio (Least Squares Mean)
Exen + Met12.56
Glim + Met7.89

Fasting Plasma Glucose at Year 3

Fasting plasma glucose at Year 3. (NCT00359762)
Timeframe: Year 3 in Period II

Interventionmmol/L (Least Squares Mean)
Exen + Met7.27
Glim + Met7.96

Fasting Proinsulin/Insulin Ratio at Year 3

Fasting proinsulin (measured in pmol/L)/insulin (measured in pmol/L) ratio at Year 3. (NCT00359762)
Timeframe: Year 3 in Period II

Interventionratio (Least Squares Mean)
Exen + Met0.22
Glim + Met0.23

Heart Rate at Year 3

Heart rate at Year 3. (NCT00359762)
Timeframe: Year 3 in Period II

Interventionbeats per minute (Least Squares Mean)
Exen + Met73.51
Glim + Met74.23

High-density Lipoprotein (HDL) Cholesterol at Year 3

HDL Cholesterol at Year 3. (NCT00359762)
Timeframe: Year 3 in Period II

Interventionmmol/L (Least Squares Mean)
Exen + Met1.31
Glim + Met1.25

Homeostasis Model Assessment of Beta-cell Function (HOMA-B) at Year 3

HOMA-B at Year 3. HOMA-B is an index of beta-cell function and was calculated as: HOMA-B = (20 x fasting insulin (measured in pmol/L))/((fasting glucose (measured in mmol/L) - 3.5) x 7.175). (NCT00359762)
Timeframe: Year 3 in Period II

Interventionratio (Least Squares Mean)
Exen + Met66.86
Glim + Met68.52

Hypoglycemia Rate Per Year

All hypoglycemia episodes were taken into account. Severe hypoglycemia: event requiring assistance of another person to administer carbohydrate, glucagons, or other resuscitative actions; Documented symptomatic hypoglycemia: event with typical symptoms accompanied by a measured plasma glucose concentration <=70 mg/dL; Asymptomatic hypoglycemia: event not accompanied by typical symptoms but with a measured plasma glucose concentration <=70 mg/dL; Probable symptomatic hypoglycemia: event with symptoms not accompanied by a plasma glucose determination. (NCT00359762)
Timeframe: Baseline to end of Period II (up to 4.5 years)

Interventionevents per subject-year (Least Squares Mean)
Exen + Met1.52
Glim + Met5.32

Hypoglycemia Rate Per Year in Period III

All hypoglycemia episodes were taken into account. Severe hypoglycemia: event requiring assistance of another person to administer carbohydrate, glucagons, or other resuscitative actions; Documented symptomatic hypoglycemia: event with typical symptoms accompanied by a measured plasma glucose concentration <=70 mg/dL; Asymptomatic hypoglycemia: event not accompanied by typical symptoms but with a measured plasma glucose concentration <=70 mg/dL; Probable symptomatic hypoglycemia: event with symptoms not accompanied by a plasma glucose determination. (NCT00359762)
Timeframe: Start of Period III to end of study

Interventionevents per subject-year (Mean)
Exen + Metformin + Glim - Randomized2.78
Exen + Met + Pio or Rosi - Randomized0.60
Glim + Met + Exen - Not Randomized4.62

Postprandial (2 Hours) Plasma Glucose at Year 3

Postprandial (2 hours) plasma glucose at Year 3. (NCT00359762)
Timeframe: Year 3 in Period II

Interventionmmol/L (Least Squares Mean)
Exen + Met12.65
Glim + Met15.45

Ratio of the 30 Minute Increment in Plasma Insulin Concentration and the 30 Minute Increment in Plasma Glucose During the Oral Glucose Tolerance Test (DI30/DG30 Ratio) at Year 3

DI30/DG30 at Year 3. DI30/DG30 ratio was calculated as (30 minute post prandial insulin - fasting insulin) (measured in pmol/L)/(30 minute post prandial glucose - fasting glucose) (measured in mmol/L). (NCT00359762)
Timeframe: Year 3 in Period II

Interventionratio (Least Squares Mean)
Exen + Met25.81
Glim + Met26.38

Systolic Blood Pressure at Year 3

Systolic Blood pressure at Year 3. (NCT00359762)
Timeframe: Year 3 in Period II

InterventionmmHg (Least Squares Mean)
Exen + Met130.58
Glim + Met135.78

Time to Treatment Failure

Treatment failure is defined as one of the following:1. HbA1c exceeding 9% at any visit after the initial 3 months of treatment (i.e., earliest at Month 6), on the maximally tolerated dose of antidiabetic agents. 2. HbA1c exceeding 7% at 2 consecutive visits 3 months apart, after the initial 6 months of treatment (i.e., earliest at Month 9), on the maximally tolerated dose of antidiabetic agents. (NCT00359762)
Timeframe: Baseline to end of Period II (up to 4.5 years)

Interventionweek (Median)
Exen + Met180.0
Glim + Met142.1

Total Cholesterol at Year 3

Total Cholesterol at Year 3. (NCT00359762)
Timeframe: Year 3 in Period II

Interventionmmol/L (Least Squares Mean)
Exen + Met4.77
Glim + Met4.75

Triglycerides at Year 3

Triglycerides at Year 3. (NCT00359762)
Timeframe: Year 3 in Period II

Interventionmmol/L (Least Squares Mean)
Exen + Met1.69
Glim + Met1.95

Number of Patients With Treatment Failure

Treatment failure is defined as one of the following:1. HbA1c exceeding 9% at any visit after the initial 3 months of treatment (i.e., earliest at Month 6), on the maximally tolerated dose of antidiabetic agents. 2. HbA1c exceeding 7% at 2 consecutive visits 3 months apart, after the initial 6 months of treatment (i.e., earliest at Month 9), on the maximally tolerated dose of antidiabetic agents. (NCT00359762)
Timeframe: Baseline to end of Period II (up to 4.5 years)

,
Interventionnumber of patients (Number)
Number of patients with treatment failureNumber of patients censored
Exen + Met203287
Glim + Met262225

Number of Hypoglycemic Events (HAE) Episodes Per Participant

A hypoglycemic event was identified by characteristic symptoms or blood glucose levels. Median of 1 and 2 events per participant was reported. (NCT01517373)
Timeframe: Baseline (Day 1) up to Week 14

Interventionevents per participant (Median)
Placebo0
PF-04937319 10 mg0
PF-04937319 50 mg0
PF-04937319 100 mg0
Glimepiride0

Number of Participants With Abnormal Laboratory Values

Hemoglobin,hematocrit,red blood cells(RBC) count:less than [<]0.8*lower limit of normal [LLN],platelets:<0.5*LLN/greater than [>]1.75*upper limit of normal [ULN],white blood cells(WBC):<0.6*LLN or >1.5*ULN,lymphocytes,total neutrophils:<0.8*LLN or >1.2*ULN, basophils,eosinophil,monocytes:>1.2*ULN;aspartate aminotransferase,alanine aminotransferase, alkaline phosphatase:>0.3*ULN,total protein,albumin:<0.8*LLN or >1.2*ULN;total bilirubin,direct bilirubin,indirect bilirubin:>1.5*ULN;triglycerides,cholesterol:>1.3*ULN, HDL:<0.8*LLN, LDL:>1.2*ULN,blood urea nitrogen,creatinine:>1.3*ULN,uric acid:>1.2*ULN;sodium: <0.95*LLN or >1.05*ULN,potassium,chloride,calcium,bicarbonate:<0.9*LLN or >1.1*ULN;creatine kinase:>2.0*ULN;glucose:<0.6*LLN or >1.5*ULN,urine WBC and RBC:>= 20/High Power Field [HPF]),urine epithelial cells (>=1 HPF),urine bacteria >20 high-powered field;qualitative urine glucose,urine blood to Hgb ratio (>=1);urine(protein,nitrite,mucus,leukocyte >=1 in urine dipstick test). (NCT01517373)
Timeframe: Baseline (Day 1) up to Week 14

Interventionparticipants (Number)
Placebo56
PF-04937319 10 mg52
PF-04937319 50 mg56
PF-04937319 100 mg54
Glimepiride51

Percentage of Participants With at Least 1 Hypoglycemic Events (HAE) Episode

A hypoglycemic event was identified by characteristic symptoms or blood glucose levels. HAE was defined as 1 of the given definitions: Characteristic symptoms of HAE with no home glucose monitoring performed where clinical picture included prompt resolution with food intake, subcutaneous glucagon, or intravenous glucose; or characteristic symptoms of HAE with home glucose monitoring measurement =< 70 milligram per deciliter (mg/dL) using ACCU-CHEK plasma-referenced home glucometers or =<74 mg/dL using International Federation of Clinical Chemistry (IFCC) referenced ACCU-CHEK or central laboratory glucometers; or any laboratory glucose value, meeting the following criterion with or without accompanying symptoms: =<49 mg/dL using ACCU-CHEK plasma-referenced home glucometers or =<53 mg/dL using IFCC referenced ACCU-CHEK or central laboratory glucometers. (NCT01517373)
Timeframe: Baseline (Day 1) up to Week 14

Interventionpercentage of participants (Number)
Placebo4.9
PF-04937319 10 mg3.3
PF-04937319 50 mg4.9
PF-04937319 100 mg6.6
Glimepiride34.4

Change From Baseline in Body Weight at Week 2, 4, 6, 8, 12 and 14

(NCT01517373)
Timeframe: Baseline (Day 1), Week 2, 4, 6, 8, 12, 14 (follow-up)

,,,,
Interventionkilogram (kg) (Mean)
Baseline (n=59, 57, 58, 61, 60)Change at Week 2 (n=59, 57, 58, 61, 58)Change at Week 4 (n=58, 56, 55, 59, 60)Change at Week 6 (n=57, 54, 55, 59, 56)Change at Week 8 (n=58, 54, 53, 58, 56)Change at Week 12 (n=56, 52, 53, 55, 54)Change at Week 14 (n=55, 51, 53, 55, 53)
Glimepiride90.388-0.0240.3100.4730.4931.2111.234
PF-04937319 10 mg89.518-0.069-0.378-0.604-0.522-0.685-0.472
PF-04937319 100 mg87.530-0.021-0.284-0.290-0.397-0.545-0.573
PF-04937319 50 mg89.860-0.028-0.074-0.228-0.311-0.961-0.978
Placebo89.859-0.402-0.620-0.564-1.082-1.529-1.478

Change From Baseline in Fasting Plasma Glucose at Week 2, 4, 6, 8 and 12

(NCT01517373)
Timeframe: Baseline (Day 1), Week 2, 4, 6, 8, 12

,,,,
Interventionmilligram per deciliter (mg/dL) (Mean)
Baseline (n=60, 59, 60, 61, 61)Change at Week 2 (n=60, 59, 60, 61, 59)Change at Week 4 (n=59, 58, 56, 59, 60)Change at Week 6 (n=58, 56, 56, 59, 57)Change at Week 8 (n=59, 56, 54, 58, 57)Change at Week 12 (n=57, 54, 54, 55, 55)
Glimepiride163.7-19.9-26.2-23.4-26.9-22.5
PF-04937319 10 mg168.7-2.0-8.4-6.9-7.0-6.2
PF-04937319 100 mg160.4-10.5-11.4-10.4-13.0-10.3
PF-04937319 50 mg174.7-7.9-7.7-7.2-13.0-9.9
Placebo161.33.1-0.5-2.60.93.4

Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12

HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as less than 6.5 percent by the study-specific central laboratory used. Change from baseline in percentage of HbA1C was reported. (NCT01517373)
Timeframe: Baseline (Day 1), Week 12

,,,,
Interventionpercentage of hemoglobin (Mean)
Baseline (n=59, 57, 55, 60, 60)Change at Week 12 (n=56, 53, 53, 54, 54)
Glimepiride8.12-1.01
PF-04937319 10 mg7.97-0.18
PF-04937319 100 mg7.88-0.64
PF-04937319 50 mg7.91-0.45
Placebo7.90-0.13

Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 2, 4, 6 and 8

HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as less than 6.5 percent by the study-specific central laboratory used. Change from baseline in percentage of HbA1C was reported. (NCT01517373)
Timeframe: Baseline (Day 1), Week 2, 4, 6, 8

,,,,
Interventionpercentage of hemoglobin (Mean)
Week 4 (n=58, 57, 55, 58, 60)Week 6 (n=57, 55, 55, 58, 55)Week 8 (n=58, 55, 53, 57, 55)
Glimepiride-0.54-0.78-0.89
PF-04937319 10 mg-0.07-0.14-0.17
PF-04937319 100 mg-0.32-0.51-0.59
PF-04937319 50 mg-0.22-0.22-0.38
Placebo-0.08-0.14-0.19

Number of Participants With Increase From Baseline Electrocardiogram (ECG) Data

Participants who met the criteria for increase from baseline in ECG data were reported. Criteria for increase from baseline data: PR interval (percent change of greater than or equal to [>=] 25/50% [if baseline value was >200 then percent change of >25% counts; if baseline value was <=200 then percent change of >50% counts]); QRS complex (percent change of >=50%); QT Fridericia's correction (QTcF) interval (change of >= 30 to <60 millisecond [msec], and change of >=60 msec). (NCT01517373)
Timeframe: Baseline (Day 1) up to Week 14

,,,,
Interventionparticipants (Number)
PR interval: Percent change of >=25/50%QRS interval: Percent change of >=50%QTcF interval: Change of >=30 to <60 msecQTcF interval: Change of >=60 msec
Glimepiride0141
PF-04937319 10 mg0152
PF-04937319 100 mg0262
PF-04937319 50 mg1182
Placebo0062

Number of Participants With Increase/Decrease From Baseline Vital Signs Data

Participants who met the criteria for increase or decrease in vital signs data were reported. Criteria for increase or decrease from baseline vital signs data: sitting systolic blood pressure (BP) of >=30 millimeter of mercury (mmHg); sitting diastolic BP of >=20 mmHg and pulse rate was based on investigator's discretion. (NCT01517373)
Timeframe: Baseline (Day 1) up to Week 14

,,,,
Interventionparticipants (Number)
Increase in systolic BP (>=30 mmHg)Increase in diastolic BP (>=20 mmHg)Decrease in systolic BP (>=30 mmHg)Decrease in diastolic BP (>=20 mmHg)
Glimepiride5215
PF-04937319 10 mg1333
PF-04937319 100 mg3456
PF-04937319 50 mg3032
Placebo2154

Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 14 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events. (NCT01517373)
Timeframe: Baseline (Day 1) up to 14 days after last dose of study treatment (up to 101 days)

,,,,
Interventionparticipants (Number)
AEsSAEs
Glimepiride361
PF-04937319 10 mg281
PF-04937319 100 mg291
PF-04937319 50 mg312
Placebo260

Percentage of Participants Achieving Less Than 6.5 Percent and Less Than 7 Percent Glycosylated Hemoglobin (HbA1c) Levels at Week 12

HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as less than 6.5 percent by the study-specific central laboratory used and data are presented in categories of less than 6.5 percent and less than 7 percent. (NCT01517373)
Timeframe: Week 12

,,,,
Interventionpercentage of participants (Number)
Less Than 6.5 PercentLess Than 7 Percent
Glimepiride18.245.5
PF-04937319 10 mg1331.5
PF-04937319 100 mg27.352.7
PF-04937319 50 mg18.527.8
Placebo7.026.3

Number of Hypoglycemic Events (HAE) Episodes Per Participant

A hypoglycemic event (HAE) was identified by characteristic symptoms or blood glucose levels. Median number of events per participant was reported (NCT01475461)
Timeframe: Baseline (Day 1) up to Week 14

Interventionevents per participant (Median)
Metformin 500 mg0
Placebo0
PF-04937319 3 mg0
PF-04937319 20 mg0
PF-04937319 50 mg0
PF-04937319 100 mg0
Sitagliptin 100 mg0

Number of Participants With Abnormal Laboratory Values

Hemoglobin,hematocrit,red blood cells(RBC) count:less than [<]0.8*lower limit of normal[LLN],platelets:<0.5*LLN/greater than [>]1.75*upper limit of normal [ULN],white blood cells(WBC):<0.6*LLN or >1.5*ULN,lymphocytes,total neutrophils:<0.8*LLN or >1.2*ULN, basophils,eosinophil,monocytes:>1.2*ULN;aspartate aminotransferase,alanine aminotransferase, alkaline phosphatase:>0.3*ULN,total protein,albumin:<0.8*LLN or >1.2*ULN;total bilirubin,direct bilirubin,indirect bilirubin:>1.5*ULN;triglycerides,cholesterol:>1.3*ULN, HDL:<0.8*LLN, LDL:>1.2*ULN,blood urea nitrogen,creatinine:>1.3*ULN,uric acid:>1.2*ULN;sodium: <0.95*LLN or >1.05*ULN,potassium,chloride,calcium,bicarbonate:<0.9*LLN or >1.1*ULN;creatine kinase:>2.0*ULN;glucose:<0.6*LLN or >1.5*ULN,urine WBC and RBC:>= 20/High Power Field [HPF]),urine epithelial cells (>=1 HPF),urine bacteria >20 high-powered field;qualitative urine glucose,urine blood to Hgb ratio (>=1);urine(protein,nitrite,mucus,leukocyte >=1 in urine dipstick test). (NCT01475461)
Timeframe: Baseline (Day 1) up to Week 14

Interventionparticipants (Number)
Placebo46
PF-04937319 3 mg49
PF-04937319 20 mg45
PF-04937319 50 mg46
PF-04937319 100 mg53
Sitagliptin 100 mg43

Percentage of Participants With at Least 1 Hypoglycemic Events (HAE) Episode

A hypoglycemic event (HAE) was identified by characteristic symptoms or blood glucose levels. HAE is defined as 1 of the given definitions: Characteristic symptoms of HAE with no home glucose monitoring performed where clinical picture included prompt resolution with food intake, subcutaneous glucagon, or intravenous glucose; or characteristic symptoms of HAE with home glucose monitoring measurement =< 70 milligram per deciliter (mg/dL) using ACCU-CHEK plasma-referenced home glucometers or =<74 mg/dL using International Federation of Clinical Chemistry (IFCC) referenced ACCU-CHEK or central laboratory glucometers; or any laboratory glucose value, meeting the following criterion with or without accompanying symptoms: =<49 mg/dL using ACCU-CHEK plasma-referenced home glucometers or =<53 mg/dL using IFCC referenced ACCU-CHEK or central laboratory glucometers. (NCT01475461)
Timeframe: Baseline (Day 1) up to Week 14

Interventionpercentage of participants (Number)
Metformin 500 mg0
Placebo0
PF-04937319 3 mg0
PF-04937319 20 mg1
PF-04937319 50 mg0
PF-04937319 100 mg2
Sitagliptin 100 mg1

Change From Baseline in Body Weight at Week 2, 4, 8, 12 and 14

(NCT01475461)
Timeframe: Baseline (Day 1), Week 2, 4, 8 , 12 , 14

,,,,,
Interventionkilogram (kg) (Mean)
Baseline (n=55, 55, 50, 56, 54, 55)Change at Week 2 (n=54, 55, 49, 56, 53, 55)Change at Week 4 (n=51, 55, 49, 55, 53, 53)Change at Week 8 (n=49, 53, 45, 52, 50, 52)Change at Week 12 (n=47, 52, 45, 52, 50, 53)Change at Week 14 (n=44, 52, 44, 52, 50, 53)
PF-04937319 100 mg91.239-0.053-0.374-0.475-0.623-0.916
PF-04937319 20 mg88.371-0.052-0.192-0.510-0.455-0.613
PF-04937319 3 mg87.8650.4350.214-0.003-0.1420.011
PF-04937319 50 mg88.066-0.283-0.203-0.270-0.352-0.492
Placebo86.446-0.239-0.704-0.823-0.804-0.588
Sitagliptin 100 mg87.025-0.384-0.353-0.702-0.917-1.172

Change From Baseline in Fasting Plasma Glucose at Week 1, 2, 4, 8, 12 and 14

(NCT01475461)
Timeframe: Baseline (Day 1), Week 1, 2, 4, 8, 12, 14

,,,,,
Interventionmilligram per deciliter (mg/dL) (Mean)
Baseline (n=56, 56, 52, 56, 55, 55)Change at Week 2 (n=54, 56, 50, 56, 54, 55)Change at Week 4 (n=52, 56, 51, 55, 54, 53)Change at Week 8 (n=50, 54, 47, 52, 51, 52)Change at Week 12 (n=48, 53, 47, 52, 51, 53)Change at Week 14 (n=45, 53, 46, 52, 51, 53)
PF-04937319 100 mg164.8-10.8-9.6-6.53.510.2
PF-04937319 20 mg155.1-3.2-0.2-2.5-3.8-3.1
PF-04937319 3 mg159.80.7-0.30.7-2.5-3.5
PF-04937319 50 mg166.1-6.8-8.3-15.2-10.8-1.0
Placebo168.3-5.2-1.8-3.1-7.5-5.9
Sitagliptin160.7-13.6-19.3-15.4-12.9-2.6

Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12

HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as less than (<) 6.5 percent (%) by the study-specific central laboratory used. Change from baseline in percentage of HbA1c in participants were reported. (NCT01475461)
Timeframe: Baseline (Day 1), Week 12

,,,,,
Interventionpercentage of hemoglobin (Mean)
Baseline (n=50,55,48,55,53,53)Change at Week 12 (n=46,52,45,52,50,53)
PF-04937319 100 mg8.31-0.80
PF-04937319 20 mg7.80-0.53
PF-04937319 3 mg8.00-0.33
PF-04937319 50 mg8.15-0.59
Placebo8.01-0.42
Sitagliptin7.89-0.79

Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 2, 4 and 8

HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as <6.5 percent by the study-specific central laboratory used. Change from baseline in percentage of HbA1c in participants were reported. (NCT01475461)
Timeframe: Baseline(Day 1), Week 2, 4, 8

,,,,,
Interventionpercentage of hemoglobin (Mean)
Change at Week 4 (n= 50, 55, 48, 55, 53, 53)Change at Week 8 (n=48, 53, 45, 52, 50, 51)
PF-04937319 100 mg-0.50-0.86
PF-04937319 20 mg-0.32-0.46
PF-04937319 3 mg-0.24-0.32
PF-04937319 50 mg-0.35-0.50
Placebo-0.20-0.36
Sitagliptin-0.52-0.77

Number of Participants With Increase From Baseline Electrocardiogram (ECG)Data

Criteria for increase from baseline data: PR interval (percent change of greater than or equal to [>=] 25/50% [if baseline>200 then percent change of >25% counts; if baseline <=200 then percent change of >50% counts]; QRS complex (percent change of >=50%); QT Fridericia's correction (QTcF) interval (change of >=30 to <60 millisecond [msec], and change of >=60 msec). (NCT01475461)
Timeframe: Baseline (Day 1) up to Week 14

,,,,,
Interventionparticipants (Number)
PR interval: Percent change of >=25/50%QRS interval: Percent change of >=50%QTcF interval: Change of >=30 to <60 msecQTcF interval: Change of >=60 msec
PF-04937319 100 mg1132
PF-04937319 20 mg0130
PF-04937319 3 mg1150
PF-04937319 50 mg0131
Placebo0071
Sitagliptin2170

Number of Participants With Increase/Decrease From Baseline Vital Signs Data

Participants who met the criteria for increase or decrease in vital signs data were reported. Criteria for increase or decrease from baseline vital signs data: sitting systolic blood pressure (BP) of >=30 millimeter of mercury (mmHg); sitting diastolic BP of >=20 mmHg and pulse rate was based on investigator's discretion. (NCT01475461)
Timeframe: Baseline (Day 1) up to Week 14

,,,,,
Interventionparticipants (Number)
Increase in systolic BP (>=30 mmHg)Increase in diastolic BP (>=20 mmHg)Decrease in systolic BP (>=30 mmHg)Decrease in diastolic BP (>=20 mmHg)
PF-04937319 100 mg3423
PF-04937319 20 mg2016
PF-04937319 3 mg2421
PF-04937319 50 mg1111
Placebo1112
Sitagliptin2211

Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 14 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events. (NCT01475461)
Timeframe: Baseline (Day 1) up to 14 days after last dose (up to 101 days)

,,,,,,
Interventionparticipants (Number)
AEsSAEs
Metformin 500 mg370
PF-04937319 100 mg241
PF-04937319 20 mg191
PF-04937319 3 mg190
PF-04937319 50 mg160
Placebo191
Sitagliptin 100 mg180

Percentage of Participants Achieving Less Than 6.5 Percent and Less Than 7 Percent Glycosylated Hemoglobin (HbA1c) Levels at Week 12

HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as <6.5 percent by the study-specific central laboratory used and data are presented in categories of <6.5 percent and <7 percent. (NCT01475461)
Timeframe: Week 12

,,,,,
Interventionpercentage of participants (Number)
<6.5 percent<7 percent
PF-04937319 100 mg17.639.2
PF-04937319 20 mg19.142.6
PF-04937319 3 mg9.426.4
PF-04937319 50 mg15.430.8
Placebo12.522.9
Sitagliptin32.156.6

Least Squares (LS) Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 30

Participant whole blood samples were collected at baseline and Week 30 to determine the LS mean HbA1c change from baseline. HbA1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation. (NCT01189890)
Timeframe: Baseline and Week 30

InterventionPercentage of HbA1c (Least Squares Mean)
Sitagliptin-0.32
Glimepiride-0.51

LS Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30

Plasma samples were collected from participants after an overnight fast at baseline and Week 30 to determine the mean change from baseline in participant FPG. (NCT01189890)
Timeframe: Baseline and Week 30

Interventionmg/dL (Least Squares Mean)
Sitagliptin-14.5
Glimepiride-21.2

LS Mean Change From Baseline in Participant Body Weight at Week 30

Participants were only permitted to wear a drape gown and undergarments (no street clothes, no shoes or socks) for this evaluation. Body weight was measured after voiding (to the nearest 0.1 kg) and measurements were collected until 2 consecutive measurements did not differ by more than 0.2 kg from each other. Body weight measurements were evaluated using a standardized, calibrated digital scale and was reported in kilograms (kg) at baseline and Week 30. (NCT01189890)
Timeframe: Baseline and Week 30

Interventionkg (Least Squares Mean)
Sitagliptin0.4
Glimepiride1.1

Number of Participants Discontinuing Study Treatment Due to An AE

"An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the~study treatment, whether or not considered related to the use of the treatment administered." (NCT01189890)
Timeframe: Up to Week 30

InterventionParticipants (Number)
Sitagliptin3
Glimepiride4

Number of Participants Experiencing An Adverse Event (AE)

"An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the~study treatment, whether or not considered related to the use of the treatment administered." (NCT01189890)
Timeframe: Up to Week 30

InterventionParticipants (Number)
Sitagliptin118
Glimepiride115

Number of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30

Symptomatic hypoglycemia was defined as an episode with clinical symptoms attributed to hypoglycemia, without regard to glucose level. Participants were instructed to complete the Hypoglycemia Assessment Log (HAL) for any symptomatic episodes he or she believed represent hypoglycemia. If a fingerstick glucose was obtained before or shortly (i.e., within a few minutes) after treating, the value was recorded in the HAL. In addition, participants were instructed to record in the HAL any fingerstick glucose values ≤70 mg/dL (≤3.9 mmol/L) regardless of the presence of clinical symptoms. (NCT01189890)
Timeframe: Up to Week 30

InterventionParticipants (Number)
Sitagliptin2
Glimepiride11

Percentage of Participants With HbA1c <6.5% at Week 30

Participant whole blood samples were collected at Week 30 to determine the number of participants achieving HbA1c <6.5% at Week 30. Hemoglobin A1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation. (NCT01189890)
Timeframe: Week 30

InterventionPercentage of Participants (Number)
Sitagliptin9.1
Glimepiride20.9

Percentage of Participants With HbA1c <7.0% at Week 30

Participant whole blood samples were collected at Week 30 to determine the number of participants achieving HbA1c <7.0% at Week 30. HbA1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation. (NCT01189890)
Timeframe: Week 30

InterventionPercentage of Participants (Number)
Sitagliptin33.5
Glimepiride46.6

Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate. (NCT01075282)
Timeframe: Baseline, 52 weeks

Interventionpercentage of glycosylated hemoglobin (Least Squares Mean)
LY2189265 1.5 mg-1.08
LY2189265 0.75 mg-0.76
Insulin Glargine-0.63

Change From Baseline to 26 Weeks and 78 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate. (NCT01075282)
Timeframe: Baseline, 26 weeks, and 78 weeks

,,
Interventionpercent (Least Squares Mean)
26 weeks (n=263, 266, 258)78 weeks (n=263, 267, 259)
Insulin Glargine-0.65-0.59
LY2189265 0.75 mg-0.89-0.62
LY2189265 1.5 mg-1.16-0.90

Change From Baseline to 26, 52 and 78 Weeks for Body Mass Index

Body mass index (BMI) is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionkilograms per square meter (kg/m^2) (Least Squares Mean)
26 weeks (n=257, 261, 245)52 weeks (n=250, 252, 238)78 weeks (n=246, 244, 238)
Insulin Glargine0.440.620.59
LY2189265 0.75 mg-0.50-0.39-0.39
LY2189265 1.5 mg-0.64-0.64-0.64

Change From Baseline to 26, 52 and 78 Weeks for Body Weight

Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionkilogram (kg) (Least Squares Mean)
26 weeks52 weeks78 weeks
Insulin Glargine1.011.441.28
LY2189265 0.75 mg-1.47-1.33-1.54
LY2189265 1.5 mg-1.82-1.87-1.96

Change From Baseline to 26, 52 and 78 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Blood Glucose (SMBG) Profiles

The self-monitored blood glucose (SMBG) data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 3 AM or 5 hours after bedtime. Least Squares (LS) means of the mean of the 8 time points (Daily Mean) were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionmillimoles per liter (mmol/L) (Least Squares Mean)
26 weeks (n=199, 204, 190)52 weeks (n=180, 185, 176)78 weeks (n=172, 164, 168)
Insulin Glargine-1.58-1.44-1.47
LY2189265 0.75 mg-1.46-1.32-1.15
LY2189265 1.5 mg-1.79-1.69-1.55

Change From Baseline to 26, 52 and 78 Weeks in the EuroQol 5 Dimension

The European Quality of Life - 5 dimensions (EQ-5D) questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part of the questionnaire consists of a 100-mm visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) and adjusted by treatment, country, and baseline. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionunits on a scale (Least Squares Mean)
EQ-5D UK, 26 weeks (n=257, 254, 249)EQ-5D UK, 52 weeks (n=259, 260, 253)EQ-5D UK, 78 weeks (n=259, 260, 253)VAS, 26 weeks (n=253, 252, 243)VAS, 52 weeks (n=260, 258, 252)VAS, 78 weeks (n=260, 258, 252)
Insulin Glargine-0.01-0.040.000.81.12.2
LY2189265 0.75 mg0.000.000.003.42.33.2
LY2189265 1.5 mg0.010.010.013.33.23.8

Change From Baseline to 26, 52 and 78 Weeks in the Impact of Weight on Activities of Daily Living

"The Impact of Weight on Activities of Daily Living questionnaire (renamed the Ability to Perform Physical Activities of Daily Living Questionnaire [APPADL]) contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = not at all difficult and 1 = unable to do. The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate." (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionunits on a scale (Least Squares Mean)
26 weeks (n=256, 256, 248)52 weeks (n=260, 261, 249)78 weeks (n=260, 261, 249)
Insulin Glargine-0.3-0.6-0.3
LY2189265 0.75 mg0.10.40.3
LY2189265 1.5 mg0.70.91.0

Change From Baseline to 26, 52 and 78 Weeks in the Impact of Weight on Self-Perception

The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionunits on a scale (Least Squares Mean)
26 weeks (n=258, 258, 251)52 weeks (n=260, 261, 252)78 weeks (n=260, 261, 252)
Insulin Glargine-0.10.10.1
LY2189265 0.75 mg0.20.20.3
LY2189265 1.5 mg0.10.50.5

Change From Baseline to 26, 52 and 78 Weeks in the Low Blood Sugar Survey

The Low Blood Sugar Survey (LBSS) contains 33 items comprised of 2 subscales (behavior and worry), each of which is rated on a 5-point numeric rating scale from 0 (never) to 4 (almost always). It captures behavioral changes associated with the concerns and experiences of hypoglycemia and the degree to which participants are worried about certain aspects associated with hypoglycemia during the previous 4 weeks. The behavior (or avoidance) subscale has 15 items, and the worry (or affect) subscale has 18 items. Subscale scores are calculated by summing participant responses to items (behavior range 0-60; worry range 0-72). A total score is calculated as the sum of both subscales (range 0-132). Higher scores indicate greater negative impact on subscales and total score. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionunits on a scale (Least Squares Mean)
26 weeks (n=255, 255, 244)52 weeks (n=258, 259, 245)78 weeks (n=258, 259, 245)
Insulin Glargine0.3-1.0-2.0
LY2189265 0.75 mg-2.4-4.1-4.7
LY2189265 1.5 mg-2.8-4.2-4.6

Change From Baseline to 26, 52 and 78 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval

The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionmilliseconds (msec) (Least Squares Mean)
QTcF interval, 26 weeks (n=240, 245, 229)QTcF interval, 52 weeks (n=231, 240, 228)QTcF interval, 78 weeks (n=221, 220, 222)PR interval, 26 weeks (n=240, 245, 229)PR interval, 52 weeks (n=230, 240, 227)PR interval, 78 weeks (n=221, 220, 222)
Insulin Glargine1.243.704.441.241.501.21
LY2189265 0.75 mg-0.101.343.442.331.883.27
LY2189265 1.5 mg-1.711.551.662.782.612.62

Change From Baseline to 26, 52 and 78 Weeks on Electrocardiogram Parameters, Heart Rate

Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionbeats per minute (bpm) (Least Squares Mean)
26 weeks (n=241, 247, 231)52 weeks (n=232, 242, 231)78 weeks (n=223, 222, 225)
Insulin Glargine-1.24-1.01-0.26
LY2189265 0.75 mg0.900.380.47
LY2189265 1.5 mg2.642.412.49

Change From Baseline to 26, 52 and 78 Weeks on Pancreatic Enzymes

Amylase (total and pancreas-derived) and lipase concentrations were measured. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionunits/liter (Median)
Amylase (total), 26 weeksAmylase (total), 52 weeksAmylase (total), 78 weeksAmylase (pancreas-derived), 26 weeksAmylase (pancreas-derived), 52 weeksAmylase (pancreas-derived), 78 weeksLipase, 26 weeksLipase, 52 weeksLipase, 78 weeks
Insulin Glargine2.0003.0001.0001.0001.0000.000-1.000-1.000-2.000
LY2189265 0.75 mg4.0005.0004.0003.0003.0002.0005.0004.0004.000
LY2189265 1.5 mg4.0004.0004.0003.0003.0002.0005.0004.0004.000

Change From Baseline to 26, 52 and 78 Weeks on Serum Calcitonin

(NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionpicogram/milliliter (Mean)
26 weeks (n=266, 267, 258)52 weeks (n=266, 269, 259)78 weeks (n=267, 269, 259)
Insulin Glargine0.1490.1760.151
LY2189265 0.75 mg0.0970.1320.035
LY2189265 1.5 mg0.1630.1280.086

Change From Baseline to 26, 52, and 78 Weeks on Blood Pressure

Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionmilliliter of mercury (mmHG) (Least Squares Mean)
SBP, 26 weeks (n=257, 261, 245)SBP, 52 weeks (n=250, 252, 240)SBP, 78 weeks (n=246, 244, 238)DBP, 26 weeks (n=257, 261, 245)DBP, 52 weeks (n=250, 252, 240)DBP, 78 weeks (n=246, 244, 238)
Insulin Glargine-0.030.510.51-0.29-0.93-1.04
LY2189265 0.75 mg-1.600.09-0.59-0.17-0.19-0.36
LY2189265 1.5 mg-1.280.17-0.70-0.16-0.26-0.44

Change From Baseline to 52 and 78 Weeks in Glucagon Concentration

Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 52, and 78 weeks

,,
Interventionpicomoles per liter (pmol/L) (Least Squares Mean)
52 weeks (n=232, 231, 228)78 weeks (n=235, 235, 232)
Insulin Glargine-3.85-3.65
LY2189265 0.75 mg-3.31-3.37
LY2189265 1.5 mg-3.91-3.57

Change From Baseline to 52 and 78 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)

The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S), as percentages of a normal reference population (normal young adults). The normal reference population for both HOMA2-B and HOMA-2S were set at 100%. Least Squares (LS) means of change from baseline of C-peptide based HOMA2-%B and HOMA2-%S were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 52, and 78 weeks

,
Interventionpercentage of HOMA2 (Least Squares Mean)
HOMA2-%B, 52 weeks (n=175, 181)HOMA2-%B, 78 weeks (n=167, 165)HOMA2-%S, 52 weeks (n=175,181)HOMA2-%S, 78 weeks (n=167, 165)
LY2189265 0.75 mg24.6015.66-2.66-3.62
LY2189265 1.5 mg29.9528.54-2.89-2.64

Change in Baseline to 26, 52 and 78 Weeks on Pulse Rate

Sitting pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks

,,
Interventionbeats per minute (bpm) (Least Squares Mean)
26 weeks (n=257, 260, 245)52 weeks (n=250, 252, 240)78 weeks (n=246, 244, 238)
Insulin Glargine-1.21-0.52-0.91
LY2189265 0.75 mg0.740.510.61
LY2189265 1.5 mg1.561.291.31

Number of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than 7% at 26, 52 and 78 Weeks

Number of participants achieving HbA1c levels less than 7.0% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model. (NCT01075282)
Timeframe: 26, 52, and 78 weeks

,,
Interventionparticipants (Number)
26 weeks (n=263, 266, 258)52 weeks (n=263, 267, 259)78 weeks (n=263, 267, 259)
Insulin Glargine848079
LY2189265 0.75 mg1229991
LY2189265 1.5 mg153140129

Number of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than or Equal to 6.5% at 26, 52 and 78 Weeks

Number of participants achieving HbA1c levels less than or equal to 6.5% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model. (NCT01075282)
Timeframe: 26, 52, and 78 weeks

,,
Interventionparticipants (Number)
26 weeks (n=263, 266, 258)52 weeks (n=263, 267, 259)78 weeks (n=263, 267, 259)
Insulin Glargine403543
LY2189265 0.75 mg746059
LY2189265 1.5 mg977174

Number of Participants Requiring Additional Intervention Due to Hyperglycemia at 26, 52 and 78 Weeks

Additional intervention was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. The number of participants requiring additional intervention due to hyperglycemia is summarized cumulatively at 26, 52, and 78 weeks. (NCT01075282)
Timeframe: 26, 52, and 78 weeks

,,
Interventionparticipants (Number)
26 weeks52 weeks78 weeks
Insulin Glargine0816
LY2189265 0.75 mg42034
LY2189265 1.5 mg21124

Number of Participants With Adjudicated Cardiovascular Events at 26, 52 and 78 Weeks

Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with adjudicated CV events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01075282)
Timeframe: Baseline through 26, 52, and 78 weeks

,,
Interventionparticipants (Number)
Any CV event, 26 weeksAny fatal CV event, 26 weeksAny non-fatal CV event, 26 weeksAny CV event, 52 weeksAny fatal CV event, 52 weeksAny non-fatal CV event, 52 weeksAny CV event, 78 weekAny fatal CV event, 78 weekAny non-fatal CV event, 78 week
Insulin Glargine303615918
LY2189265 0.75 mg101404616
LY2189265 1.5 mg202303303

Number of Participants With Adjudicated Pancreatitis at 26, 52 and 78 Weeks

The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01075282)
Timeframe: Baseline through 26, 52, and 78 weeks

,,
Interventionparticipants (Number)
26 weeks52 weeks78 weeks
Insulin Glargine000
LY2189265 0.75 mg111
LY2189265 1.5 mg122

Number of Participants With LY2189265 Antibodies at 26, 52, 78 Weeks and 4 Weeks After Last Dose of Study Drug (83 Weeks Maximum)

LY2189265 (Dulaglutide) anti-drug antibodies (ADA) were assessed at baseline, 26, 52, and 78 weeks, and at the safety follow-up visit 30 days after study drug discontinuation (83 weeks). The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA at each time point were summarized. (NCT01075282)
Timeframe: Baseline, 26, 52, 78, and 83 weeks

Interventionparticipants (Number)
26 weeks52 weeks78 weeks83 weeks
LY2189265 1.5 mg and 0.75 mg11310

Number of Participants With Treatment Emergent Adverse Events at 26, 52 and 78 Weeks

A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01075282)
Timeframe: 26, 52, and 78 weeks

,,
Interventionparticipants (Number)
26 weeks52 weeks78 weeks
Insulin Glargine137175192
LY2189265 0.75 mg146175188
LY2189265 1.5 mg160189201

Number of Self-reported Hypoglycemic Events at 26, 52 and 78 Weeks

Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01075282)
Timeframe: Baseline through 26, 52, and 78 weeks

,,
Interventionevents (Number)
Severe HE, 26 weeksSevere HE, 52 weeksSevere HE, 78 weeksDocumented symptomatic HE, 26 weeksDocumented symptomatic HE, 52 weeksDocumented symptomatic HE, 78 weeksAsymptomatic HE, 26 weeksAsymptomatic HE, 52 weeksAsymptomatic HE, 78 weeksNocturnal HE, 26 weeksNocturnal HE, 52 weeksNocturnal HE, 78 weeksProbable symptomatic HE, 26 weeksProbable symptomatic HE, 52 weeksProbable symptomatic HE, 78 weeks
Insulin Glargine122447789103360910931358240519635202226
LY2189265 0.75 mg000315444515484709911117147184192428
LY2189265 1.5 mg112311515607500757884145185215111720

Rate of Self-reported Hypoglycemic Events at 26, 52 and 78 Weeks

Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01075282)
Timeframe: Baseline through 26, 52, and 78 weeks

,,
Interventionevents per participant per year (Mean)
Severe HE, 26 weeksSevere HE, 52 weeksSevere HE, 78 weeksDocumented symptomatic HE, 26 weeksDocumented symptomatic HE, 52 weeksDocumented symptomatic HE, 78 weeksAsymptomatic HE, 26 weeksAsymptomatic HE, 52 weeksAsymptomatic HE, 78 weeksNocturnal HE, 26 weeksNocturnal HE, 52 weeksNocturnal HE, 78 weeksProbable symptomatic HE, 26 weeksProbable symptomatic HE, 52 weeksProbable symptomatic HE, 78 weeks
Insulin Glargine0.010.010.013.643.343.034.824.413.801.862.071.810.150.080.07
LY2189265 0.75 mg0.000.000.002.521.971.663.582.682.380.960.650.590.140.090.07
LY2189265 1.5 mg0.010.000.012.352.031.673.793.082.561.230.900.770.080.070.05

Change in Fasting Plasma Glucose (FPG) From Baseline to Week 52

The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change. (NCT01137812)
Timeframe: Day 1 (Baseline) and Week 52

Interventionmg/dL (Least Squares Mean)
Canagliflozin 300 mg-29.9
Sitagliptin 100 mg-5.85

Change in HbA1c From Baseline to Week 52

The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change. (NCT01137812)
Timeframe: Day 1 (Baseline) and Week 52

InterventionPercent (Least Squares Mean)
Canagliflozin 300 mg-1.03
Sitagliptin 100 mg-0.66

Change in Systolic Blood Pressure (SBP) From Baseline to Week 52

The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change. (NCT01137812)
Timeframe: Day 1 (Baseline) and Week 52

InterventionmmHg (Least Squares Mean)
Canagliflozin 300 mg-5.06
Sitagliptin 100 mg0.85

Percent Change in Body Weight From Baseline to Week 52

The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean percent change. (NCT01137812)
Timeframe: Day 1 (Baseline) and Week 52

InterventionPercent change (Least Squares Mean)
Canagliflozin 300 mg-2.5
Sitagliptin 100 mg0.3

Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52

The table below shows the mean percent change in HDL-C from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change. (NCT01137812)
Timeframe: Day 1 (Baseline) and Week 52

InterventionPercent change (Least Squares Mean)
Canagliflozin 300 mg7.6
Sitagliptin 100 mg0.6

Percent Change in Triglycerides From Baseline to Week 52

The table below shows the mean percent change in triglycerides from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change. (NCT01137812)
Timeframe: Day 1 (Baseline) and Week 52

InterventionPercent change (Least Squares Mean)
Canagliflozin 300 mg9.6
Sitagliptin 100 mg11.9

Percentage of Patients With HbA1c <7% at Week 52

The table below shows the percentage of patients with HbA1c <7% at Week 52 in each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the percentage. (NCT01137812)
Timeframe: Week 52

InterventionPercentage of patients (Number)
Canagliflozin 300 mg47.6
Sitagliptin 100 mg35.3

Change in 2-hour Post-prandial Glucose From Baseline to Week 26

The table below shows the least-squares (LS) mean change in 2-hour post-prandial glucose from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 26

Interventionmg/dL (Least Squares Mean)
Placebo/Sitagliptin-9.79
Canagliflozin 100 mg-47.9
Canagliflozin 300 mg-57.1
Sitagliptin 100 mg-49.3

Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26

The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 26

Interventionmg/dL (Least Squares Mean)
Placebo/Sitagliptin2.47
Canagliflozin 100 mg-27.3
Canagliflozin 300 mg-37.8
Sitagliptin 100 mg-20.2

Change in Fasting Plasma Glucose (FPG) From Baseline to Week 52

The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 52 for each active treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus sitagliptin) in the LS mean change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 52

Interventionmg/dL (Least Squares Mean)
Canagliflozin 100 mg-26.2
Canagliflozin 300 mg-35.2
Sitagliptin 100 mg-17.7

Change in HbA1c From Baseline to Week 26

The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent (Least Squares Mean)
Placebo/Sitagliptin-0.17
Canagliflozin 100 mg-0.79
Canagliflozin 300 mg-0.94
Sitagliptin 100 mg-0.82

Change in HbA1c From Baseline to Week 52

The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each active treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus sitagliptin) in the LS mean change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 52

InterventionPercent (Least Squares Mean)
Canagliflozin 100 mg-0.73
Canagliflozin 300 mg-0.88
Sitagliptin 100 mg-0.73

Change in Systolic Blood Pressure (SBP) From Baseline to Week 26

The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 26

InterventionmmHg (Least Squares Mean)
Placebo/Sitagliptin1.52
Canagliflozin 100 mg-3.84
Canagliflozin 300 mg-5.06
Sitagliptin 100 mg-1.83

Change in Systolic Blood Pressure (SBP) From Baseline to Week 52

The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 52 for each active treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus sitagliptin) in the LS mean change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 52

InterventionmmHg (Least Squares Mean)
Canagliflozin 100 mg-3.53
Canagliflozin 300 mg-4.65
Sitagliptin 100 mg-0.66

Percent Change in Body Weight From Baseline to Week 26

The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean percent change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent change (Least Squares Mean)
Placebo/Sitagliptin-1.2
Canagliflozin 100 mg-3.7
Canagliflozin 300 mg-4.2
Sitagliptin 100 mg-1.2

Percent Change in Body Weight From Baseline to Week 52

The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 52 for each active treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus sitagliptin) in the LS mean percent change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 52

InterventionPercent change (Least Squares Mean)
Canagliflozin 100 mg-3.8
Canagliflozin 300 mg-4.2
Sitagliptin 100 mg-1.3

Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26

The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean percent change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent change (Least Squares Mean)
Placebo/Sitagliptin3.7
Canagliflozin 100 mg10.4
Canagliflozin 300 mg12.1
Sitagliptin 100 mg5.0

Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52

The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 52 for each active treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus sitagliptin) in the LS mean percent change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 52

InterventionPercent change (Least Squares Mean)
Canagliflozin 100 mg11.2
Canagliflozin 300 mg13.3
Sitagliptin 100 mg6.0

Percent Change in Triglycerides From Baseline to Week 26

The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean percent change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent change (Least Squares Mean)
Placebo/Sitagliptin3.2
Canagliflozin 100 mg1.6
Canagliflozin 300 mg-1.4
Sitagliptin 100 mg1.0

Percent Change in Triglycerides From Baseline to Week 52

The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 52 for each active treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus sitagliptin) in the LS mean percent change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 52

InterventionPercent change (Least Squares Mean)
Canagliflozin 100 mg1.9
Canagliflozin 300 mg2.7
Sitagliptin 100 mg-0.4

Percentage of Patients With HbA1c <7% at Week 26

The table below shows the percentage of patients with HbA1c <7% at Week 26 in each treatment group. The statistical analyses show the treatment differences between each canagliflozin or sitagliptin group and placebo. (NCT01106677)
Timeframe: Week 26

InterventionPercentage of patients (Number)
Placebo/Sitagliptin29.8
Canagliflozin 100 mg45.5
Canagliflozin 300 mg57.8
Sitagliptin 100 mg54.5

Change in 2-hour Post-prandial Glucose From Baseline to Week 26 (High Glycemic Substudy)

The table below shows the least-squares (LS) mean change in 2-hour post-prandial glucose from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy. (NCT01081834)
Timeframe: Day 1 (Baseline) and Week 26

Interventionmg/dL (Least Squares Mean)
Canagliflozin 100 mg-118
Canagliflozin 300 mg-126

Change in 2-hour Post-prandial Glucose From Baseline to Week 26 (Main Study)

The table below shows the least-squares (LS) mean change in 2-hour post-prandial glucose from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01081834)
Timeframe: Day 1 (Baseline) and Week 26

Interventionmg/dL (Least Squares Mean)
Placebo5.19
Canagliflozin 100 mg-42.9
Canagliflozin 300 mg-58.8

Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 (High Glycemic Substudy)

The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy. (NCT01081834)
Timeframe: Day 1 (Baseline) and Week 26

Interventionmg/dL (Least Squares Mean)
Canagliflozin 100 mg-81.7
Canagliflozin 300 mg-86.3

Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 (Main Study)

The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01081834)
Timeframe: Day 1 (Baseline) and Week 26

Interventionmg/dL (Least Squares Mean)
Placebo8.33
Canagliflozin 100 mg-27.2
Canagliflozin 300 mg-35.0

Change in HbA1c From Baseline to Week 26 (High Glycemic Substudy)

The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy. (NCT01081834)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent (Least Squares Mean)
Canagliflozin 100 mg-2.13
Canagliflozin 300 mg-2.56

Change in HbA1c From Baseline to Week 26 (Main Study)

The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01081834)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent (Least Squares Mean)
Placebo0.14
Canagliflozin 100 mg-0.77
Canagliflozin 300 mg-1.03

Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 (High Glycemic Substudy)

The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy. (NCT01081834)
Timeframe: Day 1 (Baseline) and Week 26

InterventionmmHg (Least Squares Mean)
Canagliflozin 100 mg-4.47
Canagliflozin 300 mg-4.97

Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 (Main Study)

The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01081834)
Timeframe: Day 1 (Baseline) and Week 26

InterventionmmHg (Least Squares Mean)
Placebo0.38
Canagliflozin 100 mg-3.34
Canagliflozin 300 mg-5.04

Percent Change in Body Weight From Baseline to Week 26 (High Glycemic Substudy)

The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy. (NCT01081834)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent change (Least Squares Mean)
Canagliflozin 100 mg-3.0
Canagliflozin 300 mg-3.8

Percent Change in Body Weight From Baseline to Week 26 (Main Study)

The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change. (NCT01081834)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent change (Least Squares Mean)
Placebo-0.6
Canagliflozin 100 mg-2.8
Canagliflozin 300 mg-3.9

Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (High Glycemic Substudy)

The table below shows the least-squares mean percent change in HDL-C from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy. (NCT01081834)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent change (Least Squares Mean)
Canagliflozin 100 mg2.4
Canagliflozin 300 mg10.8

Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (Main Study)

The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change. (NCT01081834)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent change (Least Squares Mean)
Placebo4.4
Canagliflozin 100 mg11.2
Canagliflozin 300 mg10.5

Percent Change in Triglycerides From Baseline to Week 26 (High Glycemic Substudy)

The table below shows the least-squares mean percent change in triglycerides from Baseline to Week 26 for each treatment group in patients randomized to the High Glycemic Substudy. (NCT01081834)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent change (Least Squares Mean)
Canagliflozin 100 mg-0.6
Canagliflozin 300 mg-12.7

Percent Change in Triglycerides From Baseline to Week 26 (Main Study)

The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change. (NCT01081834)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent change (Least Squares Mean)
Placebo7.8
Canagliflozin 100 mg2.5
Canagliflozin 300 mg-2.4

Percentage of Patients With HbA1c <7% at Week 26 (High Glycemic Substudy)

The table below shows the percentage of patients with HbA1c <7% at Week 26 for each treatment group in patients randomized to the High Glycemic Substudy. (NCT01081834)
Timeframe: Week 26

InterventionPercentage of patients (Number)
Canagliflozin 100 mg17.4
Canagliflozin 300 mg11.6

Percentage of Patients With HbA1c <7% at Week 26 (Main Study)

The table below shows the percentage of patients with HbA1c <7% at Week 26. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage. (NCT01081834)
Timeframe: Week 26

InterventionPercentage of patients (Number)
Placebo20.6
Canagliflozin 100 mg44.5
Canagliflozin 300 mg62.4

Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26

The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106625)
Timeframe: Day 1 (Baseline) and Week 26

Interventionmg/dL (Least Squares Mean)
Placebo4.11
Canagliflozin 100 mg-18.2
Canagliflozin 300 mg-30.5

Change in HbA1c From Baseline to Week 26

The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106625)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent (Least Squares Mean)
Placebo-0.13
Canagliflozin 100 mg-0.85
Canagliflozin 300 mg-1.06

Change in Systolic Blood Pressure (SBP) From Baseline to Week 26

The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106625)
Timeframe: Day 1 (Baseline) and Week 26

InterventionmmHg (Least Squares Mean)
Placebo-2.65
Canagliflozin 100 mg-4.89
Canagliflozin 300 mg-4.27

Percent Change in Body Weight From Baseline to Week 26

The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change. (NCT01106625)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent change (Least Squares Mean)
Placebo-0.7
Canagliflozin 100 mg-2.1
Canagliflozin 300 mg-2.6

Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26

The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change. (NCT01106625)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent change (Least Squares Mean)
Placebo3.2
Canagliflozin 100 mg5.7
Canagliflozin 300 mg6.5

Percent Change in Triglycerides From Baseline to Week 26

The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change. (NCT01106625)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent change (Least Squares Mean)
Placebo11.6
Canagliflozin 100 mg5.4
Canagliflozin 300 mg8.5

Percentage of Patients With HbA1c <7% at Week 26

The table below shows the percentage of patients with HbA1c<7% at Week 26 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage. (NCT01106625)
Timeframe: Week 26

InterventionPercentage of patients (Number)
Placebo18
Canagliflozin 100 mg43.2
Canagliflozin 300 mg56.6

Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26

The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26

Interventionmg/dL (Least Squares Mean)
Placebo7.39
Canagliflozin 100 mg-18.1
Canagliflozin 300 mg-20.3

Change in HbA1c From Baseline to Week 26

The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent (Least Squares Mean)
Placebo-0.03
Canagliflozin 100 mg-0.60
Canagliflozin 300 mg-0.73

Change in Region Percent Total Fat From Baseline to Week 26 in a Subset of Patients Undergoing Specific Dual-energy X-ray Absorptiometry (DXA) Analysis for Body Composition

Region percent total fat = body fat as a percentage of (body fat + lean body mass + bone mass content). The table below shows the least-squares (LS) mean change in region percent total fat from Baseline to Week 26 for each treatment group in patients randomized to the subset of patients undergoing specific dual-energy X-ray absorptiometry (DXA) analysis for body composition. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent (Least Squares Mean)
Placebo0.00
Canagliflozin 100 mg-1.03
Canagliflozin 300 mg-1.18

Change in Systolic Blood Pressure (SBP) From Baseline to Week 26

The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26

InterventionmmHg (Least Squares Mean)
Placebo1.10
Canagliflozin 100 mg-3.52
Canagliflozin 300 mg-6.79

Change in Tissue Percent Total Fat From Baseline to Week 26 in a Subset of Patients Undergoing Specific Dual-energy X-ray Absorptiometry (DXA) Analysis for Body Composition

Tissue percent total fat = body fat as a percentage of body fat + lean body mass. The table below shows the least-squares (LS) mean change in tissue percent total fat from Baseline to Week 26 for each treatment group in patients randomized to the subset of patients undergoing specific DXA analysis for body composition. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent (Least Squares Mean)
Placebo0.02
Canagliflozin 100 mg-1.04
Canagliflozin 300 mg-1.18

Change in Total Fat From Baseline to Week 26 in a Subset of Patients Undergoing Specific Dual-energy X-ray Absorptiometry (DXA) Analysis for Body Composition

The table below shows the least-squares (LS) mean change in total fat from Baseline to Week 26 for each treatment group in patients randomized to the subset of patients undergoing specific DXA analysis for body composition. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26

Interventionkg (Least Squares Mean)
Placebo-0.28
Canagliflozin 100 mg-1.87
Canagliflozin 300 mg-2.38

Percent Change in Body Weight From Baseline to Week 26

The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent change (Least Squares Mean)
Placebo-0.1
Canagliflozin 100 mg-2.4
Canagliflozin 300 mg-3.1

Percent Change in Distal Forearm Bone Mineral Density (BMD) From Baseline to Week 26

The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in distal forearm BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent change (Least Squares Mean)
Placebo-0.5
Canagliflozin 100 mg-0.7
Canagliflozin 300 mg-0.8

Percent Change in Femoral Neck Bone Mineral Density (BMD) From Baseline to Week 26

The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in femoral neck BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent change (Least Squares Mean)
Placebo-1.0
Canagliflozin 100 mg-0.7
Canagliflozin 300 mg-0.6

Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26

The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 or each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent change (Least Squares Mean)
Placebo1.5
Canagliflozin 100 mg6.8
Canagliflozin 300 mg6.2

Percent Change in Lumbar Spine Bone Mineral Density (BMD) From Baseline to Week 26

The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in lumbar spine BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent change (Least Squares Mean)
Placebo0.5
Canagliflozin 100 mg0.7
Canagliflozin 300 mg0.2

Percent Change in Total Hip Bone Mineral Density (BMD) From Baseline to Week 26

The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in total hip BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent change (Least Squares Mean)
Placebo-0.5
Canagliflozin 100 mg-0.9
Canagliflozin 300 mg-1.0

Percent Change in Triglycerides From Baseline to Week 26

The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26

InterventionPercent change (Least Squares Mean)
Placebo7.7
Canagliflozin 100 mg2.8
Canagliflozin 300 mg8.4

Percentage of Patients With HbA1c <7% at Week 26

The table below shows the percentage of patients with HbA1c <7% at Week 26 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage. (NCT01106651)
Timeframe: Week 26

InterventionPercentage of patients (Number)
Placebo28.0
Canagliflozin 100 mg47.7
Canagliflozin 300 mg58.5

Change From Baseline in Body Weight at Week 30

Change in body weight following 30 weeks of therapy (i.e., body weight at Week 30 minus body weight at baseline) (NCT00993187)
Timeframe: Baseline and Week 30

Interventionkg (Least Squares Mean)
Sitagliptin/Metformin-0.83
Glimepiride0.90

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30

Blood glucose was measured on a fasting basis (collected after an 8- to 10-hour fast). FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 30 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 30 minus FPG at baseline). (NCT00993187)
Timeframe: Baseline and Week 30

Interventionmg/dL (Least Squares Mean)
Sitagliptin/Metformin-47.0
Glimepiride-23.5

Change From Baseline in Hemoglobin A1C (HbA1C) at Week 30

HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Change in A1C following 30 weeks of therapy (i.e., A1C at Week 30 minus A1C at baseline). (NCT00993187)
Timeframe: Baseline and Week 30

InterventionPercent of total hemoglobin (Least Squares Mean)
Sitagliptin/Metformin-1.5
Glimepiride-0.7

Number of Participants Who Discontinued Study Drug Due to an Adverse Event

An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product. (NCT00993187)
Timeframe: Up to 30 weeks

InterventionParticipants (Number)
Sitagliptin/Metformin8
Glimepiride8

Number of Participants Who Experienced at Least One Adverse Event (AE)

An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product. (NCT00993187)
Timeframe: Up to 32 weeks

InterventionParticipants (Number)
Sitagliptin/Metformin88
Glimepiride101

Percentage of Participants With HbA1C < 7.0% at Week 30

HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). (NCT00993187)
Timeframe: Week 30

InterventionPercentage of Participants (Number)
Sitagliptin/Metformin81.2
Glimepiride40.1

Percentage of Participants With One or More Episodes of Hypoglycemia

Symptomatic episodes assessed as likely to be due to hypoglycemia were reported by investigators as adverse experiences of hypoglycemia. Adverse experiences of hypoglycemia were based on all reports of hypoglycemia; a concurrent glucose measurement was not required. (NCT00993187)
Timeframe: Up to Week 30

InterventionPercentage of participants (Number)
Sitagliptin/Metformin5.5
Glimepiride20.1

Change From Baseline in 2 Hours Post Meal Endothelial Independent Vasodilation (EIDV) on Day 28

Endothelial function 2h post-meal was measured by endothelial independent vasodilation (EIDV). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline. (NCT01703286)
Timeframe: baseline and day 28 for each treatment arm

Interventionpercentage (Mean)
Linagliptin 5 mg1.003
Glimepiride 1-4 mg1.053
Placebo0.981

Change From Baseline in Flow Mediated Vasodilation (FMD) 2 h Post Meal on Day 28

Endothelial function 2 hours post meal was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline. (NCT01703286)
Timeframe: baseline and day 28 for each treatment arm

InterventionPercentage (Geometric Mean)
Linagliptin 5 mg1.262
Glimepiride 1-4 mg1.045
Placebo1.009

Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28

Endothelial function under fasted condition was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline. (NCT01703286)
Timeframe: baseline and day 28 for each treatment arm

Interventionpercentage (Geometric Mean)
Linagliptin 5 mg0.885
Glimepiride 1-4 mg1.002
Placebo1.002

Number of Patients With Adverse Events

Number of patients with any adverse events (NCT01703286)
Timeframe: up to 20 weeks

Interventionparticipants (Number)
Linagliptin 5 mg11
Glimepiride 1-4 mg25
Placebo14
REP - Linagliptin 5 mg4
REP - Glimepiride 1-4 mg7
Rep - Placebo7

Change From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2)

HbA1c is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Change from baseline reflects the Week 44 A1C minus baseline A1C. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used. Change from baseline was based on the constrained longitudinal data analysis (cLDA) model including all available measurements from baseline through the last visit. The terms in the cLDA model include treatment, time in weeks (categorical), regions, and treatment-by-time interaction. (NCT01709305)
Timeframe: Phase 2 Baseline (Week 20) and Week 44

InterventionPercent (Least Squares Mean)
Phase 2: Metformin + Sitagliptin + Glimepiride-0.65
Phase 2: Metformin + Sitagliptin + Repaglinide-0.62
Phase 2: Metformin + Sitagliptin + Acarbose-0.46
Phase 2: Metformin + Sitagliptin + Gliclazide-0.69

Change From Phase 2 Baseline to Week 44 in Participant Body Weight (Phase 2)

Change from baseline in body weight in Phase 2 was reported. Change from baseline reflects the Week 44 body weight minus baseline body weight. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used. (NCT01709305)
Timeframe: Phase 2 Baseline (Week 20), Week 44

Interventionkg (Mean)
Phase 2: Metformin + Sitagliptin + Glimepiride0.4
Phase 2: Metformin + Sitagliptin + Repaglinide0.2
Phase 2: Metformin + Sitagliptin + Acarbose-0.9
Phase 2: Metformin + Sitagliptin + Gliclazide0.2

Percentage of Participants With a Gastrointestinal (GI) AE of Nausea (Phase 2)

"The percentage of participants with a GI AE of nausea was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride0
Phase 2: Metformin + Sitagliptin + Repaglinide0
Phase 2: Metformin + Sitagliptin + Acarbose0.4
Phase 2: Metformin + Sitagliptin + Gliclazide0.2

Percentage of Participants With a GI AE of Abdominal Pain (Phase 2)

"The percentage of participants with a GI AE of abdominal pain was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride0
Phase 2: Metformin + Sitagliptin + Repaglinide0
Phase 2: Metformin + Sitagliptin + Acarbose0.4
Phase 2: Metformin + Sitagliptin + Gliclazide0.2

Percentage of Participants With a GI AE of Diarrhea (Phase 2)

"The percentage of participants with a GI AE of diarrhea was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride0.5
Phase 2: Metformin + Sitagliptin + Repaglinide0.4
Phase 2: Metformin + Sitagliptin + Acarbose0.4
Phase 2: Metformin + Sitagliptin + Gliclazide0.9

Percentage of Participants With a GI AE of Vomiting (Phase 2)

"The percentage of participants with a GI AE of vomiting was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride0.2
Phase 2: Metformin + Sitagliptin + Repaglinide0
Phase 2: Metformin + Sitagliptin + Acarbose0.2
Phase 2: Metformin + Sitagliptin + Gliclazide0.2

Percentage of Participants With Hypoglycemia Events (Phase 2)

Hypoglycemia events represent epidsodes symptomatic of hypoglycemia (e.g., weakness, dizziness, shakiness, increased sweating, palpitations, or confusion) and/or finger stick glucose values of ≤70 mg/dL (3.9 mmol/L). The percentage of participants with hypoglycemia events was reported. (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride8.9
Phase 2: Metformin + Sitagliptin + Repaglinide6.1
Phase 2: Metformin + Sitagliptin + Acarbose0.5
Phase 2: Metformin + Sitagliptin + Gliclazide3.6

Change From Baseline in Body Weight at 52 W

(NCT01183104)
Timeframe: Baseline and 52 W

Interventionkg (Mean)
Sitagliptin-0.367
Glimepiride0.309

Change From Baseline in HbA1c at 52 W

(NCT01183104)
Timeframe: Baseline and 52 W

Interventionpercent (Least Squares Mean)
Sitagliptin-0.66
Glimepiride-0.77

Change From Baseline in HOMA-β at 52 W

β cell function is measured by the Homeostatic Model Assessment(HOMA-β). HOMA β = [20 x fasting insulin (μU/mL)] / [fasting plasma glucose (mmol/L) - 3.5] (NCT01183104)
Timeframe: Baseline and 52 W

Interventionpercent (Mean)
Sitagliptin10.2
Glimepiride23.7

Change From Baseline in Insulin/Proinsulin Ratio at 52 W

(NCT01183104)
Timeframe: Baseline and 52 W

Interventionratio (Mean)
Sitagliptin-0.049
Glimepiride-0.002

Number of Participants With Hypoglycaemia

(NCT01183104)
Timeframe: From baseline to 52 W

InterventionParticipants (Count of Participants)
Sitagliptin7
Glimepiride23

The Number of Participants Achieving HbA1c < 6.9 %

(NCT01183104)
Timeframe: 52 W

InterventionParticipants (Count of Participants)
Sitagliptin89
Glimepiride86

Primary Major Macrovascular Events

Myocardial infarction (MI), intervention for coronary artery or Peripheral Vascular Disease (PVD), severe inoperable Coronary Artery Disease (CAD), new or worsening Congestive Heart Failure (CHF), stroke, Cardiovascular (CV) death, or amputation for ischemic gangrene. (NCT00032487)
Timeframe: Post baseline time to the first major macrovascular event up to 82 months

Interventionparticipants (Number)
Arm 1264
Arm 2235

Secondary Endpoint

New or worsening angina, new transient ischemic attack (TIA), new intermittent claudication or critical limb ischemia with Doppler evidence or total mortality. (NCT00032487)
Timeframe: Post baseline time to first event up to 82 months

Interventionparticipants (Number)
Arm 1283
Arm 2312

Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline

The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention

Interventionpercentage (Mean)
Insulin Glargine, Metformin, Exenatide-2.43
Insulin Glargine, Metformin, Prandial Insulin0.44

HbA1C Levels

% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks

Intervention% of HbA1C (Mean)
Insulin Glargine, Metformin, Exenatide7.1
Insulin Glargine, Metformin, Prandial Insulin7.2

Number of Participants With Hypoglycemia

Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks

InterventionParticipants (Count of Participants)
Insulin Glargine, Metformin, Exenatide0
Insulin Glargine, Metformin, Prandial Insulin0

Weight Change During Trial

Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks

Interventionkg (Mean)
Insulin Glargine, Metformin, Exenatide-4.8
Insulin Glargine, Metformin, Prandial Insulin0.7

Change From Baseline in Body Weight at Week 30

Change from baseline at Week 30 was defined as Week 30 minus Week 0. (NCT00701090)
Timeframe: Week 0 to Week 30

InterventionKilograms (Least Squares Mean)
Sitagliptin-0.8
Glimepiride1.2

Change From Baseline in FPG (Fasting Plasma Glucose) at Week 30

Change from baseline at Week 30 was defined as Week 30 minus Week 0. (NCT00701090)
Timeframe: Week 0 to Week 30

Interventionmg/dL (Least Squares Mean)
Sitagliptin-14.6
Glimepiride-17.5

Change From Baseline in HbA1c at Week 30

Patient-level HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 30 HbA1c percent minus the Week 0 HbA1c percent. (NCT00701090)
Timeframe: Week 0 to Week 30

InterventionPercent (Least Squares Mean)
Sitagliptin-0.47
Glimepiride-0.54

Percent of Patients With A1C <6.5% at Week 30

(NCT00701090)
Timeframe: Week 30

InterventionPercentage of Participants (Number)
Sitagliptin21.2
Glimepiride27.5

Percent of Patients With A1C <7.0% at Week 30

(NCT00701090)
Timeframe: Week 30

InterventionPercentage of Participants (Number)
Sitagliptin52.4
Glimepiride59.6

Percent of Patients With at Least One Hypoglycemia Episode of Any Type at Week 30

(NCT00701090)
Timeframe: Week 0 to Week 30

InterventionPercentage of Participants (Number)
Sitagliptin7.0
Glimepiride22.0

Change From Baseline in Adiponectin.

The change between Adiponectin collected at week 24 or final visit and Adiponectin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionμg/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID6.79
Glimepiride 2 mg and Metformin 850 mg BID0.72

Change From Baseline in Diastolic Blood Pressure.

The change between Diastolic Blood Pressure measured at week 24 or final visit and Diastolic Blood Pressure measured at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

InterventionmmHg (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-1.3
Glimepiride 2 mg and Metformin 850 mg BID-0.1

Change From Baseline in E-Selectin.

The change between the value of E-Selectin collected at week 24 or final visit and E-Selectin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionng/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-3.7
Glimepiride 2 mg and Metformin 850 mg BID-0.5

Change From Baseline in Erythrocyte Deformability (0.30%).

The change between the 0.30 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID1.3
Glimepiride 2 mg and Metformin 850 mg BID-0.4

Change From Baseline in Erythrocyte Deformability (0.60%)

The change between the 0.60 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID2.4
Glimepiride 2 mg and Metformin 850 mg BID-0.5

Change From Baseline in Erythrocyte Deformability (1.20).

The change between the 1.20 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID3.2
Glimepiride 2 mg and Metformin 850 mg BID-1.1

Change From Baseline in Erythrocyte Deformability (12.00).

The change between the 12.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID2.7
Glimepiride 2 mg and Metformin 850 mg BID-1.3

Change From Baseline in Erythrocyte Deformability (3.00).

The change between the 3.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID3.3
Glimepiride 2 mg and Metformin 850 mg BID-.15

Change From Baseline in Erythrocyte Deformability (30.00).

The change between the 30.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID2.5
Glimepiride 2 mg and Metformin 850 mg BID-1.3

Change From Baseline in Erythrocyte Deformability (6.00).

The change between the 6.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID3.1
Glimepiride 2 mg and Metformin 850 mg BID-1.4

Change From Baseline in Erythrocyte Deformability (60.00).

The change between the 60.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID2.7
Glimepiride 2 mg and Metformin 850 mg BID-1.3

Change From Baseline in Fasting Glucose.

The change between Fasting Glucose collected at week 24 or final visit and Fasting Glucose collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-21.6
Glimepiride 2 mg and Metformin 850 mg BID-21.1

Change From Baseline in Fasting Intact Proinsulin.

The change between Fasting Intact Proinsulin collected at week 24 or final visit and Fasting Intact Proinsulin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpmol/L (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-5.18
Glimepiride 2 mg and Metformin 850 mg BID-0.11

Change From Baseline in Glycosylated Hemoglobin.

The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 or final visit and Glycosylated Hemoglobin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-0.83
Glimepiride 2 mg and Metformin 850 mg BID-0.95

Change From Baseline in High Sensitivity C-reactive Protein (≤ 10 mg/L).

The change between the value of High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at week 24 or final visit and High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/L (Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-0.87
Glimepiride 2 mg and Metformin 850 mg BID0.00

Change From Baseline in High Sensitivity C-reactive Protein (Original).

The change between the value of High Sensitivity C-reactive Protein collected at week 24 or final visit and High Sensitivity C-reactive Protein collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/L (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-0.21
Glimepiride 2 mg and Metformin 850 mg BID-0.04

Change From Baseline in High-Density Lipoprotein Cholesterol.

The change between HDL-Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID3.3
Glimepiride 2 mg and Metformin 850 mg BID-0.4

Change From Baseline in High-Density Lipoprotein/Low-Density Lipoprotein Ratio.

The change between High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at week 24 or final visit and High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID0.1
Glimepiride 2 mg and Metformin 850 mg BID0.3

Change From Baseline in Low-Density Lipoprotein Cholesterol.

The change between Low-Density Lipoprotein Cholesterol collected at week 24 or final visit and Low-Density Lipoprotein Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID9.7
Glimepiride 2 mg and Metformin 850 mg BID11.2

Change From Baseline in Low-Density Lipoprotein Subfractions.

The change between the value of Low-Density Lipoprotein Subfractions collected at week 24 or final visit and Low-Density Lipoprotein Subfractions collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID6.2
Glimepiride 2 mg and Metformin 850 mg BID6.1

Change From Baseline in Matrix Metallo Proteinase-9.

The change between the value of Baseline in Matrix Metallo Proteinase-9 collected at week 24 or final visit and Baseline in Matrix Metallo Proteinase-9 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionng/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID31.4
Glimepiride 2 mg and Metformin 850 mg BID51.6

Change From Baseline in Nitrotyrosine.

The change between the value of Nitrotyrosine collected at week 24 or final visit and Nitrotyrosine collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionnmol/L (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-2.7
Glimepiride 2 mg and Metformin 850 mg BID32.5

Change From Baseline in Platelet Function.

The change between the value of Platelet Function by PFA 100 collected at week 24 or final visit and Platelet Function by PFA 100 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionsec (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-30.3
Glimepiride 2 mg and Metformin 850 mg BID-1.0

Change From Baseline in Soluble CD40 Ligand.

The change between the value of Soluble CD40 Ligand collected at week 24 or final visit and Soluble CD40 Ligand collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpg/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-40.7
Glimepiride 2 mg and Metformin 850 mg BID102.4

Change From Baseline in Soluble Intracellular Adhesion Molecule.

The change between the value of Baseline in Soluble Intracellular Adhesion molecule at week 24 or final visit and Baseline in Soluble Intracellular Adhesion molecule collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionng/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-13.0
Glimepiride 2 mg and Metformin 850 mg BID-3.2

Change From Baseline in Soluble Vascular Cell Adhesion Molecule.

The change between the value of Soluble Vascular Cell Adhesion Molecule collected at week 24 or final visit and Soluble Vascular Cell Adhesion Molecule collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionng/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID11.6
Glimepiride 2 mg and Metformin 850 mg BID3.3

Change From Baseline in Systolic Blood Pressure.

The change between Systolic Blood Pressure measured at week 24 or final visit and Systolic Blood Pressure measured at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

InterventionmmHg (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-2.5
Glimepiride 2 mg and Metformin 850 mg BID0.5

Change From Baseline in Thromboxane B2.

The change between the value of Thromboxane B2 collected at week 24 or final visit and Thromboxane B2 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpg/mL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-216.4
Glimepiride 2 mg and Metformin 850 mg BID527.8

Change From Baseline in Triglycerides.

The change between the value of Triglycerides collected at week 24 or final visit and Triglycerides collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-40.9
Glimepiride 2 mg and Metformin 850 mg BID-16.7

Change From Baseline in Von-Willebrand Factor.

The change between the value of Von-Willebrand Factor collected at week 24 or final visit and Von-Willebrand Factor collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionpercent (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID-19.5
Glimepiride 2 mg and Metformin 850 mg BID1.4

Intake of Study Medication Greater Than 80% and Less Than 120%.

The change between the Intake of study medication greater than 80% at week 24 or final visit and Baseline and the Intake of study medication greater than 80% at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionparticipants (Number)
Pioglitazone 15 mg and Metformin 850 mg BID136
Glimepiride 2 mg and Metformin 850 mg BID137

The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.

The increase in High-Density Lipoprotein (HDL) Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Least Squares Mean)
Pioglitazone 15 mg and Metformin 850 mg BID3.2
Glimepiride 2 mg and Metformin 850 mg BID-0.3

8-Iso Prostaglandin F2α (8-iso PGF2α) Excretion Rate

8-Iso Prostaglandin F2α (8-iso PGF2α) excretion rate measured during the 24 hours preceding the CGM system removal. The nocturnal glycemia measured by CGM system will be defined as the average of glycemic values collected between midnight and breakfast time. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
Interventionpg/mL (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)361.9373.5
Glimepiride/Metformin325.1320.4

Duration of Hyperglycaemia (>126 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
InterventionHours (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)17.3115.30
Glimepiride/Metformin17.5310.83

Duration of Hypoglycaemia (<60 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
InterventionHours (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)0.510.14
Glimepiride/Metformin00.08

Duration of Hypoglycaemia (<80 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
InterventionHours (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)0.850.64
Glimepiride/Metformin0.240.41

Duration of Severe Hyperglycaemia (>150 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
InterventionHours (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)11.286.39
Glimepiride/Metformin12.354.23

Episodes of Hyperglycaemia (>126 mg/dL) at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
InterventionEpisodes (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)3.915.36
Glimepiride/Metformin4.055.90

Episodes of Hypoglycaemia (<60 mg/dL) at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
InterventionEpisodes (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)0.500.14
Glimepiride/Metformin00.1

Episodes of Hypoglycaemia (<80 mg/dL) at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
InterventionEpisodes (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)0.640.50
Glimepiride/Metformin0.300.80

Episodes of Severe Hyperglycaemia (>150 mg/dL) at Baseline Compared to After 12 Weeks on Treatment

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
InterventionEpisodes (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)4.005.00
Glimepiride/Metformin3.552.95

Glycaemia According to CGMS (Basal Incremental AUC or Values Above 1 mg/dL), mg/dL

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. The concentrations of glucose will be assessed from the AUC calculations on glycaemic values measured by CGM system. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
Interventionmg/dL (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)905.6534.5
Glimepiride/Metformin850.1355.0

Glycaemia According to CGMS (Dawn), mg/dL

"Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.The glycemia at dawn measured by CGM system will be defined as the average of glycemic values recorded between 4 AM and breakfast time." (NCT00318656)
Timeframe: Baseline and 12 weeks

,
Interventionmg/dL (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)145.0130.6
Glimepiride/Metformin138.6124.7

Glycaemia According to CGMS (Diurnal), mg/dL

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.The diurnal glycemia measured by CGM system will be the average of glycemic values recorded between breakfast time and midnight. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
Interventionmg/dL (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)162.1139.1
Glimepiride/Metformin158.7130.13

Glycaemia According to CGMS (MAGE), mg/dL

Calculation of the Mean amplitude of glycemic excursion (MAGE) was obtained by measuring the arithmetic mean of the major glucose concentration increases or decreases on days 2 and 3 of glycaemic profile and then averaging results on the two days. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
Interventionmg/dL (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)75.144.2
Glimepiride/Metformin61.650.8

Glycaemia According to CGMS (Nocturnal), mg/dL

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations.The nocturnal glycemia measured by CGM system will be defined as the average of glycemic values collected between midnight and breakfast time. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
Interventionmg/dL (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)148.4130.2
Glimepiride/Metformin140.4126.3

Glycaemia According to CGMS (Postprandial Incremental AUC or Values Above 1 mg/dL), mg/dL

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. The concentrations of glucose will be assessed from the AUC calculations on glycaemic values measured by CGM system. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
Interventionmg/dL (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)522.8356.9
Glimepiride/Metformin443.0362.7

Glycaemia According to CGMS (Total Area Under the Curve (AUC) for Values Above 1 mg/dL), mg/dL

Continuous Glycemic Monitoring System, Medtronic (CGMS®) System Gold downloads data to a computer for evaluation of glucose variations. The concentrations of glucose will be assessed from the AUC calculations on glycaemic values measured by CGM system. (NCT00318656)
Timeframe: Baseline and 12 weeks

,
Interventionmg/dL (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)1428.2891.4
Glimepiride/Metformin1293.1717.7

HbA1c (Glycosylated Hemoglobin)

Uncontrolled HbA1c>8.5%. HbA1c and fasting blood glucose taken at hospital (NCT00318656)
Timeframe: Baseline and 12 weeks

,
InterventionPercentage (Mean)
Baseline12 weeks
Avandamet® (Rosiglitazone/Metformin)7.87.4
Glimepiride/Metformin7.77.1

Fasting Plasma Glucose (FPG) Change From Baseline at Week 18 (Interim Analysis)

This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. Means are adjusted for baseline FPG, baseline HbA1c, prior OADs and reason for metformin intolerance (Interim Analysis). (NCT00740051)
Timeframe: Baseline and week 18

Interventionmg/dl (Mean)
Placebo7.2
Linagliptin-13.3

HbA1c Change From Baseline at Week 18 (Final Analysis)

HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the Week 0 HbA1c percent. Means are adjusted for baseline HbA1c, prior OADs and reason for metformin intolerance. HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the Week 0 HbA1c percent. Means are adjusted for baseline HbA1c, prior OADs and reason for metformin intolerance. The primary analysis was re-run at the completion of the study in the final study report. (NCT00740051)
Timeframe: Baseline and week 18

Interventionpercent (Mean)
Placebo0.21
Linagliptin-0.39

HbA1c Change From Baseline at Week 18 (Interim Analysis)

HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the Week 0 HbA1c percent. Means are adjusted for baseline HbA1c, prior OADs and reason for metformin intolerance. (NCT00740051)
Timeframe: Baseline and week 18

Interventionpercent (Mean)
Placebo0.14
Linagliptin-0.44

Percentage of Patients With HbA1c Lowering by 0.5% at Week 18 (Interim Analysis)

Odds ratios are adjusted for baseline HbA1c, prior OADs and reason for metformin intolerance. (NCT00740051)
Timeframe: Week 18

Interventionpercent of patients (Number)
Placebo17.8
Linagliptin36.1

Percentage of Patients With HbA1c<6.5 at Week 18 (Interim Analysis)

Odds ratios are adjusted for baseline HbA1c, prior OADs and reason for metformin intolerance. (NCT00740051)
Timeframe: Week 18

Interventionpercent of patients (Number)
Placebo2.9
Linagliptin8.9

Percentage of Patients With HbA1c<7.0 at Week 18 (Interim Analysis)

Odds ratios are adjusted for baseline HbA1c, prior OADs and reason for metformin intolerance. (NCT00740051)
Timeframe: Week 18

Interventionpercent of patients (Number)
Placebo11.8
Linagliptin23.5

The Change in FPG From Baseline by Visit Over Time

This change from baseline reflects the FPG (at weeks 6, 12, 18, 22, 26, 30, 34, 40, 46, 52) minus the Week 0 FPG. (NCT00740051)
Timeframe: Baseline and weeks 6,12,18, 22, 26, 30, 34, 40, 46, 52

,
Interventionmg/dL (Mean)
Change from baseline at week 6 (N=63, 134)Change from baseline at week 12 (N=55,92)Change from baseline at week 18 (N=47, 115)Change from baseline at week 22 (N=46, 110)Change from baseline at week 26 (N=50, 108)Change from baseline at week 30 (N=48, 95)Change from baseline at week 34 (N=48, 95)Change from baseline at week 40 (N=47, 92)Change from baseline at week 46 (N=47, 92)Change from baseline at week 52 (N=43, 86)
Linagliptin-8.4-14.3-12.9-14.0-17.0-19.1-15.8-19.0-18.1-14.0
Placebo/Glimepiride9.75.45.0-19.3-22.6-31.4-25.6-19.5-22.8-19.1

The Change in HbA1c From Baseline by Visit Over Time

HbA1c is measured as a percentage. Thus, this change from baseline reflects the HbA1c percent (at weeks 6, 12, 18, 22, 26, 30, 34, 40, 46, 52) minus the Week 0 HbA1c percent. (NCT00740051)
Timeframe: Baseline and weeks 6,12, 18, 22, 26, 30, 34, 40, 46, 52

,
Interventionpercent (Mean)
Change from baseline at week 6 (N=64, 136)Change from baseline at week 12 (N=57, 129)Change from baseline at week 18 (N=47, 118)Change from baseline at week 22 (N=46, 113)Change from baseline at week 26 (N=50, 110)Change from baseline at week 30 (N=49, 98)Change from baseline at week 34 (N=50, 96)Change from baseline at week 40 (N=49, 94)Change from baseline at week 46 (N=45, 92)Change from baseline at week 52 (N=45, 92)
Linagliptin-0.21-0.43-0.38-0.40-0.48-0.49-0.49-0.45-0.42-0.44
Placebo/Glimepiride0.260.260.10-0.32-0.53-0.79-0.75-0.73-0.78-0.72

Correlation Between HbA1c Values at Baseline and Hypoglycemia Scores at Week 12

Coefficient of correlation as measured using linear regression analysis for association between two variables, HbA1c values at baseline and hypoglycemia scores. A positive correlation coefficient indicates that as one value increases the other value increases, or as as one value decreases the other value decreases. (NCT00907881)
Timeframe: Baseline and Week 12

InterventionCorrelation coefficient (Number)
All Participants0.0026

Correlation Between HbA1c Values at Week 12 and Hypoglycemia Scores

Coefficient of correlation was measured using a linear regression analysis for the association between two variables, HbA1c values at Week 12 and hypoglycemia scores. A negative correlation coefficient indicates that as one value increases the other value decreases, and vice versa. (NCT00907881)
Timeframe: Week 12

InterventionCorrelation coefficient (Number)
All Participants-0.1215

Correlation Between HbA1c Values at Week 12 and Hypoglycemia Scores by Sub-group (Demographic/Disease Parameters)

Sub-group analyses based on Karl pearson coefficient of correlation for HbA1c values at Week 12 and hypoglycemia score. Participants were grouped based on gender, age, body mass index, and duration of diabetes. A negative correlation coefficient indicates that as one value increases the other value decreases, and vice versa. (NCT00907881)
Timeframe: Week 12

InterventionCorrelation coefficient (Number)
Male, n=526Female, n=417Age 18-34 years, n=45Age 35-44 years, n=171Age 45-64 years, n=595Age 65 years and older, n=138Body mass index <25 kg/m^2, n=370Body mass index 25-30 kg/m^2, n=394Body mass index >30 kg/m^2, n=183Duration of diabetes <5 years, n=640Duration of diabetes 5-10 years, n=239Duration of diabetes >10 years, n=49
All Participants-0.1654-0.0756-0.1636-0.1034-0.1222-0.0984-0.0100-0.2188-0.1688-0.1201-0.1503-0.1316

Hypoglycemia Symptom Score by Sub-group (Demographic/Disease Parameters)

Sub-group analyses of mean hypoglycemia symptom score. Participants were grouped based on gender, age, hypoglycemia severity, body mass index, duration of diabetes, and number of oral hypoglycemic agents. Hypoglycemia symptom score (measured by Stanford Hypoglycemia Questionnaire) is a score on a scale with a possible range of 0 (best) to 7 (worst). The questionnaire was administered by the physician at Week 12. (NCT00907881)
Timeframe: Week 12

InterventionScore on a scale (Mean)
Male, n=526Female, n=417Age 18-34 years, n=45Age 35-44 years, n=171Age 45-64 years, n=595Age 65 years and older, n=138Mild hypoglycemia, n=286Moderate hypoglycemia, n=168Severe hypoglycemia, n=15Body mass index <25 kg/m^2, n=370Body mass index 25-30 kg/m^2, n=394Body mass index >30 kg/m^2, n=183Duration of T2DM <5 years, n=640Duration of T2DM 5-10 years, n=239Duration of T2DM >10 years, n=49No background oral hypoglycemic agents, n=201 background oral hypoglycemic agent, n=8542 background oral hypoglycemic agents, n=693 background oral hypoglycemic agents, n=7
All Participants0.871.120.910.870.961.181.592.362.531.010.950.960.881.151.290.600.971.300.00

Change From Baseline in A1C at Week 24

Hemoglobin A1C (A1C) is measured as percent. Thus this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent. (NCT00106704)
Timeframe: Baseline and 24 Weeks

InterventionPercent (Least Squares Mean)
Sitagliptin-0.45
Placebo/ Pioglitazone0.28

Change From Baseline in FPG at Week 24

The change from baseline is the Week 24 Fasting Plasma Glucose (FPG) minus the Week 0 FPG. (NCT00106704)
Timeframe: Baseline and 24 Weeks

Interventionmg/dL (Least Squares Mean)
Sitagliptin-4.4
Placebo/ Pioglitazone15.7

Number of Subjects Experiencing Any of the Composite Endpoint A Cardiovascular Events

Due to low event rates, number of subjects experiencing any of the composite endpoint A cardiovascular events is being reported instead of time to first occurrence. Endpoint A conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks

InterventionParticipants (Number)
Pioglitazone QD5
Glimepiride QD6

Number of Subjects Experiencing Any of the Composite Endpoint B Cardiovascular Events

Due to low event rates, number of subjects experiencing any of the composite endpoint B cardiovascular events is being reported instead of time to first occurrence. Endpoint B conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks

InterventionParticipants (Number)
Pioglitazone QD40
Glimepiride QD41

Number of Subjects Experiencing Any of the Composite Endpoint C Cardiovascular Events

Due to low event rates, number of subjects experiencing any of the composite endpoint C cardiovascular events is being reported instead of time to first occurrence. Endpoint C conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks

Interventionparticipants (Number)
Pioglitazone QD11
Glimepiride QD13

Nominal Change From Baseline in Normalized Total Atheroma Volume

The nominal change in normalized total atheroma volume as measured by the average of plaque areas for all slices of anatomically comparable segments of the target coronary artery multiplied by the mean number of matched slices in the population. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued. (NCT00225277)
Timeframe: Baseline and Final Visit (up to 72 weeks)

,
InterventionPercent volume (Least Squares Mean)
BaselineNominal Change from Baseline
Glimepiride QD217.619-1.480
Pioglitazone QD206.579-5.528

Nominal Change From Baseline in Percent Atheroma Volume

The nominal change from baseline in percent atheroma volume for all slices of anatomically comparable segments of the target coronary artery. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued. (NCT00225277)
Timeframe: Baseline and Final Visit (up to 72 weeks)

,
InterventionPercent volume (Least Squares Mean)
BaselineNominal Change from Baseline
Glimepiride QD40.0160.725
Pioglitazone QD40.592-0.161

Number of Cardiovascular Events as Adjudicated by the Clinical Endpoint Committee

The incidence of cardiovascular events and composite endpoints occurring within 30 days of last dose as adjudicated by the Clinical Endpoint Committee. Abbreviations: PCI: Percutaneous Coronary Intervention; CABG: Coronary Artery Bypass Graft; CHF: Congestive Heart Failure. (NCT00225277)
Timeframe: Up to 72 weeks

,
InterventionNumber of Events (Number)
Nonfatal Myocardial InfarctionNonfatal StrokeCoronary Revascularization: PCI/CABG counted onceCoronary Revascularization: PCICoronary Revascularization: CABGCarotid Endarterectomy/StentingHospitalization for Unstable AnginaCHF Hospitalization: new/exacerbated counted onceHospitalization for New CHFHospitalization for Exacerbated CHFNoncardiovascular MortalityCardiovascular MortalityComposite Endpoint AComposite Endpoint BComposite Endpoint C
Glimepiride QD4130282025231164113
Pioglitazone QD2029255144400354011

Comparison of Changes in Fasting Serum Glucose (FSG)With Pioglitazone and Metformin

Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug

,
Interventionmmol/l (Mean)
Baseline FSG3rd Month FSG
Metformin ( 002 Group)6.26.5
Pioglitazone (001 Group)6.95.4

Comparison of Changes in Fasting Serum Insulin (FSI)With Pioglitazone and Metformin

Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug

,
InterventionμU/ml (Mean)
Baseline FSI3rd month FSI
Metformin ( 002 Group)13.013.9
Pioglitazone (001 Group)16.212.3

Comparison of Changes in Glycosylated Hemoglobin (HbA1c)With Pioglitazone and Metformin

Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug

,
Interventionpercentage (Mean)
Baseline HbA1c3rd month HbA1c
Metformin ( 002 Group)7.87.0
Pioglitazone (001 Group)7.36.7

Comparison of Changes in HOMA Percent B and HOMA Percent S With Pioglitazone and Metformin

"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug

,
Interventionpercentage (Mean)
Baseline HOMA percent beta cells function3rd month HOMA percent beta cells functionBaseline HOMA percent sensitivity3rd month HOMA percent sensitivity
Metformin ( 002 Group)109.3116.076.267.2
Pioglitazone (001 Group)118.9132.351.169.3

Comparison of Changes in Insulin Levels (HOMA IR,QUICKI) With Pioglitazone and Metformin

"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug

,
InterventionScore on a scale ( SI unit) (Mean)
Baseline QUICKI3rd month QUICKIBaseline HOMA IR3rd month HOMA IR
Metformin ( 002 Group)0.570.543.74.3
Pioglitazone (001 Group)0.520.595.12.9

Comparison of Changes in Lipid Profiles With Pioglitazone and Metformin

"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug

,
Interventionmg/dl (Mean)
Baseline TC3rd month TCBaseline TG3rd month TGBaseline HDL3rd month HDLBaseline LDL3rd month LDL
Metformin (002 Group)193.0177.0166.0175.034.434.7125.6112.0
Pioglitazone (001 Group)182.01781831953333.2112.8105.5

Reviews

68 reviews available for glimepiride and Diabetes Mellitus, Adult-Onset

ArticleYear
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
    Journal of medicinal chemistry, 2009, Apr-09, Volume: 52, Issue:7

    Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Glucose;

2009
Clinical Evidence and Practice-Based Guidelines on the Utility of Basal Insulin Combined Oral Therapy (Metformin and Glimepiride) in the Current Era.
    Current diabetes reviews, 2023, Volume: 19, Issue:8

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglyce

2023
Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride.
    Diabetes care, 2018, Volume: 41, Issue:8

    Topics: Adult; Aged; Benzhydryl Compounds; Bone Density; Clinical Trials, Phase I as Topic; Clinical Trials,

2018
Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.
    Journal of cellular physiology, 2019, Volume: 234, Issue:3

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Exenatide; Female; Glyburide; Humans; M

2019
Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes.
    Expert review of endocrinology & metabolism, 2019, Volume: 14, Issue:2

    Topics: Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug C

2019
Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:8

    Topics: Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopat

2013
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison beween canagliflozin and glimepiride].
    Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139 Suppl 2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Canagliflozin; Clinical Trials, Phase III

2014
Mortality risk among sulfonylureas: a systematic review and network meta-analysis.
    The lancet. Diabetes & endocrinology, 2015, Volume: 3, Issue:1

    Topics: Aged; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Female; Glipizide; Humans;

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
    Diabetes care, 2015, Volume: 38, Issue:6

    Topics: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liraglut

2015
Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis.
    International journal of clinical practice, 2015, Volume: 69, Issue:3

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Humans;

2015
[Sulfonylureas in today's blood glucose lowering therapy. New data on advantages and potential barriers of an "old" antidiabetic group].
    Orvosi hetilap, 2015, Mar-29, Volume: 156, Issue:13

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gliclazide; Humans; Hu

2015
Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.
    Journal of diabetes investigation, 2016, Volume: 7 Suppl 1

    Topics: Animals; Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like

2016
Updates on Managing Type 2 Diabetes Mellitus with Natural Products: Towards Antidiabetic Drug Development.
    Current medicinal chemistry, 2018, Volume: 25, Issue:39

    Topics: Biological Products; Diabetes Mellitus, Type 2; Drug Discovery; Gliclazide; Glucose Transporter Type

2018
Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    The Cochrane database of systematic reviews, 2016, Oct-17, Volume: 10

    Topics: Adult; Benzamides; Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2;

2016
Translating science into clinical practice: focus on vildagliptin in combination with metformin.
    Diabetes, obesity & metabolism, 2009, Volume: 11 Suppl 2

    Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination

2009
Ethnic origin is unrelated to autoimmunity and residual pancreatic function in 471 youth with clinically diagnosed type 2 diabetes.
    Pediatric diabetes, 2009, Volume: 10, Issue:4

    Topics: Administration, Oral; Adolescent; Algorithms; Autoimmunity; Child; Diabetes Mellitus, Type 2; Drug C

2009
The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
    Trends in cardiovascular medicine, 2009, Volume: 19, Issue:3

    Topics: Carotid Arteries; Chicago; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Human

2009
The role of glimepiride in the treatment of type 2 diabetes mellitus.
    Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:2

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylurea Compounds

2010
Liraglutide. Type 2 diabetes: more prudent to continue using exenatide.
    Prescrire international, 2010, Volume: 19, Issue:107

    Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Hu

2010
Optimizing outcomes for GLP-1 agonists.
    The Journal of the American Osteopathic Association, 2011, Volume: 111, Issue:2 Suppl 1

    Topics: Algorithms; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide

2011
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:2

    Topics: Animals; ATP-Binding Cassette Transporters; Carbamates; Cardiovascular Diseases; Cricetinae; Cyclohe

2012
[Incretin-based therapy for treating patients with type 2 diabetes].
    Orvosi hetilap, 2011, Nov-27, Volume: 152, Issue:48

    Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibito

2011
The design of the liraglutide clinical trial programme.
    Diabetes, obesity & metabolism, 2012, Volume: 14 Suppl 2

    Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combina

2012
[PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 9

    Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Plaqu

2011
Management of diabetes and pancreatic cancer.
    Oncology nursing forum, 2012, Volume: 39, Issue:5

    Topics: Adenocarcinoma; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2012
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type

2013
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type

2013
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type

2013
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type

2013
Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected].
    Vascular health and risk management, 2012, Volume: 8

    Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medi

2012
[Liraglutide: new results in the treatment of type 2 diabetes mellitus].
    Drugs of today (Barcelona, Spain : 1998), 2012, Volume: 48 Suppl B

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combinatio

2012
[Glimepiride].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 9

    Topics: Adenosine Triphosphate; Animals; ATP-Binding Cassette Transporters; Clinical Trials as Topic; Diabet

2002
[Combination therapy with insulin and sulfonylurea].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 9

    Topics: Adult; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Human

2002
[Progress in studies on antidiabetic agents].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2001, Volume: 36, Issue:9

    Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insuli

2001
[Sulfonylurea receptors and their interaction with glimepiride].
    Likars'ka sprava, 2003, Issue:2

    Topics: ATP-Binding Cassette Transporters; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Ag

2003
[Glimepiride--an oral antidiabetic agent].
    Medicinski arhiv, 2003, Volume: 57, Issue:2

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylurea Compounds

2003
Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience.
    Clinical therapeutics, 2003, Volume: 25, Issue:3

    Topics: Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relat

2003
Long-acting sulfonylureas -- long-acting hypoglycaemia.
    The Medical journal of Australia, 2004, Jan-19, Volume: 180, Issue:2

    Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Drug Monitoring; Fatal Outcome; F

2004
[Glimepiride in daily practice].
    Przeglad lekarski, 2003, Volume: 60, Issue:6

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylurea Compounds

2003
Timely initiation of basal insulin.
    The American journal of medicine, 2004, Feb-02, Volume: 116 Suppl 3A

    Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination

2004
Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride.
    Pharmacotherapy, 2004, Volume: 24, Issue:5

    Topics: Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Ag

2004
[Therapies for newly-onset diabetic patients].
    Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 2

    Topics: Acarbose; Cyclohexanes; Diabetes Mellitus, Type 2; Diet Therapy; Enzyme Inhibitors; Exercise Therapy

2005
[Retrolective study design -- a new tool of evidence-based medicine].
    Deutsche medizinische Wochenschrift (1946), 2005, Jul-08, Volume: 130 Suppl 2

    Topics: Blood Glucose; Blood Glucose Self-Monitoring; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2

2005
Insulin secretagogues: who, what, when, and how?
    Current diabetes reports, 2005, Volume: 5, Issue:5

    Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypogly

2005
Sulphonylureas in the management of type 2 diabetes during the fasting month of Ramadan.
    Journal of the Indian Medical Association, 2005, Volume: 103, Issue:8

    Topics: Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Fasting; Holidays; Humans; Hypoglycemia; Hypoglyce

2005
[Knack of treatment with oral hypoglycemic drugs in the elderly].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:1

    Topics: Aged; Biguanides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glyburide; Humans; Hypoglyce

2006
Are sulfonylureas passé?
    Current diabetes reports, 2006, Volume: 6, Issue:5

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylurea Compounds; Weight Gain

2006
Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination.
    Vascular health and risk management, 2007, Volume: 3, Issue:2

    Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug

2007
Pioglitazone plus glimepiride: a promising alternative in metabolic control.
    International journal of clinical practice. Supplement, 2007, Issue:153

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Lipids; Pa

2007
Pioglitazone hydrochloride/glimepiride.
    Drugs of today (Barcelona, Spain : 1998), 2007, Volume: 43, Issue:7

    Topics: Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Pioglitazone; Sulfonylure

2007
A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes.
    Vascular health and risk management, 2007, Volume: 3, Issue:5

    Topics: Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combinati

2007
Clinical profile of glimepiride.
    Diabetes research and clinical practice, 1995, Volume: 28 Suppl

    Topics: Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Controlled C

1995
Clinical profile of the novel sulphonylurea glimepiride.
    Diabetes research and clinical practice, 1996, Volume: 31 Suppl

    Topics: Blood Glucose; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trial

1996
An overview of the safety and tolerance of glimepiride.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1996, Volume: 28, Issue:9

    Topics: Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic A

1996
Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1996, Volume: 28, Issue:9

    Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Sulfonyl

1996
Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1996, Volume: 28, Issue:9

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney Di

1996
Cardiovascular effects of sulphonylurea derivatives.
    Diabetologia, 1997, Volume: 40 Suppl 2

    Topics: Adenosine Triphosphate; Animals; Cardiovascular System; Diabetes Mellitus, Type 2; Glyburide; Humans

1997
[Clinical efficacy of glimepiride].
    Nihon rinsho. Japanese journal of clinical medicine, 1997, Volume: 55 Suppl

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Humans; Hypoglycemic Agents; Insuli

1997
Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
    Drugs, 1998, Volume: 55, Issue:4

    Topics: Blood Glucose; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relatio

1998
The newly developed sulfonylurea glimepiride: a new ingredient, an old recipe.
    The Netherlands journal of medicine, 1998, Volume: 52, Issue:5

    Topics: Diabetes Mellitus, Type 2; Drug Evaluation; Humans; Hypoglycemic Agents; Insulin; Safety; Sulfonylur

1998
Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus.
    The Annals of pharmacotherapy, 1998, Volume: 32, Issue:10

    Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylurea Compo

1998
Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus.
    The Annals of pharmacotherapy, 1998, Volume: 32, Issue:10

    Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylurea Compo

1998
Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus.
    The Annals of pharmacotherapy, 1998, Volume: 32, Issue:10

    Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylurea Compo

1998
Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus.
    The Annals of pharmacotherapy, 1998, Volume: 32, Issue:10

    Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylurea Compo

1998
Type 2 diabetes: glycemic targets and oral therapies for older patients.
    Geriatrics, 1998, Volume: 53, Issue:11

    Topics: 1-Deoxynojirimycin; Acarbose; Age Factors; Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type

1998
[Sulfonylurea drug--a new sulfonylurea drug for type 2 diabetes].
    Nihon rinsho. Japanese journal of clinical medicine, 1999, Volume: 57, Issue:3

    Topics: Diabetes Mellitus, Type 2; Hypoglycemic Agents; Sulfonylurea Compounds

1999
[Present status in the treatment of type 2 diabetes mellitus. Insulin-secreting agents].
    La Revue de medecine interne, 1999, Volume: 20 Suppl 3

    Topics: Adenosine Triphosphate; Administration, Oral; Benzamides; Binding Sites; Diabetes Mellitus, Type 2;

1999
Treatment of diabetes mellitus: implications of the use of oral agents.
    American heart journal, 1999, Volume: 138, Issue:5 Pt 1

    Topics: Acarbose; Administration, Oral; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; G

1999
[Metformin-induced lactic acidosis].
    Deutsche medizinische Wochenschrift (1946), 2000, Mar-03, Volume: 125, Issue:9

    Topics: Acidosis, Lactic; Acute Disease; Coma; Combined Modality Therapy; Contraindications; Diabetes Mellit

2000
New agents for Type 2 diabetes.
    Bailliere's best practice & research. Clinical endocrinology & metabolism, 1999, Volume: 13, Issue:2

    Topics: Anti-Obesity Agents; Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglyce

1999
Combining sulfonylureas and other oral agents.
    The American journal of medicine, 2000, Apr-17, Volume: 108 Suppl 6a

    Topics: Acarbose; Administration, Oral; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, D

2000
[Sulphonylurea derivatives and the cardiovascular system].
    Przeglad lekarski, 2000, Volume: 57 Suppl 4

    Topics: Animals; Cardiovascular System; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; P

2000
Clinical review of glimepiride.
    Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:4

    Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents;

2001
[Glimepiride (Amaryl): a review of its pharmacological and clinical profile].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2001, Volume: 118, Issue:1

    Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin;

2001

Trials

283 trials available for glimepiride and Diabetes Mellitus, Adult-Onset

ArticleYear
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
    Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:1

    Topics: Adamantane; Adipose Tissue; Adolescent; Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipe

2022
Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial.
    Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:1

    Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Pept

2022
Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
    Cardiovascular diabetology, 2021, 12-17, Volume: 20, Issue:1

    Topics: Aged; Biomarkers; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Double-Blind Meth

2021
Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
    Cardiovascular diabetology, 2021, 12-17, Volume: 20, Issue:1

    Topics: Aged; Biomarkers; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Double-Blind Meth

2021
Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
    Cardiovascular diabetology, 2021, 12-17, Volume: 20, Issue:1

    Topics: Aged; Biomarkers; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Double-Blind Meth

2021
Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
    Cardiovascular diabetology, 2021, 12-17, Volume: 20, Issue:1

    Topics: Aged; Biomarkers; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Double-Blind Meth

2021
Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study.
    PloS one, 2022, Volume: 17, Issue:2

    Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Endothelium; Fema

2022
Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study.
    Diabetes & metabolism journal, 2022, Volume: 46, Issue:5

    Topics: Autoimmune Diseases; Blood Glucose; Blood Glucose Self-Monitoring; Cholesterol; Diabetes Mellitus, T

2022
Effects of 26 weeks of treatment with empagliflozin versus glimepiride on the myocardial glucose metabolic rate in patients with type 2 diabetes: The randomized, open-label, crossover, active-comparator FIORE trial.
    Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:12

    Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fluorodeoxyglucose F18; Glucose; Humans; Sodium-Glu

2022
Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial.
    Diabetes care, 2022, 09-01, Volume: 45, Issue:9

    Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fibrosis; Glucosides; Humans; Inflammation; Liver;

2022
Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial.
    Journal of diabetes investigation, 2022, Volume: 13, Issue:12

    Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic A

2022
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
    The New England journal of medicine, 2022, 09-22, Volume: 387, Issue:12

    Topics: Albuminuria; Blood Glucose; Cardiovascular Diseases; Comparative Effectiveness Research; Diabetes Co

2022
Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
    The New England journal of medicine, 2022, 09-22, Volume: 387, Issue:12

    Topics: Blood Glucose; Comparative Effectiveness Research; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase I

2022
Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial.
    Journal of cardiology, 2023, Volume: 81, Issue:6

    Topics: Biomarkers; Canagliflozin; Diabetes Mellitus, Type 2; Heart Failure; Humans; Natriuretic Peptide, Br

2023
Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial.
    Journal of cardiology, 2023, Volume: 81, Issue:6

    Topics: Biomarkers; Canagliflozin; Diabetes Mellitus, Type 2; Heart Failure; Humans; Natriuretic Peptide, Br

2023
Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial.
    Journal of cardiology, 2023, Volume: 81, Issue:6

    Topics: Biomarkers; Canagliflozin; Diabetes Mellitus, Type 2; Heart Failure; Humans; Natriuretic Peptide, Br

2023
Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial.
    Journal of cardiology, 2023, Volume: 81, Issue:6

    Topics: Biomarkers; Canagliflozin; Diabetes Mellitus, Type 2; Heart Failure; Humans; Natriuretic Peptide, Br

2023
Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study.
    Nutrients, 2023, Jan-03, Volume: 15, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gastrointestinal Microbiome; Gl

2023
Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial.
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:6

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; G

2023
Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi-heart study.
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:8

    Topics: Aged; Diabetes Mellitus, Type 2; Echocardiography; Female; Heart; Humans; Hypoglycemic Agents; Male;

2023
Relationship Between Canagliflozin, Sodium Glucose Cotransporter 2 Inhibitor, and Hematopoietic Effects in Patients With Diabetes and Mild Heart Failure: Results From the CANDLE Trial.
    Journal of cardiovascular pharmacology, 2023, 07-01, Volume: 82, Issue:1

    Topics: Canagliflozin; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic A

2023
Comparative study of Dapagliflozin versus Glimepiride effect on insulin regulated aminopeptidase (IRAP) and interleukin-34 (IL-34) in patient with type 2 diabetes mellitus.
    Scientific reports, 2023, 04-18, Volume: 13, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; In

2023
Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
    JAMA internal medicine, 2023, 07-01, Volume: 183, Issue:7

    Topics: Adult; Albuminuria; Diabetes Mellitus, Type 2; Disease Progression; Female; Glomerular Filtration Ra

2023
Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
    Diabetes & metabolism journal, 2023, Volume: 47, Issue:5

    Topics: Diabetes Mellitus, Type 2; Glucose; Humans; Liraglutide; MicroRNAs

2023
The effects of early short-term insulin treatment vs. glimepiride on beta cell function in newly diagnosed type 2 diabetes with HbA1c above 9.
    Turkish journal of medical sciences, 2023, Volume: 53, Issue:2

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hy

2023
Effect of coadministration of omega-3 fatty acids with glimepiride on glycemic control, lipid profile, irisin, and sirtuin-1 in type 2 diabetes mellitus patients: a randomized controlled trial.
    BMC endocrine disorders, 2023, Nov-25, Volume: 23, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Omega-3; Fibronectins; G

2023
Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
    Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:7

    Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double

2020
Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB).
    Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:9

    Topics: Administration, Oral; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhib

2020
Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
    Journal of diabetes investigation, 2020, Volume: 11, Issue:6

    Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Fe

2020
Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial.
    Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:10

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases

2020
Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs.
    Journal of endocrinological investigation, 2021, Volume: 44, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antimalarials; Biomarkers; Diabetes Mellitus, Type 2;

2021
Evaluation of Bioequivalency and Pharmacokinetic Parameters for Two Formulations of Glimepiride 1-mg in Chinese Subjects.
    Drug design, development and therapy, 2020, Volume: 14

    Topics: Adolescent; Adult; Asian People; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relati

2020
Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial.
    Diabetes care, 2020, Volume: 43, Issue:11

    Topics: Adult; Aged; Chemokine CXCL12; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptida

2020
Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease.
    Diabetes research and clinical practice, 2020, Volume: 170

    Topics: Adiponectin; Atherosclerosis; Biomarkers; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus,

2020
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
    Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipep

2021
Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study.
    Diabetologia, 2021, Volume: 64, Issue:6

    Topics: Aged; Blood Glucose; Cognition; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypo

2021
Effect of Dosage Reduction of Hypoglycemic Multidrug Regimens on the Incidences of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramaḍān: A Randomized Controlled Trial.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycemic

2021
A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Current medical research and opinion, 2017, Volume: 33, Issue:10

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Heterocyclic Com

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
    Diabetes research and clinical practice, 2017, Volume: 131

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-L

2017
The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:12

    Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dinoprost; Drug Therapy, Combination; Female;

2017
A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.
    BMC endocrine disorders, 2017, Nov-06, Volume: 17, Issue:1

    Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fema

2017
Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:5

    Topics: Adult; Diabetes Mellitus, Type 2; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Foll

2018
Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus.
    BMC neurology, 2018, Jan-15, Volume: 18, Issue:1

    Topics: Aged; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypogly

2018
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.
    Metabolism: clinical and experimental, 2018, Volume: 85

    Topics: Adiponectin; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Canagliflozin; Diabetes Mellitus,

2018
Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.
    Drug safety, 2018, Volume: 41, Issue:6

    Topics: Adult; Aged; Alanine Transaminase; Benzofurans; Chemical and Drug Induced Liver Injury; Clinical Tri

2018
Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.
    Journal of diabetes, 2018, Volume: 10, Issue:8

    Topics: Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV I

2018
Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:9

    Topics: Aged; Asia, Eastern; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon

2018
Comparison of Adherence to Glimepiride/Metformin Sustained Release Once-daily Versus Glimepiride/Metformin Immediate Release BID Fixed-combination Therapy Using the Medication Event Monitoring System in Patients With Type 2 Diabetes.
    Clinical therapeutics, 2018, Volume: 40, Issue:5

    Topics: Aged; Body Mass Index; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Female; Glycated Hemo

2018
Pharmacoeconomic evaluation of glimepiride combined with other drugs in the treatment of diabetes.
    Pakistan journal of pharmaceutical sciences, 2018, Volume: 31, Issue:3(Special)

    Topics: Acarbose; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combin

2018
Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects.
    Clinical pharmacology in drug development, 2019, Volume: 8, Issue:3

    Topics: Adolescent; Adult; Bridged Bicyclo Compounds, Heterocyclic; Cross-Over Studies; Diabetes Mellitus, T

2019
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:11

    Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides;

2018
Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:12

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug The

2018
Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial.
    BMJ open, 2018, 10-03, Volume: 8, Issue:10

    Topics: Blood Glucose; Blood Glucose Self-Monitoring; Cross-Over Studies; Denmark; Diabetes Mellitus, Type 2

2018
Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:3

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Equi

2019
Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:4

    Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Female;

2019
Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:4

    Topics: Aged; Blood Glucose; Bone Density; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type

2019
Long-term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study.
    Acta diabetologica, 2019, Volume: 56, Issue:5

    Topics: Aged; Apolipoprotein A-I; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glycat

2019
Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post-hoc analyses of a randomized, double-blind, phase III study.
    Journal of diabetes investigation, 2020, Volume: 11, Issue:1

    Topics: Aged; Asian People; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind

2020
Sitagliptin improves diastolic cardiac function but not cardiorespiratory fitness in adults with type 2 diabetes.
    Journal of diabetes and its complications, 2019, Volume: 33, Issue:8

    Topics: Aged; Blood Glucose; Cardiorespiratory Fitness; Diabetes Mellitus, Type 2; Diastole; Dipeptidyl-Pept

2019
Incident Hepatocellular Carcinoma Risk in Patients Treated with a Sulfonylurea: A Nationwide, Nested, Case-Control Study.
    Scientific reports, 2019, 06-12, Volume: 9, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Glicla

2019
The differential influence of glimepiride and glibenclamide on insulin resistance and adiponectin levels in patients with type 2 diabetes.
    Endocrine journal, 2019, Oct-28, Volume: 66, Issue:10

    Topics: Adiponectin; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agent

2019
Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients.
    The Journal of the Association of Physicians of India, 2018, Volume: 66, Issue:8

    Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin

2018
A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy.
    Diabetes research and clinical practice, 2019, Volume: 155

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Hu

2019
Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus.
    Diabetes technology & therapeutics, 2013, Volume: 15, Issue:4

    Topics: Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug

2013
Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 years.
    International journal of clinical practice, 2013, Volume: 67, Issue:4

    Topics: Analysis of Variance; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule;

2013
[Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
    Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138 Suppl 1

    Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Diabetes Me

2013
Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study.
    Cardiovascular diabetology, 2013, Apr-08, Volume: 12

    Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhi

2013
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:10

    Topics: Adiponectin; Blood Glucose; Body Mass Index; C-Reactive Protein; Cyclohexanes; Diabetes Mellitus, Ty

2013
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:10

    Topics: Adiponectin; Blood Glucose; Body Mass Index; C-Reactive Protein; Cyclohexanes; Diabetes Mellitus, Ty

2013
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:10

    Topics: Adiponectin; Blood Glucose; Body Mass Index; C-Reactive Protein; Cyclohexanes; Diabetes Mellitus, Ty

2013
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:10

    Topics: Adiponectin; Blood Glucose; Body Mass Index; C-Reactive Protein; Cyclohexanes; Diabetes Mellitus, Ty

2013
Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical tri
    Diabetologia, 2013, Volume: 56, Issue:7

    Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glycated Hemogl

2013
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).
    Diabetes care, 2013, Volume: 36, Issue:8

    Topics: Adult; Blood Glucose; Comparative Effectiveness Research; Cost-Benefit Analysis; Diabetes Mellitus,

2013
Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes.
    Rejuvenation research, 2013, Volume: 16, Issue:5

    Topics: Aged; Aged, 80 and over; Arginine; Diabetes Mellitus, Type 2; Female; Fibronectins; Glucose Intolera

2013
Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:12

    Topics: Adamantane; Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitu

2013
Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:12

    Topics: Adamantane; Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitu

2013
Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:12

    Topics: Adamantane; Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitu

2013
Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:12

    Topics: Adamantane; Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitu

2013
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
    Lancet (London, England), 2013, Sep-14, Volume: 382, Issue:9896

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Canagliflozin; Diabetes Mellitus,

2013
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
    Lancet (London, England), 2013, Sep-14, Volume: 382, Issue:9896

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Canagliflozin; Diabetes Mellitus,

2013
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
    Lancet (London, England), 2013, Sep-14, Volume: 382, Issue:9896

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Canagliflozin; Diabetes Mellitus,

2013
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
    Lancet (London, England), 2013, Sep-14, Volume: 382, Issue:9896

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Canagliflozin; Diabetes Mellitus,

2013
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
    Cardiovascular diabetology, 2013, Sep-05, Volume: 12

    Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Pressure; Body Mass Index; Clinical Protocols; Diabete

2013
Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:11

    Topics: Administration, Oral; Aged; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglu

2013
Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:11

    Topics: Administration, Oral; Aged; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglu

2013
Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:11

    Topics: Administration, Oral; Aged; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglu

2013
Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:11

    Topics: Administration, Oral; Aged; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglu

2013
Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedu

2014
Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:5

    Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibit

2014
Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:5

    Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibit

2014
Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:5

    Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibit

2014
Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:5

    Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibit

2014
Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:5

    Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibit

2014
Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:5

    Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibit

2014
Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:5

    Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibit

2014
Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:5

    Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibit

2014
Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:5

    Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibit

2014
The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study.
    BMC research notes, 2013, Nov-11, Volume: 6

    Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Hypoglycemic Age

2013
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
    JACC. Cardiovascular imaging, 2013, Volume: 6, Issue:11

    Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease;

2013
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
    JACC. Cardiovascular imaging, 2013, Volume: 6, Issue:11

    Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease;

2013
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
    JACC. Cardiovascular imaging, 2013, Volume: 6, Issue:11

    Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease;

2013
Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
    JACC. Cardiovascular imaging, 2013, Volume: 6, Issue:11

    Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease;

2013
C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study.
    Diabetes care, 2014, Volume: 37, Issue:1

    Topics: Adult; Aged; Autoimmunity; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycat

2014
The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study.
    Acta diabetologica, 2014, Volume: 51, Issue:2

    Topics: Adolescent; Adult; Aged; Blood Glucose; C-Peptide; Chi-Square Distribution; Diabetes Mellitus, Type

2014
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-i
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:8

    Topics: 1-Deoxynojirimycin; Aged; alpha-Glucosidases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inh

2014
Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
    Diabetes/metabolism research and reviews, 2014, Volume: 30, Issue:7

    Topics: Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, C

2014
Adding glimepiride to insulin+metformin in type 2 diabetes of more than 10 years' duration--a randomised, double-blind, placebo-controlled, cross-over study.
    Diabetes research and clinical practice, 2014, Volume: 103, Issue:2

    Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therap

2014
Both glimepiride and high-dose metformin are important for sustained glucose lowering in Japanese type 2 diabetes patients on glimepiride-sitagliptin-metformin therapy: subanalysis of a single-center, open-label, randomized study.
    Diabetes technology & therapeutics, 2014, Volume: 16, Issue:7

    Topics: Administration, Oral; Aged; Aged, 80 and over; Asian People; Blood Glucose; Diabetes Mellitus, Type

2014
Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response

2014
Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
    Current medical research and opinion, 2014, Volume: 30, Issue:7

    Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2014
Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE).
    Atherosclerosis, 2014, Volume: 234, Issue:2

    Topics: Adult; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hy

2014
Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
    Journal of diabetes, 2015, Volume: 7, Issue:2

    Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Case-Control Studies; China;

2015
Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.
    Diabetic medicine : a journal of the British Diabetic Association, 2014, Volume: 31, Issue:12

    Topics: Adamantane; Adiponectin; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Chol

2014
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
    Metabolism: clinical and experimental, 2014, Volume: 63, Issue:7

    Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method

2014
HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
    Diabetes care, 2014, Volume: 37, Issue:8

    Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female

2014
Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.
    Diabetes care, 2014, Volume: 37, Issue:7

    Topics: Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fast

2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, D

2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, D

2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, D

2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, D

2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, D

2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, D

2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, D

2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, D

2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, D

2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, D

2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, D

2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, D

2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, D

2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, D

2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, D

2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, D

2014
Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:1

    Topics: Aged; Asia; Blood Glucose Self-Monitoring; Circadian Rhythm; Diabetes Mellitus, Type 2; Drug Dosage

2015
Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.
    Diabetes care, 2014, Volume: 37, Issue:9

    Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide 1; Gluc

2014
Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride.
    Endocrine journal, 2014, Volume: 61, Issue:12

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inh

2014
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
    Diabetes care, 2015, Volume: 38, Issue:3

    Topics: Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Ther

2015
Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:2

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; D

2015
Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind M

2015
Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial.
    Diabetes care, 2015, Volume: 38, Issue:2

    Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-

2015
Effect of ketotifen in obese patients with type 2 diabetes mellitus.
    Journal of diabetes and its complications, 2015, Volume: 29, Issue:3

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Huma

2015
Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION).
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:7

    Topics: Adamantane; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptid

2015
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).
    Diabetes & vascular disease research, 2015, Volume: 12, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Cardiovascular Diseases; Clinical Protoco

2015
Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:7

    Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Administration Schedule

2015
Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:8

    Topics: Aged; Benzofurans; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Doubl

2015
Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:8

    Topics: Aged; Benzofurans; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Doubl

2015
Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:8

    Topics: Aged; Benzofurans; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Doubl

2015
Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:8

    Topics: Aged; Benzofurans; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Doubl

2015
Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes.
    Diabetes research and clinical practice, 2015, Volume: 109, Issue:1

    Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Fatty

2015
Differences between Mitiglinide/Voglibose Fixed-dose Combination and Glimepiride in Modifying Low-density Lipoprotein Heterogeneity in Japanese Type-2 Diabetic Patients: A Pilot Study.
    Drug research, 2016, Volume: 66, Issue:2

    Topics: Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glycated He

2016
Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial.
    Drugs & aging, 2015, Volume: 32, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diet; D

2015
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).
    Diabetes care, 2015, Volume: 38, Issue:12

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastrointestinal Diseas

2015
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).
    Diabetes care, 2015, Volume: 38, Issue:12

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastrointestinal Diseas

2015
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).
    Diabetes care, 2015, Volume: 38, Issue:12

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastrointestinal Diseas

2015
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).
    Diabetes care, 2015, Volume: 38, Issue:12

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastrointestinal Diseas

2015
A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
    Drug research, 2016, Volume: 66, Issue:2

    Topics: 1-Deoxynojirimycin; Adult; Benzhydryl Compounds; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Inter

2016
Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
    Cardiovascular diabetology, 2015, Sep-04, Volume: 14

    Topics: Aged; Biomarkers; Blood Glucose; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Diabet

2015
Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus.
    Pakistan journal of pharmaceutical sciences, 2015, Volume: 28, Issue:5

    Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combin

2015
Open-label randomized non-inferiority trial of a fixed-dose combination of glimepiride and atorvastatin for the treatment of people whose Type 2 diabetes is uncontrolled on metformin.
    Diabetic medicine : a journal of the British Diabetic Association, 2016, Volume: 33, Issue:8

    Topics: Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Co

2016
Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes.
    Diabetes research and clinical practice, 2015, Volume: 110, Issue:3

    Topics: Aged; CD4-Positive T-Lymphocytes; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fem

2015
COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2016, Volume: 22, Issue:4

    Topics: Adult; Aged; Bone Density; Calcium; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fracture

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; D

2016
Effects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes.
    Endocrine journal, 2016, Volume: 63, Issue:3

    Topics: Aged; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combin

2016
Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:5

    Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Dr

2016
A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:5

    Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Resistance;

2016
[New attempt in a benefit evaluation].
    MMW Fortschritte der Medizin, 2015, Dec-14, Volume: 157, Issue:21-22

    Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination;

2015
Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
    Cardiovascular diabetology, 2016, Apr-04, Volume: 15

    Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin;

2016
Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.
    Journal of diabetes, 2017, Volume: 9, Issue:4

    Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diarrhea; Double-Blind Method; Drug Th

2017
Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients.
    Current vascular pharmacology, 2016, Volume: 14, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Biomarkers; Blood Glucose; Cholesterol; Diabet

2016
Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride.
    Journal of diabetes investigation, 2017, Volume: 8, Issue:2

    Topics: Adamantane; Cardiovascular Diseases; Chemokine CXCL12; Cross-Over Studies; Diabetes Mellitus, Type 2

2017
Hypoglycemia in Frail Elderly Patients With Type 2 Diabetes Mellitus Treated With Sulfonylurea.
    Journal of diabetes science and technology, 2017, Volume: 11, Issue:2

    Topics: Aged; Aged, 80 and over; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Female; Frail Eld

2017
A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1).
    PloS one, 2016, Volume: 11, Issue:10

    Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Antioxidants; Biomarkers; Blood Pressure; Body Mass Ind

2016
Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
    Clinical therapeutics, 2016, Volume: 38, Issue:12

    Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-

2016
Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study).
    Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:6

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated H

2017
A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
    Cardiovascular diabetology, 2017, 01-21, Volume: 16, Issue:1

    Topics: Aged; Biomarkers; Brachial Artery; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopath

2017
Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163, a marker for activated macrophage, in individuals with type 2 diabetes mellitus.
    Diabetes research and clinical practice, 2017, Volume: 126

    Topics: Aged; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Biomarkers; Blood Glucose; Diabetes M

2017
Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
    Science China. Life sciences, 2017, Volume: 60, Issue:3

    Topics: Acarbose; Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe

2017
Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial).
    Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:8

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aging; Blood Glucose Self-Monitoring; Diabetes

2017
Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride.
    Diabetes & vascular disease research, 2008, Volume: 5, Issue:3

    Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Ther

2008
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662

    Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1;

2009
Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease.
    Diabetes & vascular disease research, 2008, Volume: 5, Issue:4

    Topics: Adiponectin; Aged; C-Reactive Protein; Diabetes Mellitus, Type 2; Diastole; Drug Therapy, Combinatio

2008
Glucose control and vascular complications in veterans with type 2 diabetes.
    The New England journal of medicine, 2009, Jan-08, Volume: 360, Issue:2

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N

2009
Glucose control and vascular complications in veterans with type 2 diabetes.
    The New England journal of medicine, 2009, Jan-08, Volume: 360, Issue:2

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N

2009
Glucose control and vascular complications in veterans with type 2 diabetes.
    The New England journal of medicine, 2009, Jan-08, Volume: 360, Issue:2

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N

2009
Glucose control and vascular complications in veterans with type 2 diabetes.
    The New England journal of medicine, 2009, Jan-08, Volume: 360, Issue:2

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N

2009
Glucose control and vascular complications in veterans with type 2 diabetes.
    The New England journal of medicine, 2009, Jan-08, Volume: 360, Issue:2

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N

2009
Glucose control and vascular complications in veterans with type 2 diabetes.
    The New England journal of medicine, 2009, Jan-08, Volume: 360, Issue:2

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N

2009
Glucose control and vascular complications in veterans with type 2 diabetes.
    The New England journal of medicine, 2009, Jan-08, Volume: 360, Issue:2

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N

2009
Glucose control and vascular complications in veterans with type 2 diabetes.
    The New England journal of medicine, 2009, Jan-08, Volume: 360, Issue:2

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N

2009
Glucose control and vascular complications in veterans with type 2 diabetes.
    The New England journal of medicine, 2009, Jan-08, Volume: 360, Issue:2

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N

2009
Glucose control and vascular complications in veterans with type 2 diabetes.
    The New England journal of medicine, 2009, Jan-08, Volume: 360, Issue:2

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N

2009
Glucose control and vascular complications in veterans with type 2 diabetes.
    The New England journal of medicine, 2009, Jan-08, Volume: 360, Issue:2

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N

2009
Glucose control and vascular complications in veterans with type 2 diabetes.
    The New England journal of medicine, 2009, Jan-08, Volume: 360, Issue:2

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N

2009
Glucose control and vascular complications in veterans with type 2 diabetes.
    The New England journal of medicine, 2009, Jan-08, Volume: 360, Issue:2

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N

2009
Glucose control and vascular complications in veterans with type 2 diabetes.
    The New England journal of medicine, 2009, Jan-08, Volume: 360, Issue:2

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N

2009
Glucose control and vascular complications in veterans with type 2 diabetes.
    The New England journal of medicine, 2009, Jan-08, Volume: 360, Issue:2

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N

2009
Glucose control and vascular complications in veterans with type 2 diabetes.
    The New England journal of medicine, 2009, Jan-08, Volume: 360, Issue:2

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N

2009
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:2

    Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Adminis

2009
Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes.
    Atherosclerosis, 2009, Volume: 205, Issue:1

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Hypoglycemic

2009
Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes.
    Geriatrics & gerontology international, 2008, Volume: 8, Issue:4

    Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated H

2008
Glimepiride increases high-density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus.
    Metabolism: clinical and experimental, 2009, Volume: 58, Issue:2

    Topics: Adiponectin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Hum

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Cardiovascular diabetology, 2009, Feb-26, Volume: 8

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studie

2009
Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
    Circulation, 2009, Apr-21, Volume: 119, Issue:15

    Topics: Adenosine Triphosphate; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combi

2009
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Metabolism: clinical and experimental, 2009, Volume: 58, Issue:8

    Topics: Administration, Oral; Adult; Aged; Blood Glucose; Body Mass Index; Caloric Restriction; Diabetes Mel

2009
Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus.
    Singapore medical journal, 2009, Volume: 50, Issue:4

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe

2009
Evaluation of the repaglinide efficiency in comparison to the glimepiride in the type 2 diabetes patients poorly regulated by the metmorfine administration.
    Bratislavske lekarske listy, 2009, Volume: 110, Issue:6

    Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated He

2009
Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride.
    Diabetes research and clinical practice, 2009, Volume: 86, Issue:1

    Topics: Aged; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents;

2009
A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus.
    Pharmacotherapy, 2009, Volume: 29, Issue:11

    Topics: Blood Glucose; Blood Pressure; Cohort Studies; Computer Simulation; Diabetes Mellitus, Type 2; Dose-

2009
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Composition; Body Weight; Delayed-Action Preparatio

2009
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Composition; Body Weight; Delayed-Action Preparatio

2009
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Composition; Body Weight; Delayed-Action Preparatio

2009
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Composition; Body Weight; Delayed-Action Preparatio

2009
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Composition; Body Weight; Delayed-Action Preparatio

2009
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Composition; Body Weight; Delayed-Action Preparatio

2009
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Composition; Body Weight; Delayed-Action Preparatio

2009
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Composition; Body Weight; Delayed-Action Preparatio

2009
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Composition; Body Weight; Delayed-Action Preparatio

2009
Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial.
    Wiener klinische Wochenschrift, 2009, Volume: 121, Issue:23-24

    Topics: Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypoglycemic Agents;

2009
Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus.
    Diabetes research and clinical practice, 2010, Volume: 88, Issue:1

    Topics: Adult; Aged; Analysis of Variance; Blood Glucose; Carbamates; Chi-Square Distribution; Diabetes Mell

2010
Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
    Diabetes care, 2010, Volume: 33, Issue:4

    Topics: Adamantane; Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemic Agents; Metformin; Nitriles; P

2010
Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes.
    Diabetes care, 2010, Volume: 33, Issue:7

    Topics: Apolipoprotein B-100; Cholesterol; Cholesterol Ester Transfer Proteins; Diabetes Mellitus, Type 2; D

2010
Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
    Primary care diabetes, 2010, Volume: 4, Issue:2

    Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans;

2010
Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus.
    Clinical science (London, England : 1979), 2010, Jul-09, Volume: 119, Issue:8

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Erythrocyte Deformability; Female

2010
Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus.
    Diabetes research and clinical practice, 2010, Volume: 89, Issue:3

    Topics: Adamantane; Aged; Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Doubl

2010
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2010, Volume: 42, Issue:9

    Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema

2010
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2010, Volume: 42, Issue:9

    Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema

2010
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2010, Volume: 42, Issue:9

    Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema

2010
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2010, Volume: 42, Issue:9

    Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema

2010
Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study.
    Arteriosclerosis, thrombosis, and vascular biology, 2010, Volume: 30, Issue:9

    Topics: Aged; Calcinosis; Carotid Artery Diseases; Chi-Square Distribution; Coronary Artery Disease; Diabete

2010
Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
    Applied health economics and health policy, 2010, Volume: 8, Issue:4

    Topics: Canada; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycate

2010
Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:7

    Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin

2010
Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study.
    Diabetes technology & therapeutics, 2010, Volume: 12, Issue:8

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug

2010
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.
    Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:9

    Topics: Adamantane; Adolescent; Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Dr

2010
Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes.
    Clinical endocrinology, 2010, Volume: 73, Issue:6

    Topics: Adult; Albuminuria; Blood Glucose; Blood Pressure; Chemokine CCL2; Creatinine; Cytokines; Diabetes M

2010
Improvement of cardio-ankle vascular index by glimepiride in type 2 diabetic patients.
    International journal of clinical practice, 2010, Volume: 64, Issue:13

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Ankle; Deoxyguanosine; Diabetes Mellitus, Type 2; Diabetic Angiop

2010
Contribution of glimepiride to basal-prandial insulin therapy in patients with type 2 diabetes.
    Diabetes research and clinical practice, 2011, Volume: 91, Issue:2

    Topics: Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemo

2011
Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Blood Pressure; China; Diabetes Mellitus,

2011
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:2

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Co

2011
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:4

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like Pe

2011
Evaluation of efficacy and tolerability of glimepiride and metformin combination: a multicentric study in patients with type-2 diabetes mellitus, uncontrolled on monotherapy with sulfonylurea or metformin.
    American journal of therapeutics, 2013, Volume: 20, Issue:1

    Topics: Administration, Oral; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Admini

2013
Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.
    Current medical research and opinion, 2011, Volume: 27, Issue:5

    Topics: Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like

2011
PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
    Diabetes technology & therapeutics, 2011, Volume: 13, Issue:6

    Topics: Adiponectin; Aged; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL;

2011
Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II).
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:9

    Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glycated Hemoglobin;

2011
The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study.
    Journal of diabetes science and technology, 2011, Mar-01, Volume: 5, Issue:2

    Topics: Aged; Biomarkers; Blood Coagulation; Blood Platelets; Body Mass Index; Diabetes Mellitus, Type 2; Fe

2011
Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients.
    European journal of pharmacology, 2011, Volume: 666, Issue:1-3

    Topics: Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Femal

2011
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:10

    Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, C

2011
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:10

    Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, C

2011
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:10

    Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, C

2011
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:10

    Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, C

2011
Exenatide improves glycemic variability assessed by continuous glucose monitoring in subjects with type 2 diabetes.
    Diabetes technology & therapeutics, 2011, Volume: 13, Issue:12

    Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Exenatide; Female; Glycated

2011
Liraglutide narrows the range of circadian glycemic variations in Japanese type 2 diabetes patients and nearly flattens these variations in drug-naive type 2 diabetes patients: a continuous glucose monitoring-based study.
    Diabetes technology & therapeutics, 2011, Volume: 13, Issue:11

    Topics: Adult; Aged; Asian People; Blood Glucose Self-Monitoring; Circadian Rhythm; Diabetes Mellitus, Type

2011
Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes.
    Diabetes/metabolism research and reviews, 2012, Volume: 28, Issue:3

    Topics: Administration, Oral; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Homeostasis; Humans;

2012
Predictive characteristics of patients achieving glycaemic control with insulin after sulfonylurea failure.
    International journal of clinical practice, 2011, Volume: 65, Issue:10

    Topics: Administration, Oral; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glyca

2011
Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
    JACC. Cardiovascular imaging, 2011, Volume: 4, Issue:10

    Topics: Aged; Anti-Inflammatory Agents; Aortic Diseases; Aortography; Biomarkers; Blood Glucose; C-Reactive

2011
Effects of pioglitazone and metformin on vascular endothelial function in patients with type 2 diabetes treated with sulfonylureas.
    Diabetes & vascular disease research, 2012, Volume: 9, Issue:1

    Topics: Aged; Biomarkers; Brachial Artery; Chi-Square Distribution; Diabetes Mellitus, Type 2; Drug Therapy,

2012
Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes.
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:1

    Topics: Adiponectin; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans

2012
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.
    Lancet (London, England), 2012, Apr-14, Volume: 379, Issue:9824

    Topics: Adult; Aged; Aged, 80 and over; Benzofurans; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response

2012
Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
    Diabetes research and clinical practice, 2012, Volume: 97, Issue:2

    Topics: Adolescent; Adult; Aged; Appetite; Australia; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2;

2012
Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
    Diabetes research and clinical practice, 2012, Volume: 97, Issue:2

    Topics: Adolescent; Adult; Aged; Appetite; Australia; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2;

2012
Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
    Diabetes research and clinical practice, 2012, Volume: 97, Issue:2

    Topics: Adolescent; Adult; Aged; Appetite; Australia; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2;

2012
Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
    Diabetes research and clinical practice, 2012, Volume: 97, Issue:2

    Topics: Adolescent; Adult; Aged; Appetite; Australia; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2;

2012
No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:10

    Topics: Adolescent; Adult; Area Under Curve; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2;

2012
Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jun-16, Volume: 379, Issue:9833

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Blood Glucose; Diabetes Mellitus,

2012
[PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 9

    Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Plaqu

2011
Effects of frequency of follow-up on quality of life of type 2 diabetes patients on oral hypoglycemics.
    Diabetes technology & therapeutics, 2012, Volume: 14, Issue:9

    Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Diabetes Mellitus, Type 2; Drug Therapy, Co

2012
Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research.
    Diabetes & vascular disease research, 2013, Volume: 10, Issue:1

    Topics: Aged; Blood Flow Velocity; Brachial Artery; Diabetes Mellitus, Type 2; Drug Therapy, Combination; El

2013
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
    Lancet (London, England), 2012, Aug-04, Volume: 380, Issue:9840

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Bl

2012
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?
    Diabetes technology & therapeutics, 2012, Volume: 14, Issue:10

    Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Di

2012
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?
    Diabetes technology & therapeutics, 2012, Volume: 14, Issue:10

    Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Di

2012
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?
    Diabetes technology & therapeutics, 2012, Volume: 14, Issue:10

    Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Di

2012
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?
    Diabetes technology & therapeutics, 2012, Volume: 14, Issue:10

    Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Di

2012
Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    The Journal of the Association of Physicians of India, 2012, Volume: 60

    Topics: Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationsh

2012
Effect of pioglitazone on testosterone in eugonadal men with type 2 diabetes mellitus: a randomized double-blind placebo-controlled study.
    Clinical endocrinology, 2013, Volume: 78, Issue:3

    Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Me

2013
Metformin, but not glimepiride, improves carotid artery diameter and blood flow in patients with type 2 diabetes mellitus.
    Clinics (Sao Paulo, Brazil), 2012, Volume: 67, Issue:7

    Topics: Blood Glucose; Carotid Arteries; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Hypoglycemic Ag

2012
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Pep

2012
Usage pattern, glycemic improvement, hypoglycemia, and body mass index changes with sulfonylureas in real-life clinical practice: results from OBSTACLE Hypoglycemia Study.
    Diabetes technology & therapeutics, 2013, Volume: 15, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type

2013
A multicenter, phase III evaluation of the efficacy and safety of a new fixed-dose pioglitazone/glimepiride combination tablet in Japanese patients with type 2 diabetes.
    Diabetes technology & therapeutics, 2013, Volume: 15, Issue:2

    Topics: Asian People; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Diet; Dose-Response Relatio

2013
Efficacy and safety of glimepiride as initial treatment in Chinese patients with Type 2 diabetes mellitus.
    Current medical research and opinion, 2013, Volume: 29, Issue:3

    Topics: Adolescent; Adult; Aged; Blood Glucose; Body Weight; China; Diabetes Mellitus, Type 2; Female; Glyca

2013
Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes.
    International journal of clinical practice, 2013, Volume: 67, Issue:3

    Topics: Adult; Aged; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Met

2013
Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:6

    Topics: Adamantane; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhi

2013
Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes.
    Diabetes care, 2002, Volume: 25, Issue:9

    Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Glucose Clamp Technique;

2002
Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects.
    Diabetes care, 2003, Volume: 26, Issue:2

    Topics: Adiponectin; Aged; Diabetes Mellitus, Type 2; Dinoprost; Female; Humans; Hypoglycemic Agents; Insuli

2003
Amaryl (glimepiride) in patients with type 2 diabetes mellitus.
    Folia medica, 2002, Volume: 44, Issue:3

    Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male

2002
Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Clinical therapeutics, 2003, Volume: 25, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasti

2003
Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
    Clinical therapeutics, 2003, Volume: 25, Issue:2

    Topics: Blood Glucose; Blood Pressure; Carbamates; Diabetes Mellitus, Type 2; Double-Blind Method; Female; H

2003
Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
    Annals of internal medicine, 2003, Jun-17, Volume: 138, Issue:12

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glycated Hemog

2003
Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
    Annals of internal medicine, 2003, Jun-17, Volume: 138, Issue:12

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glycated Hemog

2003
Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
    Annals of internal medicine, 2003, Jun-17, Volume: 138, Issue:12

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glycated Hemog

2003
Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
    Annals of internal medicine, 2003, Jun-17, Volume: 138, Issue:12

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glycated Hemog

2003
Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study.
    British journal of clinical pharmacology, 2003, Volume: 55, Issue:6

    Topics: Aged; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind

2003
Effects of glimepiride on HbA(1c) and body weight in Type 2 diabetes: results of a 1.5-year follow-up study.
    Diabetes research and clinical practice, 2003, Volume: 61, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Fol

2003
Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure.
    Collegium antropologicum, 2003, Volume: 27, Issue:1

    Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fem

2003
Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study.
    Diabetologia, 2003, Volume: 46, Issue:12

    Topics: Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Cohort Studies; Diabetes Mellitus, Type 2;

2003
Hormonal counterregulation and consecutive glimepiride serum concentrations during severe hypoglycaemia associated with glimepiride therapy.
    European journal of clinical pharmacology, 2003, Volume: 59, Issue:10

    Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Hormones; Humans

2003
Glimepiride pharmacokinetics in obese versus non-obese diabetic patients.
    The Annals of pharmacotherapy, 2004, Volume: 38, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Aged; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female;

2004
Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone.
    Diabetes, nutrition & metabolism, 2003, Volume: 16, Issue:4

    Topics: Acarbose; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemog

2003
Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus.
    Clinical therapeutics, 2004, Volume: 26, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin

2004
Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study.
    Diabetes & metabolism, 2004, Volume: 30, Issue:1

    Topics: Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Carbamates; Cholesterol; Diabetes Mellitus, Type

2004
Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
    Clinical therapeutics, 2004, Volume: 26, Issue:5

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans;

2004
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Clinical therapeutics, 2004, Volume: 26, Issue:5

    Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Th

2004
GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients.
    European journal of clinical investigation, 2004, Volume: 34, Issue:8

    Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glycated Hemoglobin; Humans; Hyp

2004
Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin.
    Diabetes, nutrition & metabolism, 2004, Volume: 17, Issue:3

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Food; Glycated Hemoglobin; Homocyst

2004
Efficacy of glimepiride in type 2 diabetic patients treated with glibenclamide.
    Diabetes research and clinical practice, 2004, Volume: 66 Suppl 1

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglyc

2004
Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
    Clinical therapeutics, 2004, Volume: 26, Issue:11

    Topics: Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination;

2004
Addition of rosiglitazone to glimepirid and metformin combination therapy in type 2 diabetes.
    Endocrine journal, 2004, Volume: 51, Issue:6

    Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Cholesterol; Diabetes

2004
Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians.
    The Journal of the Association of Physicians of India, 2004, Volume: 52

    Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; India; Insulin; Insulin Resis

2004
Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
    Diabetes care, 2005, Volume: 28, Issue:2

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hy

2005
The efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during Ramadan.
    Diabetes care, 2005, Volume: 28, Issue:2

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans;

2005
Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
    Pharmacotherapy, 2005, Volume: 25, Issue:5

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Fi

2005
Efficacy of glimepiride in Japanese type 2 diabetic subjects.
    Diabetes research and clinical practice, 2005, Volume: 68, Issue:3

    Topics: Aged; Asian People; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fe

2005
A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.
    Diabetes research and clinical practice, 2005, Volume: 69, Issue:1

    Topics: Aged; Blood Pressure; Body Size; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combi

2005
Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance.
    Diabetes & metabolism, 2005, Volume: 31, Issue:2

    Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Administration Schedule

2005
Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.
    Journal of the American College of Cardiology, 2005, Jun-21, Volume: 45, Issue:12

    Topics: Acute-Phase Proteins; Aged; Arteriosclerosis; Biomarkers; Blood Coagulation Factors; Blood Glucose;

2005
Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes.
    Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22, Issue:8

    Topics: Aged; Asian People; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combina

2005
Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2005, Volume: 37, Issue:8

    Topics: Aged; Atherosclerosis; Biomarkers; Carotid Arteries; Diabetes Mellitus, Type 2; Female; Humans; Hypo

2005
Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.
    Diabetes & metabolism, 2005, Volume: 31, Issue:3 Pt 1

    Topics: Aged; Aged, 80 and over; Area Under Curve; Blood Glucose; Carbamates; Cardiovascular Diseases; Cross

2005
Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Clinical therapeutics, 2005, Volume: 27, Issue:9

    Topics: Analysis of Variance; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Dou

2005
Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride.
    Metabolism: clinical and experimental, 2006, Volume: 55, Issue:1

    Topics: Adiponectin; Aged; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Resp

2006
Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.
    Diabetes research and clinical practice, 2006, Volume: 72, Issue:2

    Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Type 2; Fema

2006
Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Clinical therapeutics, 2005, Volume: 27, Issue:10

    Topics: Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Meth

2005
Evaluation of efficacy and safety of fixed dose combination of glimepiride 2 mg pluspioglitazone 15 mg plus metformin SR 500 mg in the management of patients with type-2 diabetes mellitus.
    Journal of the Indian Medical Association, 2005, Volume: 103, Issue:8

    Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Metformin

2005
Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes.
    Diabetes research and clinical practice, 2006, Volume: 72, Issue:3

    Topics: Aged; Blood Glucose; Body Mass Index; Body Weight; Chemotherapy, Adjuvant; Diabetes Mellitus, Type 2

2006
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.
    Diabetes, obesity & metabolism, 2006, Volume: 8, Issue:2

    Topics: Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Glycated

2006
Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis.
    The journal of medical investigation : JMI, 2006, Volume: 53, Issue:1-2

    Topics: Adipocytes; Aged; Atherosclerosis; Cytokines; Diabetes Mellitus, Type 2; Female; Glyburide; Humans;

2006
Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2005, Volume: 28, Issue:11

    Topics: Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Fema

2005
Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2006, Volume: 38, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type

2006
Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Current medical research and opinion, 2006, Volume: 22, Issue:4

    Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypog

2006
An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan.
    The Medical journal of Malaysia, 2006, Volume: 61, Issue:1

    Topics: Adult; Aged; Blood Glucose; Carbamates; Ceremonial Behavior; Diabetes Mellitus, Type 2; Fasting; Fem

2006
Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.
    Archives of medical research, 2006, Volume: 37, Issue:4

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemia; I

2006
The switch from sulfonylurea to preprandial short- acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus.
    Diabetes technology & therapeutics, 2006, Volume: 8, Issue:3

    Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose Oxidase; Glycated Hemoglo

2006
Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled
    Clinical therapeutics, 2006, Volume: 28, Issue:5

    Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combin

2006
Glycaemic control without weight gain in insulin requiring type 2 diabetes: 1-year results of the GAME regimen.
    Diabetes, obesity & metabolism, 2006, Volume: 8, Issue:5

    Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; F

2006
Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients.
    Diabetes research and clinical practice, 2007, Volume: 76, Issue:1

    Topics: Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated

2007
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
    JAMA, 2006, Dec-06, Volume: 296, Issue:21

    Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Carotid Arteries; Diabetes Mellitus, Type 2

2006
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
    JAMA, 2006, Dec-06, Volume: 296, Issue:21

    Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Carotid Arteries; Diabetes Mellitus, Type 2

2006
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
    JAMA, 2006, Dec-06, Volume: 296, Issue:21

    Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Carotid Arteries; Diabetes Mellitus, Type 2

2006
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
    JAMA, 2006, Dec-06, Volume: 296, Issue:21

    Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Carotid Arteries; Diabetes Mellitus, Type 2

2006
Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2006, Volume: 114, Issue:9

    Topics: Aged; Biphasic Insulins; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relati

2006
Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Clinical endocrinology, 2007, Volume: 66, Issue:2

    Topics: Adiponectin; Analysis of Variance; Biomarkers; Blood Glucose; C-Reactive Protein; Diabetes Mellitus,

2007
Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
    Journal of the American Geriatrics Society, 2007, Volume: 55, Issue:2

    Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fem

2007
Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study.
    Diabetes care, 2007, Volume: 30, Issue:4

    Topics: Adolescent; Body Mass Index; Child; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans;

2007
Relaxin expression correlates significantly with serum changes in VEGF in response to antidiabetic treatment in male patients with type 2 diabetes mellitus.
    Clinical laboratory, 2007, Volume: 53, Issue:3-4

    Topics: Aged; Biomarkers; Cohort Studies; Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Hypoglyc

2007
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:5

    Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy

2007
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:5

    Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy

2007
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:5

    Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy

2007
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:5

    Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy

2007
Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once- versus twice-daily dosing.
    Endocrine journal, 2007, Volume: 54, Issue:4

    Topics: Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypog

2007
Relaxin expression correlates significantly with serum fibrinogen variation in response to antidiabetic treatment in women with type 2 diabetes mellitus.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2007, Volume: 23, Issue:6

    Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Fem

2007
Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes.
    Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:8

    Topics: Adiponectin; Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycat

2008
Efficacy of insulin glargine and glimepiride in controlling blood glucose of ethnic Japanese patients with type 2 diabetes mellitus.
    Diabetes research and clinical practice, 2008, Volume: 79, Issue:1

    Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy,

2008
Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot St
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2008, Volume: 116, Issue:1

    Topics: Aged; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemogl

2008
Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot st
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2007, Volume: 115, Issue:10

    Topics: Administration, Oral; Aged; Blood Glucose; Body Mass Index; Case-Control Studies; Diabetes Mellitus,

2007
Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes - a simulation with the Diabetes Mellitus Model (DMM).
    International journal of clinical pharmacology and therapeutics, 2007, Volume: 45, Issue:12

    Topics: Adult; Aged; Computer Simulation; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, C

2007
Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes.
    Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Res

2008
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
    Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:11

    Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Pept

2008
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
    JAMA, 2008, Apr-02, Volume: 299, Issue:13

    Topics: Aged; Atherosclerosis; Coronary Vessels; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hum

2008
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
    JAMA, 2008, Apr-02, Volume: 299, Issue:13

    Topics: Aged; Atherosclerosis; Coronary Vessels; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hum

2008
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
    JAMA, 2008, Apr-02, Volume: 299, Issue:13

    Topics: Aged; Atherosclerosis; Coronary Vessels; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hum

2008
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
    JAMA, 2008, Apr-02, Volume: 299, Issue:13

    Topics: Aged; Atherosclerosis; Coronary Vessels; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hum

2008
Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.
    Circulation, 2008, Apr-22, Volume: 117, Issue:16

    Topics: Aged; Carotid Arteries; Carotid Artery Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diseas

2008
Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide.
    Diabetes research and clinical practice, 1995, Volume: 28 Suppl

    Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Gliclazide; Glyca

1995
A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.
    Diabetes care, 1996, Volume: 19, Issue:8

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Fas

1996
Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.
    Diabetes care, 1996, Volume: 19, Issue:11

    Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedu

1996
Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1996, Volume: 28, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Femal

1996
Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1996, Volume: 28, Issue:9

    Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; G

1996
The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1996, Volume: 28, Issue:9

    Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose Clamp Technique; G

1996
The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1996, Volume: 28, Issue:9

    Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise; Fem

1996
Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.
    The Annals of pharmacotherapy, 1997, Volume: 31, Issue:6

    Topics: Adult; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind M

1997
Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    Diabetic medicine : a journal of the British Diabetic Association, 1997, Volume: 14, Issue:7

    Topics: Administration, Oral; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucagon; G

1997
Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.
    Diabetes care, 1998, Volume: 21, Issue:7

    Topics: Aged; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Diabetes Mell

1998
A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful.
    Journal of clinical pharmacology, 1998, Volume: 38, Issue:7

    Topics: Administration, Oral; Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet Therapy

1998
Appropriate timing of glimepiride administration in patients with type 2 diabetes millitus: a study in Mediterranean countries.
    Endocrine, 2000, Volume: 13, Issue:1

    Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Glyc

2000
[Evaluation of efficacy, safety and tolerance of glimepiride (Amaryl) in patients with type 2 diabetes].
    Przeglad lekarski, 2000, Volume: 57 Suppl 4

    Topics: Adult; Aged; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Hum

2000
[Clinical evaluation of glimepiride in treatment of type 2 diabetes. Results of a multicenter study].
    Polskie Archiwum Medycyny Wewnetrznej, 2000, Volume: 104, Issue:2

    Topics: Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Ag

2000
Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia.
    Diabetes care, 2001, Volume: 24, Issue:4

    Topics: Aged; Aged, 80 and over; Blood Pressure; Brachial Artery; Diabetes Mellitus, Type 2; Diet, Diabetic;

2001
Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients.
    Diabetic medicine : a journal of the British Diabetic Association, 2001, Volume: 18, Issue:10

    Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Th

2001
Predictors of response to glimepiride in patients with type 2 diabetes mellitus.
    Diabetes & metabolism, 2001, Volume: 27, Issue:5 Pt 1

    Topics: Adult; Aged; Apolipoproteins; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2;

2001
Glimepiride in type 2 diabetes mellitus Thai patients.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2001, Volume: 84, Issue:9

    Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administrati

2001
Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.
    Diabetic medicine : a journal of the British Diabetic Association, 2002, Volume: 19, Issue:2

    Topics: Acetylcholine; Adult; Aged; Blood Flow Velocity; Blood Pressure; Body Mass Index; Body Weight; C-Pep

2002
Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients.
    Diabetes care, 2002, Volume: 25, Issue:7

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Hu

2002

Other Studies

188 other studies available for glimepiride and Diabetes Mellitus, Adult-Onset

ArticleYear
Increased plasma drug concentration and decreased additional insulin secretion following oral administration of glimepiride in Spontaneously Diabetic Torii rats.
    Die Pharmazie, 2022, 01-03, Volume: 77, Issue:1

    Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Insulin Se

2022
Expanding arsenal against diabetes mellitus through nanoformulations loaded with glimepiride and simvastatin: A comparative study.
    Environmental science and pollution research international, 2022, Volume: 29, Issue:34

    Topics: Administration, Oral; Animals; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Dr

2022
Self-assembled di- and tripeptide gels for the passive entrapment and pH-responsive, sustained release of an antidiabetic drug, glimepiride.
    Biomaterials science, 2022, May-04, Volume: 10, Issue:9

    Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Gels; Humans; Hydrogen-Ion Concentration; Hy

2022
Glimepiride mitigates tauopathy and neuroinflammation in P301S transgenic mice: role of AKT/GSK3β signaling.
    Inflammopharmacology, 2022, Volume: 30, Issue:5

    Topics: Animals; Caspase 3; Diabetes Mellitus, Type 2; Disease Models, Animal; Glycogen Synthase Kinase 3 be

2022
Glimepiride pharmacokinetics in overdose.
    Clinical toxicology (Philadelphia, Pa.), 2022, Volume: 60, Issue:11

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylurea Compounds

2022
Emulating the GRADE trial using real world data: retrospective comparative effectiveness study.
    BMJ (Clinical research ed.), 2022, 10-03, Volume: 379

    Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Hum

2022
Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial.
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:2

    Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hyperinsulinism; H

2023
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
    Indian journal of public health, 2022, Volume: 66, Issue:Supplement

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H

2022
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
    Indian journal of public health, 2022, Volume: 66, Issue:Supplement

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H

2022
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
    Indian journal of public health, 2022, Volume: 66, Issue:Supplement

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H

2022
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
    Indian journal of public health, 2022, Volume: 66, Issue:Supplement

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H

2022
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
    Indian journal of public health, 2022, Volume: 66, Issue:Supplement

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H

2022
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
    Indian journal of public health, 2022, Volume: 66, Issue:Supplement

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H

2022
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
    Indian journal of public health, 2022, Volume: 66, Issue:Supplement

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H

2022
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
    Indian journal of public health, 2022, Volume: 66, Issue:Supplement

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H

2022
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
    Indian journal of public health, 2022, Volume: 66, Issue:Supplement

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H

2022
[In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve
    La Revue de medecine interne, 2023, Volume: 44, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combinat

2023
[In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve
    La Revue de medecine interne, 2023, Volume: 44, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combinat

2023
[In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve
    La Revue de medecine interne, 2023, Volume: 44, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combinat

2023
[In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve
    La Revue de medecine interne, 2023, Volume: 44, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combinat

2023
DPP-4 Inhibitor and Sulfonylurea Differentially Reverse Type 2 Diabetes-Induced Blood-Brain Barrier Leakage and Normalize Capillary Pericyte Coverage.
    Diabetes, 2023, 03-01, Volume: 72, Issue:3

    Topics: Animals; Blood-Brain Barrier; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Hypogly

2023
DPP-4 Inhibitor and Sulfonylurea Differentially Reverse Type 2 Diabetes-Induced Blood-Brain Barrier Leakage and Normalize Capillary Pericyte Coverage.
    Diabetes, 2023, 03-01, Volume: 72, Issue:3

    Topics: Animals; Blood-Brain Barrier; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Hypogly

2023
DPP-4 Inhibitor and Sulfonylurea Differentially Reverse Type 2 Diabetes-Induced Blood-Brain Barrier Leakage and Normalize Capillary Pericyte Coverage.
    Diabetes, 2023, 03-01, Volume: 72, Issue:3

    Topics: Animals; Blood-Brain Barrier; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Hypogly

2023
DPP-4 Inhibitor and Sulfonylurea Differentially Reverse Type 2 Diabetes-Induced Blood-Brain Barrier Leakage and Normalize Capillary Pericyte Coverage.
    Diabetes, 2023, 03-01, Volume: 72, Issue:3

    Topics: Animals; Blood-Brain Barrier; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Hypogly

2023
In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin.
    Annals of internal medicine, 2023, Volume: 176, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; In

2023
In type 2 diabetes, liraglutide reduced CV events at 5 y vs. glargine, glimepiride, or sitagliptin.
    Annals of internal medicine, 2023, Volume: 176, Issue:1

    Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Glargine;

2023
Glimepiride Prevents 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Induced Dopamine Neurons Degeneration Through Attenuation of Glia Activation and Oxidative Stress in Mice.
    Neurotoxicity research, 2023, Volume: 41, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Diabetes Mellitus, Type 2; Disease Models, An

2023
Analytical Method Capable of Quantifying Eight Nitrosamine Impurities from Five Different Commercially Available Metformin Formulations with Glipizide, Glibenclamide, Gliclazide, Evogliptin, and Glimepiride by Ultra High Performance Liquid Chromatography
    Journal of pharmaceutical sciences, 2023, Volume: 112, Issue:5

    Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Diabetes Mellitus, Type 2; Gliclazide;

2023
Assessment of empagliflozin add-on therapy to metformin and glimepiride in patients with inadequately controlled type-2 diabetes mellitus.
    Pakistan journal of pharmaceutical sciences, 2022, Volume: 35, Issue:6(Special)

    Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Follow-Up Studies; Glycated

2022
Glimepiride: an old antidiabetic medication with potential as a new cardiovascular therapeutic?
    European journal of preventive cardiology, 2023, 06-01, Volume: 30, Issue:8

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylurea Compounds

2023
Effects of different doses glimepiride intake on the pharmacokinetics of benzbromarone in rats.
    Pakistan journal of pharmaceutical sciences, 2023, Volume: 36, Issue:1

    Topics: Animals; Benzbromarone; Diabetes Mellitus, Type 2; Drug Interactions; Rats; Sulfonylurea Compounds;

2023
COMPARATIVE EFFECT OF INSULIN, GLIMEPIRIDE, AND METFORMIN ON INFLAMMATORY MARKERS IN TYPE 2 DIABETES MELLITUS.
    Georgian medical news, 2023, Issue:335

    Topics: Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Insulin; Metformin

2023
Genetic Variants Associated with Poor Responsiveness to Sulfonylureas in Filipinos with Type 2 Diabetes Mellitus.
    Journal of the ASEAN Federation of Endocrine Societies, 2023, Volume: 38, Issue:1

    Topics: Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Sulfonylurea Compounds

2023
Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81).
    Diabetes & metabolism journal, 2023, Volume: 47, Issue:6

    Topics: Diabetes Mellitus, Type 2; Humans; Liraglutide; MicroRNAs; Sulfonylurea Compounds

2023
Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81).
    Diabetes & metabolism journal, 2023, Volume: 47, Issue:6

    Topics: Diabetes Mellitus, Type 2; Humans; Liraglutide; MicroRNAs; Sulfonylurea Compounds

2023
Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population-based cohort study.
    Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:2

    Topics: Aged; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female

2020
A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm.
    Diabetes care, 2019, Volume: 42, Issue:12

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylurea Compou

2019
Adherence and Swallowing Experience with a Modified, Smaller-sized Tablet Formulation of Metformin and Glimepiride (SR) in Indian Patients with Type 2 Diabetes Mellitus.
    The Journal of the Association of Physicians of India, 2019, Volume: 67, Issue:12

    Topics: Blood Glucose; Deglutition; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobi

2019
Eff ectiveness of Teneligliptin as an Add-on in T2DM Patients not Controlled on Metformin and Glimepiride.
    The Journal of the Association of Physicians of India, 2020, Volume: 68, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H

2020
Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging.
    Neurobiology of aging, 2020, Volume: 89

    Topics: Aging; Animals; Corpus Striatum; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dise

2020
A possible alternative therapy for type 2 diabetes using Myristica fragrans Houtt in combination with glimepiride: in vivo evaluation and in silico support.
    Zeitschrift fur Naturforschung. C, Journal of biosciences, 2020, Mar-26, Volume: 75, Issue:3-4

    Topics: Alloxan; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Fema

2020
Characterization and therapeutic efficacy evaluation of glimepiride and L-arginine co-amorphous formulation prepared by supercritical antisolvent process: Influence of molar ratio and preparation methods.
    International journal of pharmaceutics, 2020, May-15, Volume: 581

    Topics: Administration, Oral; Animals; Arginine; Blood Glucose; Calorimetry, Differential Scanning; Chemistr

2020
Risk of sudden cardiac arrest and ventricular arrhythmia with sulfonylureas: An experience with conceptual replication in two independent populations.
    Scientific reports, 2020, 06-22, Volume: 10, Issue:1

    Topics: Aged; Cohort Studies; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Female; Glipizide; Glyburid

2020
Clinical Utilization Pattern of Multiple Strengths of Glimepiride and Metformin Fixed Dose Combinations in Indian Type 2 Diabetes Patients.
    The Journal of the Association of Physicians of India, 2020, Volume: 68, Issue:7

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hy

2020
Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus.
    Medicine, 2020, Jul-17, Volume: 99, Issue:29

    Topics: Adult; Aged; Asian People; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agent

2020
Increased osteoprotegerin level is associated with impaired cardiovagal modulation in type-2 diabetic patients treated with oral antidiabetic drugs.
    BMC cardiovascular disorders, 2020, 10-20, Volume: 20, Issue:1

    Topics: Administration, Oral; Adult; Biomarkers; Cardiometabolic Risk Factors; Case-Control Studies; Diabete

2020
[Starting insulin or not? And if so, which basal insulin?]
    Nederlands tijdschrift voor geneeskunde, 2020, 09-24, Volume: 164

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Glycemic C

2020
Fournier's gangrene with dapagliflozin in a rural hospital: a case report.
    BMJ case reports, 2021, Feb-01, Volume: 14, Issue:2

    Topics: Abscess; Accidental Falls; Aged; Anti-Bacterial Agents; Benzhydryl Compounds; Debridement; Diabetes

2021
Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China.
    Journal of comparative effectiveness research, 2021, Volume: 10, Issue:6

    Topics: Benzhydryl Compounds; China; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; H

2021
Impacts of early insulin treatment vs glimepiride in diabetic patients with background metformin therapy: A nationwide retrospective cohort study.
    Medicine, 2021, Mar-05, Volume: 100, Issue:9

    Topics: Adult; Aged; Cause of Death; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglyce

2021
Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study.
    The pharmacogenomics journal, 2021, Volume: 21, Issue:5

    Topics: Cost-Benefit Analysis; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Type 2; Genotyping Techniques; He

2021
Metabolic study of ginsenoside Rg3 and glimepiride in type 2 diabetic rats by liquid chromatography coupled with quadrupole-Orbitrap mass spectrometry.
    Rapid communications in mass spectrometry : RCM, 2021, Jun-15, Volume: 35, Issue:11

    Topics: Animals; Chromatography, Liquid; Cytochrome P-450 Enzyme Inhibitors; Diabetes Mellitus, Experimental

2021
Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.
    Clinical pharmacology and therapeutics, 2022, Volume: 111, Issue:1

    Topics: Administrative Claims, Healthcare; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors

2022
Development of a Novel Zebrafish Model for Type 2 Diabetes Mellitus.
    Scientific reports, 2017, 05-03, Volume: 7, Issue:1

    Topics: Animals; Animals, Genetically Modified; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mel

2017
Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes: A retrospective cohort study.
    Medicine, 2017, Volume: 96, Issue:25

    Topics: Adult; Aged; Cardiovascular Diseases; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Pept

2017
Once-weekly oral antidiabetic agent and treatment satisfaction.
    Current medical research and opinion, 2017, Volume: 33, Issue:11

    Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Heterocyclic Compounds, 2-Ring; Humans; Hypoglycemic

2017
Once-weekly oral antidiabetic agent and treatment satisfaction.
    Current medical research and opinion, 2017, Volume: 33, Issue:11

    Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Heterocyclic Compounds, 2-Ring; Humans; Hypoglycemic

2017
The pattern of prescribing of glucose modulating agents for type 2 diabetes in general practices in England 2016/17.
    International journal of clinical practice, 2018, Volume: 72, Issue:4

    Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Costs; Drug Prescriptions; England; Exenatide

2018
Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity.
    Andrologia, 2018, Volume: 50, Issue:7

    Topics: Adult; Anti-Obesity Agents; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Com

2018
Specific PERK inhibitors enhanced glucose-stimulated insulin secretion in a mouse model of type 2 diabetes.
    Metabolism: clinical and experimental, 2019, Volume: 97

    Topics: Adenine; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; eIF-2 Kinase; Glucose; Hypergly

2019
The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data.
    Revista da Associacao Medica Brasileira (1992), 2019, Volume: 65, Issue:1

    Topics: Adamantane; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Female; Humans; H

2019
Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes.
    Romanian journal of internal medicine = Revue roumaine de medecine interne, 2019, Sep-01, Volume: 57, Issue:3

    Topics: Actins; Ceruloplasmin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gene Expression

2019
Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
    Diabetes research and clinical practice, 2019, Volume: 152

    Topics: Aged; Carbamates; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angio

2019
Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride.
    Diabetes care, 2019, Volume: 42, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Doubl

2019
[SGLT-2-inhibitor dapagliflozin: new treatment approach for diabetes type 2--new achievements, but also new questions!].
    Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138 Suppl 1

    Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glipizide; Glucosides; Glycated Hemoglobin; Glycosu

2013
Hypoglycaemia due to interaction of glimepiride with isoniazid in a patient with type 2 diabetes mellitus.
    BMJ case reports, 2013, Apr-16, Volume: 2013

    Topics: Aged; Antitubercular Agents; Diabetes Mellitus, Type 2; Drug Interactions; Female; Humans; Hypoglyce

2013
Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients.
    Diabetes care, 2013, Volume: 36, Issue:10

    Topics: Aged; Cognition Disorders; Diabetes Mellitus, Type 2; Endarterectomy, Carotid; Glyburide; Humans; Hy

2013
Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients.
    Diabetes care, 2013, Volume: 36, Issue:10

    Topics: Aged; Cognition Disorders; Diabetes Mellitus, Type 2; Endarterectomy, Carotid; Glyburide; Humans; Hy

2013
Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients.
    Diabetes care, 2013, Volume: 36, Issue:10

    Topics: Aged; Cognition Disorders; Diabetes Mellitus, Type 2; Endarterectomy, Carotid; Glyburide; Humans; Hy

2013
Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients.
    Diabetes care, 2013, Volume: 36, Issue:10

    Topics: Aged; Cognition Disorders; Diabetes Mellitus, Type 2; Endarterectomy, Carotid; Glyburide; Humans; Hy

2013
RP-LC simultaneous quantitation of co-administered drugs for (non-insulin dependent) diabetic mellitus induced dyslipidemia in active pharmaceutical ingredient, pharmaceutical formulations and human serum with UV-detector.
    Clinica chimica acta; international journal of clinical chemistry, 2013, Oct-21, Volume: 425

    Topics: Adult; Anticholesteremic Agents; Calibration; Chromatography, Reverse-Phase; Diabetes Mellitus, Type

2013
SGLT2 inhibitors for diabetes: turning symptoms into therapy.
    Lancet (London, England), 2013, Sep-14, Volume: 382, Issue:9896

    Topics: Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Sod

2013
Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus.
    Diabetes/metabolism research and reviews, 2013, Volume: 29, Issue:8

    Topics: Administration, Oral; Adult; Aged; Cardiovascular Diseases; Cohort Studies; Comorbidity; Coronary Di

2013
Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report.
    Cardiovascular diabetology, 2014, Jan-14, Volume: 13

    Topics: Aged; Diabetes Mellitus, Type 2; Female; Glycemic Index; Humans; Hypoglycemic Agents; Male; Middle A

2014
How to prevent and treat pharmacological hypoglycemias.
    Revista clinica espanola, 2014, Volume: 214, Issue:4

    Topics: Anticholesteremic Agents; Antihypertensive Agents; Diabetes Mellitus, Type 2; Female; Humans; Hyperc

2014
Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
    Journal of medical economics, 2014, Volume: 17, Issue:9

    Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like P

2014
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
    Diabetes research and clinical practice, 2015, Volume: 107, Issue:1

    Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combina

2015
Adverse drug reaction: a possible case of glimepiride-induced syndrome of inappropriate antidiuretic hormone secretion.
    Diabetes & metabolism, 2015, Volume: 41, Issue:2

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inappropriate ADH Syndrome; Male; Middle Age

2015
Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice.
    Diabetes & metabolism, 2015, Volume: 41, Issue:3

    Topics: Cohort Studies; Creatinine; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agen

2015
[Fixed-dose combination].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:3

    Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Inositol; Isoindo

2015
Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy.
    Diabetes technology & therapeutics, 2015, Volume: 17, Issue:7

    Topics: Aged; Blood Glucose; Blood Glucose Self-Monitoring; Blood Pressure; Body Weight; Diabetes Mellitus,

2015
Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
    Journal of medical economics, 2015, Volume: 18, Issue:10

    Topics: Adamantane; Body Mass Index; Cardiovascular Diseases; China; Computer Simulation; Cost-Benefit Analy

2015
Type 2 diabetes alters metabolic and transcriptional signatures of glucose and amino acid metabolism during exercise and recovery.
    Diabetologia, 2015, Volume: 58, Issue:8

    Topics: Amino Acids; Blood Glucose; Calorimetry, Indirect; Carbohydrate Metabolism; Diabetes Mellitus, Type

2015
Genotoxicity evaluation of metformin and glimepiride by micronucleus assay in exfoliated urothelial cells of type 2 diabetes mellitus patients.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2015, Volume: 83

    Topics: Adult; Aged; Biomarkers; Diabetes Mellitus, Type 2; DNA Damage; Drug Therapy, Combination; Female; G

2015
Mucosal lichenoid drug reaction associated with glimepiride: a case report.
    European review for medical and pharmacological sciences, 2015, Volume: 19, Issue:12

    Topics: Diabetes Mellitus, Type 2; Drug Eruptions; Humans; Hypoglycemic Agents; Lichenoid Eruptions; Male; M

2015
Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride.
    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2016, Volume: 25, Issue:5

    Topics: Adult; Benzhydryl Compounds; Clinical Protocols; Diabetes Mellitus, Type 2; Double-Blind Method; Dru

2016
Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis.
    BMJ (Clinical research ed.), 2015, Dec-07, Volume: 351

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Diabetes Mellitus, Type 2; Emergency Service,

2015
The effect of testosterone on cardiovascular risk factors in men with type 2 diabetes and late-onset hypogonadism treated with metformin or glimepiride.
    Pharmacological reports : PR, 2016, Volume: 68, Issue:1

    Topics: Aged; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; H

2016
Kinetics and Molecular Docking Study of an Anti-diabetic Drug Glimepiride as Acetylcholinesterase Inhibitor: Implication for Alzheimer's Disease-Diabetes Dual Therapy.
    Neurochemical research, 2016, Volume: 41, Issue:6

    Topics: Alzheimer Disease; Cholinesterase Inhibitors; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents

2016
Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
    Postgraduate medicine, 2016, Volume: 128, Issue:4

    Topics: Adiposity; Aged; Body Composition; Body Mass Index; Body Weight; Canagliflozin; Clinical Trials, Pha

2016
Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
    Postgraduate medicine, 2016, Volume: 128, Issue:4

    Topics: Adiposity; Aged; Body Composition; Body Mass Index; Body Weight; Canagliflozin; Clinical Trials, Pha

2016
Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
    Postgraduate medicine, 2016, Volume: 128, Issue:4

    Topics: Adiposity; Aged; Body Composition; Body Mass Index; Body Weight; Canagliflozin; Clinical Trials, Pha

2016
Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
    Postgraduate medicine, 2016, Volume: 128, Issue:4

    Topics: Adiposity; Aged; Body Composition; Body Mass Index; Body Weight; Canagliflozin; Clinical Trials, Pha

2016
A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
    BMC health services research, 2016, 08-05, Volume: 16, Issue:a

    Topics: Aged; Blood Glucose; Blood Pressure Determination; Canagliflozin; Diabetes Mellitus, Type 2; Double-

2016
Evaluation, efficacy and tolerability of GlucoNovax tablet in type 2 diabetic patients.
    Pakistan journal of pharmaceutical sciences, 2016, Volume: 29, Issue:4 Suppl

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide;

2016
Type 2 diabetes and metabolic syndrome - adipokine levels and effect of drugs.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2017, Volume: 33, Issue:1

    Topics: Adiponectin; Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Leptin; Male; Me

2017
Urinary Metabolomic Profiling in Zucker Diabetic Fatty Rats with Type 2 Diabetes Mellitus Treated with Glimepiride, Metformin, and Their Combination.
    Molecules (Basel, Switzerland), 2016, Oct-31, Volume: 21, Issue:11

    Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Meta

2016
Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
    Current medical research and opinion, 2017, Volume: 33, Issue:2

    Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Glucosides; Health C

2017
Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study.
    BMC endocrine disorders, 2016, Dec-01, Volume: 16, Issue:1

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated H

2016
Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
    Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:6

    Topics: Adult; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glomerular Filtration

2017
Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.
    Epidemiology (Cambridge, Mass.), 2017, Volume: 28, Issue:3

    Topics: Area Under Curve; Carbamates; Cyclohexanes; Databases, Factual; Diabetes Mellitus, Type 2; Drug Inte

2017
Glimepiride upregulates eNOS activity and inhibits cytokine-induced NF-kappaB activation through a phosphoinoside 3-kinase-Akt-dependent pathway.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:2

    Topics: Blotting, Western; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelial Ce

2009
Basal insulin glargine vs prandial insulin lispro in type 2 diabetes.
    Lancet (London, England), 2008, Aug-02, Volume: 372, Issue:9636

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Synergism; Glycated Hemoglobin; Humans; Hypoglycemia;

2008
Pioglitazone vs glimepiride in the PERISCOPE trial.
    JAMA, 2008, Aug-20, Volume: 300, Issue:7

    Topics: Atherosclerosis; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; H

2008
Pioglitazone vs glimepiride in the PERISCOPE trial.
    JAMA, 2008, Aug-20, Volume: 300, Issue:7

    Topics: Atherosclerosis; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-C

2008
Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
    The Journal of pharmacy and pharmacology, 2008, Volume: 60, Issue:9

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Fe

2008
Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis.
    Archives of dermatology, 2008, Volume: 144, Issue:10

    Topics: Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Blood Glucose; Diabete

2008
Treatment with glimepiride, but not mitiglinide and short-acting insulin, resists body weight and abdominal fat reduction under dietary energy restriction.
    Journal of atherosclerosis and thrombosis, 2009, Volume: 16, Issue:1

    Topics: Abdominal Fat; Body Weight; Diabetes Mellitus, Type 2; Diet, Reducing; Female; Humans; Insulin; Isoi

2009
Exenatide and acute pancreatitis.
    The Journal of the Association of Physicians of India, 2008, Volume: 56

    Topics: Acute Disease; Diabetes Mellitus, Type 2; Drug Interactions; Exenatide; Female; Humans; Hypoglycemic

2008
Lost in translation: modulation of the metabolic-functional relation in the diabetic human heart.
    Circulation, 2009, Apr-21, Volume: 119, Issue:15

    Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty A

2009
Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PioSwitch study.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:5

    Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Humans;

2009
The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response

2009
Triple verses glimepiride plus metformin therapy on cardiovascular risk biomarkers and diabetic cardiomyopathy in insulin resistance type 2 diabetes mellitus rats.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2009, Dec-08, Volume: 38, Issue:5

    Topics: Animals; Biomarkers; Cardiomyopathies; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Ther

2009
Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
    Diabetes research and clinical practice, 2009, Volume: 86, Issue:3

    Topics: Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Cross-Secti

2009
Efficacy and safety of insulin glargine and glimepiride in subjects with Type 2 diabetes before, during and after the period of fasting in Ramadan.
    Diabetic medicine : a journal of the British Diabetic Association, 2009, Volume: 26, Issue:12

    Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypog

2009
A novel glucokinase gene mutation and its effect on glycemic/C-peptide fluctuations in a patient with maturity-onset diabetes of the young type 2.
    Diabetes research and clinical practice, 2010, Volume: 87, Issue:3

    Topics: Adolescent; Area Under Curve; Blood Glucose; C-Peptide; Child, Preschool; Diabetes Mellitus, Type 2;

2010
Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus.
    Diabetes research and clinical practice, 2010, Volume: 88, Issue:1

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Human

2010
Novel glimepiride derivatives with potential as double-edged swords against type II diabetes.
    Archives of physiology and biochemistry, 2010, Volume: 116, Issue:1

    Topics: Adipocytes; Animals; Chlorocebus aethiops; COS Cells; Diabetes Mellitus, Type 2; Hypoglycemic Agents

2010
Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients.
    Endocrine journal, 2010, Volume: 57, Issue:6

    Topics: Aged; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Family Practice; Gliclazide

2010
The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.
    Diabetes care, 2010, Volume: 33, Issue:6

    Topics: Aged; Diabetes Mellitus, Type 2; Female; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Male; Mi

2010
Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea.
    The Annals of pharmacotherapy, 2010, Volume: 44, Issue:5

    Topics: Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Comb

2010
Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients.
    Expert opinion on drug safety, 2010, Volume: 9, Issue:5

    Topics: Age Factors; Aged; Aged, 80 and over; Blood Glucose Self-Monitoring; Comorbidity; Diabetes Mellitus,

2010
The correlation between clinical laboratory data and telomeric status of male patients with metabolic disorders and no clinical history of vascular events.
    The aging male : the official journal of the International Society for the Study of the Aging Male, 2011, Volume: 14, Issue:1

    Topics: Aged; Aged, 80 and over; Aging; Bilirubin; Clinical Laboratory Techniques; Creatine Kinase; Diabetes

2011
Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide.
    Journal of internal medicine, 2010, Volume: 268, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9;

2010
Increased frequency of micronuclei in diabetes mellitus patients using pioglitazone and glimepiride in combination.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2010, Volume: 48, Issue:12

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; DNA Damage; Drug Therapy, Combination; Epithelial Cells; Fem

2010
Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al.
    Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:12

    Topics: Body Composition; Body Weight; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Exenatide; Hu

2010
Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.
    Diabetes research and clinical practice, 2010, Volume: 90, Issue:3

    Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Metformin; Middle Aged; Obesity; Peptides; Rem

2010
Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Clinical therapeutics, 2010, Volume: 32, Issue:10

    Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Gluc

2010
Effects of glimepiride and glibenclamide on carotid atherosclerosis in type 2 diabetic patients.
    Diabetes research and clinical practice, 2011, Volume: 92, Issue:1

    Topics: Aged; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Ag

2011
[Effect of short-term intensive therapy with glimepiride and metformin in newly diagnosed type 2 diabetic patients].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2011, Volume: 31, Issue:3

    Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Male; Metformin; Sulfonylurea

2011
The effects of triple vs. dual and monotherapy with rosiglitazone, glimepiride, and atorvastatin on lipid profile and glycemic control in type 2 diabetes mellitus rats.
    Fundamental & clinical pharmacology, 2012, Volume: 26, Issue:5

    Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Melli

2012
Imaging inflammatory changes in atherosclerosis multimodal imaging hitting stride.
    JACC. Cardiovascular imaging, 2011, Volume: 4, Issue:10

    Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Aortography; Atherosclerosis; Carotid Art

2011
Imaging of pharmacologic intervention decoding therapeutic mechanism or defining effectiveness?
    JACC. Cardiovascular imaging, 2011, Volume: 4, Issue:10

    Topics: Anti-Inflammatory Agents; Aortic Diseases; Aortography; Carotid Artery Diseases; Diabetes Mellitus,

2011
Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A.
    Pharmacogenetics and genomics, 2012, Volume: 22, Issue:3

    Topics: ATP-Binding Cassette Transporters; Chlorpropamide; Cyclohexanes; Diabetes Mellitus, Type 2; Gene Exp

2012
The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
    Diabetic medicine : a journal of the British Diabetic Association, 2012, Volume: 29, Issue:8

    Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glipizide; Glyburide; Humans; Hy

2012
Could FFAR1 assist insulin secretion in type 2 diabetes?
    Lancet (London, England), 2012, Apr-14, Volume: 379, Issue:9824

    Topics: Benzofurans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Sulfones; Sulfony

2012
Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:9

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glipizide; Glyburide; Humans; Hypoglycemic Agents; K

2012
Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus.
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:7

    Topics: Administration, Oral; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypogly

2012
Multiple cerebral infarctions related to famotidine-induced eosinophilia.
    Journal of neurology, 2012, Volume: 259, Issue:10

    Topics: Acarbose; Adrenergic alpha-1 Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulc

2012
Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients.
    Diabetes research and clinical practice, 2012, Volume: 98, Issue:1

    Topics: Adult; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Typ

2012
Gene networks modified by sulphonylureas in beta cells: a pathway-based analysis of insulin secretion and cell death.
    Basic & clinical pharmacology & toxicology, 2012, Volume: 111, Issue:4

    Topics: Animals; Cell Death; Cell Line; Cluster Analysis; Diabetes Mellitus, Type 2; Gene Regulatory Network

2012
Type 2 diabetes: which drug as add-on to metformin?
    Lancet (London, England), 2012, Jun-16, Volume: 379, Issue:9833

    Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Male; Peptides; Sulfonylu

2012
Gliptin versus a sulphonylurea as add-on to metformin.
    Lancet (London, England), 2012, Aug-04, Volume: 380, Issue:9840

    Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Purine

2012
Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy.
    Endocrine journal, 2012, Volume: 59, Issue:12

    Topics: Administration, Oral; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combination

2012
Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
    Journal of medical economics, 2012, Volume: 15 Suppl 2

    Topics: Cost of Illness; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Disease Management; Exenatide; Gl

2012
Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:1

    Topics: Blood Glucose; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dr

2013
Eudragit-based nanosuspension of poorly water-soluble drug: formulation and in vitro-in vivo evaluation.
    AAPS PharmSciTech, 2012, Volume: 13, Issue:4

    Topics: Animals; Chemistry, Pharmaceutical; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug

2012
Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?
    Nature reviews. Endocrinology, 2012, Volume: 8, Issue:10

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Linaglip

2012
[Evaluation of the efficiency and safety of therapy with a combination of sulfonylurea derivatives and insulin sensitizers for type 2 diabetes mellitus].
    Terapevticheskii arkhiv, 2012, Volume: 84, Issue:8

    Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Insulin Resistance; Male; Midd

2012
Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    International journal of technology assessment in health care, 2012, Volume: 28, Issue:4

    Topics: China; Confidence Intervals; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combina

2012
[Continuous glucose monitoring in glimipiride plus metformin treated type 2 diabetic patients during the month of Ramadan].
    La Tunisie medicale, 2012, Volume: 90, Issue:10

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Humans; Hypogl

2012
Glimepiride treatment facilitates ischemic preconditioning in the diabetic heart.
    Journal of cardiovascular pharmacology and therapeutics, 2013, Volume: 18, Issue:3

    Topics: Animals; Cardiotonic Agents; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Cardiomy

2013
Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes.
    Diabetes care, 2002, Volume: 25, Issue:11

    Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Humans; Hypogl

2002
Effect of glimepiride on insulin-stimulated glycogen synthesis in cultured human skeletal muscle cells: a comparison to glibenclamide.
    Diabetes care, 2002, Volume: 25, Issue:12

    Topics: Androstadienes; Cell Culture Techniques; Cells, Cultured; Diabetes Mellitus, Type 2; Female; Glyburi

2002
Efficacy of glimepiride for the treatment of diabetes occurring during glucocorticoid therapy.
    Diabetes care, 2002, Volume: 25, Issue:12

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucocorticoids; Humans; Hypoglycemic Agents

2002
Immunoreactive insulin response to a single dose of glimepiride in lean type 2 diabetic subjects.
    The Journal of the Association of Physicians of India, 2002, Volume: 50

    Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug;

2002
Impairment of myocardial protection in type 2 diabetic patients.
    The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Blood Pressure; Chest Pain; Diabetes Mellitus, Type 2; Electro

2003
[Fear of the injection must not be an argument. Every second type 2 diabetic patient needs insulin].
    MMW Fortschritte der Medizin, 2002, Dec-05, Volume: 144, Issue:49

    Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fear; Humans; Hypoglycemic Agents; Injections,

2002
Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia.
    European journal of clinical pharmacology, 2003, Volume: 59, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Humans;

2003
Glimepiride reduces mononuclear activation of the redox-sensitive transcription factor nuclear factor-kappa B.
    Diabetes, obesity & metabolism, 2003, Volume: 5, Issue:4

    Topics: Aged; Aged, 80 and over; Blotting, Western; Diabetes Mellitus, Type 2; Electrophoretic Mobility Shif

2003
Summaries for patients. A comparison of three insulin regimens (morning glargine, bedtime glargine, or bedtime neutral protamine Hagedorn) in addition to a pill for treating type 2 diabetes.
    Annals of internal medicine, 2003, Jun-17, Volume: 138, Issue:12

    Topics: Aged; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans;

2003
Inadvertent sulfonylurea overdosage and hypoglycemia in an elderly woman: failure of serum hypoglycemia screening.
    Diabetes technology & therapeutics, 2003, Volume: 5, Issue:3

    Topics: Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Overdose; Female;

2003
Effect of glimepiride on serum adiponectin level in subjects with type 2 diabetes.
    Diabetes care, 2003, Volume: 26, Issue:7

    Topics: Adiponectin; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic

2003
Lichenoid drug eruption as a result of the recently released sulfonylurea glimepiride.
    The Australasian journal of dermatology, 2003, Volume: 44, Issue:4

    Topics: Biopsy, Needle; Diabetes Mellitus, Type 2; Drug Eruptions; Follow-Up Studies; Humans; Hypoglycemic A

2003
A diabetic woman with worsening heart failure, hunger, and tremor.
    Cleveland Clinic journal of medicine, 2003, Volume: 70, Issue:10

    Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Gastrointestinal Agents; Heart Failure; Humans; Hy

2003
Glimepiride and serum adiponectin level in type 2 diabetic subjects: response to Nagasaka et al.
    Diabetes care, 2003, Volume: 26, Issue:12

    Topics: Adiponectin; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemi

2003
Comparison of the effects of glimepiride and glibenclamide on adipose tissue tumour necrosis factor-alpha mRNA expression and cellularity.
    Diabetes, obesity & metabolism, 2004, Volume: 6, Issue:1

    Topics: Adipose Tissue; Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type

2004
Prevention of weight gain in type 2 diabetes requiring insulin treatment.
    Diabetes, obesity & metabolism, 2004, Volume: 6, Issue:2

    Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Com

2004
Insulin combination therapy in type 2 diabetes mellitus.
    Annals of internal medicine, 2004, Apr-20, Volume: 140, Issue:8

    Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin

2004
Insulin combination therapy in type 2 diabetes mellitus.
    Annals of internal medicine, 2004, Apr-20, Volume: 140, Issue:8

    Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin

2004
Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes.
    Diabetes research and clinical practice, 2004, Volume: 64, Issue:3

    Topics: Arteriosclerosis; Carotid Arteries; Carotid Artery Diseases; Chronic Disease; Diabetes Mellitus, Typ

2004
[Acute glimepiride-induced pancreatitis].
    Gastroenterologie clinique et biologique, 2004, Volume: 28, Issue:4

    Topics: Acute Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Middle Aged; Pancreatit

2004
[Glimepiride-induced cute cholestatic hepatitis].
    Annales d'endocrinologie, 2004, Volume: 65, Issue:2

    Topics: Cholestasis, Intrahepatic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Middle Aged

2004
The diagnostic value of determining the hydroxy metabolite of glimepiride (M1) in blood serum in cases of severe hypoglycaemia associated with glimepiride therapy.
    Diabetes, obesity & metabolism, 2004, Volume: 6, Issue:5

    Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemia; Hypoglycemic Agent

2004
[Warning signals insulin resistance. Insulin resistance causes not only diabetes].
    MMW Fortschritte der Medizin, 2004, Jul-22, Volume: 146, Issue:29-30

    Topics: Adolescent; Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Human

2004
Insulin resistance determines efficacy of glimepiride in Type 2 diabetic patients not well controlled by diet alone.
    Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22, Issue:2

    Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; M

2005
Cholestatic liver injury after glimepiride therapy.
    Journal of hepatology, 2005, Volume: 42, Issue:6

    Topics: Aged; Chemical and Drug Induced Liver Injury; Cholestasis; Diabetes Mellitus, Type 2; Humans; Hypogl

2005
Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.
    British journal of clinical pharmacology, 2005, Volume: 60, Issue:1

    Topics: Aged; Aryl Hydrocarbon Hydroxylases; Case-Control Studies; Cytochrome P-450 CYP2C9; Diabetes Mellitu

2005
[The change of atherogenic index of plasma (AIP) level in type 2 diabetic pedigrees and the response of AIP to Acarbose or Glimepiride in therapy of type 2 diabetes mellitus].
    Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi, 2005, Volume: 22, Issue:3

    Topics: Acarbose; Atherosclerosis; Body Mass Index; Case-Control Studies; Cholesterol, HDL; Diabetes Mellitu

2005
[Effects of glimepiride and metformin on free fatty acid in patients with Type 2 diabetes mellitus].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2004, Volume: 29, Issue:6

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Humans; Insulin Resistan

2004
[Practical ambulatory therapy for multisystem atrophy and diabetes mellitus].
    Deutsche medizinische Wochenschrift (1946), 2005, Oct-14, Volume: 130, Issue:41

    Topics: Aged; Ambulatory Care; Anti-Inflammatory Agents; Calcium; Diabetes Mellitus, Type 2; Female; Humans;

2005
Efficacy of glimepiride in patients with poorly controlled insulin-treated type 2 diabetes mellitus.
    Endocrine journal, 2005, Volume: 52, Issue:5

    Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycat

2005
[Hardly any hypoglycemias, constant weight--and still cost effective].
    MMW Fortschritte der Medizin, 2005, Nov-24, Volume: 147, Issue:47

    Topics: Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drugs, Generic; Glyburide; Humans; Hy

2005
Rosiglitazone/glimepiride (Avandaryl) for diabetes.
    The Medical letter on drugs and therapeutics, 2006, Mar-13, Volume: 48, Issue:1230

    Topics: Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Rosiglitazone; Sulfonylur

2006
Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats.
    Endocrine, 2006, Volume: 29, Issue:2

    Topics: Adipose Tissue; Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Glucose Tolerance T

2006
A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting.
    Diabetes research and clinical practice, 2007, Volume: 75, Issue:2

    Topics: Adult; Body Mass Index; Carbamates; Diabetes Mellitus, Type 2; Fasting; Female; Fructosamine; Glycat

2007
Pioglitazone/glimepiride (Duetact) for diabetes.
    The Medical letter on drugs and therapeutics, 2007, Jan-29, Volume: 49, Issue:1253

    Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Drug Interactions; Humans; H

2007
Glimepiride-induced vasculitis: a case report.
    British journal of clinical pharmacology, 2007, Volume: 64, Issue:1

    Topics: Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Risk Factors; Sulfonylurea Com

2007
Pioglitazone vs glimepiride and carotid intima-media thickness.
    JAMA, 2007, Mar-28, Volume: 297, Issue:12

    Topics: Atherosclerosis; Carotid Arteries; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglyce

2007
Pioglitazone vs glimepiride and carotid intima-media thickness.
    JAMA, 2007, Mar-28, Volume: 297, Issue:12

    Topics: Albuminuria; Atherosclerosis; Carotid Arteries; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Huma

2007
Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2008, Volume: 9, Issue:2

    Topics: Administration, Oral; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; G

2008
Polymorphonuclear leukocyte function in type-2 diabetes mellitus patients and its correlation with glycaemic control.
    Nepal Medical College journal : NMCJ, 2007, Volume: 9, Issue:2

    Topics: Adult; Aged; Blood Glucose; Chronic Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Fema

2007
[Glimepiride and the bioequivalence tests].
    Arquivos brasileiros de endocrinologia e metabologia, 2007, Volume: 51, Issue:6

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylurea Compounds; Thera

2007
[Clinical utilization of combined rosiglitazone and glimepiride in the treatment of type 2 diabetes mellitus].
    Orvosi hetilap, 2007, Dec-09, Volume: 148, Issue:49

    Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin

2007
Does PERISCOPE provide a new perspective on diabetic treatment?
    JAMA, 2008, Apr-02, Volume: 299, Issue:13

    Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Sulfonylurea

2008
Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.
    Diabetes, obesity & metabolism, 2008, Volume: 10 Suppl 1

    Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; France; Glipi

2008
Acute progression of severe insulin edema accompanied by pericardial and pleural effusion in a patient with type 2 diabetes.
    Diabetes research and clinical practice, 2008, Volume: 81, Issue:2

    Topics: Administration, Oral; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Progression; Ede

2008
Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics.
    Biochimica et biophysica acta, 1994, May-11, Volume: 1191, Issue:2

    Topics: Animals; ATP-Binding Cassette Transporters; Cell Line; Cell Membrane; Diabetes Mellitus, Type 2; Gly

1994
Enhancement by succinic acid dimethyl ester of insulin release evoked by D-glucose and glimepiride in the perfused pancreas of normoglycemic and hyperglycemic rats.
    Biochemical pharmacology, 1994, Apr-29, Volume: 47, Issue:9

    Topics: Animals; Diabetes Mellitus, Type 2; Drug Synergism; Female; Glucagon; Glucose; Hyperglycemia; Hypogl

1994
Modulation of the insulinotropic action of glibenclamide and glimepiride by nutrient secretagogues in pancreatic islets from normoglycemic and hyperglycemic rats.
    Biochemical pharmacology, 1993, May-05, Volume: 45, Issue:9

    Topics: Animals; B-Lymphocytes; Calcium; Carbon Dioxide; Diabetes Mellitus, Type 2; Glucose; Glyburide; Hype

1993
Influence of oral sulfonylurea agents on hepatic glucose uptake.
    Diabetes research and clinical practice, 1995, Volume: 28 Suppl

    Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dogs; Female; Glucose; Gluc

1995
Glimepiride for NIDDM.
    The Medical letter on drugs and therapeutics, 1996, May-24, Volume: 38, Issue:975

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylurea Compounds

1996
Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment.
    Diabetologia, 1996, Volume: 39, Issue:12

    Topics: Administration, Oral; Adult; Aged; Cohort Studies; Creatinine; Diabetes Mellitus, Type 2; Diabetic N

1996
Repaglinide, glibenclamide and glimepiride administration to normal and hereditarily diabetic rats.
    European journal of pharmacology, 1997, Sep-24, Volume: 335, Issue:2-3

    Topics: Administration, Oral; Animals; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Fasting; Female

1997
[24 years later....].
    La Revue de medecine interne, 1998, Volume: 19, Issue:10

    Topics: Cell Membrane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic

1998
[Glimepiride-induced acute hepatitis].
    Gastroenterologie clinique et biologique, 1999, Volume: 23, Issue:10

    Topics: Acute Disease; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Female; Humans; Hy

1999
[Pharma-clinics. Medication of the month. Glimepiride (Amarylle)].
    Revue medicale de Liege, 2000, Volume: 55, Issue:3

    Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Administration Schedule; Humans; Hypoglycemic

2000
[Acute cholestatic hepatitis induced by glimepiride].
    Gastroenterologie clinique et biologique, 2000, Volume: 24, Issue:12

    Topics: Acute Disease; Alcoholism; Biopsy; Chemical and Drug Induced Liver Injury; Cholestasis; Diabetes Mel

2000